<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28993732</article-id>
<article-id pub-id-type="pmc">5622197</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2017.00661</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Purinergic Signalling: Therapeutic Developments</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Burnstock</surname>
<given-names>Geoffrey</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/32994/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Autonomic Neuroscience Centre, University College Medical School</institution>
<country>London, United Kingdom</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne</institution>
<country>VIC, Australia</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: <italic>Kenneth A. Jacobson, National Institutes of Health (NIH), United States</italic></p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: <italic>Stanko S. Stojilkovic, National Institutes of Health (NIH), United States; Rennolds S. Ostrom, Chapman University, United States</italic></p>
</fn>
<corresp id="fn001">*Correspondence: <italic>Geoffrey Burnstock, <email xlink:type="simple">g.burnstock@ucl.ac.uk</email></italic></corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>661</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>9</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Burnstock.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Burnstock</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990’s when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and therapeutic potential. There was early recognition of the use of P1 receptor agonists for the treatment of supraventricular tachycardia and A<sub>2A</sub> receptor antagonists are promising for the treatment of Parkinson’s disease. Clopidogrel, a P2Y<sub>12</sub> antagonist, is widely used for the treatment of thrombosis and stroke, blocking P2Y<sub>12</sub> receptor-mediated platelet aggregation. Diquafosol, a long acting P2Y<sub>2</sub> receptor agonist, is being used for the treatment of dry eye. P2X3 receptor antagonists have been developed that are orally bioavailable and stable <italic>in vivo</italic> and are currently in clinical trials for the treatment of chronic cough, bladder incontinence, visceral pain and hypertension. Antagonists to P2X7 receptors are being investigated for the treatment of inflammatory disorders, including neurodegenerative diseases. Other investigations are in progress for the use of purinergic agents for the treatment of osteoporosis, myocardial infarction, irritable bowel syndrome, epilepsy, atherosclerosis, depression, autism, diabetes, and cancer.</p>
</abstract>
<kwd-group>
<kwd>ATP</kwd>
<kwd>adenosine</kwd>
<kwd>CNS diseases</kwd>
<kwd>peripheral diseases</kwd>
<kwd>infection</kwd>
<kwd>inflammation</kwd>
</kwd-group>
<counts>
<fig-count count="0"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="924"></ref-count>
<page-count count="55"></page-count>
<word-count count="0"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec>
<title>Introduction</title>
<p>Purinergic signalling, i.e., nucleotides as extracellular signalling molecules, was proposed in 1972 (<xref ref-type="bibr" rid="B85">Burnstock, 1972</xref>). However, this concept was not well accepted until the 1990’s when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors, and eight subtypes of the P2Y G protein-coupled receptor (<xref ref-type="bibr" rid="B657">Ralevic and Burnstock, 1998</xref>). Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling (<xref ref-type="bibr" rid="B90">Burnstock, 2007</xref>). Adenosine 5′-triphosphate (ATP) is a cotransmitter with classical transmitters in both the peripheral and central nervous systems. In addition, purines are powerful extracellular messengers to non-neuronal cells, including secretory, exocrine and endocrine, endothelial, immune, musculo-skeletal and inflammatory cells (<xref ref-type="bibr" rid="B113">Burnstock and Knight, 2004</xref>). Purinergic signalling is rapid in neurotransmission, neuromodulation and in secretion, but is also long-term in proliferation, differentiation, migration and death in development and regeneration (<xref ref-type="bibr" rid="B106">Burnstock, 2016f</xref>).</p>
<p>More recently, the focus has been on the pathophysiology and therapeutic potential of both P1 (<xref ref-type="bibr" rid="B150">Chen et al., 2013</xref>; <xref ref-type="bibr" rid="B202">de Lera Ruiz et al., 2014</xref>; <xref ref-type="bibr" rid="B478">Layland et al., 2014</xref>; <xref ref-type="bibr" rid="B506">Liu and Xia, 2015</xref>; <xref ref-type="bibr" rid="B70">Borea et al., 2016</xref>) and P2 (<xref ref-type="bibr" rid="B112">Burnstock and Kennedy, 2011</xref>; <xref ref-type="bibr" rid="B47">Bartlett et al., 2014</xref>; <xref ref-type="bibr" rid="B271">Ford et al., 2015</xref>; <xref ref-type="bibr" rid="B105">Burnstock, 2016e</xref>) receptors. Reviews focussed on different aspects of purinergic pathophysiology are also available, including inflammatory and immune disorders (<xref ref-type="bibr" rid="B37">Arulkumaran et al., 2011</xref>; <xref ref-type="bibr" rid="B422">Junger, 2011</xref>; <xref ref-type="bibr" rid="B341">Hansson et al., 2016</xref>); cancer (<xref ref-type="bibr" rid="B110">Burnstock and Di Virgilio, 2013</xref>; <xref ref-type="bibr" rid="B213">Di Virgilio and Adinolfi, 2017</xref>); gout and fibrosis (<xref ref-type="bibr" rid="B301">Gicquel et al., 2017</xref>); P2X7 receptors (R) as therapeutic targets (<xref ref-type="bibr" rid="B685">Romagnoli et al., 2008</xref>); medicinal chemistry of purinoceptors (<xref ref-type="bibr" rid="B396">Jacobson and Muller, 2016</xref>); pain (<xref ref-type="bibr" rid="B120">Burnstock and Sawynok, 2010</xref>; <xref ref-type="bibr" rid="B21">Alves et al., 2013</xref>; <xref ref-type="bibr" rid="B462">Kuan and Shyu, 2016</xref>; <xref ref-type="bibr" rid="B711">Sawynok, 2016</xref>) and adenosine kinase inhibitors (<xref ref-type="bibr" rid="B454">Kowaluk and Jarvis, 2000</xref>). A number of purine-related compounds have been patented. Therapeutic developments for disorders of different systems in the body will now follow. Reviews concerned with the early literature will be quoted, so the focus of this review will be concerned largely with the most recent findings.</p>
</sec>
<sec>
<title>Disorders of the Central Nervous System (CNS)</title>
<p>Investigations into purinergic signalling and its roles in disorders of the CNS have been reported, for instance following surgery, stroke, accidents and ischemia, neurodegenerative diseases (such as Parkinson’s, Alzheimer’s and Huntington’s diseases), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), epilepsy and neuropsychiatric disorders (including schizophrenia, depression and anxiety). Reviews covering this topic are available (<xref ref-type="bibr" rid="B92">Burnstock, 2008b</xref>; <xref ref-type="bibr" rid="B115">Burnstock et al., 2011</xref>), including the recent attention to the development of centrally penetrant P2X7R antagonists for the treatment of CNS disorders (<xref ref-type="bibr" rid="B122">Burnstock and Verkhratsky, 2012</xref>; <xref ref-type="bibr" rid="B652">Puchalowicz et al., 2014</xref>; <xref ref-type="bibr" rid="B747">Sperlagh and Illes, 2014</xref>; <xref ref-type="bibr" rid="B99">Burnstock, 2015b</xref>; <xref ref-type="bibr" rid="B170">Cisneros-Mejorado et al., 2015b</xref>).</p>
<sec>
<title>Neurodegenerative Diseases</title>
<p>Neurodegeneration in the CNS is associated with inflammation and damage to both neurons and glia (<xref ref-type="bibr" rid="B658">Rama Rao and Kielian, 2015</xref>). Reviews are available that include coverage of early papers concerned with neurodegenerative diseases (<xref ref-type="bibr" rid="B652">Puchalowicz et al., 2014</xref>; <xref ref-type="bibr" rid="B705">Santiago et al., 2014</xref>; <xref ref-type="bibr" rid="B246">Fasullo and Endres, 2015</xref>; <xref ref-type="bibr" rid="B272">Förster and Reiser, 2015</xref>; <xref ref-type="bibr" rid="B101">Burnstock, 2016a</xref>; <xref ref-type="bibr" rid="B284">Fumagalli et al., 2016</xref>). Recent attention has been directed toward the use of P2X7R antagonists for the treatment of neurodegenerative diseases (<xref ref-type="bibr" rid="B561">Metzger et al., 2017</xref>). However, adenosine acting via A<sub>2A</sub>R has also been claimed as a promising therapeutic agent for the prevention and treatment of neurodegenerative diseases (<xref ref-type="bibr" rid="B187">Cunha, 2016</xref>; <xref ref-type="bibr" rid="B344">Harmse et al., 2016</xref>; <xref ref-type="bibr" rid="B611">Olatunji et al., 2016</xref>).</p>
<sec>
<title>Alzheimer’s Disease (AD)</title>
<p>There is progressive cognitive impairment in AD, with prominent deficits in short term memory. The potential of purinergic drugs for the treatment of AD has attracted much interest in recent years. Previous studies have led to the proposal that both P2X7R and P2Y<sub>4</sub>R antagonists are potential therapeutic targets for the treatment of AD (<xref ref-type="bibr" rid="B230">Erb et al., 2015</xref>; <xref ref-type="bibr" rid="B569">Miras-Portugal et al., 2015</xref>; <xref ref-type="bibr" rid="B856">Woods et al., 2016</xref>). It has been suggested that the blockade of P2Y<sub>1</sub>R may have therapeutic potential against cognitive disturbances in AD (<xref ref-type="bibr" rid="B333">Guzman and Gerevich, 2016</xref>). β-Amyloid increased release of ATP, which potentiated excitatory synaptic activity via P2XR, effects that were blocked by P2X antagonists (<xref ref-type="bibr" rid="B698">Sáez-Orellana et al., 2016</xref>). The glycosylphosphatidylinositol-anchored prion protein binds to and modulates the expression of P2X4R, which may be involved in AD (<xref ref-type="bibr" rid="B133">Carneiro et al., 2016</xref>). Recently, a potential role has been proposed for ATP-sensitive potassium channel (K<sub>ATP</sub>) modulation as a therapeutic strategy against AD (<xref ref-type="bibr" rid="B700">Salgado-Puga et al., 2017</xref>).</p>
<p>Adenosine A<sub>3</sub>R agonists suppress amyloid-β protein precursor internalisation and amyloid-β generation (<xref ref-type="bibr" rid="B492">Li S. et al., 2015</xref>). Hippocampal adenosine A<sub>2A</sub>R up-regulation is necessary to trigger memory dysfunction in AD (<xref ref-type="bibr" rid="B186">Cunha, 2015</xref>).</p>
</sec>
<sec>
<title>Parkinson’s Disease (PD)</title>
<p>The involvement of adenosine A<sub>2A</sub>R in PD and their interactions with dopamine receptors has attracted most attention (see <xref ref-type="bibr" rid="B404">Jenner, 2014</xref>). A<sub>2A</sub>R antagonists have been proposed for the treatment of PD (<xref ref-type="bibr" rid="B404">Jenner, 2014</xref>; <xref ref-type="bibr" rid="B579">Mori, 2014</xref>; <xref ref-type="bibr" rid="B645">Pinna, 2014</xref>; <xref ref-type="bibr" rid="B596">Navarro et al., 2016</xref>). K<sub>ATP</sub> (<xref ref-type="bibr" rid="B219">Dragicevic et al., 2015</xref>) and P2X1R (<xref ref-type="bibr" rid="B288">Gan et al., 2015</xref>; <xref ref-type="bibr" rid="B596">Navarro et al., 2016</xref>; <xref ref-type="bibr" rid="B881">Yang Z. et al., 2016</xref>) in PD have also been reported, perhaps indicating new therapeutic targets. Clinical trials istradefylline, an A<sub>2A</sub>R antagonist, have taken place and it may have a beneficial effect in conjunction with commonly used anti-Parkinson’s therapies (<xref ref-type="bibr" rid="B781">Tao and Liang, 2015</xref>; <xref ref-type="bibr" rid="B802">Uchida et al., 2015</xref>; <xref ref-type="bibr" rid="B830">Vorovenci and Antonini, 2015</xref>), although in a later study, istradefylline was shown to enhance amyloid-β generation and γ-secretase activity (<xref ref-type="bibr" rid="B521">Lu et al., 2016</xref>). Oligomerisation kinetics of A<sub>2A</sub> and dopamine D<sub>2</sub>R have important implications for PD (<xref ref-type="bibr" rid="B134">Casadó-Anguera et al., 2016</xref>; <xref ref-type="bibr" rid="B258">Ferré et al., 2016</xref>; <xref ref-type="bibr" rid="B328">Guixà-González et al., 2016</xref>). Clinical trials for A<sub>2A</sub> antagonists for PD are assessed in a review (<xref ref-type="bibr" rid="B596">Navarro et al., 2016</xref>). A<sub>2A</sub>R inhibition stopped rotenone-induced motor impairment in a rat model of PD (<xref ref-type="bibr" rid="B247">Fathalla et al., 2016</xref>). A<sub>1</sub> as well as A<sub>2A</sub>R antagonists were recommended as promising candidates for treatment of PD in a recent paper (<xref ref-type="bibr" rid="B235">Essawy et al., 2017</xref>).</p>
<p>P2X7R antagonists have also been implicated in this disease (<xref ref-type="bibr" rid="B417">Jörg et al., 2014</xref>; <xref ref-type="bibr" rid="B839">Wang et al., 2017</xref>). A P2X7R antagonist, brilliant blue G, was recently shown to be protective in a lipopolysaccharide (LPS) animal model of PD (<xref ref-type="bibr" rid="B839">Wang et al., 2017</xref>).</p>
</sec>
<sec>
<title>Huntington’s Disease (HD)</title>
<p>Earlier studies reported that A<sub>2A</sub>R agonists could be therapeutically useful for HD and that P2X7R antagonists inhibited neuronal apoptosis and attenuated body weight loss and motor co-ordination deficit in HD patients. Adenosine A<sub>2A</sub>R inhibition reversed working memory deficits of HD at early stages models and it was proposed that A<sub>2A</sub>R antagonists may therapeutically reverse the cognitive deficits in HD patients (<xref ref-type="bibr" rid="B494">Li W. et al., 2015</xref>). In earlier publications, A<sub>1</sub>R agonists were suggested to be therapeutic targets (<xref ref-type="bibr" rid="B254">Ferrante et al., 2014</xref>; <xref ref-type="bibr" rid="B481">Lee and Chern, 2014</xref>). It has been claimed that K<sub>ATP</sub> channels may be potential targets for treatment of HD (<xref ref-type="bibr" rid="B330">Gupta and Sharma, 2014</xref>). Inhibition of equilibrative nucleoside transporter 1 enhances the adenosine level and may be a potential therapeutic approach for treating HD (<xref ref-type="bibr" rid="B425">Kao et al., 2017</xref>).</p>
</sec>
<sec>
<title>Amyotrophic Lateral Sclerosis</title>
<p>Involvement of A<sub>2A</sub>R, P2X4R and P2X7R in ALS has been reported (<xref ref-type="bibr" rid="B826">Volonté et al., 2016</xref>). A<sub>1</sub>R have also been implicated in ALS (<xref ref-type="bibr" rid="B595">Nascimento et al., 2015</xref>). Preconditioning with latrepirdine, an adenosine 5′-monophosphate (AMP)-activated protein kinase activator, was beneficial in the SOD1 mouse model of ALS (<xref ref-type="bibr" rid="B180">Coughlan et al., 2015</xref>). A<sub>2A</sub>R activation facilitated neuromuscular transmission in SOD1 mice during the pre-symptomatic but not symptomatic phase of the disease (<xref ref-type="bibr" rid="B594">Nascimento et al., 2014</xref>). Pharmacological inhibition of A<sub>2A</sub>R protects against degeneration of spinal motor neurons in the mouse SOD1G93A ALS model (<xref ref-type="bibr" rid="B602">Ng et al., 2015</xref>).</p>
<p>P2X7R expression was significantly reduced, leading to Ca<sup>2+</sup> disturbances in peripheral blood mononuclear cells in ALS patients (<xref ref-type="bibr" rid="B507">Liu J. et al., 2016</xref>). Low concentrations of endogenous ATP acting on P2X7R induced motor neuron death (<xref ref-type="bibr" rid="B289">Gandelman et al., 2013</xref>). Spinal cord pathology was reduced by P2X7R inhibitors in the mouse SOD1 ALS model (<xref ref-type="bibr" rid="B33">Apolloni et al., 2014</xref>).</p>
</sec>
<sec>
<title>Multiple Sclerosis</title>
<p>P2X7R and the P2YR-like GPR17 are involved in MS (<xref ref-type="bibr" rid="B647">Plemel et al., 2014</xref>; <xref ref-type="bibr" rid="B100">Burnstock, 2015c</xref>; <xref ref-type="bibr" rid="B621">Ou et al., 2016</xref>). There is upregulation of ecto-5′-nucleotidase (CD73) in experimental autoimmune encephalomyelitis, which is an MS animal model (<xref ref-type="bibr" rid="B477">Lavrnja et al., 2015</xref>). Genetic variants in P2X7R affect susceptibility to MS (<xref ref-type="bibr" rid="B324">Gu et al., 2015</xref>; <xref ref-type="bibr" rid="B697">Sadovnick et al., 2017</xref>).</p>
</sec>
</sec>
<sec>
<title>Brain Injury, Neuroprotection, and Neuroregeneration</title>
<sec>
<title>Brain Injury</title>
<p>The importance of inflammation in the responses to brain injury has been reviewed and the involvement of P1R and P2R (<xref ref-type="bibr" rid="B261">Fiebich et al., 2014</xref>; <xref ref-type="bibr" rid="B57">Beamer et al., 2016</xref>) and of P2X7R in particular (<xref ref-type="bibr" rid="B102">Burnstock, 2016b</xref>; <xref ref-type="bibr" rid="B307">Giuliani A.L. et al., 2017</xref>). The roles of purinergic signalling in neurodegeneration as a consequence of brain injury, neuroprotection and neuroregeneration have been discussed in reviews (<xref ref-type="bibr" rid="B367">Hu et al., 2014</xref>; <xref ref-type="bibr" rid="B101">Burnstock, 2016a</xref>). Ectonucleotidase activities and nucleotide levels in serum are altered by brain stab injury (<xref ref-type="bibr" rid="B628">Parabucki et al., 2014</xref>; <xref ref-type="bibr" rid="B475">Laketa et al., 2015</xref>). P2X7R antagonists appear to be effective as a treatment for radiation injury (<xref ref-type="bibr" rid="B872">Xu et al., 2015</xref>). Astrocytic <italic>p</italic>-connexin 43 stimulates neuronic autophagy through P2X7R activation in the hippocampus, resulting in brain injury-induced cognitive deficit repair (<xref ref-type="bibr" rid="B762">Sun L. et al., 2015</xref>). P2X7R antagonists have been implicated as a novel target to prevent secondary neurological injury after traumatic brain injury (<xref ref-type="bibr" rid="B443">Kimbler et al., 2012</xref>) and after spinal cord injury (<xref ref-type="bibr" rid="B635">Peng et al., 2009</xref>). P2X7R antagonists could be therapeutically effective to treat stroke patients (<xref ref-type="bibr" rid="B461">Kuan et al., 2015</xref>). P2X7R stimulation in acute ischaemic stroke is beneficial by restricting early oedema formation and perhaps by modulating responses of glia (<xref ref-type="bibr" rid="B424">Kaiser et al., 2016</xref>). Hypoxic-ischaemic brain injury increases intracellular Ca<sup>2+</sup> in oligodendrocytes, which is partly mediated by P2X7R (<xref ref-type="bibr" rid="B252">Fern et al., 2014</xref>). P2X7R antagonists may provide a new target for the treatment of cerebral ischaemia (<xref ref-type="bibr" rid="B44">Bai and Li, 2013</xref>; <xref ref-type="bibr" rid="B893">Yu Q. et al., 2013</xref>) and for the prevention of ischaemic damage to oligodendrocytes (<xref ref-type="bibr" rid="B217">Domercq et al., 2010</xref>). P2X7 antagonists or inhibition of pannexin-1 channels reduced brain damage following ischaemia (<xref ref-type="bibr" rid="B169">Cisneros-Mejorado et al., 2015a</xref>; <xref ref-type="bibr" rid="B533">Mahi et al., 2015</xref>).</p>
<p>Activation of upregulated P2Y<sub>1</sub>R results in neuroblast migration to sites of brain damage (<xref ref-type="bibr" rid="B131">Cao et al., 2015</xref>). Microglial P2Y<sub>12</sub>R activation follows neuronal injury (<xref ref-type="bibr" rid="B768">Swiatkowski et al., 2016</xref>). A<sub>2A</sub>R activation was suggested for the treatment of brain injury and subsequent neuroinflammation (<xref ref-type="bibr" rid="B192">Dai and Zhou, 2011</xref>). A<sub>2A</sub>R on cells derived from bone marrow modulate white matter lesions following chronic cerebral hypoperfusion (<xref ref-type="bibr" rid="B660">Ran et al., 2015</xref>). Diadenosine tetraphosphate (Ap<sub>4</sub>A) may be a good candidate for traumatic spinal cord injury treatment (<xref ref-type="bibr" rid="B667">Reigada et al., 2017</xref>). Adenosine kinase facilitated astrogliosis after traumatic brain injury and its inhibition in reactive astrocytes ameliorated astrogliosis-induced cell death (<xref ref-type="bibr" rid="B416">Jin et al., 2016</xref>).</p>
<p>ATP and adenosine concentrations in the brain were significantly raised during brain ischaemia to stimulate P1R and P2R (<xref ref-type="bibr" rid="B170">Cisneros-Mejorado et al., 2015b</xref>; <xref ref-type="bibr" rid="B630">Pedata et al., 2016</xref>). P2X4R expressed by microglia are involved in post-ischaemic brain inflammation (<xref ref-type="bibr" rid="B153">Cheng et al., 2014</xref>). P2X4R are required for neuroprotection via ischemic preconditioning (<xref ref-type="bibr" rid="B624">Ozaki et al., 2016</xref>). Neuronal K<sub>ATP</sub> channels play a role in hypoxic preconditioning where they decrease neonatal hypoxic-ischaemic brain injury; it has been proposed that openers of K<sub>ATP</sub> channels may prove to be therapeutically beneficial (<xref ref-type="bibr" rid="B761">Sun H.S. et al., 2015</xref>). Intranasal administration of guanosine reduced ischaemic brain damage in rats (<xref ref-type="bibr" rid="B659">Ramos et al., 2016</xref>). Ambiguously, both A<sub>2A</sub>R agonists and antagonists may protect against ischaemic brain injury (<xref ref-type="bibr" rid="B631">Pedata et al., 2014</xref>). A<sub>1</sub>R contribute to immune responses following neonatal hypoxic ischaemic brain injury (<xref ref-type="bibr" rid="B853">Winerdal et al., 2016</xref>). A valuable review of the involvement of P1R, P2XR and P2YR in brain ischemia is available (<xref ref-type="bibr" rid="B630">Pedata et al., 2016</xref>).</p>
</sec>
<sec>
<title>Neuroprotection and Neuroregeneration</title>
<p>This topic is explored in recent reviews (<xref ref-type="bibr" rid="B681">Rodrigues et al., 2015</xref>; <xref ref-type="bibr" rid="B101">Burnstock, 2016a</xref>; <xref ref-type="bibr" rid="B385">Illes et al., 2016</xref>). Inhibition of P2XR and P2YR as well as activation of P1R following ATP breakdown to adenosine released from CNS cells, have been shown to be neuroprotective. Activation of the pannexin 1/P2X7R complex contribute to the neuroprotection that occurs after ischaemic pre- and post-conditioning (<xref ref-type="bibr" rid="B533">Mahi et al., 2015</xref>). Docosahexaenoic acid in the diet is thought to be a purinergic modulator via P2XR where it protects against neurodegenerative diseases (<xref ref-type="bibr" rid="B574">Molz et al., 2015</xref>). Neuroprotection mediated by microglia is associated with P2X7R activation and release of tumour necrosis factor-α (<xref ref-type="bibr" rid="B542">Masuch et al., 2016</xref>). Blockade of P2X7R provides neuroprotection against stroke, traumatic brain injury and subarachnoid haemorrhage (<xref ref-type="bibr" rid="B911">Zhao H. et al., 2016</xref>). P2X7R antagonists improve recovery after spinal cord injury (<xref ref-type="bibr" rid="B838">Wang et al., 2004</xref>). From a recent study on P2Y<sub>2</sub>R knockout (KO) mice and murine cell lines, it was concluded that P2Y<sub>2</sub>R play a neuroprotective role in neurological disorders, especially AD (<xref ref-type="bibr" rid="B201">de Diego-Garcia et al., 2017</xref>). Neuroprotection is claimed to be mediated by P2Y<sub>13</sub> nucleotide receptors in neurons (<xref ref-type="bibr" rid="B639">Pérez-Sen et al., 2015</xref>). Activation of P2Y<sub>2</sub>R evokes regeneration of glial cells and nerves and the P2YR-like GPR17 evokes oligodendrocyte regeneration. Neural stem cell activation leads to neuroregeneration, probably via P2X4R and P2X7R. Reviews focused on the roles played by P2X4R and P2X7R (<xref ref-type="bibr" rid="B569">Miras-Portugal et al., 2015</xref>) and A<sub>2A</sub>R (<xref ref-type="bibr" rid="B672">Ribeiro et al., 2016</xref>) in neurodegeneration and neuroprotection have been published.</p>
</sec>
</sec>
<sec>
<title>Psychiatric Disorders</title>
<p>Several antipsychotic drugs (e.g., chlorpromazine, fluspirilene, and haloperidol) were found to antagonise responses mediated by P2XR. These antipsychotic drugs act therapeutically by inhibiting dopaminergic hyperactivity by suppressing P2X-mediated effects (see <xref ref-type="bibr" rid="B99">Burnstock, 2015b</xref>). Brain penetrant P2X7R antagonists are being developed as drug targets for psychiatric diseases (<xref ref-type="bibr" rid="B67">Bhattacharya and Biber, 2016</xref>). Reviews about purinergic signalling in psychiatric disorders, such as addiction, depression, schizophrenia, bipolar disorder and autism, have been previously published (<xref ref-type="bibr" rid="B874">Yamada et al., 2014</xref>; <xref ref-type="bibr" rid="B501">Lindberg et al., 2015</xref>; <xref ref-type="bibr" rid="B458">Krügel, 2016</xref>). The possibility has been raised that P1R agonists might be beneficial in the therapy of psychiatric disorders (<xref ref-type="bibr" rid="B164">Cieslak et al., 2016</xref>).</p>
<sec>
<title>Schizophrenia</title>
<p>Adenosine neuromodulation in schizophrenia has received the most attention (see <xref ref-type="bibr" rid="B671">Rial et al., 2014</xref>; <xref ref-type="bibr" rid="B168">Ciruela et al., 2015</xref>; <xref ref-type="bibr" rid="B801">Turcin et al., 2016</xref>). Deletion of A<sub>2A</sub>R from astrocytes interferes with glutamate homeostasis resulting in cognitive and psychomotor impairment in schizophrenia (<xref ref-type="bibr" rid="B543">Matos et al., 2015</xref>). It has been suggested that P2X7R and pannexin 1 channels are involved (see <xref ref-type="bibr" rid="B122">Burnstock and Verkhratsky, 2012</xref>; <xref ref-type="bibr" rid="B40">Avendano et al., 2015</xref>).</p>
</sec>
<sec>
<title>Bipolar Disorder</title>
<p>P2X7R, mediating neuroinflammation via microglial activity, contribute to bipolar disorder (see <xref ref-type="bibr" rid="B326">Gubert et al., 2013</xref>, <xref ref-type="bibr" rid="B327">2016</xref>; <xref ref-type="bibr" rid="B46">Barron et al., 2014</xref>). Serum concentrations of uric acid increase in different clinical phases of bipolar disorder (<xref ref-type="bibr" rid="B17">Albert et al., 2015</xref>) and in those patients treated with lithium (<xref ref-type="bibr" rid="B589">Muti et al., 2015</xref>). The purinergic system may become dysregulated during manic episodes and it has been proposed that raised uric acid levels could be a useful indicator of bipolar disorder manic phases (<xref ref-type="bibr" rid="B48">Bartoli et al., 2017a</xref>). Purinergic modulators that reduce levels of uric acid may be therapeutically beneficial (<xref ref-type="bibr" rid="B49">Bartoli et al., 2017b</xref>). However, a decrease in serum adenosine levels in bipolar disorder patients was reported (<xref ref-type="bibr" rid="B327">Gubert et al., 2016</xref>).</p>
</sec>
<sec>
<title>Depression and Anxiety</title>
<p>Reviews describing the roles of both P1 (A<sub>1</sub> and A<sub>2A</sub>) and P2X7R in mood disorders are available (<xref ref-type="bibr" rid="B874">Yamada et al., 2014</xref>; <xref ref-type="bibr" rid="B620">Ortiz et al., 2015</xref>). Antidepressant effects of P2X7 antagonists have been reported (<xref ref-type="bibr" rid="B636">Pereira et al., 2013</xref>; <xref ref-type="bibr" rid="B906">Zhang K. et al., 2016</xref>). P2X2R in the medial prefrontal cortex mediate the antidepressant-like actions of ATP released from astrocytes (<xref ref-type="bibr" rid="B132">Cao et al., 2013</xref>). Brilliant blue G, a P2X7R antagonist, had antidepressant and anti-inflammatory actions in mice after LPS administration (<xref ref-type="bibr" rid="B527">Ma et al., 2014</xref>). The P2X7R antagonist, A-804598, affected neuroimmune and behavioural features of stress (<xref ref-type="bibr" rid="B137">Catanzaro et al., 2014</xref>). Stress-related mood disorders activate the inflammasome via release of ATP and stimulation of P2X7R (<xref ref-type="bibr" rid="B393">Iwata et al., 2016</xref>). Co-expression of wild-type P2X7R with the polymorphism variant Gln460Arg alters receptor function associated with mood disorders (<xref ref-type="bibr" rid="B35">Aprile-Garcia et al., 2016</xref>). Increased K<sub>ATP</sub> channel activity due to a mutation led to reduced anxiety in mice (<xref ref-type="bibr" rid="B473">Lahmann et al., 2014</xref>). K<sub>ATP</sub> channels are involved in the pathogenesis of depression and may be a therapeutic target for this disorder (<xref ref-type="bibr" rid="B243">Fan et al., 2016</xref>). Altered levels of several ATP-dependent chromatin remodelling factors may be linked to high trait anxiety (<xref ref-type="bibr" rid="B852">Wille et al., 2016</xref>).</p>
<p>A<sub>2A</sub>R antagonists were reported to have antidepressant activity (<xref ref-type="bibr" rid="B874">Yamada et al., 2014</xref>). Creatine and ketamine had antidepressant effects, probably mediated by activation of A<sub>1</sub>R and A<sub>2A</sub>R (<xref ref-type="bibr" rid="B185">Cunha et al., 2015</xref>). Caffeine, acting as an A<sub>2A</sub>R antagonist, prevented depression triggered by chronic stress (<xref ref-type="bibr" rid="B428">Kaster et al., 2015</xref>; <xref ref-type="bibr" rid="B223">Dziubina et al., 2016</xref>). Striatal and extrastriatal A<sub>2A</sub>R in the forebrain regulate fear responses in mice (<xref ref-type="bibr" rid="B841">Wei et al., 2014</xref>). A<sub>2A</sub>R mediated increased interleukin (IL)-1β in the brain contributed to anxiety (<xref ref-type="bibr" rid="B158">Chiu et al., 2014</xref>). Fear and anxiety in a mouse model of post-traumatic stress disorder were alleviated by administration of a derivative of adenosine, WS0701 (<xref ref-type="bibr" rid="B371">Huang et al., 2014</xref>). A<sub>1</sub>R agonists have been used to treat anxiety, but have troublesome side-effects so positive allosteric modulators have been developed as potent anxiolytic agents (<xref ref-type="bibr" rid="B821">Vincenzi et al., 2016</xref>). An antidepressant-like effect of inosine in mice has been reported (<xref ref-type="bibr" rid="B315">Gonçalves et al., 2017</xref>).</p>
</sec>
<sec>
<title>Autism</title>
<p>Adenosine in addition to suramin, a non-selective ATP antagonist, are reported to improve behaviour in autistic individuals (<xref ref-type="bibr" rid="B541">Masino et al., 2013</xref>; <xref ref-type="bibr" rid="B597">Naviaux et al., 2014</xref>, <xref ref-type="bibr" rid="B598">2015</xref>; <xref ref-type="bibr" rid="B338">Hamidpour et al., 2016</xref>).</p>
</sec>
<sec>
<title>Addiction</title>
<p>Targeting A<sub>2A</sub>R may offer strategies for combating drug addiction. Striatopallidal A<sub>2A</sub>R signalling in the dorsomedial striatum has been suggested as a therapeutic target in drug addiction by reducing habit formation (<xref ref-type="bibr" rid="B497">Li et al., 2016</xref>). Caffeine potentiates the addictive effects of drugs of abuse, including cocaine and amphetamine derivatives (<xref ref-type="bibr" rid="B259">Ferrée, 2016</xref>).</p>
<p>Treatment of rodents with a P2X3R antagonist diminished opioid tolerance (<xref ref-type="bibr" rid="B771">Tai et al., 2010</xref>) and tolerance to morphine-induced antinociception (<xref ref-type="bibr" rid="B529">Ma et al., 2015</xref>). Lead-induced neuroinflammation via P2X7R may be responsible for the intensification of morphine tolerance (<xref ref-type="bibr" rid="B45">Baranowska-Bosiacka et al., 2016</xref>). Opiate-induced changes in brain adenosine levels may be associated with opiate addiction and withdrawal (<xref ref-type="bibr" rid="B862">Wu et al., 2013</xref>).</p>
<p>Adenosine, acting via A<sub>2A</sub>R, regulates addiction induced by cocaine. Women are more sensitive to cocaine and are therefore more vulnerable to becoming addicted. Adenosine antagonists may be an effective treatment (<xref ref-type="bibr" rid="B81">Broderick and Malave, 2014</xref>). A<sub>2A</sub>-D<sub>2</sub> receptor-receptor interactions in the dorsal striatum are differentially affected by cocaine, which contributes to compulsive drug seeking (<xref ref-type="bibr" rid="B646">Pintsuk et al., 2016</xref>).</p>
<p>Interactions between striatal A<sub>2A</sub> and glutamate (mGlu5) receptors modulate the drug-seeking effects of methamphetamine (<xref ref-type="bibr" rid="B858">Wright S.R. et al., 2016</xref>). Methamphetamine produces alterations in adenosine receptor expression in the nucleus accumbens (<xref ref-type="bibr" rid="B430">Kavanagh et al., 2015</xref>). A<sub>2A</sub>R antagonism in dorsomedial striatum reduces methamphetamine addiction (<xref ref-type="bibr" rid="B287">Furlong et al., 2015</xref>). Adenosine A<sub>2A</sub>R integrate the rewarding and motivational behaviours of methamphetamine (<xref ref-type="bibr" rid="B155">Chesworth et al., 2016</xref>). Behavioural sensitisation provides a model in animals for drug craving that underlies human addiction and sensitisation to amphetamine was reduced by P2Y<sub>1</sub>R antagonists in the mesocortico-limbic dopaminergic system (<xref ref-type="bibr" rid="B459">Krügel et al., 2013</xref>).</p>
<p>A<sub>2A</sub>R agonist treatment can help counteract nicotine addiction (<xref ref-type="bibr" rid="B402">Jastrzebska et al., 2014</xref>). A<sub>2A</sub>R are a potential target for the treatment of alcohol abuse (<xref ref-type="bibr" rid="B564">Micioni Di Bonaventura et al., 2012</xref>; <xref ref-type="bibr" rid="B360">Houchi et al., 2013</xref>). Regulation in adenosine signalling in striatal circuits in alcohol addiction was reviewed (<xref ref-type="bibr" rid="B593">Nam et al., 2013</xref>). A<sub>1</sub>R signalling contributes to the regulation of basolateral amygdala excitability and to the pathophysiology of alcohol addiction (<xref ref-type="bibr" rid="B663">Rau et al., 2014</xref>). A review of alcohol addiction discusses the role of adenosine (<xref ref-type="bibr" rid="B563">Michalak and Biala, 2016</xref>). P2X4R modulate synaptic signalling associated with alcohol addiction (<xref ref-type="bibr" rid="B276">Franklin et al., 2014</xref>; <xref ref-type="bibr" rid="B438">Khoja et al., 2016</xref>).</p>
</sec>
</sec>
<sec>
<title>Epilepsy</title>
<p>Early focus was on the role of P1R in epileptic seizures, but P2X4R and P2YR, but especially P2X7R antagonists have been recently explored as neuroleptic agents (see <xref ref-type="bibr" rid="B99">Burnstock, 2015b</xref>; <xref ref-type="bibr" rid="B229">Engel et al., 2016</xref>; <xref ref-type="bibr" rid="B662">Rassendren and Audinat, 2016</xref>; <xref ref-type="bibr" rid="B56">Beamer et al., 2017</xref>; <xref ref-type="bibr" rid="B167">Cieslak et al., 2017</xref>). Seizure-induced increases in microglial process numbers were reduced and kainate-induced seizure behaviours were exacerbated in P2Y<sub>12</sub> KO mice (<xref ref-type="bibr" rid="B239">Eyo et al., 2014</xref>). Antiepileptic consequences of deep brain stimulation may be mediated by P1R activation (<xref ref-type="bibr" rid="B568">Miranda et al., 2014</xref>). P2X3R expression was upregulated in epileptic rats and humans and it was postulated that P2X3R antagonists might be therapeutically effective (<xref ref-type="bibr" rid="B919">Zhou X. et al., 2016</xref>). The release of adenosine and ATP during on-going epileptiform activity was measured with microelectrode biosensors (<xref ref-type="bibr" rid="B278">Frenguelli and Wall, 2016</xref>). ATP levels were increased during epileptic seizures, which were not of neuronal origin (<xref ref-type="bibr" rid="B499">Lietsche et al., 2016</xref>). There is an insightful Editorial about purinergic signalling-induced neuroinflammation in epilepsy (<xref ref-type="bibr" rid="B228">Engel, 2016</xref>).</p>
<p>A role for post-transcriptional control of the P2X7R expression has been proposed and therapeutic targeting of microRNA-22 was suggested to prevent development of epilepsy and inflammation (<xref ref-type="bibr" rid="B413">Jimenez-Mateos et al., 2015</xref>). Purinergic signalling, via P2X7R, regulates neonatal seizures associated with hypophosphatasia, an inherited metabolic bone disease characterised by spontaneous seizures (<xref ref-type="bibr" rid="B716">Sebastián-Serrano et al., 2016</xref>). P2X7R antagonists were effective against hypoxia-induced neonatal seizures in mice (<xref ref-type="bibr" rid="B682">Rodriguez-Alvarez et al., 2017</xref>).</p>
</sec>
<sec>
<title>Migraine</title>
<p>The role of ATP in migraine was initially suggested to involve vascular events (see <xref ref-type="bibr" rid="B122">Burnstock and Verkhratsky, 2012</xref>; <xref ref-type="bibr" rid="B336">Haanes and Edvinsson, 2014</xref>). Later, P2X3R in nociceptive brain areas, including the thalamus and trigeminal nucleus, were investigated and their interaction with P2Y<sub>1</sub>R in trigeminal neurons (<xref ref-type="bibr" rid="B374">Hullugundi et al., 2014</xref>; <xref ref-type="bibr" rid="B536">Marchenkova et al., 2016</xref>). The therapeutic potential of antagonists to P2X7R for migraine treatment has been proposed (<xref ref-type="bibr" rid="B313">Gölöncsér and Sperlágh, 2014</xref>), as well as P2X3R and P2X2/3R antagonists (<xref ref-type="bibr" rid="B439">Kilinc et al., 2015</xref>; <xref ref-type="bibr" rid="B884">Yegutkin et al., 2016</xref>). Reviews have been published about the roles and therapeutic potential of purinergic signalling in the aetiology of migraine (<xref ref-type="bibr" rid="B165">Cieslak et al., 2015</xref>; <xref ref-type="bibr" rid="B884">Yegutkin et al., 2016</xref>).</p>
</sec>
<sec>
<title>Neuropathic Pain</title>
<p>P1R and P2R involvement in neuropathic pain has been discussed in reviews (<xref ref-type="bibr" rid="B120">Burnstock and Sawynok, 2010</xref>; <xref ref-type="bibr" rid="B115">Burnstock et al., 2011</xref>; <xref ref-type="bibr" rid="B94">Burnstock, 2014a</xref>, <xref ref-type="bibr" rid="B103">2016c</xref>). The discovery by Inoue and colleagues that antagonists to P2X4R on microglia are effective against neuropathic pain was particularly important (see <xref ref-type="bibr" rid="B796">Tsuda, 2016</xref>). Antagonists to P2X7R and P2Y<sub>12</sub>R also act on microglia to reduce neuropathic pain (see <xref ref-type="bibr" rid="B798">Tsuda and Inoue, 2016</xref>; <xref ref-type="bibr" rid="B797">Tsuda, 2017</xref>). A<sub>3</sub>R agonists delay the development of neuropathic pain (<xref ref-type="bibr" rid="B400">Janes et al., 2016</xref>). Glial P2Y<sub>2</sub>R are potential targets for the management of trigeminal-related pain (<xref ref-type="bibr" rid="B532">Magni et al., 2015</xref>). Pannexin 1 and P2X7R interactions have been suggested to play a role in chronic pain (<xref ref-type="bibr" rid="B79">Bravo et al., 2015</xref>). P2X7R antagonists have been recommended for the treatment of central post-stroke pain (<xref ref-type="bibr" rid="B461">Kuan et al., 2015</xref>). A review discusses the use of P2XR subtype antagonists for the treatment of central neuropathic pain (<xref ref-type="bibr" rid="B462">Kuan and Shyu, 2016</xref>). Purinergic signalling in the spinal dorsal horn and anterior cingulate cortex appear to be involved in neuropathic pain (<xref ref-type="bibr" rid="B799">Tsuda et al., 2017</xref>). P2X3 and P2X2/3R blockade has also been claimed to reduce chronic pain (<xref ref-type="bibr" rid="B130">Cantin et al., 2012</xref>; <xref ref-type="bibr" rid="B871">Xu et al., 2012</xref>; <xref ref-type="bibr" rid="B304">Giniatullin and Nistri, 2013</xref>).</p>
</sec>
<sec>
<title>Brain Tumours</title>
<p>Neuroblastoma, a rare childhood tumour, expresses P2X7R, which mediate proliferation. The P2X7R appears to be a regulator of neuroblastoma metabolic activity, angiogenesis and growth and may be a target for neuroblastoma treatment (<xref ref-type="bibr" rid="B24">Amoroso et al., 2015</xref>; <xref ref-type="bibr" rid="B314">Gomez-Villafuertes et al., 2015</xref>). The action of the antitumor agent, temozolomide, was increased by the antiproliferative actions of P2X7R agonists and antagonists to A<sub>3</sub>R and P2Y<sub>1</sub>R on human glioblastoma (<xref ref-type="bibr" rid="B194">D’Alimonte et al., 2015</xref>). P2X4R may also be involved in human neuroblastoma (<xref ref-type="bibr" rid="B325">Gualix et al., 2015</xref>).</p>
<p>P2X7R were over-expressed in human malignant gliomas and P2X7R antagonists decreased tumour cell numbers (<xref ref-type="bibr" rid="B244">Fang et al., 2015</xref>; <xref ref-type="bibr" rid="B580">Morrone et al., 2016</xref>; <xref ref-type="bibr" rid="B550">McLarnon, 2017</xref>). Extracellular nucleotides control glioma growth via P2X7R and P2Y<sub>6</sub>R activation (<xref ref-type="bibr" rid="B78">Braganhol et al., 2015</xref>). P2X7 and A<sub>2A</sub>R activation leads to release of cytokines by macrophages, which was prevented by antagonists to these receptors (<xref ref-type="bibr" rid="B64">Bergamin et al., 2015</xref>). P2X7R antagonists blocked the cell cytotoxicity caused by irradiation for glioma (<xref ref-type="bibr" rid="B294">Gehring et al., 2015</xref>). Purine nucleoside phosphorylase is released from rat C6 glioma cells, contributing to the purinergic system homeostasis and exhibiting a pathophysiological role (<xref ref-type="bibr" rid="B308">Giuliani P. et al., 2017</xref>).</p>
<p>It was claimed that K<sub>ATP</sub> channels are associated with tumorigenesis of human glioma (<xref ref-type="bibr" rid="B691">Ru et al., 2014</xref>). A<sub>3</sub>R blockade enhances the actions of antitumour drugs used against human glioblastoma stem-like cells (<xref ref-type="bibr" rid="B792">Torres A. et al., 2016</xref>). A<sub>1</sub> and A<sub>2B</sub>R also sensitise glioblastoma stem cells to chemotherapy (<xref ref-type="bibr" rid="B196">Daniele et al., 2014</xref>). P2Y<sub>2</sub>R interactions with caveolin-1 represents a novel target for human astrocytoma cells (<xref ref-type="bibr" rid="B538">Martinez et al., 2016</xref>).</p>
</sec>
<sec>
<title>Sleep Disorders</title>
<p>P2Y<sub>11</sub>R appear to be associated with narcolepsy (<xref ref-type="bibr" rid="B453">Kornum et al., 2011</xref>). Reduced endothelial dilation to ATP in cerebral arteries occurred in a rat model of obstructive sleep apnoea (<xref ref-type="bibr" rid="B182">Crossland et al., 2013</xref>). Adenosine is a key player in the regulation and maintenance of sleep-wake dependent neural activity changes, where dysregulation can lead to sleep-wake disorders (<xref ref-type="bibr" rid="B356">Holst et al., 2016</xref>). The A<sub>2A</sub>R antagonist, SCH58261, overcame the blood–brain barrier dysfunction as a result of sleep restriction (<xref ref-type="bibr" rid="B377">Hurtado-Alvarado et al., 2016</xref>).</p>
</sec>
</sec>
<sec>
<title>Cardiovascular Diseases</title>
<p>Reviews about this topic are available (<xref ref-type="bibr" rid="B231">Erlinge and Burnstock, 2008</xref>; <xref ref-type="bibr" rid="B349">Headrick et al., 2013</xref>; <xref ref-type="bibr" rid="B119">Burnstock and Ralevic, 2014</xref>; <xref ref-type="bibr" rid="B98">Burnstock, 2015a</xref>; <xref ref-type="bibr" rid="B118">Burnstock and Pelleg, 2015</xref>; <xref ref-type="bibr" rid="B656">Ralevic, 2015</xref>; <xref ref-type="bibr" rid="B744">Sousa and Diniz, 2017</xref>).</p>
<sec>
<title>Heart Diseases</title>
<sec>
<title>Heart Failure</title>
<p>In chronic heart failure adenosine accumulates, probably as a result of lowered adenosine deaminase (ADA) gene expression and raised CD73 activity. Adenosine therapy mediated by A<sub>1</sub>R and A<sub>3</sub>R is cardioprotective for chronic heart failure (<xref ref-type="bibr" rid="B320">Greene et al., 2016</xref>; <xref ref-type="bibr" rid="B829">Voors et al., 2017</xref>). A<sub>1</sub>R agonists attenuate cardiac hypertrophy and prevent heart failure in a mouse model (left-ventricular pressure-overload) and in a rat model (neonatal cardiac myocyte) (<xref ref-type="bibr" rid="B162">Chuo et al., 2016</xref>). A<sub>2B</sub>R agonists exert stronger cardioprotective effects against cardiac ischaemia/reperfusion injury compared to A<sub>2A</sub>R activation in rats (<xref ref-type="bibr" rid="B433">Ke et al., 2015</xref>). CD73 and A<sub>2B</sub>R agonists have been considered as therapeutic agents for myocardial ischaemia. Genetic deletion of CD39 results in increased myocardial ischaemia-reperfusion injury (<xref ref-type="bibr" rid="B737">Smith et al., 2016</xref>). Inflammatory responses initiated during ischemia-mediated immune injury may be regulated by adenosine (<xref ref-type="bibr" rid="B73">Boros et al., 2016</xref>).</p>
<p>Early studies were concerned with the role of adenosine in ischaemic and reperfusion injuries. However, there is also interest in the role of ATP. Application of ATP, prior to or just after cardiac ischaemia is cardioprotective (<xref ref-type="bibr" rid="B670">Ren et al., 2016</xref>). ATP released from the ischaemic myocardium causes reflex responses mediated by cardiac sympathetic afferent nerves (<xref ref-type="bibr" rid="B218">Dong et al., 2016</xref>). P2YR are important therapeutic targets in myocardial protection during ischemia/reperfusion (<xref ref-type="bibr" rid="B215">Djerada et al., 2017</xref>). P2Y<sub>6</sub>R could be a therapeutic target to regulate cardiac hypertrophy (<xref ref-type="bibr" rid="B171">Clouet et al., 2016</xref>). There is increased expression of P2Y<sub>2</sub> and P2X1R in the hearts of rats with congestive heart failure.</p>
<p>P2X4R are needed for neuroprotection via ischemic preconditioning (<xref ref-type="bibr" rid="B624">Ozaki et al., 2016</xref>). P2X3R expression increased in dorsal root ganglion (DRG) and superior cervical ganglia neurons, resulting in exaggerated sympathoexcitatory reflexes. NONRATT021972 siRNA decreases the upregulation of P2X7R and improves cardiac function after myocardial ischemia (<xref ref-type="bibr" rid="B800">Tu et al., 2016</xref>). Mitochondrial K<sub>ATP</sub> channels provide protection against myocardial ischemia/reperfusion injury (<xref ref-type="bibr" rid="B835">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="B723">Shimizu and Calvert, 2016</xref>). K<sub>ATP</sub> channels maintain high energy phosphates and myocardial perfusion in heart failure (<xref ref-type="bibr" rid="B399">Jameel et al., 2016</xref>).</p>
</sec>
<sec>
<title>Myocardial Infarction</title>
<p>A clinical trial (Acute Myocardial Infarction Study of Adenosine) concluded that infusion for 3 h of adenosine resulted in a reduction of infarct size (<xref ref-type="bibr" rid="B887">Yetgin et al., 2015</xref>; <xref ref-type="bibr" rid="B84">Bulluck et al., 2016</xref>). Protection against myocardial infarction was mediated by A<sub>1</sub>R in the rabbit heart. The A<sub>3</sub>R agonist IB-MECA produced cardioprotection against myocardial infarction (<xref ref-type="bibr" rid="B790">Tian et al., 2015</xref>). Microglial P2X7R in the rat hypothalamic paraventricular nuclei regulate the sympathoexcitatory responses in acute myocardial infarction (<xref ref-type="bibr" rid="B221">Du D. et al., 2015</xref>). Loss of mouse P2Y<sub>4</sub>R protects against myocardial infarction (<xref ref-type="bibr" rid="B359">Horckmans et al., 2015</xref>). CD39 reduced infarct size following ischaemia-reperfusion injury (<xref ref-type="bibr" rid="B737">Smith et al., 2016</xref>). P2Y<sub>12</sub>R antagonists have been recommended for long-term protection of patients, post-myocardial infarction (<xref ref-type="bibr" rid="B19">Alexopoulos et al., 2016</xref>). The K<sub>ATP</sub> channel opener, natakalim, improves ventricular remodelling of congestive heart failure after myocardial infarction (<xref ref-type="bibr" rid="B414">Jin, 2016</xref>).</p>
</sec>
<sec>
<title>Atrial Fibrillation</title>
<p>Adenosine reduces post-operative atrial fibrillation (AF). Up-regulation of A<sub>2A</sub>R involves abnormal calcium handling in AF. Prevention of A<sub>2A</sub>R activation in patients with AF may sustain uniform beat-to-beat responses at higher beating frequencies (<xref ref-type="bibr" rid="B573">Molina et al., 2016</xref>). Adenosine-guided pulmonary vein isolation following a randomised clinical trial was recommended to treat paroxysmal AF (<xref ref-type="bibr" rid="B531">Macle et al., 2015</xref>), although this has been queried in a more recent clinical trial (<xref ref-type="bibr" rid="B299">Ghanbari et al., 2016</xref>). ATP-induced AF has also been investigated (<xref ref-type="bibr" rid="B345">Hasebe et al., 2016</xref>). The efficacy of the P2Y<sub>12</sub> antagonists ticagrelor and prasugrel are not affected in AF (<xref ref-type="bibr" rid="B615">Ondrakova et al., 2016</xref>). The roles of adenosine and ATP in atrial arrhythmias and fibrillation have been discussed (<xref ref-type="bibr" rid="B401">Jared Bunch, 2015</xref>; <xref ref-type="bibr" rid="B61">Belhassen and Michowitz, 2016</xref>).</p>
</sec>
<sec>
<title>Supraventricular Tachycardia</title>
<p>Acute therapy by ATP for paroxysmal supraventricular tachycardia was used in the late 1940’s. In patients with paroxysmal supraventricular tachycardia bolus injection of Adenocard (adenosine) is clinically prescribed to slow conduction time via the atrioventricular node, via A<sub>1</sub>R (<xref ref-type="bibr" rid="B696">Sachdeva and Gupta, 2013</xref>). Treatment of paroxysmal supraventricular tachycardia by adenosine and ATP is discussed (<xref ref-type="bibr" rid="B485">Lerman, 2015</xref>). To provoke vasovagal reaction in syncope patients ATP and adenosine are administered together with the head-up tilt table test (<xref ref-type="bibr" rid="B274">Fragakis et al., 2015</xref>).</p>
</sec>
<sec>
<title>Cardiomyopathy</title>
<p>Cardiomyopathy can be an inherited disease, but can occur as a result of vitamin B deficiency, amyloidosis, alcoholism or viral infections. ATP synthase disruption contributes to diabetic cardiomyopathy (<xref ref-type="bibr" rid="B603">Ni et al., 2016</xref>). P2X7R involvement in dilated cardiomyopathy has been reported (<xref ref-type="bibr" rid="B537">Martinez et al., 2015</xref>).</p>
</sec>
<sec>
<title>Cardiac Fibrosis and myocarditis</title>
<p>P2Y<sub>11</sub>R agonists reduce cardiac fibrosis (<xref ref-type="bibr" rid="B140">Certal et al., 2015</xref>). Extracellular nucleotide regulation of signalling in cardiac fibrosis has been discussed (<xref ref-type="bibr" rid="B607">Novitskaya et al., 2016</xref>). The P2X7R antagonist, A740003, reduces experimental autoimmune myocarditis, suggesting a treatment for clinical myocarditis (<xref ref-type="bibr" rid="B903">Zempo et al., 2015</xref>).</p>
</sec>
<sec>
<title>Angina</title>
<p>ATP injections to treat angina pectoris associated with coronary disease were used during the 1940s, while AMP was used to treat angina. ATP treatment for patients with coronary insufficiency was also used early. Intracoronary administration of adenosine results in angina pain. Intracoronary administration of adenosine in patients with unstable angina produced decreased myonecrosis and improved coronary blood flow (<xref ref-type="bibr" rid="B448">Kizilirmak et al., 2015</xref>). In vascular pain, which encompasses pelvic and ischaemic pain, migraine and angina, it is thought that release of ATP from endothelial cells during reactive hyperaemia after vasospasm diffuses through the microvascular wall to activate P2X3R on perivascular sensory nerves to send impulses that travel to pain centres in the brain via the spinal cord (<xref ref-type="bibr" rid="B421">Joseph et al., 2015</xref>). P2X2/3R expressed on airway nociceptive sensory nerves mediate cardiovascular reflexes in conscious rats (<xref ref-type="bibr" rid="B357">Hooper et al., 2016</xref>).</p>
</sec>
<sec>
<title>Cardiac Transplants</title>
<p>Responses of the transplanted human heart to adenosine show supersensitivity. Protection of cardiac grafts from cold ischaemia/reperfusion injury is caused by donor pretreatment with AMP-activated protein kinase (<xref ref-type="bibr" rid="B880">Yang C. et al., 2016</xref>). Treatment with P2XR antagonists prolongs cardiac transplant survival.</p>
</sec>
</sec>
<sec>
<title>Vascular Diseases</title>
<sec>
<title>Hypertension</title>
<p>It has been proposed in a recent review (<xref ref-type="bibr" rid="B107">Burnstock, 2017</xref>) that there are five different ways that purinergic signalling can contribute to the development of hypertension:</p>
<list list-type="simple" prefix-word="simple">
<list-item>
<label>(1)</label>
<p>ATP released as a cotransmitter from sympathetic nerves together with noradrenaline (NA) contributes, via P2X1R, to the vasoconstriction that results from increased sympathetic vasomotor activity in hypertension. Therefore, P2X1R antagonists should be useful for the treatment of hypertension, especially since there is a substantial increase in ATP relative to NA released from sympathetic nerves in spontaneously hypertensive rats (<xref ref-type="bibr" rid="B80">Brock and Van Helden, 1995</xref>; <xref ref-type="bibr" rid="B316">Goonetilleke et al., 2013</xref>).</p>
</list-item>
<list-item>
<label>(2)</label>
<p>Release of ATP from endothelial cells by shear stress as a result of changes in blood flow acts on P2YR and P2X4R on endothelial cells to release nitric oxide (NO) resulting in vasodilation. Introduction of P2Y<sub>1</sub>, P2Y<sub>2</sub>, and P2X4 agonists would cause increased vasodilation in hypertension.</p>
</list-item>
<list-item>
<label>(3)</label>
<p>Brain stem and hypothalamic neurons mediate sympathetic nerve activity. Recent studies show that P2X3R antagonists are antihypertensive, due to reduced sympathetic nerve activity as a result of increased peripheral P2X3R-mediated carotid body chemoreceptor reflexes (<xref ref-type="bibr" rid="B644">Pijacka et al., 2016</xref>).</p>
</list-item>
<list-item>
<label>(4)</label>
<p>P2X7R in the kidney contribute to the pathophysiology of hypertension and P2X7R antagonists may have promise as clinical antihypertensive agents.</p>
</list-item>
<list-item>
<label>(5)</label>
<p>In hypertensive patients adenosine activates the vascular renin-angiotensin system. P1R agonists have been suggested for the treatment of hypertension (<xref ref-type="bibr" rid="B351">Ho M.F. et al., 2016</xref>).</p>
</list-item>
</list>
<p>Recently, P2Y<sub>6</sub>R were shown to age-dependently promote vascular remodelling in a mouse model, an effect inhibited by MRS2578, suggesting that P2Y<sub>6</sub>R are a therapeutic target for the prevention of age-related hypertension (<xref ref-type="bibr" rid="B765">Sunggip et al., 2017</xref>).</p>
</sec>
<sec>
<title>Atherosclerosis</title>
<p>ATP signalling influences the development of atherosclerosis (<xref ref-type="bibr" rid="B91">Burnstock, 2008a</xref>; <xref ref-type="bibr" rid="B257">Ferrari et al., 2015</xref>). Endothelial and smooth muscle cell proliferation are promoted by adenosine and ATP in atherosclerosis via P2Y<sub>1</sub>, P2Y<sub>2</sub>, and P1R. In a human model, adenosine, via A<sub>2A</sub>R, modulates foam cell formation (<xref ref-type="bibr" rid="B668">Reiss and Cronstein, 2012</xref>). A<sub>2B</sub> and A<sub>3</sub> antagonists reduce atherosclerotic plaque development. There are increased concentrations of circulating adenosine 5′-diphosphate (ADP) and ATP in atherosclerosis (<xref ref-type="bibr" rid="B398">Jalkanen et al., 2015</xref>). Uridine 5′-triphosphate (UTP), via P2Y<sub>2</sub>R, induces expression of vascular cell adhesion molecule-1 in coronary artery endothelial cells, which leads to the monocyte recruitment associated with atherosclerosis development. Upregulated P2Y<sub>2</sub>R mediate intimal hyperplasia in collared rabbit carotid artery. P2Y<sub>1</sub>R antagonists are a therapeutic target for neointima formation (<xref ref-type="bibr" rid="B511">Liu R. et al., 2015</xref>). Endothelial P2X4R play a more important role in intense proliferation in atherosclerosis than P2Y<sub>2</sub>R. ATP, by inducing leukocyte recruitment in mice, contributes to atherogenesis, via P2Y<sub>2</sub>, P2Y<sub>6</sub>, P2X4, and P2X7R. P2X7R are over-expressed in atherosclerosis and P2X7R deficiency leads to less plaque formation (<xref ref-type="bibr" rid="B749">Stachon et al., 2016</xref>). CD39 mRNA-coated stents may be a treatment for atherosclerosis (<xref ref-type="bibr" rid="B3">Abraham et al., 2015</xref>).</p>
<p>Atherosclerosis of coronary vessels is called coronary artery disease or coronary artery syndrome. P2Y<sub>12</sub>R antagonists combined with aspirin are beneficial for patients with acute coronary syndrome (<xref ref-type="bibr" rid="B203">De Luca et al., 2016</xref>; <xref ref-type="bibr" rid="B683">Rollini et al., 2016</xref>). A<sub>2A</sub>R on coronary arteries have also been claimed to be involved in coronary artery disease (<xref ref-type="bibr" rid="B292">Gariboldi et al., 2017</xref>).</p>
</sec>
<sec>
<title>Vascular Injury, Angiogenesis and Restenosis</title>
<p>An initiating event in the pathogenesis of vascular diseases is often vascular injury. Injured cells release ATP, which, together with adenosine, evoke endothelial and smooth muscle cell growth, proliferation, migration and death. Adenosine, following breakdown of ATP, is protective against ischaemic injury. P2Y<sub>12</sub>R antagonists are prescribed as prevention against ischaemic stroke (<xref ref-type="bibr" rid="B503">Liu F. et al., 2015</xref>). P2Y<sub>2</sub>R mediate regulation of endothelial inflammation and angiogenesis (<xref ref-type="bibr" rid="B302">Gidlöf et al., 2015</xref>).</p>
<p>Sustained control of proliferation of endothelial and smooth muscle cells as a result of P1 and P2YR activation during vascular remodelling in restenosis after angioplasty has been reported and therapeutic possibilities are being explored (<xref ref-type="bibr" rid="B88">Burnstock, 2002</xref>). Activation of A<sub>2B</sub>R stimulates angiogenesis in human microvascular endothelial cells (<xref ref-type="bibr" rid="B222">Du X. et al., 2015</xref>). Adenosine, via A<sub>2A</sub>R, stimulates wound healing and angiogenesis following tissue injury in mice. CD39 administration decreases injury-induced platelet deposition and recruitment of leukocytes and inhibits neointimal hyperplasia. A review discusses the vascular actions of P2XR in renal injury (<xref ref-type="bibr" rid="B362">Howarth et al., 2015</xref>).</p>
</sec>
<sec>
<title>Thrombosis, Inflammation, and Stroke</title>
<p>Nucleotides are extracellular mediators of vascular inflammation and thrombosis. Clopidogrel, a P2Y<sub>12</sub> antagonist, inhibits aggregation in platelets and is widely prescribed for thrombosis and stroke (<xref ref-type="bibr" rid="B706">Sarafoff et al., 2012</xref>). Other P2Y<sub>12</sub> antagonists have been developed, including ticlopidine, cangrelor, ticagrelor, prasugrel, elinogrel, BX 667, and PSB 0739. P2Y<sub>1</sub>R antagonists also have antithrombotic actions and have been recommended as a complement to current P2Y<sub>12</sub> anti-platelet strategies. The P2Y<sub>6</sub>R may be a therapeutic target for systemic inflammatory responses. Review articles are available about purinergic signalling in thrombosis and inflammation, including the use of different oral or intravenous P2Y<sub>12</sub>R antagonists (<xref ref-type="bibr" rid="B778">Tang et al., 2015</xref>; <xref ref-type="bibr" rid="B608">Nylander and Schulz, 2016</xref>; <xref ref-type="bibr" rid="B684">Rollini et al., 2017</xref>). P2X7R are pro-thrombotic and genetic KO of the gene for the P2X7R was shown to be protective in a mouse carotid artery thrombosis model (<xref ref-type="bibr" rid="B286">Furlan-Freguia et al., 2011</xref>). Adenosine, via A<sub>2A</sub>R and A<sub>3</sub>R, had antithrombotic effects (<xref ref-type="bibr" rid="B181">Cristalli et al., 1994</xref>; <xref ref-type="bibr" rid="B354">Hofer et al., 2013</xref>).</p>
</sec>
<sec>
<title>Migraine</title>
<p>Migraine pain involves two distinct cerebrovascular phases: an initial vasoconstriction (with no pain), followed by vasodilation (reactive hyperaemia) associated with pain. A purinergic hypothesis for migraine was proposed in 1981 (<xref ref-type="bibr" rid="B86">Burnstock, 1981</xref>). It was suggested that after the initial vasospasm ATP and adenosine (following breakdown of ATP) may mediate the vasodilation during reactive hyperaemia associated with pain. It was also hypothesised that stimulation of P2X3R on sensory nerve terminals located on the adventitia of the cerebral microvasculature by ATP contributed to the migraine pain. Data has also been presented recently that is consistent with the purinergic hypothesis of migraine pain (<xref ref-type="bibr" rid="B884">Yegutkin et al., 2016</xref>). P2X3R antagonists have been proposed as potential candidates for migraine treatment (<xref ref-type="bibr" rid="B831">Waeber and Moskowitz, 2003</xref>). The non-steroidal anti-inflammatory compound, naproxen, currently in use for migraine pain, blocks P2X3R-mediated responses in trigeminal neurons of the rat. Migraine could involve a chronic disorder of the sympathetic nervous system, where increased release of the sympathetic cotransmitter ATP contributes to the initial vasospasm.</p>
<p>Adenosine may also be involved in migraine. Adenosine infusion resulted in symptoms that were migraine-like and withdrawal of the P1R antagonists theophylline and caffeine also resulted in migraine-like symptoms. Clinical trials with the adenosine uptake inhibitor dipyridamole, that results in increased extracellular adenosine, were halted due to the increase of migraine attacks in all patients. Overactive P2YR on glial cells may contribute to pain transduction during migraine. Reviews have been published about the role of purinergic signalling in the aetiology of migraine and the potential of purinergic compounds (<xref ref-type="bibr" rid="B165">Cieslak et al., 2015</xref>; <xref ref-type="bibr" rid="B395">Jacobs and Dussor, 2016</xref>).</p>
</sec>
<sec>
<title>Diabetic Vascular Disease</title>
<p>There is pre-junctional A<sub>1</sub>R-mediated sympathetic neurotransmission and ATP-mediated endothelial vasodilatation in mesenteric arteries of streptozotocin (STZ) diabetic rats (<xref ref-type="bibr" rid="B117">Burnstock and Novak, 2013</xref>). There is enhanced A<sub>2A</sub>R-mediated increase in coronary flow in type 1 diabetic mice (<xref ref-type="bibr" rid="B472">Labazi et al., 2016</xref>). UTP, ATP and adenosine evoked vasodilation is reduced in the circulation of skeletal muscle of type 2 diabetic patients. Erythrocyte release of ATP is diminished in type 2 diabetics, supporting the view that a defect in the physiology of erythrocytes may contribute to diabetic vascular disease. Erythrocytes are less deformable in type 2 diabetes leading to lowered levels of deformation-induced ATP release. Low erythrocyte ATP release may contribute to the prevention and treatment of diabetic peripheral vascular disease (<xref ref-type="bibr" rid="B673">Richards et al., 2015</xref>). P2X7R expression by monocytes might play a role in the pathological changes of type 2 diabetes mellitus (<xref ref-type="bibr" rid="B860">Wu et al., 2015</xref>).</p>
</sec>
<sec>
<title>Aortic Valve Disease</title>
<p>ATP inhibits mineralisation of the aortic valve seen in calcific aortic valve disease (<xref ref-type="bibr" rid="B179">Côté et al., 2012</xref>). Increased levels of ectonucleotidase are found in calcific aortic valve disease and inhibition of ectonucleotidase with ARL67156 prevented disease development in rats.</p>
</sec>
</sec>
<sec>
<title>Blood Cell Diseases</title>
<p>Adenosine is a potential therapeutic target for the prevention and treatment of sickle cell disease (<xref ref-type="bibr" rid="B281">Fu and Davies, 2015</xref>). The circulating levels of adenosine are elevated in pregnant women with sickle cell disease (<xref ref-type="bibr" rid="B38">Ashimi et al., 2015</xref>). Amyloid-β peptide inhibits ATP release from erythrocytes, suggesting that in AD, vascular amyloid peptide may play a role.</p>
</sec>
</sec>
<sec>
<title>Diseases of the Airways</title>
<p>Reviews covering the early literature are available (<xref ref-type="bibr" rid="B109">Burnstock et al., 2012a</xref>; <xref ref-type="bibr" rid="B549">McGovern and Mazzone, 2014</xref>).</p>
<p>Inflammation occurs in most diseases of the airways, including chronic obstructive pulmonary disease (COPD), dyspnea, asthma, cystic fibrosis (CF), allergy, infection and injury. Purine nucleotide release from airway epithelial cells is raised in inflammatory processes and has an important role in the pathophysiology of chronic lung disease. P2X7R are a therapeutic target in lung hypersensitivity reactions seen in chronic inflammatory responses. P2X7R modulate lung inflammatory, fibrotic and functional changes in silicosis, an occupational lung disease (<xref ref-type="bibr" rid="B575">Monção-Ribeiro et al., 2014</xref>). P2X4R mediate acute airway inflammation by regulating dendritic cell function (<xref ref-type="bibr" rid="B851">Wiesler et al., 2016</xref>). Vagal parasympathetic reflex bronchoconstriction has a role in inflammatory airway disease. Mucin hypersecretion is stimulated in various respiratory diseases and silencing of MUC8 by siRNA increased P2Y<sub>2</sub>R-induced airway inflammation (<xref ref-type="bibr" rid="B141">Cha et al., 2015</xref>). P2Y<sub>2</sub>R have also been claimed to downregulate MUC5AC gene expression (<xref ref-type="bibr" rid="B405">Jeong et al., 2016</xref>). Nucleotides released during airway inflammation activate P2Y<sub>6</sub>R leading to further release of inflammatory cytokines (<xref ref-type="bibr" rid="B342">Hao et al., 2014</xref>). Anti-inflammatory effects of adenosine in the lung have been described involving immune cells.</p>
<sec>
<title>Asthma</title>
<p>A role of adenosine in asthma has been considered for many years, because it is a powerful bronchoconstrictor in asthmatic, but not healthy lungs and P1R antagonists have been used for the treatment of asthma (see <xref ref-type="bibr" rid="B163">Cicala and Ialenti, 2013</xref>). It was suggested earlier that the bronchoconstriction evoked by adenosine in asthma was as a result of indirect actions by release of leukotrienes, histamine or endothelin (see <xref ref-type="bibr" rid="B109">Burnstock et al., 2012a</xref>). In early reports, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub>R were all claimed to mediate inhibition of allergic airway inflammation and mast cells were shown to be involved. Expression of adenosine receptors on monocytes from patients with asthma contributes to the progression of the disease (<xref ref-type="bibr" rid="B898">Yuryeva et al., 2015</xref>). A<sub>2A</sub>R are involved in the immunological pathogenesis of asthma (<xref ref-type="bibr" rid="B836">Wang et al., 2016</xref>).</p>
<p>The roles of nucleotides in asthma has gained attention. In human lung mast cells, ATP is an important modulator of histamine release. Attenuated P2X7R function gives protection from asthma and was suggested to be age related. ATP in sputum was significantly elevated in patients with asthma, which was correlated with the percentage of neutrophils in sputum (<xref ref-type="bibr" rid="B741">Soma et al., 2016</xref>). Impaired P2X1R-mediated adhesion in eosinophils from asthmatic patients has been reported (<xref ref-type="bibr" rid="B857">Wright A. et al., 2016</xref>). P2Y<sub>6</sub>R activation was effective for treatment of a mouse model of asthma (<xref ref-type="bibr" rid="B156">Chetty et al., 2016</xref>).</p>
<p>In allergic asthma, inhalation of allergens, such as pollen spores or house dust mite allergen, or triggers such as viral infection or air pollution, trigger inflammation. For an immune response to be triggered by allergens, activation of dendritic cells is required. In allergic asthmatics, bronchoconstriction following inhaled adenosine was mediated by A<sub>1</sub>R. Selective antagonists to A<sub>2B</sub>R improve inflammatory conditions in allergic asthma (<xref ref-type="bibr" rid="B53">Basu et al., 2017</xref>). ATP plays a role in inflammation in allergic asthma by recruitment and activation of inflammatory cells. P2Y<sub>1</sub>R are involved in allergic airway inflammation, probably by regulating maturation of dendritic cells. It has also been proposed that P2Y<sub>2</sub>R in the respiratory epithelium are important sensors for airborne allergens. P2X7R have been implicated in the pathophysiology of allergy-induced lung inflammation. Activating P2X7R on hematopoietic cells, namely eosinophils or dendritic cells, may be a therapeutic approach to treat allergic asthma. Oxatomide, an anti-allergic antihistamine, is claimed to also act as a P2X7R antagonist (<xref ref-type="bibr" rid="B891">Yoshida et al., 2015</xref>). P2R act as modulators of rat eosinophil recruitment in allergic inflammation (<xref ref-type="bibr" rid="B18">Alberto et al., 2016</xref>). Asthmatic patients exhibit hypersensitivity to aerosolised ATP, but the effects of ATP are not mediated by adenosine (<xref ref-type="bibr" rid="B52">Basoglu et al., 2017</xref>).</p>
</sec>
<sec>
<title>Chronic Obstructive Pulmonary Disease (COPD)</title>
<p>COPD emphysema and chronic bronchitis. COPD is caused by gas or noxious particles, particularly in tobacco smoke, trigging a lung inflammatory response that when in the larger airways is called chronic bronchitis while in the alveoli is called emphysema.</p>
<p>The role of adenosine receptors in COPD has been the main emphasis to date. Combined stimulation of A<sub>2B</sub> and glucocorticoid receptors in epithelial cells of human airways induces genes that have anti-inflammatory potential for COPD (<xref ref-type="bibr" rid="B321">Greer et al., 2013</xref>). A<sub>2B</sub>R on human mast cells were claimed to be a strategic target for COPD and inhaled A<sub>2A</sub>R agonists have been used for the treatment of COPD. A<sub>1</sub>, A<sub>2B</sub>, and A<sub>3</sub>R antagonists have also been used to treat COPD (<xref ref-type="bibr" rid="B53">Basu et al., 2017</xref>).</p>
<p>ATP is implicated in COPD as well as adenosine. COPD is characterised by up-regulation of ATP in bronchoalveolar lavage fluid, which promotes inflammation and tissue degradation. ATP-induced pulmonary vasodilation occurs in patients with COPD. Activation of P2X7R signalling by cigarette smoke appears to play a role in the pathogenesis of emphysema. Cigarette smoke induces neutrophil ATP release via P2X7 and probably P2Y<sub>2</sub>R activation. Aerosolised ATP exacerbates the symptoms of COPD (<xref ref-type="bibr" rid="B51">Basoglu et al., 2015</xref>). A valuable review about purinergic signalling and COPD has been published recently (<xref ref-type="bibr" rid="B633">Pelleg et al., 2016</xref>).</p>
</sec>
<sec>
<title>Airway Infections</title>
<p>Antibiotics, including erythromycin, are used widely for the treatment of lower and upper respiratory tract infections. Erythromycin blocks the P2XR-mediated Ca<sup>2+</sup> influx and could represent one mechanism by which it exerts its effects. The airway epithelium has a role in activating the innate immune response during lung bacterial infections to fight the infection. Over-expression of the ectonucleotidase, CD39, promotes bacteria-induced inflammation, mediated largely by P2X7R in mouse airways. It has been proposed that P2X7R agonists together with low molecular weight anti-tuberculosis medicines could be used to treat multi-drug-resistant tuberculosis (TB) (<xref ref-type="bibr" rid="B739">Soares-Bezerra et al., 2015</xref>), although caution was advised as a polymorphism of the P2X7R was reported to increase the risk of recurrence of TB (<xref ref-type="bibr" rid="B253">Fernando et al., 2007</xref>). In infectious inflammatory diseases the roles of P2X7R and ectonucleotidases have been reviewed (<xref ref-type="bibr" rid="B577">Morandini et al., 2014</xref>). Polymorphisms of the P2X7R gene are associated with the prognosis and risk of human TB (<xref ref-type="bibr" rid="B915">Zheng X. et al., 2017</xref>). Data has been presented to support the view that P2X7R antagonists should be used to treat the aggressive forms of TB (<xref ref-type="bibr" rid="B22">Amaral et al., 2014</xref>). Selective, orally bioavailable and potent ATP synthase inhibitors show activity against both non-replicating and replicating TB (<xref ref-type="bibr" rid="B732">Singh et al., 2015</xref>). P2X7R contain the spread of <italic>Toxoplasma gondii in vivo</italic> (<xref ref-type="bibr" rid="B175">Corrêa et al., 2017</xref>). The role of purinergic signalling in a mouse model of pneumococcal meningitis has been explored (<xref ref-type="bibr" rid="B923">Zierhut et al., 2017</xref>). The authors showed that although P2X7R activated the NLRP3 inflammasome/IL-1β pathway that mediates inflammation in pneumococcal meningitis, neither suramin nor brilliant blue G affected the disease, possibly because of meningitis-associated down-regulation of brain P2X7R expression and/or a decrease in ATP levels in cerebrospinal fluid.</p>
<p>Adenosine protects against <italic>Streptococcus pneumoniae</italic> infection of the lungs by pulmonary neutrophil recruitment regulation (<xref ref-type="bibr" rid="B74">Bou Ghanem et al., 2015</xref>). Macrophages that engulf bacteria produce adenosine that suppresses sensitisation in response to early-life infections (<xref ref-type="bibr" rid="B632">Pei and Linden, 2016</xref>). Chemokine release and leukocyte recruitment are modulated by nucleotides in inflamed airways via an action on P2YR on immune and epithelial cells. Mucociliary clearance is the initial defence against infections of the airways. Airway epithelium releases ATP into the surface liquid layer that controls mucus clearance via P2R and, following breakdown to adenosine, also through P1R. Pulmonary TB patients had higher ADA activity in bronchoalveolar lavage fluid and in the sputum.</p>
<p>Infection with the malaria protozoan parasite, <italic>Plasmodium falciparum</italic>, induces ATP release from erythrocytes. Rupture of erythrocytes releases ATP during the blood-stage of <italic>P. chabaudi</italic> malaria that increases P2X7R expression on CD4<sup>+</sup> T cells. Platelet ADA, CD39, and CD73 expression was reduced in <italic>Trypanosoma evansi</italic> infected rats. A review about purinergic signalling and malaria-infected erythrocytes is available (<xref ref-type="bibr" rid="B372">Huber, 2012</xref>). Haemolysis produced by leukotoxin, a bacterial virulence factor, was increased by ATP release and P2XR activation of human erythrocytes.</p>
<p>P2X7R activation regulates inflammatory responses during acute viral infection (<xref ref-type="bibr" rid="B480">Lee et al., 2012</xref>) and is involved in the exacerbated immune response seen during influenza virus infection (<xref ref-type="bibr" rid="B487">Leyva-Grado et al., 2017</xref>). ATP, released by activated macrophages and damaged cells, modulates lung inflammation in pneumonia in cattle. Both pulmonary microvascular endothelial cells and epithelial cells expressed P2X7R mRNA.</p>
<p>The pneumovirus respiratory syncytial virus commonly causes childhood lower respiratory tract diseases. It reduces alveolar clearance, probably via UTP, released by the bronchoalveolar epithelium following infection, suggesting that P2Y<sub>2</sub>R antagonists may be therapeutically important for the treatment of severe respiratory syncytial virus bronchiolitis (<xref ref-type="bibr" rid="B808">Vanderstocken et al., 2012</xref>). Rhinoviral stimuli and ATP signalling contribute to human bronchial smooth muscle production of IL-33 by severe asthmatics (<xref ref-type="bibr" rid="B123">Calvén et al., 2015</xref>). ATP is involved in the expression and release of a major airway mucin, MUC5AC, mainly via P2Y<sub>2</sub>R and it was suggested that modulation of this pathway could be useful clinically for mucus hypersecretion following viral infections (<xref ref-type="bibr" rid="B724">Shishikura et al., 2016</xref>).</p>
</sec>
<sec>
<title>Lung Injury</title>
<p>Acute respiratory stress syndrome and lung injury can lead to respiratory failure. There is a protective effect of ATP-MgCl<sub>2</sub> in ischaemia-reperfusion lung injury. Alveolar macrophages contribute substantially to chronic lung inflammation development, including silicosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, sarcoidosis, and asbestosis.</p>
<p>Alveolar macrophages express P2X7R, which stimulate the IL-1 to IL-5 proinflammatory cytokine cascade and may be clinically relevant in lung hypersensitivity reactions occurring due to chronic inflammation. P2X7R are involved in the pathophysiology of LPS-induced lung injury and LPS-induced inflammation occurs independently of P2Y<sub>1</sub>R (<xref ref-type="bibr" rid="B518">Liverani, 2017</xref>). There is up-regulation of pulmonary P2X4 and P2X7R in both acute and chronic lung injury and P2X7R deletion, but not P2X4 deletion, was lung protective (<xref ref-type="bibr" rid="B337">Hafner et al., 2017</xref>). The initial inflammatory cells recruited during lung injury are pulmonary neutrophils and P2X7R antagonists reduced neutrophil infiltration and proinflammatory cytokine levels (<xref ref-type="bibr" rid="B570">Mishra et al., 2016</xref>).</p>
<p>Neuroendocrine body cells lining the lung epithelium at intervals, release ATP in response to distension, which then stimulates P2X3R to activate vagal sensory fibres that originate in the nodose ganglion (<xref ref-type="bibr" rid="B82">Brouns et al., 2003</xref>). This mechanism may control reflex responses to noxious gases and hyperventilation. Ventilator-induced lung injury may involve ATP release from neuroepithelial cell bodies in response to stretch and therefore may be therapeutically relevant.</p>
<p>Pulmonary fibrosis can be caused by injury. In patients with idiopathic pulmonary fibrosis A<sub>2B</sub>R signalling may promote the production of inflammatory and fibrotic mediators. Extracellular adenosine levels are closely associated with the progression of pulmonary fibrosis (<xref ref-type="bibr" rid="B523">Luo F. et al., 2016</xref>). Adenosine production by CD73 enhanced radiation-induced lung fibrosis (<xref ref-type="bibr" rid="B854">Wirsdörfer et al., 2016</xref>). LPS caused increased expression of A<sub>1</sub>, A<sub>2A</sub>, and A<sub>2B</sub> and P2YR, and decreased expression of A<sub>3</sub>R, while mechanical ventilation reduced P2Y<sub>4</sub> mRNA levels. Both A<sub>2A</sub> and A<sub>2B</sub>R were claimed to attenuate acute lung injury. Upregulated A<sub>2A</sub>R activation is likely to improve the healing process after acute LPS-induced lung injury (<xref ref-type="bibr" rid="B279">Friebe et al., 2014</xref>). A protective role for A<sub>2B</sub>R signalling has been reported to counter ischaemic lung injury (<xref ref-type="bibr" rid="B207">Densmore et al., 2017</xref>). Protective effects of A<sub>3</sub>R activation in attenuating reperfusion lung injury has also been reported. Inhibition of adenosine kinase attenuates acute lung injury (<xref ref-type="bibr" rid="B451">Köhler et al., 2016</xref>). Inhaled A<sub>2B</sub>R agonists have been recommended for the treatment of acute lung injury (<xref ref-type="bibr" rid="B353">Hoegl et al., 2015</xref>). Adenosine is detrimental in lung recovery following hyperoxic lung injury (<xref ref-type="bibr" rid="B199">Davies et al., 2016</xref>). Reviews have been written about adenosine receptors as potential therapeutic targets for acute respiratory stress syndrome and acute lung injury (<xref ref-type="bibr" rid="B712">Schepp and Reutershan, 2008</xref>; <xref ref-type="bibr" rid="B224">Eckle et al., 2009</xref>).</p>
</sec>
<sec>
<title>Cystic Fibrosis (CF)</title>
<p>Cystic fibrosis is hereditary as a result of a loss of function gene mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Some outstanding reviews about purinergic signalling in CF have been published (<xref ref-type="bibr" rid="B109">Burnstock et al., 2012a</xref>; <xref ref-type="bibr" rid="B206">Della Latta et al., 2013</xref>). The regulation of ion transport by UTP and ATP in CF and normal human airway epithelium was proposed early, in retrospect probably via P2Y<sub>2</sub> and/or P2Y<sub>4</sub>R. P2R compounds for the treatment of CF to restore Cl<sup>-</sup> secretion and/or inhibit Na<sup>+</sup> absorption are being investigated. Lipoxin A<sub>4</sub>, which stops inflammation, is inadequately produced in patients with CF, but it stimulates apical ATP release, which activates P2Y<sub>11</sub>R resulting in epithelial repair (<xref ref-type="bibr" rid="B350">Higgins et al., 2014</xref>). With the R117H mutation associated with mild forms of CF, there are faults with the gating conformational changes in the CFTR transmembrane domains, although the function of the nucleotide binding domains are unchanged (<xref ref-type="bibr" rid="B897">Yu et al., 2016</xref>). Gating of the R117H-CFTR was shown to be almost completely rectified by combined treatment with an ATP analogue [<italic>N</italic><sup>6</sup>-(2-phenylethyl)-2′-deoxy-ATP], VX-770 (Ivacaftor, currently used to treat CF) and nitrate ions (NO<sub>3</sub><sup>-</sup>). The authors concluded that future therapeutic developments might include the complementary use of ATP analogues with VX-770.</p>
<p>Cl<sup>-</sup> secretion across CF airway epithelia is restored by ATP by triggering calcium entry via P2XR. It was suggested that P2X4/6 heteromultimer receptors might be involved. CFTR activity is necessary for ATP release following erythrocyte deformation. CFTR is reduced or absent in CF and mechanical deformation of erythrocytes does not induce ATP release. Increasing nucleotide release via motion could have therapeutic implications for CF patients. Women with CF showed reduced survival compared with males. Oestrogen may lower breathing-induced release of ATP and ATP receptor-mediated [Ca<sup>2+</sup>]<sub>i</sub> increase that induces Cl<sup>-</sup> secretion. Anti-oestrogens may therefore be beneficial in the treatment of CF.</p>
<p>A<sub>1</sub>R agonists release [Ca<sup>2+</sup>]<sub>i</sub> and activate Cl<sup>-</sup> and K<sup>+</sup> currents in CF epithelial cells of the airways. A<sub>1</sub> and A<sub>2A</sub>R participate in regulation of Cl<sup>-</sup> secretion in CF airway epithelial cells. Bronchoalveolar lavage from CF patients contained high concentrations of adenosine, correlating with higher 5′-nucleotidase and lower ADA activity. Adenosine regulates CFTR via A<sub>2B</sub>R. The exhaled breath condensate biomarker, adenosine, tracks changes in lung function in CF (<xref ref-type="bibr" rid="B236">Esther et al., 2013</xref>). There is increased airway adenosine metabolism in early CF (<xref ref-type="bibr" rid="B237">Esther et al., 2015</xref>).</p>
</sec>
<sec>
<title>Lung Cancer</title>
<p>Human lung A549 epithelial-like adenocarcinoma cells express P2UR (i.e., P2Y<sub>2</sub> and/or P2Y<sub>4</sub>) that mediate increases in [Ca<sup>2+</sup>]<sub>i</sub>. In A549 cells there is calcium-dependent UTP and ATP release (with subsequent increase in adenosine levels). Erythromycin selectively inhibits influx of Ca<sup>2+</sup> induced via P2X4R stimulation in A549 lung tumour cells. A549 cells express P2Y<sub>2</sub>, P2Y<sub>4</sub>, and P2Y<sub>6</sub>, and P2X4R. ATP induces dose-dependent inhibition of growth of cell lines, including human mesothelioma (MER082), human papillary lung adenocarcinoma (H441), human squamous cell lung carcinoma (H520), human large cell lung carcinoma (H460), human small cell lung carcinoma (GLC4) and the PC14 lung adenocarcinoma cell line. ATP was released from Calu-3 cells derived from human lung adenocarcinoma, probably in response to P2Y<sub>2</sub>R activation. UTP, ATP and uridine diphosphate stimulate proliferation of lung tumour A549 cells through P2Y<sub>2</sub> and P2Y<sub>6</sub>R.</p>
<p>Autocrine ATP release and P2X7R activation affects the migration of human lung cancer cells (<xref ref-type="bibr" rid="B775">Takai et al., 2014</xref>). A significant increase in survival of non-small cell lung cancer patients with high P2X7R expression was identified compared to patients with low P2X7R expression (<xref ref-type="bibr" rid="B69">Boldrini et al., 2015</xref>). Nucleotides released by radiochemotherapy induce chemotaxis, adhesion and proliferation of human lung cancer cells and metastasis was inhibited in immunodeficient mice by purinergic receptor antagonists (<xref ref-type="bibr" rid="B713">Schneider et al., 2015</xref>). An association of P2X7, P2X4, and P2Y<sub>1</sub>R with distant metastatic lung tumours was observed and increased degradation of ATP and ADP by CD39, which influence tumour growth and metastasisation (<xref ref-type="bibr" rid="B355">Hofman et al., 2015</xref>). ATP promotes cell survival by inducing a long lasting and sustained increase in [Ca<sup>2+</sup>]<sub>i</sub> in lung cancer cells (<xref ref-type="bibr" rid="B743">Song et al., 2016</xref>). ATP binding cassette E1 promotes growth, invasion and metastasis of lung adenocarcinoma cells (<xref ref-type="bibr" rid="B791">Tian Y. et al., 2016</xref>). Ecto-5′-nucleotidase (CD73) inhibitors are currently under clinical trial to treat non-small cell lung cancer (<xref ref-type="bibr" rid="B920">Zhu et al., 2017</xref>).</p>
<p>A<sub>2B</sub>R on host immune cells may participate in promoting angiogenesis and suppressing immunity and A<sub>2B</sub>R KO mice showed reduced growth in a Lewis lung carcinoma isograft model. ATP increased the cytotoxicity of cisplatin, a common anti-cancer drug for the treatment of lung cancer, in the H460 carcinoma cell line. An A<sub>3</sub>R agonist inhibited cell proliferation by stopping the cell cycle and by apoptosis in A549 cells. Antagonism of A<sub>2A</sub>R expressed by lung adenocarcinoma tumour cells inhibited their growth (<xref ref-type="bibr" rid="B552">Mediavilla-Varela et al., 2013</xref>). A<sub>2A</sub>R expression and CD73 have opposing prognostic effects in non-small cell lung cancer (<xref ref-type="bibr" rid="B388">Inoue et al., 2017</xref>).</p>
<p>Cachexia often occurs in lung cancer patients. In clinical trials, infusion of ATP in advanced non-small cell lung cancer patients contributed beneficially by increasing body weight, muscle strength and quality of life, as well as enhancing survival (<xref ref-type="bibr" rid="B11">Agteresch et al., 2003</xref>). ATP has been claimed to reduce radiation-induced damage in patients with non-small cell lung cancer (<xref ref-type="bibr" rid="B767">Swennen et al., 2008</xref>).</p>
</sec>
<sec>
<title>Chronic Cough</title>
<p>The therapeutic promise of P2X3R antagonists for the treatment of chronic cough was first recognised by <xref ref-type="bibr" rid="B270">Ford and Undem (2013)</xref>. P2X3R are expressed by airway afferent nerves and mediate hypersensitivity of the cough reflex, which is dramatically reduced by the oral P2X3 antagonist, AF-219 (<xref ref-type="bibr" rid="B1">Abdulqawi et al., 2015</xref>). Central A<sub>1</sub>R were shown to suppress cough (<xref ref-type="bibr" rid="B225">El-Hashim et al., 2016</xref>).</p>
</sec>
<sec>
<title>Pleurisy</title>
<p>Inosine contributed with adenosine to exert, via A<sub>2</sub>R, anti-inflammatory effects in pleural inflammation (<xref ref-type="bibr" rid="B188">da Rocha Lapa et al., 2012</xref>).</p>
</sec>
<sec>
<title>Lung Allograft</title>
<p>Ecto-5′-nucleotidase (CD73) reduced rejection of airway allografts by stimulating A<sub>2A</sub>R, which is a negative modulator of lymphocyte recruitment into the allograft. P2X7R antagonists prolong mouse lung allograft survival (<xref ref-type="bibr" rid="B508">Liu et al., 2014</xref>).</p>
</sec>
</sec>
<sec>
<title>Diseases of the Special Senses</title>
<p>Purinergic signalling is involved in the physiology of the nasal organs, ear, eye and tongue. Purinergic drugs are being explored for corneal injury, retinal detachment, glaucoma, dry eye, retinitis, uveitis, rhinosinusitis, diabetic retinopathy, macular degeneration, noxious odour damage, Ménière’s disease, sensorineural deafness, tinnitus and taste defects (<xref ref-type="bibr" rid="B89">Burnstock, 2006</xref>; <xref ref-type="bibr" rid="B361">Housley et al., 2009</xref>).</p>
<sec>
<title>Eye</title>
<p>The early literature up to 2006 was reviewed (<xref ref-type="bibr" rid="B89">Burnstock, 2006</xref>) and there are more recent reviews covering the treatment of ocular diseases by purinergic drugs (<xref ref-type="bibr" rid="B334">Guzman-Aranguez et al., 2014</xref>; <xref ref-type="bibr" rid="B703">Sanderson et al., 2014</xref>; <xref ref-type="bibr" rid="B59">Beckel et al., 2016</xref>; <xref ref-type="bibr" rid="B483">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="B666">Reichenbach and Bringmann, 2016</xref>).</p>
<p>Glaucoma is characterised by progressive degeneration of retinal ganglion cells and visual loss. Elevated intraocular pressure reduction is the treatable risk factor for glaucoma. P2X7R antagonists are being explored for the treatment of glaucoma (<xref ref-type="bibr" rid="B457">Krizaj et al., 2014</xref>; <xref ref-type="bibr" rid="B637">Pérez de Lara et al., 2015</xref>; <xref ref-type="bibr" rid="B699">Sakamoto et al., 2015</xref>). There is elevation of extracellular ATP and upregulation of NTPDase1 in animal models of chronic glaucoma (<xref ref-type="bibr" rid="B522">Lu et al., 2015</xref>). Cromakalim, a K<sub>ATP</sub> channel opener, lowers intraocular pressure (<xref ref-type="bibr" rid="B689">Roy Chowdhury et al., 2015</xref>, <xref ref-type="bibr" rid="B690">2016</xref>). Evidence for the use of adenosine receptor antagonists for the treatment of glaucoma has also been presented (<xref ref-type="bibr" rid="B917">Zhong et al., 2013</xref>; <xref ref-type="bibr" rid="B7">Agarwal and Agarwal, 2014</xref>). Ap<sub>4</sub>A improves adrenergic anti-glaucomatous therapeutic effectiveness (<xref ref-type="bibr" rid="B520">Loma et al., 2015</xref>) and has recently been claimed to be an effective compound for the treatment of glaucoma (<xref ref-type="bibr" rid="B268">Fonseca et al., 2017</xref>).</p>
<p>Treatment for dry eye by a long lasting P2Y<sub>2</sub>R agonist, diquafosol, was developed by Inspire Pharmaceuticals, Inc. and is currently in use in Japan and Korea (see <xref ref-type="bibr" rid="B476">Lau et al., 2014</xref>).</p>
<p>A P2Y<sub>2</sub>R agonist, INS37217, enhances subretinal fluid reabsorption and is recommended for the treatment of retinal detachment (<xref ref-type="bibr" rid="B534">Maminishkis et al., 2002</xref>; <xref ref-type="bibr" rid="B562">Meyer et al., 2002</xref>).</p>
<p>P2X7R antagonist and A<sub>3</sub>R agonists have been implicated for the treatment of diabetic neuropathy and retinopathy (<xref ref-type="bibr" rid="B760">Sugiyama, 2014</xref>; <xref ref-type="bibr" rid="B666">Reichenbach and Bringmann, 2016</xref>), photoreceptor neurodegeneration (<xref ref-type="bibr" rid="B366">Hu et al., 2015</xref>; <xref ref-type="bibr" rid="B352">Ho T. et al., 2016</xref>), retinitis (<xref ref-type="bibr" rid="B177">Corso et al., 2016</xref>) and uveitis (<xref ref-type="bibr" rid="B913">Zhao R. et al., 2016</xref>).</p>
<p>The roles of P2Y<sub>2</sub> and P2X7R in corneal wound healing have been reviewed (<xref ref-type="bibr" rid="B567">Minns and Trinkaus-Randall, 2016</xref>; <xref ref-type="bibr" rid="B566">Minns et al., 2016</xref>). P2X7R activation in oxysterol cytotoxicity may be a target for the treatment of age-related macular degeneration (<xref ref-type="bibr" rid="B614">Olivier et al., 2016</xref>).</p>
</sec>
<sec>
<title>Ear</title>
<p>In the auditory system ATP depressed sound-evoked action potentials in the auditory nerve by stimulating P2YR. Acoustic over-stimulation can cause permanent hearing loss due to damage and death of cochlea hair cells. Noise exposure promotes the release of ATP into endolymph. ATP regulates hearing sensitivity and could be useful to treat sensorineural deafness, Ménières disease and tinnitus. UTP infusion into the deafened guinea pig inner ear rescued auditory neurons (<xref ref-type="bibr" rid="B277">Fransson et al., 2009</xref>). P2XR-mediated control of cochlear gap junctions may be protective by reducing hearing sensitivity to noise stress (<xref ref-type="bibr" rid="B921">Zhu and Zhao, 2012</xref>), perhaps via P2X2R (<xref ref-type="bibr" rid="B876">Yan et al., 2013</xref>; <xref ref-type="bibr" rid="B571">Mittal et al., 2016</xref>). Susceptibility to hearing loss and noise-induced neural injury in the mouse cochlea is regulated by A<sub>2A</sub>R (<xref ref-type="bibr" rid="B823">Vlajkovic et al., 2017</xref>).</p>
</sec>
<sec>
<title>Olfactory Organs</title>
<p>Purinergic receptors are expressed in the nasal mucosa, including P2X3R on olfactory neurons. There is enhanced odour sensitivity in the presence of antagonists to P2R suggesting that endogenous ATP at a low level normally decreases odour responsiveness. Chemosensory trigeminal neurons express P2X2R, which contribute to control of odour recognition (<xref ref-type="bibr" rid="B361">Housley et al., 2009</xref>). Activation of P2X3R negatively modulates the odour response, indicating a protective strategy for olfactory sensory neurons (<xref ref-type="bibr" rid="B895">Yu, 2015</xref>). Olfactory nerves and secretory cells in the vomeronasal organ express purinoceptors. Heat-shock protein induction by noxious odour damage is inhibited by P2R antagonists <italic>in vivo</italic>. The inhibitory effect of ATP in odour responses may contribute to the reduction of odour sensitivity following exposure to noxious fumes and could be a new mechanism for neuroprotection (<xref ref-type="bibr" rid="B896">Yu and Zhang, 2014</xref>). ATP release following injury leads to post-injury neuroregeneration and may result in the development of therapies to restore loss of smell (<xref ref-type="bibr" rid="B347">Hayoz et al., 2012</xref>). P2Y<sub>1</sub>R increase neuronal network activity in the developing olfactory bulb (<xref ref-type="bibr" rid="B265">Fischer et al., 2012</xref>). Purinergic signalling serves as a paracrine signal in regulating the neurogenesis of mouse olfactory epithelium (<xref ref-type="bibr" rid="B290">Gao L. et al., 2010</xref>). It has been claimed that purinoceptors are a therapeutic target to alleviate or restore loss of olfactory sensory neurons by the mycotoxin, satratoxin (<xref ref-type="bibr" rid="B407">Jia et al., 2011</xref>). Activation of A<sub>2</sub>R may be a novel therapeutic approach for enhancing nasal mucociliary clearance in chronic rhinosinusitis (<xref ref-type="bibr" rid="B368">Hua et al., 2013</xref>).</p>
</sec>
<sec>
<title>Tongue</title>
<p>ATP is a key neurotransmitter in the taste system, acting largely via P2X2/3 heteromultimer receptors (<xref ref-type="bibr" rid="B444">Kinnamon and Finger, 2013</xref>; <xref ref-type="bibr" rid="B807">Vandenbeuch et al., 2015</xref>). Consequently, disruption of taste function may be an unintentional consequence of therapeutic trials of pain, chronic cough and other conditions using purinergic P2X3R antagonists (<xref ref-type="bibr" rid="B806">Vandenbeuch et al., 2013</xref>).</p>
</sec>
</sec>
<sec>
<title>Immune System and Inflammation</title>
<p>P2X7, P2Y<sub>1</sub>, and P2Y<sub>2</sub>R on immune and inflammatory cells are important in immunomodulation and inflammation, and the purinergic contribution to neuroinflammation underlying neuropathology has been discussed in several recent reviews (<xref ref-type="bibr" rid="B394">Jacob et al., 2013</xref>; <xref ref-type="bibr" rid="B776">Takenouchi et al., 2014</xref>; <xref ref-type="bibr" rid="B214">Di Virgilio and Vuerich, 2015</xref>; <xref ref-type="bibr" rid="B57">Beamer et al., 2016</xref>). The role of P2X7R in particular in diseases related to neuroinflammation and the use of P2X7R centrally penetrant antagonists has been highlighted (<xref ref-type="bibr" rid="B54">Baudelet et al., 2015</xref>; <xref ref-type="bibr" rid="B212">Di Virgilio, 2015</xref>; <xref ref-type="bibr" rid="B297">Gentile et al., 2015</xref>; <xref ref-type="bibr" rid="B102">Burnstock, 2016b</xref>; <xref ref-type="bibr" rid="B197">Danquah et al., 2016</xref>; <xref ref-type="bibr" rid="B427">Karmakar et al., 2016</xref>; <xref ref-type="bibr" rid="B665">Rech et al., 2016</xref>; <xref ref-type="bibr" rid="B175">Corrêa et al., 2017</xref>; <xref ref-type="bibr" rid="B307">Giuliani A.L. et al., 2017</xref>; <xref ref-type="bibr" rid="B410">Jiang et al., 2017</xref>; <xref ref-type="bibr" rid="B914">Zheng B. et al., 2017</xref>). It has been claimed that activation of P2X1R on neutrophils and platelets is involved in regulation of thrombo-inflammation (<xref ref-type="bibr" rid="B622">Oury et al., 2015</xref>). P2Y<sub>12</sub>R activation modulates sepsis-induced inflammation (<xref ref-type="bibr" rid="B519">Liverani et al., 2016</xref>). Adenosine, acting mainly via A<sub>2A</sub>R, is also involved in neoplastic and inflammatory and immune-mediated disease states (<xref ref-type="bibr" rid="B31">Antonioli et al., 2014a</xref>; <xref ref-type="bibr" rid="B189">da Rocha Lapa et al., 2014</xref>; <xref ref-type="bibr" rid="B138">Cekic and Linden, 2016</xref>; <xref ref-type="bibr" rid="B387">Ingwersen et al., 2016</xref>; <xref ref-type="bibr" rid="B907">Zhang X. et al., 2016</xref>; <xref ref-type="bibr" rid="B240">Faas et al., 2017</xref>).</p>
</sec>
<sec>
<title>Infection</title>
<p>Reviews have been published concerned with purinergic signalling in immune cell trafficking at sites of infection (<xref ref-type="bibr" rid="B256">Ferrari et al., 2016b</xref>) and P2X7R in infectious inflammatory diseases (<xref ref-type="bibr" rid="B577">Morandini et al., 2014</xref>). Apoptosis of macrophages via ATP-stimulated P2X7R leads to the killing of the mycobacteria they contain, which may lead to new strategies to combat bacterial infections. The cytotoxic effects of ATP on macrophages are through P2X7R, while the bactericidal actions of ATP (and UTP) may be though P2Y<sub>2</sub>R. There is a valuable article about purinergic signalling in infection and autoimmune diseases (<xref ref-type="bibr" rid="B710">Savio and Coutinho-Silva, 2016</xref>). The P2X7R is a potential target for the treatment of <italic>Clostridium perfringens</italic> type C infection (<xref ref-type="bibr" rid="B590">Nagahama et al., 2015</xref>). P2X7R activation modulates cell death during <italic>Porphyromonas gingivalis</italic> infection (<xref ref-type="bibr" rid="B20">Almeida-da-Silva et al., 2016</xref>). P2X7 and P2X4R activation is protective during severe <italic>Escherichia coli</italic> infection (<xref ref-type="bibr" rid="B323">Greve et al., 2017</xref>). P2X7R develop the inflammatory response associated with sepsis (<xref ref-type="bibr" rid="B704">Santana et al., 2015</xref>) and might serve as a therapeutic target to ameliorate brain damage in sepsis (<xref ref-type="bibr" rid="B709">Savio et al., 2016</xref>). A<sub>2A</sub>R have also been recommended as a therapeutic target to treat sepsis (<xref ref-type="bibr" rid="B733">Sivak et al., 2016</xref>). The role of purinergic signalling in the immune response in sepsis has been reviewed (<xref ref-type="bibr" rid="B479">Ledderose et al., 2016</xref>). ATP protects against sepsis through P2X7R on macrophages by enhancing intracellular bacterial killing (<xref ref-type="bibr" rid="B184">Csóka et al., 2015</xref>). <italic>Chlamydiae</italic> are intracellular bacterial pathogens and these infections are influenced by inflammasomes and purinergic signalling (<xref ref-type="bibr" rid="B642">Pettengill et al., 2016</xref>). Purines modulate the inflammatory response in rats infected by <italic>Cryptococcus neoformans</italic> (<xref ref-type="bibr" rid="B200">de Azevedo et al., 2016</xref>). ADP facilitates monocyte recruitment in bacterial infection (<xref ref-type="bibr" rid="B907">Zhang X. et al., 2016</xref>). ATP synthase has been proposed as a target to kill <italic>Mycobacterium tuberculosis</italic> (<xref ref-type="bibr" rid="B780">Tantry et al., 2017</xref>). Purinergic enzymatic activities in lymphocytes and cardiomyocytes modulated the inflammatory responses of mice infected by <italic>T. cruzi</italic> (<xref ref-type="bibr" rid="B216">do Carmo et al., 2017</xref>). Adenosine restored LPS-inhibited chemotaxis via A<sub>1</sub>R, making this a promising therapeutic strategy for infectious diseases (<xref ref-type="bibr" rid="B873">Xu et al., 2017</xref>).</p>
<p>Infection by <italic>Schistosoma mansoni</italic>, a parasitic blood fluke, results in thymic atrophy. The cloning and characterisation of a P2XR (schP2X) from <italic>S. mansoni</italic> was the first non-vertebrate ATP-gated ion channel, which could be an alternative drug target to treat schistosomiasis (see <xref ref-type="bibr" rid="B112">Burnstock and Kennedy, 2011</xref>). Purinergic signalling influences the immune response to infection by <italic>Leishmania</italic>, a protozoan parasite (<xref ref-type="bibr" rid="B148">Chaves et al., 2014</xref>; <xref ref-type="bibr" rid="B264">Figueiredo et al., 2016</xref>). Purinergic signalling is involved in <italic>Trichomonas vaginalis</italic> parasite infection (<xref ref-type="bibr" rid="B554">Menezes and Tasca, 2016</xref>). The dysfunction of P1, P2Y and P2X7R and NTPDases are likely to contribute to morbidity due to human schistosomiasis (<xref ref-type="bibr" rid="B726">Silva, 2016</xref>). P2X7R are important in parasite control as they regulate T effector cells and inflammation during <italic>L. amazonensis</italic> infection (<xref ref-type="bibr" rid="B262">Figliuolo et al., 2017a</xref>). A commentary about ATP as an initiator of immunity to parasitic infections has been published (<xref ref-type="bibr" rid="B599">Nelson et al., 2017</xref>).</p>
<p>P2X7R modulate the antiviral and inflammatory processes that occur during Dengue virus-2 infection (<xref ref-type="bibr" rid="B176">Corrêa et al., 2016</xref>) and exacerbate the immune response that occurs during influenza virus infection (<xref ref-type="bibr" rid="B487">Leyva-Grado et al., 2017</xref>). P2X4R antagonists reduce herpetic pain (<xref ref-type="bibr" rid="B545">Matsumura et al., 2016</xref>). Both P2X4 and P2X7R are involved in hepatitis C virus infection (<xref ref-type="bibr" rid="B535">Manzoor et al., 2016</xref>). Purinoceptors are putative targets for the treatment of HIV-1 infection (<xref ref-type="bibr" rid="B625">Pacheco et al., 2014</xref>). Ribavirin, an adenosine analogue, exhibited potent antiviral activities (<xref ref-type="bibr" rid="B343">Hao et al., 2017</xref>).</p>
</sec>
<sec>
<title>Endocrine Diseases</title>
<p>Purinoceptors are expressed widely by endocrine glands (<xref ref-type="bibr" rid="B113">Burnstock and Knight, 2004</xref>). Actions of purines have been described in the pituitary gland, with implications for pathological as well as physiological states. 5′-Nucleotidase activity in platelets is changed by hyper- and hypothyroidism and could be a further mechanism by which alterations in thyroid hormones are related to vascular diseases. The role of purinergic signalling in thyroid hormone activities in health and disease has been reviewed (<xref ref-type="bibr" rid="B729">Silveira et al., 2013</xref>). In the ovary, follicular atresia involves cellular degeneration that is due to apoptosis evoked by P2X7R activation in both somatic and germinal follicular cells. Adiponectin, secreted by adipocytes, is anti-inflammatory, protecting against fatty liver disorder, insulin-resistant type 2 diabetes and atherosclerosis. A review including the limited knowledge of purinergic signalling in the endocrine system has been published (<xref ref-type="bibr" rid="B95">Burnstock, 2014b</xref>).</p>
<sec>
<title>Diabetes</title>
<p>Fibroblast P2YR are impaired in type 2 diabetes, which leads to lower glucose uptake, indicating that P2YR could be therapeutically useful as antidiabetic drugs. Analogues of the P2Y<sub>1</sub>R agonist, 2-methylthio ADP, have been developed for the treatment of type 2 diabetes (<xref ref-type="bibr" rid="B886">Yelovitch et al., 2012</xref>). P2YR activation potentiates insulin secretion making it a promising therapeutic target for type 2 diabetes (<xref ref-type="bibr" rid="B908">Zhang et al., 2015b</xref>; <xref ref-type="bibr" rid="B209">DeOliveira et al., 2017</xref>). Adenosine, acting via A<sub>2A</sub>R, increases pancreatic β-cell proliferation, and has been suggested as a therapeutic target for diabetes (<xref ref-type="bibr" rid="B715">Schulz et al., 2016</xref>). Uridine adenosine tetraphosphate may be a therapeutic target for diabetes (<xref ref-type="bibr" rid="B544">Matsumoto et al., 2015</xref>).</p>
<p>There is an enhancement of P2X7R-induced apoptosis on the retinal microvasculature in early diabetes. P2X7R located on glucagon-containing α cells in pancreatic islets in STZ-induced diabetic animals increase and they migrate centrally to replace missing insulin-containing β cells. P2X7R antagonists have been proposed as a therapeutic target to cause immunosuppression and tolerance induction in pancreatic islet transplantation (<xref ref-type="bibr" rid="B14">Aikin, 2013</xref>; <xref ref-type="bibr" rid="B814">Vergani et al., 2013</xref>). NONRATT021972 siRNA decreases the expression of P2X7 mRNA and protein in DRG, reducing mechanical and thermal hyperalgesia in type 2 diabetic rats (<xref ref-type="bibr" rid="B514">Liu et al., 2016</xref>c). Type 1 diabetes impairs P2X7R signalling in osteocytes that affects osteoblast function and maintenance of bone health (<xref ref-type="bibr" rid="B717">Seref-Ferlengez et al., 2016</xref>). STZ-induced type 1 diabetes was prevented in P2X7R KO mice (<xref ref-type="bibr" rid="B818">Vieira et al., 2016</xref>). Diabetic sympathetic neuropathy in type 2 diabetic rats was reduced by decreasing the expression of P2X7R in superior cervical ganglia (<xref ref-type="bibr" rid="B859">Wu et al., 2016</xref>). P2X7R are expressed in pancreatic cancer cells. P2X7R antagonists are likely to be effective therapeutic agents (<xref ref-type="bibr" rid="B300">Giannuzzo et al., 2016</xref>).</p>
<p>P2X3R antagonists have been proposed for the treatment of diabetic neuropathic pain (<xref ref-type="bibr" rid="B329">Guo et al., 2015</xref>; <xref ref-type="bibr" rid="B908">Zhang et al., 2015b</xref>; <xref ref-type="bibr" rid="B634">Peng et al., 2017</xref>; <xref ref-type="bibr" rid="B661">Rao et al., 2017</xref>). Recently P2X7R have also been claimed to be involved in painful diabetic neuropathy in rats (<xref ref-type="bibr" rid="B515">Liu et al., 2017</xref>). P2X7R polymorphisms are associated with severe diabetic neuropathic pain scores (<xref ref-type="bibr" rid="B804">Ursu et al., 2014</xref>). A<sub>1</sub>R agonists improve mechanical allodynia in a painful diabetic neuropathy mouse model (<xref ref-type="bibr" rid="B429">Katz et al., 2015</xref>).</p>
<p>There is up-regulation of hippocampal A<sub>2A</sub>R in STZ-diabetes and A<sub>2A</sub>R antagonists gave neuroprotection. A<sub>2A</sub>R are a therapeutic target for diabetic retinopathy (<xref ref-type="bibr" rid="B380">Ibrahim et al., 2011</xref>). Reduced expression of A<sub>1</sub>R in pancreatic α-cells could result in the development of type 1 diabetes (<xref ref-type="bibr" rid="B888">Yip et al., 2013</xref>). There is increased expression of A<sub>2B</sub>R in women with gestational diabetes mellitus (<xref ref-type="bibr" rid="B855">Wojcik et al., 2014</xref>). In diabetic rats, A<sub>2B</sub>R agonists improve erectile function (<xref ref-type="bibr" rid="B843">Wen et al., 2015</xref>). It was suggested that reduction in A<sub>3</sub>R expression/function may slow the progression of diabetic neuropathy (<xref ref-type="bibr" rid="B877">Yan H. et al., 2016</xref>). Blockade of ATP synthase interaction with cyclophilin D has been proposed as a promising therapeutic target to treat diabetic encephalopathy (<xref ref-type="bibr" rid="B878">Yan S. et al., 2016</xref>).</p>
<p>K<sub>ATP</sub> channels have neuroprotective effects in patients with type 2 diabetes (<xref ref-type="bibr" rid="B512">Liu R. et al., 2016</xref>; <xref ref-type="bibr" rid="B692">Rubaiy, 2016</xref>). P2Y<sub>1</sub> and P2Y<sub>2</sub>R mediate relaxation of the rat corpus cavernosum and may improve erectile function in men with diabetes (<xref ref-type="bibr" rid="B331">Gür et al., 2009</xref>).</p>
<p>An A<sub>2A</sub>R agonist was shown to enhance healing of chronic diabetic foot ulcers in a clinical trial (<xref ref-type="bibr" rid="B748">Squadrito et al., 2014</xref>; <xref ref-type="bibr" rid="B576">Montesinos et al., 2015</xref>). Adenosine kinase inhibitors attenuate inflammation in diabetic retinopathy (<xref ref-type="bibr" rid="B226">Elsherbiny et al., 2013a</xref>). Retinal inflammation in diabetic retinopathy is mediated by ADA2 and the anti-inflammatory activity of A<sub>2A</sub>R signalling is impaired with increased ADA2 activity (<xref ref-type="bibr" rid="B227">Elsherbiny et al., 2013b</xref>).</p>
<p>Several reviews about purinergic signalling in diabetes and its therapeutic potential are available (<xref ref-type="bibr" rid="B117">Burnstock and Novak, 2013</xref>; <xref ref-type="bibr" rid="B166">Cieslak and Roszek, 2014</xref>; <xref ref-type="bibr" rid="B29">Antonioli et al., 2015</xref>; <xref ref-type="bibr" rid="B273">Fotino et al., 2015</xref>; <xref ref-type="bibr" rid="B446">Kishore et al., 2015</xref>; <xref ref-type="bibr" rid="B558">Merighi et al., 2015</xref>; <xref ref-type="bibr" rid="B822">Vindeirinho et al., 2016</xref>). The involvement of purinergic signalling in diabetic nephropathy is discussed later in the Section on Kidney.</p>
</sec>
</sec>
<sec>
<title>Obesity</title>
<p>ATP released as a cotransmitter from sympathetic nerves, stimulates brown adipocytes. ATP stimulates lipogenesis in rat adipocytes, regulating fat stores not via established hormones. Adipocytes express two different P2YR subtypes and P2Y<sub>11</sub>R activation inhibited insulin-stimulated lepton production and lipolysis stimulation. P2Y<sub>4</sub>R mediate inhibition of cardiac fat formation (<xref ref-type="bibr" rid="B484">Lemaire et al., 2016</xref>). The anti-obesity effects of sesamol, a potent anti-inflammatory compound, is mediated by AMP-activated protein kinase (<xref ref-type="bibr" rid="B312">Go et al., 2017</xref>). Blocking P2Y<sub>6</sub>R activation in the CNS with the antagonist MRS2578 inhibits feeding in mice (<xref ref-type="bibr" rid="B753">Steculorum et al., 2017</xref>).</p>
<p>Some ATP effects are as a result of adenosine, after breakdown of ATP, which is also involved in the activities of adipocytes. Adenosine increased lipolysis and induced thermogenesis in brown adipocytes via A<sub>2A</sub>R (<xref ref-type="bibr" rid="B311">Gnad et al., 2014</xref>). They showed that A<sub>2A</sub>R antagonists counteract high fat-induced obesity in mice. Administration of A<sub>2A</sub>R agonists to obese mice caused improvements in glucose homeostasis and adipose tissue inflammation, suggesting that this may show promise for therapeutic treatment of obesity (<xref ref-type="bibr" rid="B209">DeOliveira et al., 2017</xref>).</p>
<p>There is disturbance of adiponectin secretion in obese patients and adiponectin release is controlled by ATP (<xref ref-type="bibr" rid="B875">Yamauchi and Kadowaki, 2013</xref>). A combination of Ca<sup>2+</sup> and ATP augments vesicular release of adiponectin (<xref ref-type="bibr" rid="B452">Komai et al., 2014</xref>). Both ATP and adenosine have roles in the regulation of leptin secretion from adipocytes (<xref ref-type="bibr" rid="B769">Szkudelski, 2007</xref>). There is abnormal fat distribution in P2X7R KO mice (<xref ref-type="bibr" rid="B58">Beaucage et al., 2014</xref>). Manipulation of P2XR signalling may represent a novel therapeutic target in metabolically unhealthy obesity under inflammatory conditions (<xref ref-type="bibr" rid="B626">Pandolfi et al., 2016</xref>). There is protection of rats on high fat diet by adenosine (<xref ref-type="bibr" rid="B482">Lee, 2015</xref>). Perivascular adipose tissue of heavy smokers has increased expression of P2X7R and inflammasome components leading to increased release of inflammatory cytokines (<xref ref-type="bibr" rid="B687">Rossi et al., 2014</xref>).</p>
</sec>
<sec>
<title>Gut Disorders</title>
<p>Purinergic signalling plays an important role in a variety of gut activities (<xref ref-type="bibr" rid="B500">Liñán-Rico et al., 2015</xref>; <xref ref-type="bibr" rid="B104">Burnstock, 2016d</xref>; <xref ref-type="bibr" rid="B147">Chaudhury et al., 2016</xref>). ATP is a cotransmitter in non-adrenergic, non-cholinergic inhibitory nerves involved in peristalsis, a synaptic transmitter in submucosal and myenteric ganglia, it mediates mucosal secretion and vascular control of the gastrointestinal tract. Both interstitial cells of Cajal and enteric glial cells express P2R.</p>
<p>Investigations of purinoceptors as therapeutic candidates for gut disorders are underway (<xref ref-type="bibr" rid="B30">Antonioli et al., 2013</xref>; <xref ref-type="bibr" rid="B609">Ochoa-Cortes et al., 2014</xref>; <xref ref-type="bibr" rid="B104">Burnstock, 2016d</xref>).</p>
<sec>
<title>Inflammatory Bowel Disease (IBD)</title>
<p>Nucleotides and their receptors are involved in the pathogenesis of IBD, of which ulcerative colitis (UC) and Crohn’s disease are the main types. P2Y<sub>6</sub>R are highly expressed on the T cells infiltrating IBD, suggesting that P2Y<sub>6</sub>R may play a role in the pathogenesis of IBD. P2X7R agonists are involved in colonic motor dysfunction associated with bowel inflammation in rats (<xref ref-type="bibr" rid="B32">Antonioli et al., 2014b</xref>) and are over-expressed in gut mucosa of patients with IBD. P2X7R KO mice are protected against gut inflammation (<xref ref-type="bibr" rid="B263">Figliuolo et al., 2017b</xref>). ATP activates mast cells, which further promote the inflammatory process (<xref ref-type="bibr" rid="B466">Kurashima and Kiyono, 2016</xref>). Oestrogen receptor β activation plays a therapeutic role in IBD by down-regulation of P2X3 and P2X7R (<xref ref-type="bibr" rid="B525">Ma B. et al., 2016</xref>). The roles of P2X7R in IBD are discussed in reviews (<xref ref-type="bibr" rid="B467">Kurashima et al., 2015</xref>; <xref ref-type="bibr" rid="B211">Diezmos et al., 2016</xref>).</p>
<p>P2X7R-expressing enteric neurons are differentially affected in UC based on their chemical codes (<xref ref-type="bibr" rid="B190">da Silva et al., 2015</xref>). In a later paper, it was shown that UC affected secretory and vasodilatory neurons, enteric sensory neurons and enteric glia of the submucosal plexus expressing P2X7R (<xref ref-type="bibr" rid="B191">da Silva et al., 2017</xref>). The P2X7R antagonist, A438079, down-regulated the production of proinflammatory cytokines and attenuated murine colitis, indicating that P2X7R mediate inflammatory responses during UC (<xref ref-type="bibr" rid="B834">Wan P. et al., 2016</xref>). Activation of P2X7R triggers the death of mucosal regulatory T cells (<xref ref-type="bibr" rid="B263">Figliuolo et al., 2017b</xref>). There was P2XR enhancement in an animal model of UC. MicroRNA-16 and microRNA-206 have pro-inflammatory roles in UC by down-regulating A<sub>2A</sub> and A<sub>3</sub>R expression (<xref ref-type="bibr" rid="B789">Tian T. et al., 2016</xref>; <xref ref-type="bibr" rid="B863">Wu et al., 2017</xref>).</p>
<p>There is increased expression of P2X7R in the inflamed mucosa in Crohn’s disease, suggesting that P2X7R antagonists may be targets for treatment of Crohn’s disease (<xref ref-type="bibr" rid="B601">Neves et al., 2014</xref>; <xref ref-type="bibr" rid="B234">Eser et al., 2015</xref>; <xref ref-type="bibr" rid="B834">Wan P. et al., 2016</xref>; <xref ref-type="bibr" rid="B263">Figliuolo et al., 2017b</xref>). P2X3R antagonists are being explored as therapeutic agents against colic and UC pain (<xref ref-type="bibr" rid="B234">Eser et al., 2015</xref>), as well as antibodies against P2X3R (<xref ref-type="bibr" rid="B205">Deiteren et al., 2015</xref>; <xref ref-type="bibr" rid="B211">Diezmos et al., 2016</xref>; <xref ref-type="bibr" rid="B721">Shcherbatko et al., 2016</xref>).</p>
<p>The potential of P2X3R to treat irritable bowel syndrome has been suggested. In diarrhoea-predominant irritable bowel syndrome there is increased expression of P2Y<sub>1</sub> and P2Y<sub>2</sub>R, which was associated with abdominal pain (<xref ref-type="bibr" rid="B524">Luo Y. et al., 2016</xref>). P2X7R in DRG play a role in transmission of the nociceptive signal from the gut (<xref ref-type="bibr" rid="B513">Liu S. et al., 2015</xref>). A review about purinergic mediators in the control of intestinal inflammation and irritable bowel syndrome is available (<xref ref-type="bibr" rid="B467">Kurashima et al., 2015</xref>).</p>
</sec>
<sec>
<title>Motility Disorders</title>
<p>Purinergic signalling is involved in gastrointestinal motility disorders, including diarrhoea and constipation (<xref ref-type="bibr" rid="B411">Jiménez et al., 2014</xref>). Purinergic fast inhibitory junction potentials are impaired in Hirschsprung’s disease (<xref ref-type="bibr" rid="B412">Jiménez et al., 2015</xref>). P2X4 and P2X7R activity was potentiated in enteric glia isolated from mice treated long-term with morphine (<xref ref-type="bibr" rid="B68">Bhave et al., 2017</xref>).</p>
<p>A review focuses on the pathophysiological roles of P2YR in inflammation (<xref ref-type="bibr" rid="B833">Wan H.X. et al., 2016</xref>). Aged mice have a lower ability to deal with inflammation evoked by <italic>Candida albicans</italic> infection, due to a lower gut density of A<sub>2A</sub>R, which reduce inflammation (<xref ref-type="bibr" rid="B680">Rodrigues et al., 2016</xref>).</p>
</sec>
<sec>
<title>Colorectal Cancer</title>
<p>Apoptosis is induced by extracellular ATP and ATP also reduced growth of primary cultures of colorectal carcinomas, possibly via P2Y<sub>2</sub>R (see <xref ref-type="bibr" rid="B110">Burnstock and Di Virgilio, 2013</xref>; <xref ref-type="bibr" rid="B833">Wan H.X. et al., 2016</xref>). Purinergic responses of HT-29 cells, a colonic adenocarcinoma cell line, are mediated by P2Y<sub>2</sub> and/or P2Y<sub>4</sub>R. Enhanced expression of A<sub>2B</sub>R on colorectal cancer cells that are proliferating suggests that antagonists to A<sub>2B</sub>R may be a promising therapeutic target for colorectal cancer (<xref ref-type="bibr" rid="B526">Ma et al., 2010</xref>; <xref ref-type="bibr" rid="B572">Molck et al., 2016</xref>). 8-Chloro adenosine inhibited growth of colorectal cancer cell lines 80514 and HCT116 <italic>in vivo</italic> and <italic>in vitro</italic>. A phase II, multi-centre study of CF101, an A<sub>3</sub>R agonist, showed stabilisation of tumour in 35% of refractory metastatic colorectal cancer patients. P2X7R antagonists reduce tumour occurrence in a colitis-associated cancer mouse model (<xref ref-type="bibr" rid="B355">Hofman et al., 2015</xref>). There is high expression of the ectonucleotidase CD39 in human rectal adenocarcinoma (<xref ref-type="bibr" rid="B904">Zhang et al., 2015a</xref>).</p>
</sec>
</sec>
<sec>
<title>Diseases of the Kidney</title>
<p>Reviews are available (<xref ref-type="bibr" rid="B111">Burnstock et al., 2014a</xref>; <xref ref-type="bibr" rid="B556">Menzies et al., 2017</xref>; <xref ref-type="bibr" rid="B623">Oyarzun et al., 2017</xref>), including one that focuses on the roles played by ATP released as a cotransmitter from sympathetic nerves in renal diseases (<xref ref-type="bibr" rid="B116">Burnstock and Loesch, 2017</xref>).</p>
<p>Purinoceptors are richly expressed in the glomerulus, renal vascular system and nephron in the kidney, including subtypes involved in the regulation of glomerular filtration, renin secretion and transport of nutrients, ions, water and toxins. The distribution of NTPDases 1 and 2 parallels the distribution of P2R in the kidney, influencing physiological and pathophysiological renal events (see <xref ref-type="bibr" rid="B111">Burnstock et al., 2014a</xref>). Adenosine and ATP have protective effects against renal ischaemic-reperfusion injury, and have been investigated for transplantation-induced erythrocytosis and chronic renal failure treatment. It has been suggested that nephron luminal P2R are part of an epithelial ‘secretory’ defence mechanism against harmful particles or bacteria. Increased expression of P2X7R in glomerulonephritis, hypertension, polycystic kidney disease (PKD) and diabetes may be therapeutically relevant as a novel treatment of kidney failure.</p>
<sec>
<title>Renal Injury and Failure</title>
<p>ATP contributes to kidney remodelling and progression toward chronic renal failure (with associated sympathetic overactivity). P2X7R are expressed weakly in healthy glomerulus, but after glomerular injury (e.g., in hypertension and diabetes) are upregulated, mostly in podocytes, but also in mesangial and endothelial cells (<xref ref-type="bibr" rid="B828">Vonend et al., 2004</xref>). P2X7R play a role in altered intracellular calcium homeostasis in peripheral blood mononuclear cells of chronic kidney disease patients (<xref ref-type="bibr" rid="B474">Lajdova et al., 2012</xref>). P2X7R mediate deleterious renal epithelial-fibroblast cross-talk. P2X7R antagonists may be therapeutic targets to prevent and treat morbidity and mortality in kidney injury (<xref ref-type="bibr" rid="B902">Zarjou and Agarwal, 2011</xref>). P2X7R antagonists were protective against ischaemic acute kidney injury in mice (<xref ref-type="bibr" rid="B879">Yan et al., 2015</xref>). Arterial calcification is a feature in chronic kidney disease patients and ATP signalling is involved (see <xref ref-type="bibr" rid="B266">Fish et al., 2013</xref>). Cyclosporine is a potent immunosuppressive agent, but with limitations because of its side effect of nephrotoxicity. However, treatment with ATP following pre-treatment with verapamil greatly reduces nephrotoxicity. ATP is an important contributor to innate immunity regulation in primary idiopathic nephrotic syndrome. There is increased renal fibrosis in P2X4R-deficient mice following unilateral ureteric obstruction (<xref ref-type="bibr" rid="B442">Kim et al., 2014</xref>).</p>
<p>Adenosine mediates haemodynamic changes in adult renal failure. A<sub>2B</sub>R-mediated IL-6 induction contributes to renal fibrogenesis and this receptor has therapeutic potential for treatment of chronic kidney disease (<xref ref-type="bibr" rid="B322">Grenz et al., 2012</xref>). Dendritic cells and macrophages activated by A<sub>2A</sub>R agonists attenuate acute renal injury (<xref ref-type="bibr" rid="B491">Li et al., 2012</xref>; <xref ref-type="bibr" rid="B795">Truong et al., 2016</xref>). There is a review describing A<sub>2A</sub>R in acute kidney injury (<xref ref-type="bibr" rid="B819">Vincent and Okusa, 2015</xref>).</p>
</sec>
<sec>
<title>Polycystic Kidney Disease (PKD)</title>
<p>The genetic disorder PKD results in abnormal proliferation of tubular cells of the adult nephron, leading to progressive dilation of tubules and formation of fluid-filled cysts that destroy by compression neighbouring tissue. In the cysts ATP is released at high concentrations. The <italic>Caenorhabditis elegans</italic> nematode is an animal model for investigating basic molecular mechanisms underlying human autosomal dominant PKD; the <italic>C. elegans</italic> PKD-2 and LOV-1 proteins are homologues of human polycystin (PC)-1 and PC-2 proteins. Nucleotide release is involved in both fluid flow and pressure responses and its role in altered mechanosensory transduction in PKD is considered in a review (<xref ref-type="bibr" rid="B629">Patel and Honoré, 2010</xref>).</p>
<p>Cysts in the collecting ducts of the <italic>cpk/cpk</italic> mouse model of congenital PKD express P2X7R, where they mediate cyst development. P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, P2Y<sub>6</sub>, P2X5, and P2X7R were found on the lining epithelial cells of renal cysts in the rat Han:SPRD cy/+ model of autosomal dominant PKD. Expression of mRNA and protein for P2Y<sub>2</sub>, P2Y<sub>6</sub>, and P2X7R increased substantially as the disease developed. ATP inhibits renal cyst growth, via P2X7R. The P2X7R antagonists, oxidised ATP and A-438079, reduced cyst formation via extracellular signal-regulated kinase-dependent pathways in a zebrafish model of PKD (<xref ref-type="bibr" rid="B146">Chang et al., 2011</xref>). Nucleotides in the lumen fluid of cysts stimulate P2YR resulting in increased growth of Madin Darby canine kidney-derived cysts. Knocking out PKD-1 gene expression increased A<sub>3</sub>R in human renal cells (<xref ref-type="bibr" rid="B12">Aguiari et al., 2009</xref>). There is a review about the functional and therapeutic importance of purinergic signalling in PKD (<xref ref-type="bibr" rid="B383">Ilatovskaya et al., 2016</xref>).</p>
</sec>
<sec>
<title>Ischaemia</title>
<p>Proximal tubular ATP declines rapidly in ischaemic acute renal failure. There was early recognition that there was restoration after ischaemia by perfusion of ATP-MgCl<sub>2</sub> and A<sub>3</sub>R KO mice were shown to be protected against ischaemic renal failure. The ectonucleotidase CD73 protects the kidney from ischaemia-reperfusion injury via production of adenosine and free radical reduction (<xref ref-type="bibr" rid="B409">Jian et al., 2012</xref>). The role of adenosine in protection from renal ischaemia-reperfusion injury has been investigated and discussed in reviews (<xref ref-type="bibr" rid="B883">Yap and Lee, 2012</xref>; <xref ref-type="bibr" rid="B676">Roberts et al., 2013</xref>; <xref ref-type="bibr" rid="B707">Sashindranath et al., 2017</xref>).</p>
</sec>
<sec>
<title>Nephritis</title>
<p>Glomerulonephritis is one of the leading causes of end-stage renal disease. Increased expression of pro-apoptotic P2X7R has been demonstrated in both experimental and human glomerulonephritis, which suggests that P2X7R antagonists may have therapeutic potential (<xref ref-type="bibr" rid="B210">Deplano et al., 2013</xref>). It was shown later that P2X7R-deficiency attenuated renal injury in experimental glomerulonephritis (<xref ref-type="bibr" rid="B784">Taylor et al., 2009</xref>). P2X7R blockade attenuates lupus nephritis by inhibiting inflammasome activation (<xref ref-type="bibr" rid="B912">Zhao et al., 2013</xref>) and protects against cisplatin-induced nephrotoxicity (<xref ref-type="bibr" rid="B910">Zhang et al., 2014</xref>). The P2R antagonist, pyridoxal-phosphate-6-azophenyl-2′,4′-disulfonate (PPADS), effectively inhibits mesangial cell proliferation in a rat mesangial proliferative glomerulonephritis model. Tubuloglomerular feedback is greatly reduced in Thy-1 nephritic rats, but exogenous 5′-nucleotidase improved it. In P2Y<sub>1</sub>R KO mice, there is protection against fibrosis and death by renal failure as a result of experimental crescentic glomerulonephritis. Adenosine uptake inhibitors attenuated glomerulonephritis in mice. A<sub>2A</sub>R agonists may treat macrophage-mediated experimental glomerulonephritis. A<sub>2A</sub>R agonists reduced inflammation in mouse kidneys, suggesting a therapeutic approach for human lupus nephritis.</p>
</sec>
<sec>
<title>Hypertension</title>
<p>Hypertension is a feature of chronic renal disease; this is due largely to sympathetic overactivity as a result of afferent signals from the kidney and triggering sympathetic tone resetting by activation of hypothalamic centres (<xref ref-type="bibr" rid="B619">Orth et al., 2001</xref>). ATP is a cotransmitter released from sympathetic nerves, whose activity is increased in hypertension.</p>
<p>There is an enhanced P2R-mediated vasoconstriction of both efferent and afferent arterioles in chronic angiotensin II-induced hypertensive rats, with predominant P2X1 and P2X7R control of glomerular haemodynamics (<xref ref-type="bibr" rid="B275">Franco et al., 2017</xref>). In connexin 30 KO mice, epithelial sodium channels that are unable to respond to changes in sodium levels as a result of reduced paracrine ATP feedback regulation may play a role in salt-sensitive hypertension. Mice lacking P2Y<sub>2</sub>R have salt-resistant hypertension. The P2X7R is expressed weakly in healthy kidney glomerulus, but expression is significantly increased in hypertension (<xref ref-type="bibr" rid="B828">Vonend et al., 2004</xref>; <xref ref-type="bibr" rid="B557">Menzies et al., 2015</xref>). P2X7R antagonists inhibited the development of renal injury and salt-sensitive hypertension in Dahl salt-sensitive rats (<xref ref-type="bibr" rid="B406">Ji et al., 2012</xref>). Activation of A<sub>1</sub>R in mouse proximal tubules, modulated deoxycorticosterone acetate-salt hypertension.</p>
</sec>
<sec>
<title>Diabetic Nephropathy</title>
<p>Adenosine receptor agonists protect STZ-diabetic rats from nephropathy (<xref ref-type="bibr" rid="B782">Taskiran et al., 2016</xref>). A review discusses the role of A<sub>2B</sub>R antagonists as therapeutic treatment of diabetic nephropathy (<xref ref-type="bibr" rid="B654">Quezada et al., 2013</xref>). CD73 generation of adenosine attenuates diabetic nephropathy (<xref ref-type="bibr" rid="B773">Tak et al., 2014</xref>). A<sub>3</sub>R antagonists reduced fibrosis in diabetic nephropathy (<xref ref-type="bibr" rid="B456">Kretschmar et al., 2016</xref>). AMP-activated protein kinase has been proposed as a potential treatment of diabetic nephropathy (<xref ref-type="bibr" rid="B127">Cameron et al., 2016</xref>). Chronic A<sub>2A</sub>R stimulation prevents proteinuria and glomerular damage in experimental diabetes (<xref ref-type="bibr" rid="B640">Persson et al., 2015</xref>).</p>
<p>P2X7R agonists evoke renal inflammation and injury induced by high-fat diet in type 2 diabetes, suggesting that P2X7R antagonists might be of therapeutic interest (<xref ref-type="bibr" rid="B740">Solini et al., 2013</xref>). P2X7R expression was increased in the STZ diabetic rat model (<xref ref-type="bibr" rid="B828">Vonend et al., 2004</xref>). It has been suggested that P2X7R antagonists may be a useful coadjuvant treatment to delay the progression of diabetic nephropathy (<xref ref-type="bibr" rid="B679">Rodrigues et al., 2014</xref>). Data has been presented to suggest that activation of P2X7R contributes to the high prevalence of kidney disease found in diabetics (<xref ref-type="bibr" rid="B679">Rodrigues et al., 2014</xref>; <xref ref-type="bibr" rid="B556">Menzies et al., 2017</xref>). Deletion of the P2Y<sub>2</sub>R reduced the development of nephrogenic diabetes insipidus polyuria induced by lithium. Blockade of P2Y<sub>12</sub>R in the renal collecting duct alleviates nephrogenic diabetes insipidus (<xref ref-type="bibr" rid="B909">Zhang et al., 2015c</xref>).</p>
</sec>
<sec>
<title>Nephrotoxicant Injury</title>
<p>Drug-induced nephrotoxicity was reduced by ATP-MgCl<sub>2</sub>. A<sub>1</sub>R antagonists are protective against cisplatin-induced acute kidney injury in rats (<xref ref-type="bibr" rid="B303">Gill et al., 2009</xref>). Adenosine antagonists are protective against acute renal failure. A<sub>1</sub>R antagonists also reduce nephrotoxicity induced by the immunosuppressive agent cyclosporine. Cyclosporine increases plasma adenosine levels in kidney transplant patients. A<sub>3</sub>R antagonism is effective against acute tacrolimus toxicity.</p>
</sec>
<sec>
<title>Cancer</title>
<p>P2X7R are strongly expressed on human embryonic kidney tumours, associated with increased proliferation (<xref ref-type="bibr" rid="B6">Adinolfi et al., 2012</xref>). The anthraquinone, emodin, inhibits human embryonic kidney cancer cell invasiveness by antagonising P2X7R (<xref ref-type="bibr" rid="B403">Jelassi et al., 2013</xref>). A prognostic indicator for post-operative cancer-specific survival of clear-cell renal cell carcinoma patients is P2X7R expression (<xref ref-type="bibr" rid="B517">Liu Z. et al., 2015</xref>).</p>
</sec>
</sec>
<sec>
<title>Diseases of the Lower Urinary Tract</title>
<p>The early literature has been thoroughly reviewed (<xref ref-type="bibr" rid="B97">Burnstock, 2014d</xref>; <xref ref-type="bibr" rid="B434">Keay et al., 2014</xref>).</p>
<sec>
<title>Urinary Bladder</title>
<p>In contrast to laboratory animals, where the purinergic component of bladder parasympathetic cotransmission is about 50%, in healthy human bladder it is approximately 2% although ATP receptors are expressed by the smooth muscle. In pathological conditions, however, such as neurogenic bladder, outflow obstruction and interstitial cystitis (IC), the purinergic component can be as much as 40% and is consequently a therapeutic target. Botulinum neurotoxin type A (BTXA) is often used to treat bladder incontinence, where it inhibits ATP release as well as acetylcholine (ACh) release both from parasympathetic nerves and urothelial cells. Bladder epithelial cell release of ATP from patients with IC was substantially higher compared to healthy controls. Dysfunction in micturition involves P2X3R in rats with chronic spinal cord-injury, suggesting that P2X3R antagonists could be used to treat neurogenic bladder dysfunction.</p>
<sec>
<title>Overactive Bladder (OAB) Syndrome</title>
<p>There are valuable reviews that discuss the roles of purinergic signalling in OAB (<xref ref-type="bibr" rid="B555">Meng et al., 2012</xref>; <xref ref-type="bibr" rid="B695">Sacco et al., 2015</xref>). OAB syndrome, which increases in old age, is characterised by frequency, nocturia and urgency, with or without urge incontinence. Women with an OAB exhibit higher ATP levels in their urine compared to controls, suggesting that this could be used as a prognostic marker for detrusor overactivity (<xref ref-type="bibr" rid="B154">Cheng et al., 2013</xref>; <xref ref-type="bibr" rid="B728">Silva-Ramos et al., 2013</xref>). The increased urine ATP concentration is due to increased release of ATP from proliferating urothelium and reduced metabolism of ATP (<xref ref-type="bibr" rid="B728">Silva-Ramos et al., 2013</xref>). P2X3R are present in the human bladder and, when upregulated, may play a role in the pathophysiology of OAB.</p>
<p>Patients with metabolic syndrome, where the risk of developing cardiovascular disease and diabetes is increased, exhibit a higher incidence of OAB. P2X3R expression is increased in subepithelial sensory nerves resulting in increased bladder activity. OAB is common among PD patients and inhibition of overactivity by A<sub>2A</sub>R antagonists occurs, probably by acting in the CNS to regulate the micturition reflex (<xref ref-type="bibr" rid="B447">Kitta et al., 2012</xref>). Uridine diphosphate via P2Y<sub>6</sub>R regulates abnormal smooth muscle activity in the OAB and increases contractions due to P2X1R activation (<xref ref-type="bibr" rid="B894">Yu W. et al., 2013</xref>). P2Y<sub>6</sub>-deficiency increases micturition frequency and reduces contractility in the mouse urinary bladder (<xref ref-type="bibr" rid="B445">Kira et al., 2017</xref>).</p>
</sec>
<sec>
<title>Unstable Bladder</title>
<p>Unstable bladder (also referred to as detrusor instability or detrusor hyperreflexia) is either neurogenic or idiopathic in origin. Neurogenic detrusor instability can occur as a result of a stroke, or pelvic or spinal cord injury, as well as in PD and MS. Neurogenic bladders are hyper-responsive to ATP, via P2X3R.</p>
<p>Expression of P2X2R in both urothelium and detrusor muscle of suprasacral spinal cord injury patients are similar to P2X2R expression in bladder tissue from idiopathic overactive bladder patients. ATP levels increased in the rat spinal cord-injured bladder that activates P2X3 and P2X2/3R on afferent nerve fibres resulting in neurogenic bladder overactivity (<xref ref-type="bibr" rid="B586">Munoz et al., 2012</xref>). P2YR agonists ADP, UTP and uridine diphosphate originating in the urothelium augment the contractile overactivity following spinal cord injury. Sympathetic nerve hyperactivity may play a role in reflex sympathetic dystrophy where increased ATP would be released as a cotransmitter to activate P2X1R on smooth muscle resulting in increased contractions of the bladder and P2X3R on sensory nerve fibre terminals resulting in bladder reflexes and nociception. Inhibition of P2X7R expressed at spinal cord injury sites improved the dysfunction of neurogenic bladder (<xref ref-type="bibr" rid="B587">Munoz et al., 2017</xref>).</p>
<p>Urothelial cell ATP release (both resting and evoked) was substantially more from rat bladders following chronic spinal cord injury, contributing to bladder hyperactivity development. In a mouse bladder overactivity model, bradykinin facilitated the release of ATP from nerve terminals via prejunctional receptors (<xref ref-type="bibr" rid="B241">Fabiyi and Brading, 2006</xref>).</p>
<p>In the absence of P2X3R in KO mice, there is bladder hyperactivity (<xref ref-type="bibr" rid="B172">Cockayne et al., 2000</xref>; <xref ref-type="bibr" rid="B824">Vlaskovska et al., 2001</xref>). AF-219, a P2X3 and P2X2/3R antagonist that is metabolically stable and orally bioavailable, is being investigated as a treatment for urinary tract dysfunction (<xref ref-type="bibr" rid="B269">Ford and Cockayne, 2011</xref>).</p>
<p>Idiopathic detrusor instability patients show abnormal bladder purinergic transmission, which may contribute to the symptoms of OAB (<xref ref-type="bibr" rid="B27">Andersson and Hedlund, 2002</xref>; <xref ref-type="bibr" rid="B617">O’Reilly et al., 2002</xref>). There is greater potency of ATP via P2X1R for generating detrusor contractions in unstable bladder patients. Urothelial release of ATP from human bladders from patients with detrusor overactivity occurs in both idiopathic and neurogenic conditions (<xref ref-type="bibr" rid="B465">Kumar et al., 2010</xref>). Oxybutynin, administered chronically, results in a shift from muscarinic to purinergic transmission in the rat bladder wall. Expression of P2X3R is increased on suburothelial sensory nerve fibres in idiopathic detrusor overactivity patients (<xref ref-type="bibr" rid="B505">Liu H. et al., 2013</xref>).</p>
</sec>
<sec>
<title>Interstitial Cystitis (IC)/Bladder Pain Syndrome</title>
<p>The possible roles of ATP and adenosine in IC/bladder pain syndrome are discussed in a review (<xref ref-type="bibr" rid="B815">Veselá et al., 2012a</xref>). Hypoosmotic mechanical stimulation of urothelial cells released ATP that was substantially increased in cyclophosphamide-induced inflamed bladder (<xref ref-type="bibr" rid="B736">Smith et al., 2005</xref>). In rats with cystitis induced by hydrochloric acid, purinergic receptors were lost, although release of ATP from mucosal cells was increased.</p>
<p>Contractions of the rat bladder mediated by parasympathetic nerve stimulation and release of ATP and ACh, were reduced in cyclophosphamide-induced cystitis (<xref ref-type="bibr" rid="B817">Veselá et al., 2012b</xref>), while P2XR function in sensory neurons was enhanced. The purinergic component was abolished in the neurogenic bladder following desensitisation with α,β-methylene ATP (α,β-meATP). ATP release due to stretch from bladder urothelium from IC patients was greater compared to healthy urothelium and P2X3R expression was upregulated. Urothelial cells from cats with feline IC responded to α,β-meATP, indicating increased expression of urothelial P2XR. There is mechanical hypersensitivity of the bladder in feline IC together with greater release of ATP from the urothelium; P2X1R expression is reduced and P2Y<sub>2</sub>R expression is lost.</p>
<p>A<sub>1</sub>R blockade during the initial phase of IC/bladder pain syndrome was suggested as a treatment for this condition (<italic><xref ref-type="bibr" rid="B36">Aronsson et al., 2012</xref></italic>). The A<sub>1</sub>R in rat urinary bladder is decreased in cyclophosphamide-induced cystitis (<xref ref-type="bibr" rid="B816">Veselá et al., 2011</xref>).</p>
<p>In neutrophils and macrophages in the submucosa of the bladder from mice with cyclophosphamide-induced haemorrhagic cystitis, expression of P2X7R is increased (<xref ref-type="bibr" rid="B539">Martins et al., 2012</xref>). Treatment with A-438079, a P2X7R antagonist, or genetic ablation of this receptor reduced nociceptive behaviour.</p>
</sec>
<sec>
<title>Outflow Obstruction</title>
<p>P2X1R expression in smooth muscle of the bladder was increased in the human obstructed bladder. In animal models of outlet obstruction, <italic>in vivo</italic> release of ATP from urothelial cells was increased compared to controls (<xref ref-type="bibr" rid="B16">Akino et al., 2011</xref>). Contractions to ATP were reduced in obstructed urinary bladder of rats (<xref ref-type="bibr" rid="B734">Sjuve Scott et al., 2004</xref>). There is P2X3R up-regulation in interstitial cells of Cajal in an experimental rat model of partial bladder outflow obstruction (<xref ref-type="bibr" rid="B498">Li et al., 2013</xref>). In the pig, partial bladder outlet obstruction resulted in reduced contractions in response to electrical field stimulation as well as to purinergic agonists (<xref ref-type="bibr" rid="B565">Milicic et al., 2006</xref>), but in the rat partial outlet obstruction model, contractions to ATP were increased after 2 weeks and 3 months (<xref ref-type="bibr" rid="B588">Murakami et al., 2008</xref>). Patients with bladder outflow obstruction release higher amounts of ATP into the urine (<xref ref-type="bibr" rid="B727">Silva-Ramos et al., 2016</xref>).</p>
</sec>
<sec>
<title>Botulinum Toxin A (BTXA) and ATP Release</title>
<p>BTXA is increasingly being used to treat detrusor overactivity. In an early paper, it was shown that BTXA inhibited ATP as well as ACh release from parasympathetic nerves. Recently, BTX has been shown to inhibit ATP release from the urothelium (<xref ref-type="bibr" rid="B144">Chancellor et al., 2008</xref>; <xref ref-type="bibr" rid="B382">Ikeda Y. et al., 2012</xref>; <xref ref-type="bibr" rid="B183">Cruz, 2013</xref>). Daytime frequency, urgency, nocturia and pain were decreased by injection of BTXA into the human bladder. BTX is used to treat OAB syndrome and bladder hypersensory states (<xref ref-type="bibr" rid="B34">Apostolidis et al., 2005</xref>; <xref ref-type="bibr" rid="B39">Atiemo et al., 2005</xref>).</p>
</sec>
<sec>
<title>Chronic Alcohol Consumption and Bladder Function</title>
<p>Chronic consumption of ethanol impairs purinoceptor-mediated relaxation of detrusor smooth muscle of the rat (<xref ref-type="bibr" rid="B124">Calvert et al., 2002</xref>). Ethanol also alters neuronal P2XR.</p>
</sec>
<sec>
<title>Diabetic Bladder</title>
<p>Damage to human urinary bladder autonomic nerves and disturbances in micturition in diabetes have been recognised for many years. Urothelial release of ATP has been reported to play a role in bladder dysfunction in type 2 diabetes (<xref ref-type="bibr" rid="B840">Wang Z. et al., 2013</xref>). There is a transient increase in sensitivity of the STZ rat whole bladder preparation to α,β-meATP. The cholinergic component of nerve-mediated contractions was reduced in diabetic rat and rabbit bladders, but the purinergic component was increased (<xref ref-type="bibr" rid="B584">Mumtaz et al., 2006</xref>).</p>
<p>In STZ mice, the urinary bladder had weaker nerve-mediated contractions in response to electrical field stimulation in contrast to normal mouse bladder. Ca<sup>2+</sup> regulation of ATP release may be impaired in diabetes. Increased adenosine- and ATP-mediated relaxant responses, together with increased ATP-mediated contractile responses were observed in bladders from 8-week STZ diabetic rats. The enhanced contractions of STZ-diabetic rat bladders to nerve stimulation and ATP peaked between 6 and 9 weeks, but dropped to control levels by 12–20 weeks (<xref ref-type="bibr" rid="B195">Daneshgari et al., 2006</xref>). There is also an increase in release of ATP in STZ female rat bladders (<xref ref-type="bibr" rid="B585">Munoz et al., 2008</xref>). There is upregulation of P2X1R in the bladder of STZ-induced diabetes in the early phase, but downregulation of the P2X2R (<xref ref-type="bibr" rid="B504">Liu et al., 2008</xref>). Bladder overactivity occurring 2 months after induction of diabetes with STZ was accompanied by enhanced expression of P2Y<sub>2</sub> and P2Y<sub>4</sub>R (<xref ref-type="bibr" rid="B758">Suadicani et al., 2009</xref>).</p>
</sec>
<sec>
<title>Bacterial Infection</title>
<p>Bacterial infection of the bladder causes urgency, urinary incontinence and overactivity. Urine ATP concentrations were reduced during episodes of bacteriuria (<xref ref-type="bibr" rid="B832">Walsh et al., 2013</xref>). An ATP assay method has been employed for many years to test for bacteriuria in urine.</p>
</sec>
<sec>
<title>Bladder Cancer</title>
<p>The growth of bladder cancer cells is reduced by ATP, both <italic>in vivo</italic> and <italic>in vitro</italic> (<xref ref-type="bibr" rid="B719">Shabbir et al., 2008</xref>; <xref ref-type="bibr" rid="B718">Shabbir and Burnstock, 2009</xref>). Doxorubicin, used to treat bladder cancer, has side effects, such as increased urgency and urinary frequency. Quercetin, a plant-derived flavonoid, prevents bladder cancer in cells lines, by suppressing cell proliferation and inducing arrest of the cell cycle or cell death by inhibiting the activity of ecto-nucleotidases (<xref ref-type="bibr" rid="B678">Rockenbach et al., 2013</xref>). In humans with bladder papillary carcinoma urothelial differentiation was correlated with the expression and localisation of P2X3 and P2X5R (<xref ref-type="bibr" rid="B755">Sterle et al., 2014</xref>). High CD73 immunoreactivity was associated with reduced bladder tumour progression (<xref ref-type="bibr" rid="B847">Wettstein et al., 2015</xref>). P2X7R protein favoured survival of patients with bladder urothelial cell carcinoma (<xref ref-type="bibr" rid="B365">Hu J. et al., 2016</xref>).</p>
</sec>
<sec>
<title>Bladder Pain</title>
<p>In 1995, P2X3 homomultimer and P2X2/3 heteromultimer receptors were cloned and were localised on sensory nerve endings. Purinergic mechanosensory transduction was proposed (<xref ref-type="bibr" rid="B87">Burnstock, 1999</xref>), suggesting that release of ATP from urothelial cells as a result of distension stimulates P2X3 and P2X2/3R on suburothelial sensory nerve endings to activate high threshold nociceptive nerve fibres that reach the cortex pain centres (<xref ref-type="bibr" rid="B93">Burnstock, 2009</xref>). Distension of the bladder stimulates discharge in the nociceptive sensory nerves, which can be mimicked by ATP and can be inhibited by P2X3R antagonists (<xref ref-type="bibr" rid="B824">Vlaskovska et al., 2001</xref>). Stimulation of bladder P2X3R sensitises bladder afferent nerves, mimicking the sensitising effect of cyclophosphamide-induced cystitis. P2X3R are a potential target for therapeutic treatment of bladder pain. P2Y<sub>2</sub>R are also expressed on bladder sensory nerves and are claimed to mediate increased stimulation of P2XR-mediated activity, playing a role in bladder pain syndrome (IC) (<xref ref-type="bibr" rid="B151">Chen et al., 2010</xref>).</p>
</sec>
</sec>
<sec>
<title>Urethra</title>
<p>The principal non-adrenergic, non-cholinergic inhibitory transmitter to the urethra is NO, but a small component of purinergic neurotransmission is also involved (<xref ref-type="bibr" rid="B25">Andersson, 2001</xref>). ATP causes urethral relaxation, probably via P2Y<sub>1</sub>R, in pigs, guinea-pigs, rabbits and hamsters. The responses to non-adrenergic, non-cholinergic nerve stimulation were blocked by α,β-meATP, indicating that the P2X1R subtype was involved.</p>
<p>Sensory nerve fibres supplying the urethra may release ATP during axon reflex activity. Prostaglandins, produced following stimulation of P2YR, contribute to contractions of the urethra in pathophysiological conditions. In the rat, SC19220 (a prostaglandin E1 antagonist), lowered detrusor tone leading to increased bladder capacity and decreased voiding efficiency. Some sensory functions in the urethra are mediated by afferent fibres that express P2X3R (<xref ref-type="bibr" rid="B128">Canda et al., 2006</xref>). A review that discusses the therapeutic opportunities offered by K<sub>ATP</sub> channels in the urethra is available (<xref ref-type="bibr" rid="B471">Kyle, 2014</xref>).</p>
</sec>
<sec>
<title>Ureter</title>
<p>The ureter motor innervation is sparse, perhaps because peristaltic activity is not neurogenic, but myogenic. The dominant nerves in the ureter are sensory, confined mainly to the suburothelial plexus. These nerves contribute to vesicoureteral reflux that activates reflexes that modulate urine delivery to the bladder.</p>
<p>ATP constricts the pig ureter, while intravesical adenosine evoked relaxation via A<sub>2B</sub>R. In the ureter, ATP, α,β-meATP and adenosine evoked transient decreases in the frequency of peristalsis. In the rat ureter expression of P2X1R was shown on smooth muscle, while P2X5 and perhaps P2X7R are expressed on urothelium and P2X6R in the layer beneath the urothelium. P2X3R are localised on subepithelial sensory nerves that mediate nociception produced by release of ATP following distension of urothelial cells (<xref ref-type="bibr" rid="B449">Knight et al., 2002</xref>; <xref ref-type="bibr" rid="B686">Rong and Burnstock, 2004</xref>). Some ureter purinoceptors are likely to participate in long-term (trophic) events during development and regeneration, such as cell proliferation, differentiation, migration and cell death. The human ureter releases ATP in response to distension and human ureteric suburothelial sensory nerves express P2X3R (<xref ref-type="bibr" rid="B126">Calvert et al., 2008b</xref>). In a review of the pharmacology and physiology of the human ureter, it was proposed that purinergic receptors may prove to be analgesic targets to treat ureteral colicky pain and to facilitate ureteral stone passage (<xref ref-type="bibr" rid="B129">Canda et al., 2007</xref>).</p>
<p>Seven days after unilateral ureteral obstruction of wild-type mice, it was shown that there was increased expression of P2X7R associated with fibrogenic responses and inflammation in the cortex. However, in P2X7R KO mice, the alterations seen in the wild-type mice were not present. It was suggested that P2X7R antagonists may play a role in preventing renal interstitial fibrosis. In A<sub>2A</sub>R KO mice with unilateral ureteral obstruction, there was a substantially increased progression of renal interstitial fibrosis (<xref ref-type="bibr" rid="B868">Xiao et al., 2013</xref>).</p>
</sec>
</sec>
<sec>
<title>Diseases of the Liver</title>
<p>In the liver, the two epithelial cell types that secrete bile, i.e., hepatocytes and cholangiocytes, express purinoceptor in the plasma membrane. Modulation of the release of ATP and purinergic signalling may be novel strategies to manage cholestasis and other bile flow disorders. Both quiescent and activated hepatic stellate cells (HSC) express purinergic receptors: P2Y<sub>2</sub> and P2Y<sub>4</sub>R on quiescent and P2Y<sub>6</sub>R on activated HSC. P2YR on satellite cells could be a therapeutic target to treat or prevent liver fibrosis. Reviews concerned with purinergic signalling in liver disease are available (<xref ref-type="bibr" rid="B121">Burnstock et al., 2014b</xref>; <xref ref-type="bibr" rid="B812">Vaughn et al., 2014</xref>).</p>
<sec>
<title>Liver Injury, Inflammation, Immune Regulation and Repair</title>
<p>Purinergic signalling regulates the immune response in the liver. In A<sub>1</sub>R KO mice α-naphthylisothiocyanate-induced cholestatic liver injury was decreased. CD39-deficient mice treated with adenosine, probably via A<sub>2A</sub>R, were protected from reperfusion injury (<xref ref-type="bibr" rid="B764">Sun et al., 2011</xref>). A<sub>1</sub>R antagonists abolished ischaemic preconditioning. After the resection of bile-duct-ligated cirrhotic livers, an A<sub>2A</sub>R agonist improved liver function (<xref ref-type="bibr" rid="B392">Iskandarov et al., 2016</xref>). Inhalation of high concentrations of hydrogen protects against ischaemia/reperfusion injury through A<sub>2A</sub>R activation (<xref ref-type="bibr" rid="B489">Li H. et al., 2017</xref>). Adenosine, via A<sub>2B</sub> or A<sub>3</sub>R, accelerates the cell cycle during partial hepatectomy-induced liver regeneration in rats (<xref ref-type="bibr" rid="B553">Mendieta-Condado et al., 2007</xref>). In mice, ATL-146e, a selective A<sub>2A</sub>R agonist, prevented concanavalin A-induced acute liver injury.</p>
<p>P2Y<sub>2</sub>R activation in mice makes a major contribution to endotoxin-induced acute liver injury (<xref ref-type="bibr" rid="B702">Samuel et al., 2010</xref>). In mice with acute liver injury, P2Y<sub>2</sub>R mediate neutrophil infiltration, regulating immune responses associated with death of hepatocytes. P2Y<sub>2</sub>R antagonists might be useful to treat inflammatory liver disease (<xref ref-type="bibr" rid="B42">Ayata et al., 2012</xref>). A review discusses the role of purinergic signalling in sterile liver injury (<xref ref-type="bibr" rid="B612">Oliveira et al., 2013</xref>).</p>
<p>Infusion of ATP-MgCl<sub>2</sub> was shown early to improve hepatic function and survival following hepatic ischaemia and after reperfusion. During ischaemia there is a substantial loss of ATP from hepatocytes. Resistance of hepatocytes to hypoxia is promoted by P2Y<sub>2</sub>R. In mice, CD39 deletion from natural killer (NK) cells reduced hepatic ischaemia/reperfusion injury, indicating that during liver regeneration ATP modulates NK cell function. UTP acting via P2Y<sub>2</sub> and/or P2Y<sub>4</sub>R before induction of ischaemia attenuates post-ischaemic hepatocyte apoptosis resulting in a reduction of liver damage (<xref ref-type="bibr" rid="B62">Ben-Ari et al., 2009</xref>). Platelet aggregation triggered by ADP may have a role in ischaemia reperfusion injury (<xref ref-type="bibr" rid="B714">Schulte am Esch et al., 2010</xref>).</p>
<p>ATP released from sympathetic nerves and from hepatocytes, may participate in the regulation of liver repair. In P2Y<sub>2</sub>R KO mice, hepatocellular proliferation is impaired, indicating that ATP has a trophic role in liver regeneration and growth after injury (<xref ref-type="bibr" rid="B787">Thevananther et al., 2008</xref>). ATP release following partial hepatectomy in rats regulates liver regeneration. Apyrase (CD39/NTPDase1) reduces extracellular ATP allowing NK cells to play a role in the regulation of the immune response and to improve liver regeneration (<xref ref-type="bibr" rid="B319">Graubardt et al., 2013</xref>). After partial hepatectomy, liver regeneration is enhanced by the K<sub>ATP</sub> opener, diazoxide (<xref ref-type="bibr" rid="B591">Nakagawa et al., 2012</xref>).</p>
<p>Hepatocyte lipoapoptosis contributes to hepatic inflammation in lipotoxic liver injury. Pannexin1 may contribute to hepatic inflammation by increasing ATP release in lipotoxic liver injury (<xref ref-type="bibr" rid="B867">Xiao et al., 2012</xref>). Acetaminophen (APAP), used to reduce pain and fever, may damage hepatocytes. In mouse APAP-induced inflammation models, full injury following an overdose involved P2X7R activation (<xref ref-type="bibr" rid="B23">Amaral et al., 2013</xref>). P2X7R activate hepatic caspase-1 as well as the migration of neutrophils into the liver, suggesting that ATP may play a major role in the development of inflammasomes following overdose of APAP (<xref ref-type="bibr" rid="B358">Hoque et al., 2012</xref>). A438079, a P2X7R antagonist, is protective against APAP-induced liver injury (<xref ref-type="bibr" rid="B870">Xie et al., 2013</xref>). P2X4R are involved in liver regeneration after partial hepatectomy in mice (<xref ref-type="bibr" rid="B65">Besnard et al., 2016</xref>). P2X1R-regulated IL-22 secretion is required for liver regeneration (<xref ref-type="bibr" rid="B463">Kudira et al., 2016</xref>).</p>
</sec>
<sec>
<title>Fibrosis and Hepatic Stellate Cells (HSC)</title>
<p>Liver fibrosis followed by cirrhosis is a common cause of liver failure. HSC are the main fibrogenic cells of the liver, which express nucleotide receptors that are functional (<xref ref-type="bibr" rid="B460">Kruglov et al., 2007</xref>) and mediate phospholipase D activity (<xref ref-type="bibr" rid="B63">Benitez-Rajal et al., 2006</xref>).</p>
<p>Adenosine A<sub>2B</sub>R play pro-fibrotic roles in human HSC (<xref ref-type="bibr" rid="B916">Zhong et al., 2007</xref>). During fibrosis, HSC proliferate and undergo senescence and A<sub>2A</sub>R mediate both these key processes, suggesting that A<sub>2A</sub>R antagonists are potential antifibrotics (<xref ref-type="bibr" rid="B13">Ahsan, 2011</xref>). A<sub>2A</sub>R contribute to the pathogenesis of hepatic fibrosis and A<sub>2A</sub>R antagonists may reduce ethanol-induced stellate cell activation and fibrosis (<xref ref-type="bibr" rid="B770">Szuster-Ciesielska et al., 2012</xref>; <xref ref-type="bibr" rid="B157">Chiang et al., 2013</xref>). MRS1754, an A<sub>2B</sub>R antagonist, reduced hepatic collagen deposition during fibrosis progression (<xref ref-type="bibr" rid="B756">Stoll et al., 2012</xref>).</p>
<p>Activation of P2Y<sub>2</sub> and P2Y<sub>6</sub>R regulates procollagen-1 transcription and may be targets to treat or prevent liver fibrosis, thereby avoiding cirrhosis and chronic liver failure. PPADS, a P2R antagonist, inhibited HSC proliferation and prevented the development of non-biliary liver fibrosis (<xref ref-type="bibr" rid="B220">Dranoff et al., 2007</xref>). NTPDase2 is a preferential ATPase that greatly influences inflammation and biliary type fibrogenesis. Ecto-5′-nucleotidase (CD73) gene expression in HSC and portal fibroblasts increased during myofibroblastic differentiation and is a therapeutic target for antifibrotic therapy (<xref ref-type="bibr" rid="B248">Fausther et al., 2012</xref>).</p>
<p>Human platelet ATP release contributes to reduced type I collagen production and HSC activation <italic>in vitro</italic> (<xref ref-type="bibr" rid="B381">Ikeda N. et al., 2012</xref>). In progressive fibrosis, eicosapentaenoic acid replenishes hepatic levels of ATP leading to a reduction of steatosis and inflammation (<xref ref-type="bibr" rid="B408">Jia et al., 2012</xref>). Blockade of the P2X7R-NLRP3 inflammasome axis is considered to be a potential therapeutic target for liver fibrosis (<xref ref-type="bibr" rid="B410">Jiang et al., 2017</xref>).</p>
</sec>
<sec>
<title>Cirrhosis</title>
<p>Liver injury induced by alcohol is associated with enhanced inflammatory responses and adenosine, acting via A<sub>2A</sub>R, may prove to be an effective strategy for reducing liver injury (<xref ref-type="bibr" rid="B651">Pritchard et al., 2011</xref>). During fulminant hepatitis, A<sub>2A</sub>R contribute to the anti-inflammatory actions that limit liver damage (<xref ref-type="bibr" rid="B160">Choukèr et al., 2008</xref>). In cirrhosis, platelet dysfunction is partly mediated by purinergic signalling. Cerebral A<sub>1</sub>R are involved in liver cirrhosis (<xref ref-type="bibr" rid="B77">Boy et al., 2008</xref>). Ectonucleotidase NTPDase 2 is down-regulated in biliary cirrhosis. It has also been claimed that endogenous A<sub>1</sub>R activation may protect mice against liver injury induced by acute ethanol by reducing oxidative stress and decreasing the accumulation of lipid (<xref ref-type="bibr" rid="B882">Yang et al., 2013</xref>). ATP-MgCl<sub>2</sub> was used early to improve survival following massive hepatectomy in cirrhotic rats and adenosine partially reversed cirrhosis induced by carbon tetrachloride. In alcoholic liver disease, ATP and uric acid mediate inflammatory cross-talk between immune cells and hepatocytes (<xref ref-type="bibr" rid="B641">Petrasek et al., 2015</xref>). A<sub>2A</sub>R are involved in the pathogenesis of hepatic cirrhosis (<xref ref-type="bibr" rid="B143">Chan et al., 2006</xref>).</p>
</sec>
<sec>
<title>Hepatitis</title>
<p><italic>In vitro</italic> infection by duck hepatitis B virus, <italic>Rous sarcoma</italic> virus, and hepatitis delta virus was inhibited by suramin. Sympathetic nerves influence immune-mediated experimental hepatitis (<xref ref-type="bibr" rid="B600">Neuhuber and Tiegs, 2004</xref>) and ATP released as a cotransmitter with NA is probably involved. In autoimmune hepatitis P2X7R regulate NKT cells (<xref ref-type="bibr" rid="B432">Kawamura et al., 2006</xref>). P2X7R activation participates in hepatitis delta and hepatitis B virus infection of human hepatocytes (<xref ref-type="bibr" rid="B783">Taylor and Han, 2010</xref>). Leptin-induced GLUT4 function in stellate cells in non-alcoholic steatohepatitis is mediated by P2X7R (<xref ref-type="bibr" rid="B145">Chandrashekaran et al., 2016</xref>). Chronic hepatitis C virus infection evokes progressive liver disease, exhibiting cirrhosis, insulin resistance, fibrosis and finally liver cancer. P2X4 and P2X7R may be a major component of the purinergic signalling complex in hepatitis C virus-induced liver pathogenesis (<xref ref-type="bibr" rid="B535">Manzoor et al., 2016</xref>). In rats, A<sub>2A</sub>R stimulation inhibited hepatocyte lipotoxicity and non-alcoholic steatohepatitis (<xref ref-type="bibr" rid="B386">Imarisio et al., 2012</xref>). Adenosine, via A<sub>2A</sub>R, controls NKT-cell-dependent hepatitis induction (<xref ref-type="bibr" rid="B759">Subramanian et al., 2014</xref>). Purinergic mechanisms involved in autoimmune hepatitis have been reviewed (<xref ref-type="bibr" rid="B426">Kapila et al., 2013</xref>).</p>
</sec>
<sec>
<title>Liver Transplantation</title>
<p>Human liver can be maintained successfully under hypothermic conditions for a maximum of 10 h using adenosine at high concentrations, although overcoming ischaemic damage is a major obstacle. However, infusion of ATP can preserve cells injured sublethally by enhancing their recovery following ischaemic injury and purinergic receptor antagonists prevent cold preservation-induced cell death. Upregulation of CD39 post-adenoviral infection prolongs transplant graft survival. After transplantation regeneration of the donor liver is important and ATP, via P2Y<sub>2</sub>R, activates hepatocyte cell cycle progression and proliferation <italic>in vitro</italic> and modulates growth factor activities <italic>in vivo</italic> (<xref ref-type="bibr" rid="B788">Thevananther et al., 2004</xref>). A<sub>2A</sub>R stimulation down regulated adhesion molecules, proinflammatory cytokines and ultimately improved liver function following liver transplantation in rats (<xref ref-type="bibr" rid="B779">Tang et al., 2010</xref>). In post-transplant allografts, purinergic signalling is used to predict as well as monitor progression of fibrosis and rejection. Blood from acute rejection patients showed raised intracellular levels of ATP in CD4<sup>+</sup> lymphocytes (<xref ref-type="bibr" rid="B653">Qu et al., 2017</xref>).</p>
</sec>
<sec>
<title>Liver Cancer</title>
<p>Primary liver malignant tumours are subdivided in to hepatocarcinoma, bile duct carcinoma (cholangiocarcinoma) and hepatocholangiocarcinoma. ATP increases calcium uptake by rat hepatoma cells, probably via P2Y<sub>2</sub> or P2Y<sub>4</sub>R subtypes. There is upregulation of P2Y<sub>2</sub>R in human hepatocellular carcinoma cells (<xref ref-type="bibr" rid="B772">Tak et al., 2016</xref>), which mediates proliferation and migration of the cells (<xref ref-type="bibr" rid="B869">Xie et al., 2014</xref>). Carcinoma-specific expression of P2Y<sub>11</sub>R make a major contribution to ATP-induced signalling that controls cell migration in human hepatocellular carcinoma cells (<xref ref-type="bibr" rid="B437">Khalid et al., 2017</xref>). CD39 KO mice showed an increased incidence of spontaneous and induced hepatocellular carcinoma. Intra-arterial injection of an inhibitor of ATP production was suggested as a novel liver cancer therapy. The effects of ATP infusions <italic>in vivo</italic> on rat hepatocarcinomas have been investigated (<xref ref-type="bibr" rid="B280">Frontini et al., 2011</xref>). P2X3R over-expression is involved in poor recurrence-free survival in hepatocellular carcinoma patients and identifies the P2X3R as a potential therapeutic target (<xref ref-type="bibr" rid="B547">Maynard et al., 2015</xref>). Inhibition by adenosine of hepatoma cell growth was reported early.</p>
<p>The A<sub>3</sub>R agonist, CF101, inhibited liver metastasis (following colon carcinoma) (<xref ref-type="bibr" rid="B50">Bar-Yehuda et al., 2008</xref>). CF102, another selective A<sub>3</sub>R agonist, has anti-inflammatory and anti-tumour effects on the liver and was studied in a clinical trial for hepatocellular carcinoma patients (<xref ref-type="bibr" rid="B754">Stemmer et al., 2010</xref>). A<sub>2B</sub>R are strongly expressed in human hepatoma cellular carcinoma (<xref ref-type="bibr" rid="B866">Xiang et al., 2006</xref>). Mouse regulatory T cell CD39 expression mediated inhibition of NK cell activity and promoted hepatic metastatic tumour growth (<xref ref-type="bibr" rid="B763">Sun et al., 2013</xref>). Liver metastasis from colorectal cancer is one of the main causes of cancer-related morbidity and ATP-chemotherapy may effectively treat initially unresectable colorectal liver metastasis (<xref ref-type="bibr" rid="B376">Hur et al., 2012</xref>). In hepatocellular carcinoma, up-regulation of ATP-binding cassette transporter genes is mediated by cellular microRNAs (<xref ref-type="bibr" rid="B72">Borel et al., 2012</xref>).</p>
</sec>
</sec>
<sec>
<title>Diseases of the Reproductive System</title>
<p>Reviews are available about purinergic signalling in the reproductive system in both health and disease (<xref ref-type="bibr" rid="B96">Burnstock, 2014c</xref>; <xref ref-type="bibr" rid="B318">Gorodeski, 2015</xref>).</p>
<sec>
<title>Disorders of the Male Reproductive Tract</title>
<sec>
<title>Erectile Dysfunction</title>
<p>Abnormalities in purinergic signalling, including impaired ATP-mediated cavernosal relaxation, may contribute to erectile dysfunction associated with prostate enlargement and diabetes and may provide a target for therapy (<xref ref-type="bibr" rid="B375">Hupertan et al., 2012</xref>; <xref ref-type="bibr" rid="B844">Wen and Xia, 2012</xref>). Normal penile erectile function involves a fine balance between contraction and relaxation in the corpus cavernosum smooth muscle. The strong relaxation induced by ATP via P2YR on human corpus cavernosum is comparable to that produced by NO, thus ATP together with an NO donor may prove to be effective for erectile disorders (<xref ref-type="bibr" rid="B375">Hupertan et al., 2012</xref>). ATP released from sympathetic nerves leads to relaxation of cavernosum smooth muscle via P2Y<sub>4</sub>R, whereas ADP, after breakdown of ATP released from endothelial cells, acts via P2Y<sub>1</sub>R on endothelial cells to produce relaxation via NO (<xref ref-type="bibr" rid="B125">Calvert et al., 2008a</xref>). P2XR might also be involved (<xref ref-type="bibr" rid="B332">Gur et al., 2007</xref>; <xref ref-type="bibr" rid="B643">Phillips et al., 2014</xref>).</p>
<p>In anaesthetised dogs, ATP and adenosine induce penile tumescence, probably via A<sub>2</sub>R; pelvic nerve stimulation also produced tumescence. Impaired adenosine signalling via A<sub>1</sub>R contributes to erectile dysfunction (<xref ref-type="bibr" rid="B604">Ning et al., 2012a</xref>). Elevated adenosine signalling, via A<sub>2B</sub>R, may contribute to priapism, where there is persistent penile erection lasting at least 4 h without sexual excitation (<xref ref-type="bibr" rid="B193">Dai et al., 2009</xref>; <xref ref-type="bibr" rid="B605">Ning et al., 2012b</xref>). A review highlights adenosine signalling in penile tissue as a potential therapeutic target to treat erectile disorders (<xref ref-type="bibr" rid="B844">Wen and Xia, 2012</xref>). Impaired erectile function occurs in CD73 KO mice resulting in decreased endogenous adenosine. Corpus cavernosum from men suffering from vasculogenic erectile dysfunction show lower ectonucleotidase CD39 activity resulting in ATP accumulation. Human corpus cavernosum relaxation by P2R agonists was substantially reduced in erectile dysfunction patients (<xref ref-type="bibr" rid="B245">Faria et al., 2010</xref>). ATP release from cavernosal tissue increased in patients following prostatectomy. Activating ATP-mediated pathways may restore erectile function in diabetics where there is impaired NO bioavailability. It has been suggested that P2X3 antagonists may improve recovery of erectile function (<xref ref-type="bibr" rid="B488">Li C.L. et al., 2015</xref>).</p>
</sec>
<sec>
<title>Male Fertility and Contraception</title>
<p>ATP increases the fertilising potential of sperm in humans and is used to treat spermatozoa during <italic>in vitro</italic> fertilisation. In P2X1R KO mice fertility was diminished with decreased number of spermatozoa in the ejaculate (<xref ref-type="bibr" rid="B583">Mulryan et al., 2000</xref>). This raises the possibility that P2X1R antagonists would provide a safe and effective contraceptive (<xref ref-type="bibr" rid="B848">White et al., 2013</xref>). In rat testes, during spermatogenesis there is differential, stage-dependent immunostaining for P2XR subtypes (<xref ref-type="bibr" rid="B309">Glass et al., 2001</xref>), suggesting purinergic targets for both fertility and contraception. ATP triggers the acrosome reaction via P2X7R in human spermatozoa (<xref ref-type="bibr" rid="B794">Torres-Fuentes et al., 2015</xref>). Purinergic signalling plays a role in the maturation of sperm cells in the testes. When the selective P2X1 and P2X3R desensitiser, α,β-meATP, was injected into the cauda epididymis, fertility in male rats was impaired. Adenosine stimulates human sperm motility via A<sub>2</sub>R.</p>
</sec>
<sec>
<title>Prostatic Hyperplasia</title>
<p>Purinergic compounds have been suggested for the therapeutic treatment of benign prostatic hyperplasia (<xref ref-type="bibr" rid="B26">Andersson et al., 2002</xref>). Injection of BTX into the prostate, which reduces ATP and ACh release, treats bladder obstruction hyperactivity, by decreasing prostate size and as such improving urine flow rate (<xref ref-type="bibr" rid="B161">Chuang and Chancellor, 2006</xref>).</p>
</sec>
</sec>
<sec>
<title>Disorders of the Female Reproductive Tract</title>
<p>Regulating the proliferation of ovarian granulosa cells as well as steroidogenesis contributes to ovarian pathophysiology, since in rats with polycystic ovarian syndrome, theca hyperplasia occurs (<xref ref-type="bibr" rid="B701">Salvetti et al., 2009</xref>). The hydrolysis of ADP and ATP was reduced by ovariectomy and oestradiol replacement therapy (<xref ref-type="bibr" rid="B648">Pochmann et al., 2004</xref>). Ovarian tumours arise largely from the surface of squamous-to-cuboid mesothelium covering the ovary. ATP stimulated mitogen-activated kinase in neoplastic and pre-neoplastic surface epithelium, suggesting that co-released ATP from sympathetic nerves may contribute to the regulation of cell proliferation in neoplastic epithelial cells from the surface of the ovary (<xref ref-type="bibr" rid="B159">Choi et al., 2003</xref>).</p>
<p>In the human fallopian tube, ATP-mediated contractions are increased during acute purulent inflammation, probably as a result of upregulation of P2X1 and P2X2R (<xref ref-type="bibr" rid="B924">Ziganshin et al., 2008</xref>). It has been claimed that targeting P2X7R may lead to new treatments to prevent uterine contractions in preterm deliveries. A naturally occurring P2X7 splice variant, the P2X7jR, blocks P2X7R-mediated actions (<xref ref-type="bibr" rid="B251">Feng et al., 2006</xref>). It is co-expressed with P2X7R in female reproductive tract epithelia. The P2X7j isoform hetero-oligomerises with the P2X7R and co-expression of P2X7R and P2X7jR blocks ATP-induced pore formation, and abolishes agonist-induced apoptosis. P2Y<sub>2</sub>R agonists may be a non-hormonal alternative therapy for treating vaginal dryness in post-menopausal women. ATP is considered as a therapeutic target to control uterine activity during difficult labours (<xref ref-type="bibr" rid="B899">Zafrah and Alotaibi, 2017</xref>).</p>
<p>The P2X7R contributes to the control of cervical infections. P2X7R-mediated activation of cervical epithelial cells inhibits <italic>Chlamydia</italic> and mycobacteria infection (<xref ref-type="bibr" rid="B198">Darville et al., 2007</xref>). ATP regresses endometriosis in a rat model (<xref ref-type="bibr" rid="B905">Zhang C. et al., 2016</xref>). Adenosine in the placenta mediates the placental disturbances induced by alcohol, perhaps contributing to the pathogenesis of foetal alcohol syndrome (<xref ref-type="bibr" rid="B4">Acevedo et al., 1997</xref>). Adenosine protects vaginal epithelial cells from <italic>T. vaginalis</italic> cytotoxicity (<xref ref-type="bibr" rid="B554">Menezes and Tasca, 2016</xref>). Plasma adenosine is raised in hyperemesis gravidarum (severe morning sickness) and serves as a prejunctional modulator of sympathetic neurotransmission, which limits further progression of this pregnancy-related disease (<xref ref-type="bibr" rid="B890">Yoneyama et al., 2004</xref>).</p>
<sec>
<title>Preeclampsia</title>
<p>ATP infusion in pregnant rats involved an inflammatory response that occurs in preeclampsia (<xref ref-type="bibr" rid="B745">Spaans et al., 2014a</xref>). Elevated placental adenosine signalling contributes to the pathogenesis of preeclampsia (<xref ref-type="bibr" rid="B389">Iriyama et al., 2015</xref>). Hypoxia stimulates ATP release, which is rapidly broken down to adenosine by ectonucleotidases and women with preeclampsia and their foetuses have increased circulating adenosine concentrations. There is elevation of adenosine A<sub>2A</sub>R expression in placental biopsies, villous explants and placental microvillous membranes (<xref ref-type="bibr" rid="B827">von Versen-Höynck et al., 2009</xref>). In preeclampsia A<sub>2B</sub>R on microvascular endothelial cells have also been implicated (<xref ref-type="bibr" rid="B232">Escudero et al., 2008</xref>). Reduced adenosine-mediated angiogenesis in preeclamptic pregnancies may be associated with hypertension development in the offspring (<xref ref-type="bibr" rid="B233">Escudero et al., 2014</xref>). The interaction between A<sub>2A</sub>R and the angiotensin system may be involved in the early growth of the placenta. A<sub>2A</sub>R expression is raised in pre-eclampsia, perhaps as a consequence of poor placental perfusion in preeclampsia (<xref ref-type="bibr" rid="B468">Kurlak et al., 2015</xref>). Elevation of ADA activity in women with preeclampsia may contribute to their increased levels of uric acid and pro-inflammatory immune activity (<xref ref-type="bibr" rid="B305">Giorgi et al., 2016</xref>). Release of ATP increases in preeclampsia following hypoxia and oxidative/nitrative stress, which acts on P2X4R to influence homeostasis of the placenta (<xref ref-type="bibr" rid="B677">Roberts et al., 2007</xref>). There is deficient spiral artery remodelling and trophoblast invasion in preeclampsia, both of which may be inhibited by ATP-induced activated macrophages (<xref ref-type="bibr" rid="B746">Spaans et al., 2014b</xref>). It was concluded from a study of the relationship between the foeto-placental adenosine release and utero-placental circulatory insufficiency in pregnancies featuring preeclampsia, that foetal plasma adenosine increases before utero-placental insufficiency induces generalised foetal hypoxia (<xref ref-type="bibr" rid="B889">Yoneyama et al., 1996</xref>).</p>
</sec>
</sec>
<sec>
<title>Malignant Cancer of Reproductive Organs</title>
<sec>
<title>Prostate Cancer</title>
<p>Prostate cancer is the second most common male cancer and the third leading cause of cancer death. Prostate cancer cells are sensitive to extracellular ATP. ATP and adenosine inhibit the growth of human prostate cancer cells (<xref ref-type="bibr" rid="B486">Lertsuwan et al., 2017</xref>), identified at that time to act via P2Y<sub>1</sub>, P2Y<sub>2</sub> and/or P2Y<sub>4</sub>, P2Y<sub>6</sub> and P2Y<sub>11</sub>R subtypes. Activation of P2Y<sub>1</sub>R inhibited growth and induced cell death of prostate cancer PC-3 cells and P2Y<sub>1</sub>R agonists were claimed to be therapeutically promising for prostate cancer (<xref ref-type="bibr" rid="B842">Wei et al., 2011</xref>).</p>
<p>However, prostate tumour cells were shown later to also express P2X4, P2X5, and P2X7R in PC-3 cells and P2X4 and P2X5R in DU145 cells. ATP inhibited tumour cell growth, but not by UTP or adenosine, while 2′(3′)-<italic>O</italic>-(4-benzoylbenzoyl) ATP increased apoptotic cell death in PC-3 cells, probably via P2X7R. CD73 KO mice resist prostate carcinogenesis and CD73 promoted <italic>de novo</italic> prostate tumorigenesis. Anti-CD73 monoclonal antibodies decreased tumour growth and metastasis in the prostate (<xref ref-type="bibr" rid="B750">Stagg et al., 2012</xref>).</p>
<p>There are many polymorphisms of the P2X7R (<xref ref-type="bibr" rid="B283">Fuller et al., 2009</xref>), which, as well as resulting in loss of function, alter receptor activity. Cytolytic P2X7R expression was found in 116 prostate cancer pathology specimens (<xref ref-type="bibr" rid="B735">Slater et al., 2004</xref>). In normal tissues from patients with no evidence of cancer, P2X7R were not expressed, suggesting that the appearance of P2X7R is an early marker of prostate cancer.</p>
<p>Prostate tumour cell proliferation is inhibited by adenosine. A<sub>3</sub>R activation by IB-MECA inhibited proliferation of prostate cancer cells and induced cell cycle arrest and apoptosis (<xref ref-type="bibr" rid="B8">Aghaei et al., 2012</xref>). Activation of A<sub>3</sub>R suppressed prostate cancer metastasis (<xref ref-type="bibr" rid="B397">Jajoo et al., 2009</xref>). The ATP synthase β subunit also plays a role in prostate cancer metastasis (<xref ref-type="bibr" rid="B493">Li W. et al., 2017</xref>).</p>
</sec>
<sec>
<title>Breast Cancer</title>
<p>Inhibition of growth of human breast cancer cells by ATP was shown for the first time in 1993. Chemotherapeutic ATP release from breast tumour cells of mice increased tumour regression through apoptosis and it was suggested that P2Y<sub>2</sub> and/or P2Y<sub>4</sub>R were involved. Oestrogen, acting via oestrogen receptor α, promoted proliferation of breast cancer cells by down-regulating expression of P2Y<sub>2</sub>R and reducing P2Y<sub>2</sub>R-induced increase in [Ca<sup>2+</sup>]<sub>i</sub> (<xref ref-type="bibr" rid="B490">Li et al., 2011</xref>). P2Y<sub>2</sub>R activation by ATP released from cancer cells induces the invasion of metastatic breast cancer cells (<xref ref-type="bibr" rid="B238">Eun et al., 2015</xref>). Up-regulation of P2Y<sub>6</sub>R occurs in the mesenchymal phenotype of breast cancer cells and inhibition of P2Y<sub>6</sub>R may be a useful therapeutic target for metastasis of breast cancer (<xref ref-type="bibr" rid="B43">Azimi et al., 2016</xref>; <xref ref-type="bibr" rid="B528">Ma X. et al., 2016</xref>).</p>
<p>Antibody therapy with anti-CD73 inhibited breast tumour growth and metastasis (<xref ref-type="bibr" rid="B751">Stagg et al., 2010</xref>). Bisphosphonates are also effective inhibitors of breast cancer (<xref ref-type="bibr" rid="B249">Fehm et al., 2012</xref>). Proteomic analysis of human breast carcinoma revealed upregulation of ATP synthase in tumours and the ATP synthase inhibitor, aurovertin B, inhibited proliferation of several breast cancer cell lines (<xref ref-type="bibr" rid="B370">Huang et al., 2008</xref>). Malignant breast carcinoma cells release ATP making the pre-metastatic environment suitable for micro-metastasis in lymph nodes and associated afferent lymph vessels (<xref ref-type="bibr" rid="B431">Kawai et al., 2008</xref>).</p>
<p>In breast tumour cells ATP increased [Ca<sup>2+</sup>]<sub>i</sub> and high concentrations produced apoptosis via P2X7R. Activation of P2X7R in the human breast cancer cell line, T47D, increased cell migration and development of metastases, suggesting that P2X7R antagonists may have therapeutic roles (<xref ref-type="bibr" rid="B865">Xia et al., 2015</xref>). The role of hypoxia in the regulation of tumour progression has been debated. However, P2X7R expression is increased by hypoxia and hypoxia-driven increase in P2X7R enhances tumour cell invasion and migration. Silencing of P2X5R inhibited cell proliferation and may be a new mechanism to target cancer metastasis.</p>
<p>A<sub>1</sub> and A<sub>3</sub>R mRNA are expressed on human breast tumours (<xref ref-type="bibr" rid="B627">Panjehpour et al., 2012</xref>). Adenosine induces tumour cell proliferation and migration of T-47D and MCF-7 breast carcinoma cell lines (<xref ref-type="bibr" rid="B582">Mujoomdar et al., 2004</xref>). MDA-MB-231, a human breast cancer cell line, expressed A<sub>2B</sub>R, which mediated cell proliferation and A<sub>2B</sub>R inhibition slowed growth of breast tumours (<xref ref-type="bibr" rid="B139">Cekic et al., 2012</xref>). A<sub>3</sub>R agonists reduced bone metastasis of breast cancer, suggesting a therapeutic approach to bone-residing breast cancer (<xref ref-type="bibr" rid="B810">Varani et al., 2013</xref>).</p>
</sec>
<sec>
<title>Cervical Cancer</title>
<p>HeLa cells from human cervical cancer are used to study purinergic signalling involvement in cancer. Activation of P2Y<sub>2</sub> R with UTP and ATP caused proliferation of HeLa cells. P2Y<sub>4</sub> and P2Y<sub>6</sub> R expression increased during proliferation. Stimulation of P2Y<sub>1</sub>R on HeLa cells triggered epidermal growth factor receptor mitogen signalling and P2Y<sub>1</sub> antagonists reduced proliferation. Permeabilisation of cervical cancer cells to a cytotoxin is activated by P2YR (<xref ref-type="bibr" rid="B83">Bukhari et al., 2015</xref>). P2Y<sub>6</sub>R activation induces HeLa cell migration (<xref ref-type="bibr" rid="B296">Gendaszewska-Darmach and Szustak, 2016</xref>). Oestrogen reversed the apoptotic activity mediated by P2X7R in normal human cervix, but not in cervical epithelial cancer cells. A truncated P2X7R variant (P2X7-j), expressed in cervical cancer cells, antagonised the P2X7R through hetero-oligomerisation. Gentle mechanical stimulation released ATP from HeLa cells. The presence of ectonucleotidase in human cervical cancer cell regulates the levels of nucleotides, limiting their effects (<xref ref-type="bibr" rid="B60">Beckenkamp et al., 2014</xref>).</p>
</sec>
</sec>
<sec>
<title>Ovarian Cancer</title>
<p>ATP raised [Ca<sup>2+</sup>]<sub>i</sub> and stimulated growth of SKOV-3 and OVCAR-3 human ovarian carcinoma cells. ATP may act as a messenger to control the ovarian epithelial cell cycle through P2Y<sub>2</sub>R on human ovarian cancer cells. A<sub>2</sub>R antagonists inhibited angiogenic activity of human ovarian cancer cells. The treatment of human ovarian carcinoma with cisplatin in the presence of ATP results in additive cytotoxicity (<xref ref-type="bibr" rid="B688">Rotte et al., 2010</xref>). P2X7R were highly expressed in both human ovarian tumours and ovarian cancer cell lines and paracrine release of ATP acts on P2X7R to cause proliferation of ovarian cancer cells (<xref ref-type="bibr" rid="B813">Vazquez-Cuevas et al., 2014</xref>).</p>
<sec>
<title>Uterine Cancer</title>
<p>P2Y<sub>2</sub>R play a role in the control of the cell cycle and in the suppression of proliferation of human endometrial carcinoma cells. The P2X7R has been used as a biomarker for uterine epithelial cancers. There is decreased P2X7R expression on endometrial epithelium in pre-cancerous and cancer cells (<xref ref-type="bibr" rid="B495">Li et al., 2007</xref>, <xref ref-type="bibr" rid="B496">2009</xref>). Activation of P2X7R-dependent apoptosis has a chemotherapeutic growth-preventive effect on pre-cancerous and early cancerous epithelial lesions (<xref ref-type="bibr" rid="B282">Fu et al., 2009</xref>; <xref ref-type="bibr" rid="B317">Gorodeski, 2009</xref>). Loss of CD73 in endometrial cancer allows for tumour progression (<xref ref-type="bibr" rid="B76">Bowser et al., 2016</xref>). A higher proportion of ADA2<sup>∗</sup>1/<sup>∗</sup>1 genotype was observed in women with uterine leiomyomas (<xref ref-type="bibr" rid="B310">Gloria-Bottini et al., 2016</xref>).</p>
</sec>
</sec>
</sec>
<sec>
<title>Skin Diseases</title>
<p>Reviews about purinergic signalling in the skin during health and disease have been published (<xref ref-type="bibr" rid="B114">Burnstock et al., 2012b</xref>; <xref ref-type="bibr" rid="B298">Geraghty et al., 2016</xref>). Changes in P2R subtype expression occurs in the epidermis during proliferative disorders, such as psoriasis and scleroderma, and P2Y<sub>2</sub>R may be a novel target to treat these disorders. ATP plays an important role in wound healing, the defence response, innate immunity and inflammation in the skin and might be an important therapeutically in psoriasis and scleroderma.</p>
<sec>
<title>Psoriasis</title>
<p>Psoriasis is a chronic skin disease involving epidermal hyperproliferation. ATP and parathyroid hormone-related protein increased proliferation in HaCaT cells and may account for the hyperproliferation that occurs in psoriasis. P2Y<sub>2</sub>R contribute to epidermal homeostasis and indicate a possible therapy for psoriasis. P2Y<sub>11</sub>R mediate IL-6 production in human keratinocytes, which is important in psoriasis (<xref ref-type="bibr" rid="B391">Ishimaru et al., 2013</xref>). P2X7R signalling induces inflammation leading to differentiation of Th17 lymphocytes, which are involved in the pathogenesis and potential treatment of psoriasis (<xref ref-type="bibr" rid="B440">Killeen et al., 2013</xref>). P2X7R play a role in shaping the inflammatory microenvironment in psoriasis (<xref ref-type="bibr" rid="B502">Lioi et al., 2015</xref>). Strong P2X7R expression is confined to the basal layer cell membrane, while P2Y<sub>1</sub>R were expressed all through the psoriatic epidermis.</p>
<p>In the blood of psoriasis patients, there are high levels of adenosine. Adenosine raised cyclic AMP levels in lesions of epidermis from psoriasis patients. There is a defective purine nucleotide synthetic pathway in patients with psoriasis and nucleotide metabolism is altered in psoriatic keratinocytes. In psoriasis patients, ADA levels were significantly elevated in both serum and epidermis. It was concluded from a clinical trial that caffeine, a P1R antagonist, is an inexpensive, safe and effective treatment for psoriasis. The role of adenosine as an endogenous mediator of the pathogenesis of psoriasis has been reviewed (<xref ref-type="bibr" rid="B260">Festugato, 2015</xref>) and clinical trials for the use of A<sub>3</sub>R agonists for the treatment of psoriasis described (<xref ref-type="bibr" rid="B71">Borea et al., 2015</xref>; <xref ref-type="bibr" rid="B450">Kofoed et al., 2015</xref>). A<sub>2A</sub>R are upregulated in psoriasis and A<sub>2A</sub>R agonists may counteract inflammation in this disease (<xref ref-type="bibr" rid="B559">Merighi et al., 2017</xref>). A<sub>2B</sub>R are also expressed by human epidermal keratinocytes and their expression is reduced in psoriasis (<xref ref-type="bibr" rid="B28">Andrés et al., 2017</xref>).</p>
</sec>
<sec>
<title>Scleroderma</title>
<p>Scleroderma encompasses a spectrum of disorders that cause dermal fibrosis and systemic sclerosis (SSc). SSc is a severe disease of the connective tissue of affected organs, including the skin. Adenosine A<sub>2A</sub>R contribute to the pathogenesis of dermal fibrosis and may be a therapeutic target to treat and prevent dermal fibrosis in scleroderma (<xref ref-type="bibr" rid="B142">Chan and Cronstein, 2010</xref>). Fibroblasts from SSc patients had a high rate of spontaneous IL-6 release, which was increased by ATP stimulation. SSc fibroblasts expressed mRNA for P2X3, P2X4, P2X7, P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>4</sub>, and P2Y<sub>6</sub>, suggesting a possible therapeutic role for P2R antagonists in SSc patients via modulation of fibroblast function.</p>
</sec>
<sec>
<title>Skin Inflammation</title>
<p>The skin is an immune defence organ. Chemical, immune-specific or physical insults evoke increased expression of proinflammatory mediators, in particular keratinocytes release chemokines. Release of ATP is associated with inflammation of the skin, as well as increase in expression of, in particular, P2X7 and perhaps P2Y<sub>1</sub>R, and subsequent release of proinflammatory cytokines. Skin inflammation is reduced by P2X7R antagonists.</p>
<p>In ectonucleotidase (CD39) KO mice, rapid ATP release from keratinocytes is triggered by irritant chemicals causing exacerbated skin inflammation. Ultraviolet (UV) radiation evokes ATP release from keratinocytes and P2Y<sub>6</sub>R mediate UV radiation-induced inflammatory responses (<xref ref-type="bibr" rid="B774">Takai et al., 2011</xref>). ATP, when released after trauma or infection, may enhance immunoresponses and P2R agonists may increase vaccine efficacy. A<sub>1</sub> and A<sub>2</sub>R may function as cutaneous neurogenic pro-inflammatory mediators. Human skin keratinocytes infected by <italic>Staphylococcus aureus</italic>, which releases α-toxin, exhibited a transient reduction in cellular ATP levels (<xref ref-type="bibr" rid="B766">Suriyaphol et al., 2009</xref>). P2X3 and P2X2/3 nociceptive receptors on sensory nerve endings are increased in inflamed skin and antagonists to these receptors have been developed as analgesics.</p>
</sec>
<sec>
<title>Wound Healing</title>
<p>Topically applied A<sub>2B</sub> and particularly A<sub>2A</sub>R agonists promote cutaneous wound healing in both healthy and diabetic conditions. A<sub>2A</sub>R agonists also promote collagen production by dermal fibroblasts. Adenosine inhibits proliferation of vascular smooth muscle cells via A<sub>2</sub>R activation. A review discusses the involvement of A<sub>2A</sub> and A<sub>2B</sub>R signalling in wound healing and fibrosis (<xref ref-type="bibr" rid="B720">Shaikh and Cronstein, 2016</xref>).</p>
<p>ATP and ADP also play a role in wound healing. ATP, released by damaged cells and physiologically during gentle mechanical stimulation, contributes to wound healing, tissue repair and regeneration. Cutaneous wound healing is accelerated by Mg-ATP, probably by increasing synthesis of vascular endothelial growth factor. Release of ATP from platelets and other cells during wound healing results in an increase in [Ca<sup>2+</sup>]<sub>i</sub> in keratinocytes, associated with epidermal growth and differentiation. ATP improves ischaemic skin flap survival after surgery, while P2R antagonists accelerate barrier repair.</p>
<p>There is acute inflammation in the initial phase of wound healing. ATP is involved in the development of inflammation through P2X7R-mediated production and release of cytokines from immune cells. The presence of P2X7R on immune cells mediates killing of intracellular pathogens by stimulating apoptosis of the host macrophage, chemo-attraction and cell adhesion. In contrast, adenosine has anti-inflammatory effects. ATP released following infection and trauma acts as an endogenous adjuvant to increase the immune response and P2R agonists may enhance the efficacy of vaccines.</p>
<p>Wound healing also involves new vessel growth (angiogenesis) and both ATP and adenosine contribute to cell proliferation and migration during angiogenesis. In cultured porcine artery smooth muscle cells, ADP and ATP stimulate DNA synthesis and cell proliferation. ATP and UTP are mitogenic in human vascular smooth muscle cells and P2Y<sub>2</sub> and P2Y<sub>4</sub>R might be involved.</p>
<p>Wound healing is delayed in denervated wounds. In a rat model of this, P2X5, P2X7, P2Y<sub>1</sub>, and P2Y<sub>2</sub>R expression was altered in the epidermis. P2Y<sub>1</sub>R expression was increased in the basal proliferating layer of keratinocytes in the regenerating epidermis, while P2Y<sub>2</sub>R were significantly decreased. ATP and UTP, probably via P2Y<sub>2</sub>R, increased proliferation of the MCS-P5 murine keratinocyte cell line, and enhanced wound healing in mice (<xref ref-type="bibr" rid="B435">Kehasse et al., 2013</xref>; <xref ref-type="bibr" rid="B415">Jin et al., 2014</xref>). ATP release and P2YR signalling mediate electric field-stimulated directional keratinocyte migration (<xref ref-type="bibr" rid="B674">Riding and Pullar, 2016</xref>). A review discussed the clinical applications of purinergic compounds to enhance wound healing (<xref ref-type="bibr" rid="B295">Gendaszewska-Darmach and Kucharska, 2011</xref>).</p>
</sec>
<sec>
<title>Warts</title>
<p>Warts are caused by human papillomavirus infection of epidermis basal keratinocytes. P2X5R staining was increased in warts. P2X7R immunoreactivity was found in hyperkeratotic areas of the stratum corneum and in nuclei of koilocytes in the wart suprabasal layers. The nuclei positive for P2X7R were shrunken, showing much more intense P2X7R staining. The expression of P2X7R in the nucleus of human papillomavirus-infected cells was associated with disruption of the cellular machinery. P2X7R agonists may be used to trigger apoptosis in these virally infected cells. P2X5 and P2X7R are being explored for the treatment of warts.</p>
</sec>
<sec>
<title>Allergy</title>
<p>Contact allergen sensitisation involves immune system activation by endogenous danger signals. P2X7R KO mice exhibit resistance to contact hypersensitivity. P2X7R KO dendritic cells do not induce sensitisation in response to contact allergens or release IL-1β in response to ATP. This suggests that P2X7R are crucial for release of ATP from skin in response to contact allergens. Interference with P2X7R signalling could be a therapeutic approach to prevent allergic contact dermatitis.</p>
</sec>
<sec>
<title>Hailey–Hailey and Darier Diseases</title>
<p>These are autosomal dominant skin disorders and are characterised by epidermal keratinocyte dissociation (acantholysis) at the epidermis suprabasal layer. In lesions P2Y<sub>2</sub>R are not localised on acantholytic cells, but P2X7R appear in the plasma membranes, potentially mediating apoptosis.</p>
</sec>
<sec>
<title>Barrier Function</title>
<p>The skin protects the water-rich internal organs from environmental dryness, with the stratum corneum being critical to the water-impermeable barrier. Topical application of ATP and α,β-meATP via P2XR delayed barrier recovery, damaged by surfactant, organic solvent or tape stripping. P2R antagonists, however, accelerated barrier repair. In mice skin wounds healed faster following treatment with ATP-encapsulated fusogenic lipid vesicles rather than with lipid vesicles. PPADS, a P2XR antagonist, accelerates skin barrier repair and prevented epidermal hyperplasia.</p>
</sec>
<sec>
<title>Burns</title>
<p>There is increased concentration of adenosine in burn blister fluid, and depletion of ATP in skin after thermal injury. ATP has a protective effect against skin burns. ATP-MgCl<sub>2</sub> administration following burn injury reversed the damage to the intravascular clearing of lipid emulsions within the reticuloendothelial immune system. Glucose metabolism was affected by ATP in thermally injured skin.</p>
<p>Burn injury produces severe pain and the relieving effects of tetramethylpyrazine, a Chinese medicine, are claimed to be due to it acting as a P2X3R antagonist (<xref ref-type="bibr" rid="B291">Gao Y. et al., 2010</xref>). Skin P2X3R expression was increased on sensory nerve terminals in first and second degree burns, but, following treatment with tetramethylpyrazine, P2X3R expression was reduced. P2X3R may play a role in the short-lasting thermal hyperalgesia induced by mild heat injury (<xref ref-type="bibr" rid="B285">Füredi et al., 2010</xref>). After a superficial skin burn, adenosine reduced the skin area showing hypersensitivity.</p>
</sec>
<sec>
<title>Pain</title>
<p>Skin pain is associated with changes in sympathetic nerve activity and ATP released from rat sympathetic nerves as a cotransmitter with NA may modulate cutaneous nociceptors. P2X3R are expressed on sensory neurons in DRG, nodose and trigeminal ganglia that innervate cutaneous tissues. ATP and ADP stimulate skin afferent nerve terminals and skin cell damage stimulates nociceptive sensory nerves via ATP release. In rat skin with carrageenan-induced inflammation, nociceptors can be selectively activated with α,β-meATP, indicating the involvement of P2X3R. ATP contributes to the enhanced sensitivity of inflamed skin nociceptors, leading to heat hyperalgesia. P2X3R antagonists are anti-nociceptive. UV light evokes hypersensitivity of skin to ATP-induced pain. After subcutaneous bee venom injection, there is reduction of prolonged pain by PPADS, and it was suggested that stimulation of P2XR in the spinal cord contributes to cutaneous pain. The terminals of nociceptive neurons in the skin are targets for P2X3R antagonists. UTP sensitises a subpopulation of cutaneous C-fibre nociceptors to mechanical stimuli. There is increased P2X3R expression on calcitonin gene-related peptide-positive sensory fibres during the growth of tumours, mediating nociception. Increased expression of skin glial cell neurotrophic factor increases the mechanical sensitivity of nociceptive afferents expressing P2X3R.</p>
<p>Ecto-5′-nucleotidase (CD73) is located on nociceptive terminals and epidermal keratinocytes in the epidermis, which, by hydrolysing AMP to adenosine, is suggested to be anti-nociceptive. Blockade of peripheral P2Y<sub>1</sub>R prevents thermal hyperalgesia (<xref ref-type="bibr" rid="B470">Kwon et al., 2014</xref>). Mechanical allodynia is induced by α,β-meATP, which sensitises P2X3R on cutaneous nociceptive sensory fibres (<xref ref-type="bibr" rid="B669">Ren et al., 2015</xref>).</p>
<p>Reviews with coverage of purinergic signalling and cutaneous pain are available (<xref ref-type="bibr" rid="B922">Zhu and Lu, 2010</xref>; <xref ref-type="bibr" rid="B103">Burnstock, 2016c</xref>).</p>
</sec>
<sec>
<title>Dermatitis</title>
<p>In irritant dermatitis, there is a pathogenic role for keratinocyte-derived ATP. The necrosis produced by the chemical irritant croton oil was prevented by the pre-treatment with A438079, a selective P2X7R antagonist (<xref ref-type="bibr" rid="B901">Zanin et al., 2015</xref>). Topical application of A<sub>2A</sub> antagonists prevents radiation dermatitis (<xref ref-type="bibr" rid="B638">Perez-Aso et al., 2016</xref>).</p>
</sec>
<sec>
<title>Skin Cancer</title>
<p>Different subtypes of P1R and P2R are involved in skin cancer, playing roles in differentiation, apoptosis and proliferation. The roles of purinoceptors are complicated because there are multiple receptor subtypes on the same cell, which can have opposing effects. For example, P2Y<sub>2</sub>R mediate an increase in tumour cell numbers, while P2Y<sub>1</sub>, P2X5, and P2X7R mediate a decrease in cell numbers. In cancers of the skin, proliferation outweighs apoptotic cell death.</p>
<p>UV light is a stimulus for the genesis of cutaneous cancer, including basal and squamous cell carcinoma as well as melanoma, where the UV-B component has the most severe effects. UV-B irradiation decreases the amount of P2X1, P2Y<sub>2</sub>, and P2X7R, which contributes to the malignant transformation of keratinocytes (<xref ref-type="bibr" rid="B693">Ruzsnavszky et al., 2011</xref>).</p>
<sec>
<title>Basal and Squamous Cell Carcinomas</title>
<p>Basal cell and squamous cell carcinoma are tumours that generally occur after the age of 50, squamous cell carcinoma being the more common and aggressive of the two. Nucleoside analogues reduced basal cell carcinoma growth. A human cutaneous squamous cell (epidermal) carcinoma cell line, A431, express P2R that induce increases in [Ca<sup>2+</sup>]<sub>i</sub>. ATP-stimulated A431 cells induced production of inositol-trisphosphate, suggesting the involvement of P2YR. P2X5 and P2YR were strongly expressed on both squamous and basal cell carcinomas. P2X7R are expressed in apoptotic cells in superficial multifocal and infiltrative cells and in the necrotic centre of nodular basal cell carcinomas. Expression of P2Y<sub>1</sub>R was confined to the stroma surrounding tumours. P2Y<sub>4</sub>R were present only in basal cell carcinomas. ATP and UTP at low concentrations induced an increase in the number of A431 cells, while high concentrations substantially decreased cell numbers.</p>
<p>ATP via P2X7R caused apoptosis of A431 cells and UTP and adenosine (after ATP breakdown) also induced cell death (<xref ref-type="bibr" rid="B825">Völkl et al., 2008</xref>). 2′(3′)-<italic>O</italic>-(4-Benzoylbenzoyl) ATP, a potent P2X7R agonist, reduced skin carcinoma and papilloma and formation (<xref ref-type="bibr" rid="B282">Fu et al., 2009</xref>). ADA in saliva was shown to be a diagnostic marker of tongue squamous cell carcinoma (<xref ref-type="bibr" rid="B655">Rai et al., 2011</xref>).</p>
</sec>
<sec>
<title>Melanoma</title>
<p>Malignant melanoma, which is highly metastatic, is derived from melanocytes. ATP inhibited the growth of both human and animal melanoma cells <italic>in vivo</italic>. CD39 is over-expressed in differentiated human melanomas. Expression of P2X7R was increased in superficial spreading melanoma patients, which were later shown to be functional and may be a therapeutic target for melanoma therapy (<xref ref-type="bibr" rid="B849">White et al., 2005</xref>). A low pH environment as seen in solid tumours induced ATP release from B16 melanoma cells, which increases proliferation via P2X7R. Oxidised ATP, a P2X7R antagonist, inhibited tumour growth (<xref ref-type="bibr" rid="B346">Hattori et al., 2012</xref>). P2Y<sub>1</sub>, P2Y<sub>2</sub>, and P2Y<sub>6</sub>R mRNA and protein expression was observed in human melanomas. The presence of P2Y<sub>1</sub> and P2X7R, which had been suggested to be therapeutic targets for melanoma treatment using ATP, was demonstrated by immunohistochemistry (<xref ref-type="bibr" rid="B850">White et al., 2009</xref>). The release of ATP from murine B16 melanoma cells was shown to upregulate CD39 expression on regulatory T cells. Dying tumour cells release ATP, which accumulates at high concentrations and acts as an immune danger signal, although it can also kill adjacent tumour cells directly via P2X7R (<xref ref-type="bibr" rid="B250">Feng et al., 2011</xref>). Accelerated melanoma tumour progression in mice lacking P2X7R has been reported (<xref ref-type="bibr" rid="B5">Adinolfi et al., 2015</xref>). γ-Irradiation that induces arrest in tumour cell growth and death, induced P2X7R-dependent release of ATP from B16 cells (<xref ref-type="bibr" rid="B610">Ohshima et al., 2010</xref>).</p>
<p>In an animal model of melanoma, tumour growth was reduced in CD73 KO mice (<xref ref-type="bibr" rid="B885">Yegutkin et al., 2011</xref>). Implanting B16 cells into CD73 KO mice, thereby decreasing the production of adenosine, resulted in reduced tumour growth (<xref ref-type="bibr" rid="B675">Ring et al., 2011</xref>). Adenosine potentiated the <italic>in vivo</italic> actions of chemotherapeutic agents. Antimetastatic therapies based on inhibition of A<sub>1</sub>R activation have been suggested. A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub>R subtypes are expressed in the A375 human malignant melanoma cell line. A<sub>3</sub>R activation resulted in growth inhibition of melanoma cells (<xref ref-type="bibr" rid="B578">Morello et al., 2011</xref>). However, another study claimed that adenosine, acting through A<sub>3</sub>R, induced cell proliferation of human malignant melanoma C32 cells (<xref ref-type="bibr" rid="B738">Soares et al., 2012</xref>). A<sub>2B</sub>R antagonists impaired IL-8 production that is raised in malignant melanoma patients, while A<sub>3</sub>R antagonists decreased vascular endothelial growth factor that promotes human carcinoma cell angiogenesis and metastasis (<xref ref-type="bibr" rid="B560">Merighi et al., 2009</xref>). Adenosine is a potent immunoregulatory factor modulating cytotoxic activity and cytokine production of anti-melanoma specific T cells.</p>
<p>In conclusion, P2Y<sub>2</sub>R mediate proliferation, P2X5R mediate differentiation (i.e., are antiproliferative) and P2X7R mediate cell death. Therefore, P2Y<sub>2</sub>R antagonists and P2X5 and P2X7R agonists have therapeutic potential for the treatment of skin cancer.</p>
</sec>
</sec>
</sec>
<sec>
<title>Musculoskeletal Diseases</title>
<p>Reviews that include discussion of the pathophysiology of musculoskeletal diseases have been published (<xref ref-type="bibr" rid="B108">Burnstock et al., 2013</xref>; <xref ref-type="bibr" rid="B892">Young et al., 2013</xref>; <xref ref-type="bibr" rid="B10">Agrawal and Gartland, 2015</xref>; <xref ref-type="bibr" rid="B420">Jørgensen et al., 2015</xref>; <xref ref-type="bibr" rid="B618">Orriss et al., 2016</xref>). There are multiple purinoceptor subtypes expressed by bone and cartilage, which are potential targets for original therapeutic strategies to inhibit bone resorption in osteoporosis, rheumatoid arthritis (RA), periodontitis and tumour-induced osteolysis.</p>
<sec>
<title>Muscular Dystrophy</title>
<p>ATP was used early to treat myopathies, although the mechanism of action was not known. Allopurinol has been used for the treatment of Duchenne muscular dystrophy (DMD). It counteracts low purine nucleotide degradation levels that occur in Duchenne muscle, but chronic administration of allopurinol failed to improve DMD symptoms. Lymphoblastoid cells from DMD patients were found to be highly sensitive to ATP stimulation.</p>
<p>The <italic>mdx</italic> model of DMD, lacking the dystrophin protein, mimics muscle damage and subsequent regeneration. Sequential expression of P2X5, P2Y<sub>1</sub> and P2X2R was described during muscle regeneration in the <italic>mdx</italic> model (<xref ref-type="bibr" rid="B694">Ryten et al., 2004</xref>). It was claimed recently that a P2Y<sub>2</sub>R antagonist may ameliorate cardiomyopathy in DMD (<xref ref-type="bibr" rid="B208">De Oliveira Moreira et al., 2017</xref>). P2Y<sub>1</sub>R were expressed on infiltrating immune cells. A purinergic dystrophic phenotype was seen during the earliest stage of developing dystrophic muscle. Dystrophic myoblasts express P2X4 and P2X7R proteins and it was claimed that antagonists to these receptors may be of potential therapeutic benefit. ATP signalling is altered in muscular dystrophy, but was partly recovered after nifedipine treatment (<xref ref-type="bibr" rid="B805">Valladares et al., 2014</xref>). It was claimed that dihydropyridines may be used as a therapeutical tool to reduce muscle damage observed in dystrophic muscles. It was suggested that P2XR antagonists alter the adaptive immune component in the muscle infiltrates in DMD and are a promising therapeutic approach to treat DMD (<xref ref-type="bibr" rid="B293">Gazzerro et al., 2015</xref>).</p>
<p>Myofascial pain is a feature of DMD and ATP stimulates myofascial nociceptors. P2X7R upregulation occurs in dystrophic <italic>mdx</italic> mouse muscles and treatment with P2X7R antagonists slows the progression of DMD (<xref ref-type="bibr" rid="B731">Sinadinos et al., 2015</xref>). Sensitivity to ATP is higher, release of ATP is greater and expression of P2Y<sub>2</sub>R is increased, but P2Y<sub>1</sub>R expression is decreased in <italic>mdx</italic> mice. A review about purinergic receptors in DMD was published (<xref ref-type="bibr" rid="B455">Krasowska et al., 2014</xref>).</p>
</sec>
<sec>
<title>Myasthenia Gravis (MG)</title>
<p>Myasthenia gravis is an autoimmune disease, which affects the neuromuscular junction. Lack of neuronal A<sub>2A</sub>R-mediated Ca<sub>v</sub> 1 (L-type) influx causes tetanic failure in MG (<xref ref-type="bibr" rid="B606">Noronha-Matos et al., 2011</xref>). It was suggested that the adenosinergic pathway was dysfunctional in autoimmune MG and that stimulation of CD73 activity and A<sub>2A</sub>R may have therapeutic potential for MG (<xref ref-type="bibr" rid="B613">Oliveira et al., 2015</xref>).</p>
</sec>
<sec>
<title>Fibromyalgia</title>
<p>Fibromyalgia (a musculoskeletal disease) is characterised by allodynia, as well as mood disorders. In fibromyalgia patients, there are decreased levels of ATP in platelets perhaps contributing to the pathogenesis of the disease (<xref ref-type="bibr" rid="B55">Bazzichi et al., 2008</xref>).</p>
</sec>
<sec>
<title>Osteoporosis</title>
<p>Osteoporosis, characterised by bone mass loss (bone mineral density decrease), leads to a high risk of bone fracture. The P2X7R is considered to be important in relation to the treatment of osteoporosis (<xref ref-type="bibr" rid="B469">Kvist et al., 2014</xref>). P2X7R plays a critical role in both cortical and cancellous bone mass augmentation and were shown to stimulate cancellous and periosteal bone formation and inhibit cancellous bone resorption during growth. Single nucleotide polymorphisms of the P2X7R gene are associated with the risk of fractures, decrease in bone mineral density and osteoporosis. P2X7R are involved in the formation of human osteoclasts. P2X7R antagonists are being considered for the treatment of osteoporosis and with remodelling disorders, where bone mass is reduced (<xref ref-type="bibr" rid="B418">Jørgensen et al., 2011</xref>). Skeletal pain accompanies osteoporosis and P2X2/3R might have a role in osteoporosis patients under a high bone turnover state (<xref ref-type="bibr" rid="B379">Iba and Yamashita, 2016</xref>). P2X5R may be a therapeutic target for treatment for inflammatory bone loss (<xref ref-type="bibr" rid="B441">Kim et al., 2017</xref>). Polymorphisms in the P2X4 and P2X7R genes (<xref ref-type="bibr" rid="B378">Husted et al., 2013</xref>) and the Leu46Pro polymorphism of the human P2Y<sub>2</sub>R gene were linked to bone mineral density and the risk of osteoporosis in Dutch fracture patients (<xref ref-type="bibr" rid="B845">Wesselius et al., 2013</xref>). It was suggested that clopidogrel, a P2Y<sub>12</sub>R antagonist used for stroke and thrombosis, increases the risk of fractures in osteoporotic patients (<xref ref-type="bibr" rid="B419">Jørgensen et al., 2012</xref>). P2Y<sub>13</sub>R antagonists have also been proposed for the treatment of osteoporosis (<xref ref-type="bibr" rid="B837">Wang N. et al., 2013</xref>).</p>
<p>Adenosine receptors are involved in osteoporosis (<xref ref-type="bibr" rid="B551">McPhee and Whiting, 1989</xref>). <italic>Trans</italic>-differentiation of osteoblasts to adipocytes, which involves A<sub>2B</sub>R, may contribute to the pathogenesis of osteoporosis (<xref ref-type="bibr" rid="B664">Rayalam et al., 2011</xref>). P1R might be targets for treating osteoporosis and other diseases characterised by excessive bone turnover.</p>
</sec>
<sec>
<title>Osteoarthritis (OA)</title>
<p>Osteoarthritis is a degenerative joint disease as a result of wear of the articular cartilage due to abnormal load to the joint or from infection, trauma or due to ageing. The pain from OA is due largely to inflammation. Increased ATP levels and 5′-nucleotidase activity are present in osteoarthritic joint synovial fluid, compared to the joints from RA patients, particularly from osteoarthritic patients where deposition of calcium-containing crystals were also present. ATP contributes to pathologic mineralisation in articular cartilage and therefore P2R antagonists might provide therapeutic tools for crystal-associated arthritis (<xref ref-type="bibr" rid="B178">Costello et al., 2011</xref>). ATP levels in knee synovial fluid of patients with OA are related to pain intensity (<xref ref-type="bibr" rid="B464">Kumahashi et al., 2011</xref>). P2X3 and P2X2/3R play an important role in the development of articular hyperalgesia of arthritic joints (<xref ref-type="bibr" rid="B785">Teixeira et al., 2016</xref>). In the long-term complications following total hip arthroplasty, different polymorphic variants of the P2X7R are associated with high or reduced periprosthetic osteolysis (<xref ref-type="bibr" rid="B581">Mrazek et al., 2010</xref>). There are elevated concentrations of ATP in the synovial fluid of dogs with OA (<xref ref-type="bibr" rid="B793">Torres B.T. et al., 2016</xref>). Purinergic signalling, via P2R, produces calcium oscillations in migratory chondrogenic progenitor cells isolated from OA cartilage (<xref ref-type="bibr" rid="B546">Matta et al., 2015</xref>). Platelets promote cartilage repair and chondrocyte proliferation via release of ADP in a rodent model of OA, suggesting that P2Y<sub>1</sub> or P2Y<sub>12</sub>R agonists may be useful for treatment of OA (<xref ref-type="bibr" rid="B918">Zhou Q. et al., 2016</xref>). Treatment with the selective P2X7R antagonist, AZD9056, produced pain-relieving and anti-inflammatory effects in rats with OA (<xref ref-type="bibr" rid="B364">Hu H. et al., 2016</xref>).</p>
<p>Adenosine signalling is also involved in OA. Adenosine, produced following breakdown of ATP, is released from chondrocytes and contributes to tissue damage in arthritic conditions. The regulation of LPS-induced IL-6 release involves A<sub>2A</sub>R, indicating that adenosine has a regulatory role in controlling osteoclastogenesis and inflammation. Electromagnetic field stimulation up-regulates A<sub>2A</sub>R in synovial fibroblasts and adenosine, acting through both A<sub>1</sub> and A<sub>2A</sub>R, had anti-inflammatory activity to control joint inflammation (<xref ref-type="bibr" rid="B204">De Mattei et al., 2009</xref>). A<sub>2A</sub> and A<sub>3</sub>R agonists modulate prostaglandin E<sub>2</sub> and cytokine release in human osteoarthritic fibroblasts (<xref ref-type="bibr" rid="B616">Ongaro et al., 2012</xref>). Adenosine receptors also mediate regulation of inflammatory responses in human synoviocytes (<xref ref-type="bibr" rid="B811">Varani et al., 2010b</xref>). A<sub>2A</sub>R agonists are used to reduce joint destruction due to septic arthritis (<xref ref-type="bibr" rid="B173">Cohen et al., 2004</xref>). A<sub>2A</sub>R deletion resulted in the development of OA in mice, suggesting that A<sub>2A</sub>R agonists might be a target for the treatment of OA (<xref ref-type="bibr" rid="B174">Corciulo et al., 2017</xref>).</p>
</sec>
<sec>
<title>Rheumatoid Arthritis (RA)</title>
<p>The potential involvement in RA of purinergic signalling was recognised first in the 1990’s when concentrations of adenosine, after released ATP was broken down, were reduced in synovial fluid in RA compared to OA. Increased levels of adenosine as a treatment for RA was suggested. UTP and ATP activate calcium-mobilising P2UR to synergistically act with IL-1 to stimulate release of prostaglandin E<sub>2</sub> from human rheumatoid synovial cells. Hypotonic stress promotes ATP release and cell proliferation via transient receptor potential vanilloid 4 activation in RA rat synovial fibroblasts (<xref ref-type="bibr" rid="B363">Hu et al., 2017</xref>).</p>
<p>IL-1β is a proinflammatory cytokine that substantially contributes to the progression of RA. ATP, through P2X7R, induced increased levels of IL-1β in RA patient blood samples compared to control samples. Mononuclear cells from these patients were more sensitive to stimulation by ATP, possibly because of P2X7R genetic polymorphism (<xref ref-type="bibr" rid="B650">Portales-Cervantes et al., 2012</xref>). P2X7R are involved in the pathogenesis of RA and systemic lupus erythematosus (<xref ref-type="bibr" rid="B649">Portales-Cervantes et al., 2010</xref>). P2X7R mRNA and protein are expressed in human rheumatoid synoviocytes. Studies of arthritis animal models suggest an <italic>in vivo</italic> role for the P2X7R in the progression of this inflammatory disease. There was a lower incidence and reduced severity of the symptoms of arthritis induced by anti-collagen treatment in P2X7R KO mice. Therefore targeting the P2X7R may be a potential treatment for RA. P2X7R antagonists in the collagen-induced animal model of RA reduced destruction of peripheral inflammatory tissue. In a later study, it was claimed that AZD9056, a P2X7R antagonist, was not effective against RA (<xref ref-type="bibr" rid="B436">Keystone et al., 2012</xref>). P2X7R antagonists are being investigated for clinical use against inflammatory joint pain (<xref ref-type="bibr" rid="B66">Beswick et al., 2010</xref>). A multicentre, double-blind, placebo-controlled clinical trial showed that ATP infusions reduced inflammation and disease symptoms in patients with RA (<xref ref-type="bibr" rid="B75">Bours et al., 2010</xref>).</p>
<p>Bovine chondrocytes express P2X1 and P2X3R and following stimulation there was release of inflammatory mediators. Therefore antagonists to these receptors may be therapeutically useful for articular cartilage resorption and diseases involving inflammation. There was an increased platelet response to ADP in RA patients (<xref ref-type="bibr" rid="B530">Mac Mullan et al., 2010</xref>).</p>
<p>Sympathetic nerves mediate proinflammatory responses during the initial phase of arthritis induced by type II collagen, probably via cytokines such as interferon-γ released in response to the sympathetic cotransmitters ATP and NA (<xref ref-type="bibr" rid="B757">Straub et al., 2008</xref>). α,β-MeATP-sensitive P2XR (probably P2X3) are expressed on rat knee joint peripheral nociceptive afferent fibres and the increased ATP levels in damaged and inflamed tissues, may contribute to nociception and pain. P2X3R were found on nociceptive sensory fibres in lumber facet joints, where low back pain originates (<xref ref-type="bibr" rid="B390">Ishikawa et al., 2005</xref>). Changes in P2X3R expression on DRG neurons that label isolectin B4 were seen following the induction of RA (<xref ref-type="bibr" rid="B41">Averill et al., 2008</xref>). P2X3R expressed on trigeminal ganglia also contribute to orofacial pressure pain in monoarthritis of the temporomandibular joint. Plasma extravasation in the rat knee joint induced by bradykinin was enhanced by ATP, released as a cotransmitter from sympathetic nerves. Intravenous guanethidine, which inhibits release of sympathetic cotransmitters, proved to be effective in RA patients. <italic>Uncaria tomentosa</italic> extract affects the metabolism of adenine nucleotides and has been suggested as an adjuvant to treat arthritis (<xref ref-type="bibr" rid="B136">Castilhos et al., 2015</xref>).</p>
<p>The evidence showing a role for adenosine in RA has been reviewed (<xref ref-type="bibr" rid="B809">Varani et al., 2010a</xref>). Increased activity of ADA was seen in synovial fluid from patients with RA as well as in rheumatoid synovial fibroblasts (<xref ref-type="bibr" rid="B592">Nakamachi et al., 2003</xref>). The ImmuKnow assay might effectively identify RA patients that are more at risk of developing infections (<xref ref-type="bibr" rid="B15">Akimoto et al., 2013</xref>). Signalling via the A<sub>2A</sub>R caused modification of the cytokine milieu in RA (<xref ref-type="bibr" rid="B540">Masahiro et al., 2003</xref>). Over-expression of A<sub>3</sub>R was observed in peripheral blood mononuclear cells of RA patients. Patients with RA had greater expression A<sub>3</sub>R in the synovium (<xref ref-type="bibr" rid="B752">Stamp et al., 2012</xref>). There are increased levels of A<sub>2A</sub> and A<sub>3</sub>R on the lymphocytes and neutrophils of RA patients. In the dorsal horn of rats with induced RA, A<sub>1</sub>R agonists decreased activation of <italic>c-fos</italic> and astrocytes. In a later study of the adjuvant-induced monoarthritis model an A<sub>3</sub> specific agonist prevented bone resorption. ATP, working via A<sub>2</sub>R, also reduced joint injury. A phase II clinical trial provided evidence for A<sub>3</sub>R agonists as a treatment for RA (<xref ref-type="bibr" rid="B267">Fishman et al., 2008</xref>; <xref ref-type="bibr" rid="B730">Silverman et al., 2008</xref>). CGS 21680, an agonist of the A<sub>2A</sub>R, reduced progression of murine type II collagen-induced arthritis (<xref ref-type="bibr" rid="B548">Mazzon et al., 2011</xref>). A<sub>2A</sub>R agonists ameliorate adjuvant-induced arthritis in rats (<xref ref-type="bibr" rid="B820">Vincenzi et al., 2013</xref>). Methotrexate (MTX) is often used to treat RA. In human joints with inflammatory disease, MTX treatment involved A<sub>2A</sub>R. Adenosine via A<sub>2B</sub>R prevented MTX-induced inhibition of osteoclast bone destruction in arthritis induced by adjuvant (<xref ref-type="bibr" rid="B786">Teramachi et al., 2011</xref>). In RA patients treated with MTX, studies of polymorphisms of the genes involved in adenosine release concluded that genotyping may help identify patients who would most benefit from MTX treatment (<xref ref-type="bibr" rid="B846">Wessels et al., 2006</xref>). Anti-tumour necrosis factor-α has also been used to treat RA, but it raises the risk of reactivating tuberculosis. ADA assay is a specific and sensitive test for the quick diagnosis of rheumatoid effusions (<xref ref-type="bibr" rid="B900">Zakeri et al., 2012</xref>).</p>
</sec>
<sec>
<title>Tooth Pain</title>
<p>There are many sensory nerves, originating in the trigeminal ganglia, expressing P2X3R in tooth pulp and ATP is released from odontoblasts in response to mechanical stimulation to act on these receptors, resulting in pain (<xref ref-type="bibr" rid="B722">Shibukawa et al., 2015</xref>). LPS-induced pulp inflammation increased the expression of P2XR in trigeminal sensory nerves (<xref ref-type="bibr" rid="B152">Chen et al., 2014</xref>). Mechanical or cold stimulation of odontoblast processes in dentin tubules, results in ATP release and dental pain (<xref ref-type="bibr" rid="B516">Liu X. et al., 2015</xref>). Therefore P2X3R antagonists may be therapeutically useful to reduce toothache.</p>
</sec>
<sec>
<title>Bone Cancer Pain</title>
<p>Bone metastases, common in prostate and breast cancer patients, may cause substantial bone loss and pain. Purinergic signalling involvement in bone cancer was initially reported in the 1990’s when P2U (i.e., P2Y<sub>2</sub>/P2Y<sub>4</sub>) receptors were cloned from osteoclastoma. The expression of P2Y<sub>2</sub>R from human osteoclasts from bone giant cell tumour was later reported. Butyl benzyl phthalate, which interferes with mammalian ion channel receptors, inhibited ATP-induced cell proliferation via P2XR in human osteosarcoma HOS cells (<xref ref-type="bibr" rid="B510">Liu and Chen, 2010</xref>). ATP was used in autologous bone marrow transplantation for removing residual tumour cells. In mice, a type of human apyrase, APT102, in addition to aspirin disrupts bone metastasis (<xref ref-type="bibr" rid="B803">Uluçkan et al., 2008</xref>). Release of ATP from tumour cells further stimulates osteoclast formation and activity, contributing to bone destruction that often happens around tumour metastases. Bisphosphonates, used to treat osteoporosis, treat bone cancer and may involve apoptosis induced by ApppI, an ATP analogue produced by bisphosphonates (<xref ref-type="bibr" rid="B725">Sillero et al., 2009</xref>).</p>
<p>Purinergic signalling plays a role in bone cancer pain. Bone pain can be relieved by radiation therapy, which may be related to the Ca<sup>2+</sup>-signalling cascade, mediated by P2X6R. In a mouse model of cancer pain, increased expression of P2X3R on calcitonin gene-related peptide immunoreactive DRG neurons during tumour growth, it was claimed that ATP had a role in cancer-related pain (<xref ref-type="bibr" rid="B509">Liu M. et al., 2013</xref>). In rats, systemic inhibition of P2X3 and P2X2/3R with AF-353 strongly attenuated bone cancer pain-related behaviour (<xref ref-type="bibr" rid="B423">Kaan et al., 2010</xref>). In mice, administration of A-317491, a selective P2X3 and P2X2/3R antagonist, attenuated the early stages of bone pain in cancer (<xref ref-type="bibr" rid="B339">Hansen et al., 2012</xref>). Functional up-regulation of P2X3R has been described in DRG of bone cancer pain in a rat model (<xref ref-type="bibr" rid="B861">Wu et al., 2012</xref>).</p>
<p>In P2X7R KO mice, bone cancer pain-related behaviours had an earlier onset (<xref ref-type="bibr" rid="B340">Hansen et al., 2011</xref>). Most human osteosarcomas expressed P2X7R isoforms A and B (<xref ref-type="bibr" rid="B306">Giuliani et al., 2014</xref>) and P2X7R are involved in cancer-induced bone pain and P2X7R antagonists were suggested as a useful analgesic target (<xref ref-type="bibr" rid="B242">Falk et al., 2015</xref>). P2Y<sub>1</sub>R signalling in the DRG and spinal cord may mediate pain from bone cancer (<xref ref-type="bibr" rid="B149">Chen et al., 2012</xref>). Activation of K<sub>ATP</sub> channels at the spinal cord level reduces pain associated with bone cancer (<xref ref-type="bibr" rid="B864">Xia et al., 2014</xref>). Stimulation by AMP-activated protein kinase suppresses neuroinflammation and reduces bone cancer pain (<xref ref-type="bibr" rid="B742">Song et al., 2015</xref>).</p>
</sec>
<sec>
<title>Myeloma</title>
<p>Multiple myeloma (cancer of plasma cells) involves osteolytic bone lesions, due largely to enhanced osteoclast activity. A<sub>2</sub>R may be therapeutically useful to treat and prevent multiple myeloma-induced bone disease as activation of A<sub>2A</sub>R reduces osteoclast function, while activation of A<sub>2B</sub>R stimulates osteoblast differentiation (<xref ref-type="bibr" rid="B348">He et al., 2012</xref>). 8-Amino-adenosine is another possible therapeutic compound for the treatment of multiple myeloma.</p>
</sec>
<sec>
<title>Severe Combined Immunodeficiency</title>
<p>A major cause of severe combined immunodeficiency are genetic defects in the ADA gene. Lack of ADA causes accumulation of adenosine. Bone defects as a result of reduced osteoclastogenesis together with a defect in osteoblast function leading to low bone formation were seen in about a half of early-onset ADA-deficient patients (<xref ref-type="bibr" rid="B708">Sauer et al., 2009</xref>). Further, the microenvironment of bone marrow in ADA KO mice had a lower ability to support haematopoiesis. In ADA KO mice, treatment with gene therapy, bone marrow transplantation or enzyme replacement, led to a full recovery. ADA-transduced hematopoietic stem cell gene therapy also enhanced the growth of children with this disease.</p>
</sec>
<sec>
<title>Dwarfism (Achondroplasia)</title>
<p>This is a congenital dysplasia of the skeleton as a result in a mutation in the gene encoding fibroblast growth factor receptor type 3 (FGR3). Ap<sub>4</sub>A diminished the expression of the achondroplasic FGFR3 receptor and P2Y<sub>1</sub>, P2Y<sub>2</sub>, P2Y<sub>6</sub>, and P2Y<sub>11</sub>R are expressed by achondroplasic chondrocytes mediating the action of Ap<sub>4</sub>A (<xref ref-type="bibr" rid="B335">Guzmán-Aránguez et al., 2008</xref>). Ap<sub>4</sub>A reversed the morphological changes supporting a therapeutic role for Ap<sub>4</sub>A as a possible treatment of dwarfism (<xref ref-type="bibr" rid="B373">Huete et al., 2011</xref>).</p>
</sec>
<sec>
<title>Paget’s Disease</title>
<p>There is an increase in osteoclast numbers in Paget’s disease, leading to an increase in bone resorption and a high turnover of bone. Bisphosphonates have been employed as a treatment for Paget’s disease and P2X7 antagonists have also been considered (<xref ref-type="bibr" rid="B9">Agrawal et al., 2010</xref>).</p>
</sec>
<sec>
<title>Ossification of the Posterior Longitudinal Ligament of the Spine</title>
<p>This disease causes neurological damage as a result of ectopic bone formation in spinal ligaments. In this disease, extracellular ATP in ossification of cell cultures of the posterior longitudinal ligament of the spine (OPLL) is increased. P2Y<sub>1</sub>R are highly expressed in OPLL cells. Mechanical stress and ATP increase the levels of osteopontin and alkaline phosphatase mRNA in OPLL cells, effects that can be inhibited by MRS2179, a selective P2Y<sub>1</sub>R antagonist. Over-expression of P2Y<sub>1</sub>R in OPLL-induced mineralisation resulted in ectopic bone formation in the spinal ligament cells of patients with OPLL (<xref ref-type="bibr" rid="B777">Tanaka et al., 2011</xref>).</p>
</sec>
</sec>
<sec>
<title>Concluding Comments</title>
<p>Clinical interventions involving purinergic signalling are just beginning. However, the beginning and future of purinergic compounds for the treatment of a wide range of diseases is described in this review. P2Y<sub>12</sub>R antagonists, such as clopidogrel and ticagrelor, are currently in wide use for stroke and thrombosis, as are P2Y<sub>2</sub>R agonists for dry eye and A<sub>1</sub>R agonists for supraventricular tachycardia. The use of P2X7R antagonists for the treatment of inflammatory diseases is promising, but the presence of polymorphic variations of this receptor is holding up the development of selective antagonists appropriate for each disease. P2X3R antagonists are in clinical trials for use against visceral pain, chronic cough and hypertension. A<sub>2A</sub>R agonists are in use for the treatment of PD, and perhaps soon in wider use. P2X1R antagonists are being investigated for treatment of bladder disorders and hypertension, while P2X4, P2X7 and A<sub>3</sub>R antagonists are being explored for neuropathic pain. Treatments with inhalation of ectonucleotidases to alter the balance of ATP and adenosine and inhibitors of ATP release, are also a therapeutic approach being explored. The development of novel purinergic compounds by medicinal chemists that are orally available and stable <italic>in vivo</italic> would be a significant advantage in developing therapeutic approaches, including centrally penetrant P2X7R antagonists (<xref ref-type="bibr" rid="B2">Able et al., 2011</xref>).</p>
<p>The majority of the therapeutic approaches for many heart disorders based on purinergic signalling manipulation are not fully understood yet and strategies to overcome the side-effects of treatment need to be considered. The pathophysiological roles of purinergic signalling in blood vessels are clearer and it plays an important role in controlling vascular tone and remodelling. Immunologic factors related to purinergic signalling are attracting more attention and should be considered (<xref ref-type="bibr" rid="B138">Cekic and Linden, 2016</xref>). Human embryonic stem cells are able to self-renew and have the potential to differentiate into different cell types, including cardiovascular progenitor cells. This system of differentiation is being investigated for cardiac regenerative therapy (<xref ref-type="bibr" rid="B369">Huang et al., 2016</xref>). The single nucleotide polymorphisms in purinergic receptor genes and their association with diseases are being explored for potential use as diagnosis biomarkers (see <xref ref-type="bibr" rid="B135">Caseley et al., 2014</xref>). Purinoceptors modulate neural stem cell proliferation, differentiation, migration and cell death and could be therapeutic approaches for the treatment of neurological and psychiatric illnesses (<xref ref-type="bibr" rid="B384">Illes and Rubini, 2017</xref>). MicroRNAs modulating purinergic signalling are gaining interest as potential original therapeutic targets and disease biomarkers (<xref ref-type="bibr" rid="B255">Ferrari et al., 2016a</xref>).</p>
<p>Although still in its infancy, clinical use of purinergic compounds has started. Several relevant pharmacological interventions are currently in clinical use. The lack of more established purinergic therapies may be due to there being relatively few receptor subtype-specific agonists and antagonists that are both effective and stable <italic>in vivo</italic> (see <xref ref-type="bibr" rid="B396">Jacobson and Muller, 2016</xref>). In some situations, a degree of redundancy is present, with several different subtypes of receptor mediating similar functional effects. Purinergic signalling is implicated in multiple disorders and therefore offers many potential future therapeutic targets. It should be noted, however, that since most purinoceptors are ubiquitous, to selectively target specific cell types may prove to be a challenge. As well as the development of selective agonists and antagonists, therapeutic strategies will probably include compounds that control P2R expression, inhibitors of extracellular ATP breakdown and inhibitors or enhancers of ATP transport. Understanding the interactions of purinergic signalling with other established signalling systems will be necessary.</p>
</sec>
<sec>
<title>Author Contributions</title>
<p>The author confirms being the sole contributor of this work and approved it for publication.</p>
</sec>
<sec>
<title>Conflict of Interest Statement</title>
<p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer SS and handling Editor declared their shared affiliation.</p>
</sec>
</body>
<back>
<ack>
<p>I am greatly indebted to Dr. Gillian E. Knight for the excellent editorial work in the preparation of this manuscript.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdulqawi</surname><given-names>R.</given-names></name><name><surname>Dockry</surname><given-names>R.</given-names></name><name><surname>Holt</surname><given-names>K.</given-names></name><name><surname>Layton</surname><given-names>G.</given-names></name><name><surname>Mccarthy</surname><given-names>B. G.</given-names></name><name><surname>Ford</surname><given-names>A. P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.</article-title>
<source/><italic>Lancet</italic>
<volume>385</volume>
<fpage>1198</fpage>–<lpage>1205</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61255-1</pub-id><pub-id pub-id-type="pmid">25467586</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Able</surname><given-names>S. L.</given-names></name><name><surname>Fish</surname><given-names>R. L.</given-names></name><name><surname>Bye</surname><given-names>H.</given-names></name><name><surname>Booth</surname><given-names>L.</given-names></name><name><surname>Logan</surname><given-names>Y. R.</given-names></name><name><surname>Nathaniel</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>162</volume>
<fpage>405</fpage>–<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01025.x</pub-id><pub-id pub-id-type="pmid">20840537</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>M. K.</given-names></name><name><surname>Nolte</surname><given-names>A.</given-names></name><name><surname>Reus</surname><given-names>R.</given-names></name><name><surname>Behring</surname><given-names>A.</given-names></name><name><surname>Zengerle</surname><given-names>D.</given-names></name><name><surname>Avci-Adali</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>In vitro study of a novel stent coating using modified CD39 messenger RNA to potentially reduce stent angioplasty-associated complications.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>10</volume>:<issue>e0138375</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0138375</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acevedo</surname><given-names>C. G.</given-names></name><name><surname>Huambachano</surname><given-names>A.</given-names></name><name><surname>Perez</surname><given-names>E.</given-names></name><name><surname>Rojas</surname><given-names>S.</given-names></name><name><surname>Bravo</surname><given-names>I.</given-names></name><name><surname>Contreras</surname><given-names>E.</given-names></name></person-group> (<year>1997</year>). <article-title>Effect of ethanol on human placental transport and metabolism of adenosine.</article-title>
<source/><italic>Placenta</italic>
<volume>18</volume>
<fpage>387</fpage>–<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1016/S0143-4004(97)80038-0</pub-id><pub-id pub-id-type="pmid">9250700</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adinolfi</surname><given-names>E.</given-names></name><name><surname>Capece</surname><given-names>M.</given-names></name><name><surname>Franceschini</surname><given-names>A.</given-names></name><name><surname>Falzoni</surname><given-names>S.</given-names></name><name><surname>Giuliani</surname><given-names>A. L.</given-names></name><name><surname>Rotondo</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Accelerated tumor progression in mice lacking the ATP receptor P2X7.</article-title>
<source/><italic>Cancer Res.</italic>
<volume>75</volume>
<fpage>635</fpage>–<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1259</pub-id><pub-id pub-id-type="pmid">25542861</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adinolfi</surname><given-names>E.</given-names></name><name><surname>Raffaghello</surname><given-names>L.</given-names></name><name><surname>Giuliani</surname><given-names>A. L.</given-names></name><name><surname>Cavazzini</surname><given-names>L.</given-names></name><name><surname>Capece</surname><given-names>M.</given-names></name><name><surname>Chiozzi</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Expression of P2X7 receptor increases in vivo tumor growth.</article-title>
<source/><italic>Cancer Res.</italic>
<volume>72</volume>
<fpage>2957</fpage>–<lpage>2969</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1947</pub-id><pub-id pub-id-type="pmid">22505653</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R.</given-names></name><name><surname>Agarwal</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways.</article-title>
<source/><italic>Expert Opin. Ther. Targets</italic>
<volume>18</volume>
<fpage>527</fpage>–<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1517/14728222.2014.888416</pub-id><pub-id pub-id-type="pmid">24579961</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghaei</surname><given-names>M.</given-names></name><name><surname>Karami-Tehrani</surname><given-names>F.</given-names></name><name><surname>Panjehpour</surname><given-names>M.</given-names></name><name><surname>Salami</surname><given-names>S.</given-names></name><name><surname>Fallahian</surname><given-names>F.</given-names></name></person-group> (<year>2012</year>). <article-title>Adenosine induces cell-cycle arrest and apoptosis in androgen-dependent and -independent prostate cancer cell lines, LNcap-FGC-10, DU-145, and PC3.</article-title>
<source/><italic>Prostate</italic>
<volume>72</volume>
<fpage>361</fpage>–<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1002/pros.21438</pub-id><pub-id pub-id-type="pmid">21656837</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>A.</given-names></name><name><surname>Buckley</surname><given-names>K. A.</given-names></name><name><surname>Bowers</surname><given-names>K.</given-names></name><name><surname>Furber</surname><given-names>M.</given-names></name><name><surname>Gallagher</surname><given-names>J. A.</given-names></name><name><surname>Gartland</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>The effects of P2X7 receptor antagonists on the formation and function of human osteoclasts in vitro.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>6</volume>
<fpage>307</fpage>–<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-010-9181-z</pub-id><pub-id pub-id-type="pmid">21103214</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>A.</given-names></name><name><surname>Gartland</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>P2X7 receptors: role in bone cell formation and function.</article-title>
<source/><italic>J. Mol. Endocrinol.</italic>
<volume>54</volume>
<fpage>R75</fpage>–<lpage>R88</lpage>. <pub-id pub-id-type="doi">10.1530/JME-14-0226</pub-id><pub-id pub-id-type="pmid">25591582</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agteresch</surname><given-names>H. J.</given-names></name><name><surname>Burgers</surname><given-names>S. A.</given-names></name><name><surname>Van Der Gaast</surname><given-names>A.</given-names></name><name><surname>Wilson</surname><given-names>J. H.</given-names></name><name><surname>Dagnelie</surname><given-names>P. C.</given-names></name></person-group> (<year>2003</year>). <article-title>Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients.</article-title>
<source/><italic>Anticancer Drugs</italic>
<volume>14</volume>
<fpage>639</fpage>–<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1097/00001813-200309000-00009</pub-id><pub-id pub-id-type="pmid">14501386</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguiari</surname><given-names>G.</given-names></name><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Bogo</surname><given-names>M.</given-names></name><name><surname>Mangolini</surname><given-names>A.</given-names></name><name><surname>Vincenzi</surname><given-names>F.</given-names></name><name><surname>Durante</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A3 adenosine receptors in human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1792</volume>
<fpage>531</fpage>–<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2009.03.001</pub-id><pub-id pub-id-type="pmid">19285554</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahsan</surname><given-names>M. K.</given-names></name></person-group> (<year>2011</year>). <article-title>The adenosine A2 receptor enhances primary rat HSC proliferation and inhibits senescence by down-regulation of P53 and RB.</article-title>
<source/><italic>Hepatology</italic>
<volume>54</volume>
<fpage>750A</fpage>–<lpage>751A</lpage>. <pub-id pub-id-type="doi">10.3389/fphar.2014.00069</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aikin</surname><given-names>R. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Targeting purinergic receptors in islet transplantation.</article-title>
<source/><italic>Diabetes Metab. Res. Rev.</italic>
<volume>62</volume>
<fpage>1394</fpage>–<lpage>1395</lpage>. <pub-id pub-id-type="doi">10.2337/db13-0211</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akimoto</surname><given-names>M.</given-names></name><name><surname>Yunoue</surname><given-names>S.</given-names></name><name><surname>Otsubo</surname><given-names>H.</given-names></name><name><surname>Yoshitama</surname><given-names>T.</given-names></name><name><surname>Kodama</surname><given-names>K.</given-names></name><name><surname>Matsushita</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis.</article-title>
<source/><italic>Mod. Rheumatol.</italic>
<volume>23</volume>
<fpage>19</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s10165-012-0621-1</pub-id><pub-id pub-id-type="pmid">22374112</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akino</surname><given-names>H.</given-names></name><name><surname>Nagase</surname><given-names>K.</given-names></name><name><surname>Watanabe</surname><given-names>N.</given-names></name><name><surname>Tanase</surname><given-names>K.</given-names></name><name><surname>Oyama</surname><given-names>N.</given-names></name><name><surname>Miwa</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>ATP release from blassers is increased in-vivo and suppressed by alpha-1 adrenoceptor blocker in a rat model of bladder outlet obstruction.</article-title>
<source/><italic>Eur. Urol. Suppl.</italic>
<volume>10</volume>
<fpage>303</fpage>–<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/S1569-9056(11)60955-X</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>U.</given-names></name><name><surname>De Cori</surname><given-names>D.</given-names></name><name><surname>Aguglia</surname><given-names>A.</given-names></name><name><surname>Barbaro</surname><given-names>F.</given-names></name><name><surname>Bogetto</surname><given-names>F.</given-names></name><name><surname>Maina</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Increased uric acid levels in bipolar disorder subjects during different phases of illness.</article-title>
<source/><italic>J. Affect. Disord</italic>
<volume>173</volume>
<fpage>170</fpage>–<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2014.11.005</pub-id><pub-id pub-id-type="pmid">25462413</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberto</surname><given-names>A. V.</given-names></name><name><surname>Faria</surname><given-names>R. X.</given-names></name><name><surname>De Menezes</surname><given-names>J. R.</given-names></name><name><surname>Surrage</surname><given-names>A.</given-names></name><name><surname>Da Rocha</surname><given-names>N. C.</given-names></name><name><surname>Ferreira</surname><given-names>L. G.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Role of P2 receptors as modulators of rat eosinophil recruitment in allergic inflammation.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>11</volume>:<issue>e0145392</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0145392</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexopoulos</surname><given-names>D.</given-names></name><name><surname>Xanthopoulou</surname><given-names>I.</given-names></name><name><surname>Moulias</surname><given-names>A.</given-names></name><name><surname>Lekakis</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Long-term P2Y12-receptor antagonists in post-myocardial infarction patients: facing a new trilemma?</article-title>
<source/><italic>J. Am. Coll. Cardiol.</italic>
<volume>68</volume>
<fpage>1223</fpage>–<lpage>1232</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2016.05.088</pub-id><pub-id pub-id-type="pmid">27609686</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida-da-Silva</surname><given-names>C. L.</given-names></name><name><surname>Morandini</surname><given-names>A. C.</given-names></name><name><surname>Ulrich</surname><given-names>H.</given-names></name><name><surname>Ojcius</surname><given-names>D. M.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling during <italic>Porphyromonas gingivalis</italic> infection.</article-title>
<source/><italic>Biomed. J.</italic>
<volume>39</volume>
<fpage>251</fpage>–<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1016/j.bj.2016.08.003</pub-id><pub-id pub-id-type="pmid">27793267</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alves</surname><given-names>L. A.</given-names></name><name><surname>Bezerra</surname><given-names>R. J.</given-names></name><name><surname>Faria</surname><given-names>R. X.</given-names></name><name><surname>Ferreira</surname><given-names>L. G.</given-names></name><name><surname>Da Silva Frutuoso</surname><given-names>V.</given-names></name></person-group> (<year>2013</year>). <article-title>Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain.</article-title>
<source/><italic>Molecules</italic>
<volume>18</volume>
<fpage>10953</fpage>–<lpage>10972</lpage>. <pub-id pub-id-type="doi">10.3390/molecules180910953</pub-id><pub-id pub-id-type="pmid">24013409</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaral</surname><given-names>E. P.</given-names></name><name><surname>Ribeiro</surname><given-names>S. C.</given-names></name><name><surname>Lanes</surname><given-names>V. R.</given-names></name><name><surname>Almeida</surname><given-names>F. M.</given-names></name><name><surname>De Andrade</surname><given-names>M. R.</given-names></name><name><surname>Bomfim</surname><given-names>C. C.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Pulmonary infection with hypervirulent Mycobacteria reveals a crucial role for the P2X7 receptor in aggressive forms of tuberculosis.</article-title>
<source/><italic>PLOS Pathog.</italic>
<volume>10</volume>:<issue>e1004188</issue>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1004188</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaral</surname><given-names>S. S.</given-names></name><name><surname>Oliveira</surname><given-names>A. G.</given-names></name><name><surname>Marques</surname><given-names>P. E.</given-names></name><name><surname>Quintão</surname><given-names>J. L.</given-names></name><name><surname>Pires</surname><given-names>D. A.</given-names></name><name><surname>Resende</surname><given-names>R. R.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Altered responsiveness to extracellular ATP enhances acetaminophen hepatotoxicity.</article-title>
<source/><italic>Cell Commun. Signal.</italic>
<volume>11</volume>:<issue>10</issue>
<pub-id pub-id-type="doi">10.1186/1478-811X-11-10</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amoroso</surname><given-names>F.</given-names></name><name><surname>Capece</surname><given-names>M.</given-names></name><name><surname>Rotondo</surname><given-names>A.</given-names></name><name><surname>Cangelosi</surname><given-names>D.</given-names></name><name><surname>Ferracin</surname><given-names>M.</given-names></name><name><surname>Franceschini</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma.</article-title>
<source/><italic>Oncogene</italic>
<volume>34</volume>
<fpage>5240</fpage>–<lpage>5251</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2014.444</pub-id><pub-id pub-id-type="pmid">25619831</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>K. E.</given-names></name></person-group> (<year>2001</year>). <article-title>Neurotransmission and drug effects in urethral smooth muscle.</article-title>
<source/><italic>Scand. J. Urol. Nephrol. Suppl.</italic>
<volume>207</volume>
<fpage>26</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1080/003655901750174854</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>K. E.</given-names></name><name><surname>Chapple</surname><given-names>C. R.</given-names></name><name><surname>Höfner</surname><given-names>K.</given-names></name></person-group> (<year>2002</year>). <article-title>Future drugs for the treatment of benign prostatic hyperplasia.</article-title>
<source/><italic>World J. Urol.</italic>
<volume>19</volume>
<fpage>436</fpage>–<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1007/s00345-002-0253-8</pub-id><pub-id pub-id-type="pmid">12022712</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>K. E.</given-names></name><name><surname>Hedlund</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>Pharmacologic perspective on the physiology of the lower urinary tract.</article-title>
<source/><italic>Urology</italic>
<volume>60</volume>
<fpage>13</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/S0090-4295(02)01786-7</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrés</surname><given-names>R. M.</given-names></name><name><surname>Terencio</surname><given-names>M. C.</given-names></name><name><surname>Arasa</surname><given-names>J.</given-names></name><name><surname>Payá</surname><given-names>M.</given-names></name><name><surname>Valcuende-Cavero</surname><given-names>F.</given-names></name><name><surname>Navalón</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Adenosine A2A and A2B receptors differentially modulate keratinocyte proliferation: possible deregulation in psoriatic epidermis.</article-title>
<source/><italic>J. Invest. Dermatol.</italic>
<volume>137</volume>
<fpage>123</fpage>–<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2016.07.028</pub-id><pub-id pub-id-type="pmid">27498346</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonioli</surname><given-names>L.</given-names></name><name><surname>Blandizzi</surname><given-names>C.</given-names></name><name><surname>Csóka</surname><given-names>B.</given-names></name><name><surname>Pacher</surname><given-names>P.</given-names></name><name><surname>Haskó</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Adenosine signalling in diabetes mellitus - pathophysiology and therapeutic considerations.</article-title>
<source/><italic>Nat. Rev. Endocrinol.</italic>
<volume>11</volume>
<fpage>228</fpage>–<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1038/nrendo.2015.10</pub-id><pub-id pub-id-type="pmid">25687993</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonioli</surname><given-names>L.</given-names></name><name><surname>Colucci</surname><given-names>R.</given-names></name><name><surname>Pellegrini</surname><given-names>C.</given-names></name><name><surname>Giustarini</surname><given-names>G.</given-names></name><name><surname>Tuccori</surname><given-names>M.</given-names></name><name><surname>Blandizzi</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications.</article-title>
<source/><italic>Pharmacol. Ther.</italic>
<volume>139</volume>
<fpage>157</fpage>–<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.04.002</pub-id><pub-id pub-id-type="pmid">23588157</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonioli</surname><given-names>L.</given-names></name><name><surname>Csóka</surname><given-names>B.</given-names></name><name><surname>Fornai</surname><given-names>M.</given-names></name><name><surname>Colucci</surname><given-names>R.</given-names></name><name><surname>Kókai</surname><given-names>E.</given-names></name><name><surname>Blandizzi</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2014a</year>). <article-title>Adenosine and inflammation: what’s new on the horizon?</article-title>
<source/><italic>Drug Discov. Today</italic>
<volume>19</volume>
<fpage>1051</fpage>–<lpage>1068</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2014.02.010</pub-id><pub-id pub-id-type="pmid">24607729</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonioli</surname><given-names>L.</given-names></name><name><surname>Giron</surname><given-names>M. C.</given-names></name><name><surname>Colucci</surname><given-names>R.</given-names></name><name><surname>Pellegrini</surname><given-names>C.</given-names></name><name><surname>Sacco</surname><given-names>D.</given-names></name><name><surname>Caputi</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2014b</year>). <article-title>Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>9</volume>:<issue>e116253</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0116253</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apolloni</surname><given-names>S.</given-names></name><name><surname>Amadio</surname><given-names>S.</given-names></name><name><surname>Parisi</surname><given-names>C.</given-names></name><name><surname>Matteucci</surname><given-names>A.</given-names></name><name><surname>Potenza</surname><given-names>R. L.</given-names></name><name><surname>Armida</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis.</article-title>
<source/><italic>Dis. Model Mech.</italic>
<volume>7</volume>
<fpage>1101</fpage>–<lpage>1109</lpage>. <pub-id pub-id-type="doi">10.1242/dmm.017038</pub-id><pub-id pub-id-type="pmid">25038061</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apostolidis</surname><given-names>A.</given-names></name><name><surname>Popat</surname><given-names>R.</given-names></name><name><surname>Yiangou</surname><given-names>Y.</given-names></name><name><surname>Cockayne</surname><given-names>D.</given-names></name><name><surname>Ford</surname><given-names>A. P.</given-names></name><name><surname>Davis</surname><given-names>J. B.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.</article-title>
<source/><italic>J. Urol.</italic>
<volume>174</volume>
<fpage>977</fpage>–<lpage>982</lpage>. <pub-id pub-id-type="doi">10.1097/01.ju.0000169481.42259.54</pub-id><pub-id pub-id-type="pmid">16094018</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aprile-Garcia</surname><given-names>F.</given-names></name><name><surname>Metzger</surname><given-names>M. W.</given-names></name><name><surname>Paez-Pereda</surname><given-names>M.</given-names></name><name><surname>Stadler</surname><given-names>H.</given-names></name><name><surname>Acuña</surname><given-names>M.</given-names></name><name><surname>Liberman</surname><given-names>A. C.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Co-Expression of wild-type P2X7R with Gln460Arg variant alters receptor function.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>11</volume>:<issue>e0151862</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0151862</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aronsson</surname><given-names>P.</given-names></name><name><surname>Johnsson</surname><given-names>M.</given-names></name><name><surname>Vesela</surname><given-names>R.</given-names></name><name><surname>Winder</surname><given-names>M.</given-names></name><name><surname>Tobin</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Adenosine receptor antagonism suppresses functional and histological inflammatory changes in the rat urinary bladder.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>171</volume>
<fpage>49</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2012.10.006</pub-id><pub-id pub-id-type="pmid">23142515</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arulkumaran</surname><given-names>N.</given-names></name><name><surname>Unwin</surname><given-names>R. J.</given-names></name><name><surname>Tam</surname><given-names>F. W.</given-names></name></person-group> (<year>2011</year>). <article-title>A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.</article-title>
<source/><italic>Expert Opin. Investig. Drugs</italic>
<volume>20</volume>
<fpage>897</fpage>–<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1517/13543784.2011.578068</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashimi</surname><given-names>O.</given-names></name><name><surname>Parchim</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>A.</given-names></name><name><surname>Iriyama</surname><given-names>T.</given-names></name><name><surname>Sibai</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Circulating adenosine levels are elevated in pregnant women with sickle cell disease through 2,3-DPG induction.</article-title>
<source/><italic>Am. J. Obstet. Gynecol.</italic>
<volume>212</volume>
<fpage>S409</fpage>–<lpage>S410</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2014.10.1060</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atiemo</surname><given-names>H.</given-names></name><name><surname>Wynes</surname><given-names>J.</given-names></name><name><surname>Chuo</surname><given-names>J.</given-names></name><name><surname>Nipkow</surname><given-names>L.</given-names></name><name><surname>Sklar</surname><given-names>G. N.</given-names></name><name><surname>Chai</surname><given-names>T. C.</given-names></name></person-group> (<year>2005</year>). <article-title>Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model.</article-title>
<source/><italic>Urology</italic>
<volume>65</volume>
<fpage>622</fpage>–<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1016/j.urology.2004.10.057</pub-id><pub-id pub-id-type="pmid">15780404</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avendano</surname><given-names>B. C.</given-names></name><name><surname>Montero</surname><given-names>T. D.</given-names></name><name><surname>Chávez</surname><given-names>C. E.</given-names></name><name><surname>Von Bernhardi</surname><given-names>R.</given-names></name><name><surname>Orellana</surname><given-names>J. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Prenatal exposure to inflammatory conditions increases Cx43 and Panx1 unopposed channel opening and activation of astrocytes in the offspring effect on neuronal survival.</article-title>
<source/><italic>Glia</italic>
<volume>63</volume>
<fpage>2058</fpage>–<lpage>2072</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22877</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Averill</surname><given-names>S.</given-names></name><name><surname>Inglis</surname><given-names>J. J.</given-names></name><name><surname>King</surname><given-names>V. R.</given-names></name><name><surname>Thompson</surname><given-names>S. W.</given-names></name><name><surname>Cafferty</surname><given-names>W. B.</given-names></name><name><surname>Shortland</surname><given-names>P. J.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Reg-2 expression in dorsal root ganglion neurons after adjuvant-induced monoarthritis.</article-title>
<source/><italic>Neuroscience</italic>
<volume>155</volume>
<fpage>1227</fpage>–<lpage>1236</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2008.06.049</pub-id><pub-id pub-id-type="pmid">18652880</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayata</surname><given-names>C. K.</given-names></name><name><surname>Ganal</surname><given-names>S. C.</given-names></name><name><surname>Hockenjos</surname><given-names>B.</given-names></name><name><surname>Willim</surname><given-names>K.</given-names></name><name><surname>Vieira</surname><given-names>R. P.</given-names></name><name><surname>Grimm</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Purinergic P2Y2 receptors promote neutrophil infiltration and hepatocyte death in mice with acute liver injury.</article-title>
<source/><italic>Gastroenterology</italic>
<volume>143</volume>
<fpage>k1620</fpage>–<lpage>1629</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2012.08.049</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azimi</surname><given-names>I.</given-names></name><name><surname>Beilby</surname><given-names>H.</given-names></name><name><surname>Davis</surname><given-names>F. M.</given-names></name><name><surname>Marcial</surname><given-names>D. L.</given-names></name><name><surname>Kenny</surname><given-names>P. A.</given-names></name><name><surname>Thompson</surname><given-names>E. W.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Altered purinergic receptor-Ca2+ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.</article-title>
<source/><italic>Mol. Oncol.</italic>
<volume>10</volume>
<fpage>166</fpage>–<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/j.molonc.2015.09.006</pub-id><pub-id pub-id-type="pmid">26433470</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>H. Y.</given-names></name><name><surname>Li</surname><given-names>A. P.</given-names></name></person-group> (<year>2013</year>). <article-title>P2X7 receptors in cerebral ischemia.</article-title>
<source/><italic>Neurosci. Bull.</italic>
<volume>29</volume>
<fpage>390</fpage>–<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1007/s12264-013-1338-7</pub-id><pub-id pub-id-type="pmid">23640286</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baranowska-Bosiacka</surname><given-names>I.</given-names></name><name><surname>Listos</surname><given-names>J.</given-names></name><name><surname>Gutowska</surname><given-names>I.</given-names></name><name><surname>Hoy-Mokrzynska</surname><given-names>A.</given-names></name><name><surname>Kolasa-Wolosiuk</surname><given-names>A.</given-names></name><name><surname>Tarnowski</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Effects of perinatal exposure to lead (Pb) on purine receptor expression in the brain and gliosis in rats tolerant to morphine analgesia.</article-title>
<source/><italic>Toxicology</italic>
<volume>339</volume>
<fpage>19</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2015.10.003</pub-id><pub-id pub-id-type="pmid">26478469</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Barron</surname><given-names>M. L.</given-names></name><name><surname>Werry</surname><given-names>E. L.</given-names></name><name><surname>Mcgregor</surname><given-names>I. S.</given-names></name><name><surname>Kassiou</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>“P2X7 in bipolar and depressive disorders,” in</article-title>
<source/><italic>Pathologies of Calcium Channels</italic>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Weiss</surname><given-names>N.</given-names></name><name><surname>Koschak</surname><given-names>A.</given-names></name></person-group> (<publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>635</fpage>–<lpage>661</lpage>.</mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>R.</given-names></name><name><surname>Stokes</surname><given-names>L.</given-names></name><name><surname>Sluyter</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>66</volume>
<fpage>638</fpage>–<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1124/pr.113.008003</pub-id><pub-id pub-id-type="pmid">24928329</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoli</surname><given-names>F.</given-names></name><name><surname>Carrà</surname><given-names>G.</given-names></name><name><surname>Clerici</surname><given-names>M.</given-names></name></person-group> (<year>2017a</year>). <article-title>Update on bipolar disorder biomarker candidates: what about uric acid/adenosine hypothesis?</article-title>
<source/><italic>Expert Rev. Mol. Diagn.</italic>
<volume>17</volume>
<fpage>105</fpage>–<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1080/14737159.2017.1270757</pub-id><pub-id pub-id-type="pmid">27935329</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartoli</surname><given-names>F.</given-names></name><name><surname>Crocamo</surname><given-names>C.</given-names></name><name><surname>Dakanalis</surname><given-names>A.</given-names></name><name><surname>Brosio</surname><given-names>E.</given-names></name><name><surname>Miotto</surname><given-names>A.</given-names></name><name><surname>Capuzzi</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2017b</year>). <article-title>Purinergic system dysfunctions in subjects with bipolar disorder: a comparative cross-sectional study.</article-title>
<source/><italic>Compr. Psychiatry</italic>
<volume>73</volume>
<fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.comppsych.2016.09.011</pub-id><pub-id pub-id-type="pmid">27837679</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Yehuda</surname><given-names>S.</given-names></name><name><surname>Stemmer</surname><given-names>S. M.</given-names></name><name><surname>Madi</surname><given-names>L.</given-names></name><name><surname>Castel</surname><given-names>D.</given-names></name><name><surname>Ochaion</surname><given-names>A.</given-names></name><name><surname>Cohen</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-κB signal transduction pathways.</article-title>
<source/><italic>Int. J. Oncol.</italic>
<volume>33</volume>
<fpage>287</fpage>–<lpage>295</lpage>.<pub-id pub-id-type="pmid">18636149</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basoglu</surname><given-names>O. K.</given-names></name><name><surname>Barnes</surname><given-names>P. J.</given-names></name><name><surname>Kharitonov</surname><given-names>S. A.</given-names></name><name><surname>Pelleg</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Effects of aerosolized adenosine 5′-triphosphate in smokers and patients with COPD.</article-title>
<source/><italic>Chest</italic>
<volume>148</volume>
<fpage>430</fpage>–<lpage>435</lpage>. <pub-id pub-id-type="doi">10.1378/chest.14-2285</pub-id><pub-id pub-id-type="pmid">25590209</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basoglu</surname><given-names>O. K.</given-names></name><name><surname>Pelleg</surname><given-names>A.</given-names></name><name><surname>Kharitonov</surname><given-names>S. A.</given-names></name><name><surname>Barnes</surname><given-names>P. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Contrasting effects of ATP and adenosine on capsaicin challenge in asthmatic patients.</article-title>
<source/><italic>Pulm. Pharmacol. Ther.</italic>
<volume>45</volume>
<fpage>13</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.pupt.2017.04.004</pub-id><pub-id pub-id-type="pmid">28392320</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>S.</given-names></name><name><surname>Barawkar</surname><given-names>D. A.</given-names></name><name><surname>Ramdas</surname><given-names>V.</given-names></name><name><surname>Patel</surname><given-names>M.</given-names></name><name><surname>Waman</surname><given-names>Y.</given-names></name><name><surname>Panmand</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Design and synthesis of novel xanthine derivatives as potent and selective A2B adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases.</article-title>
<source/><italic>Eur. J. Med. Chem.</italic>
<volume>134</volume>
<fpage>218</fpage>–<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2017.04.014</pub-id><pub-id pub-id-type="pmid">28415011</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudelet</surname><given-names>D.</given-names></name><name><surname>Lipka</surname><given-names>E.</given-names></name><name><surname>Millet</surname><given-names>R.</given-names></name><name><surname>Ghinet</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.</article-title>
<source/><italic>Curr. Med. Chem.</italic>
<volume>22</volume>
<fpage>713</fpage>–<lpage>729</lpage>. <pub-id pub-id-type="doi">10.2174/0929867322666141212120926</pub-id><pub-id pub-id-type="pmid">25515510</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazzichi</surname><given-names>L.</given-names></name><name><surname>Giannaccini</surname><given-names>G.</given-names></name><name><surname>Betti</surname><given-names>L.</given-names></name><name><surname>Fabbrini</surname><given-names>L.</given-names></name><name><surname>Schmid</surname><given-names>L.</given-names></name><name><surname>Palego</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia.</article-title>
<source/><italic>Clin. Biochem.</italic>
<volume>41</volume>
<fpage>1084</fpage>–<lpage>1090</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2008.06.012</pub-id><pub-id pub-id-type="pmid">18634773</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beamer</surname><given-names>E.</given-names></name><name><surname>Fischer</surname><given-names>W.</given-names></name><name><surname>Engel</surname><given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>The ATP-gated P2X7 receptor as a target for the treatment of drug-resistant epilepsy.</article-title>
<source/><italic>Front. Neurosci.</italic>
<volume>11</volume>:<issue>21</issue>
<pub-id pub-id-type="doi">10.3389/fnins.2017.00021</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beamer</surname><given-names>E.</given-names></name><name><surname>Gölöncsér</surname><given-names>F.</given-names></name><name><surname>Horváth</surname><given-names>G.</given-names></name><name><surname>Bekö</surname><given-names>K.</given-names></name><name><surname>Otrokocsi</surname><given-names>L.</given-names></name><name><surname>Koványi</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Purinergic mechanisms in neuroinflammation: an update from molecules to behavior.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>94</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.09.019</pub-id><pub-id pub-id-type="pmid">26384652</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaucage</surname><given-names>K. L.</given-names></name><name><surname>Xiao</surname><given-names>A.</given-names></name><name><surname>Pollmann</surname><given-names>S. I.</given-names></name><name><surname>Grol</surname><given-names>M. W.</given-names></name><name><surname>Beach</surname><given-names>R. J.</given-names></name><name><surname>Holdsworth</surname><given-names>D. W.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Loss of P2X7 nucleotide receptor function leads to abnormal fat distribution in mice.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>10</volume>
<fpage>291</fpage>–<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9388-x</pub-id><pub-id pub-id-type="pmid">24222214</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckel</surname><given-names>J. M.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Civan</surname><given-names>M. M.</given-names></name><name><surname>Mitchell</surname><given-names>C. H.</given-names></name></person-group> (<year>2016</year>). <article-title>Treatment of retinal disorders with purinergic drugs: beyond receptors.</article-title>
<source/><italic>J. Ocul. Pharmacol. Ther.</italic>
<volume>32</volume>
<fpage>488</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1089/jop.2016.29020.jbe</pub-id><pub-id pub-id-type="pmid">27754823</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckenkamp</surname><given-names>A.</given-names></name><name><surname>Santana</surname><given-names>D. B.</given-names></name><name><surname>Bruno</surname><given-names>A. N.</given-names></name><name><surname>Calil</surname><given-names>L. N.</given-names></name><name><surname>Casali</surname><given-names>E. A.</given-names></name><name><surname>Paccez</surname><given-names>J. D.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Ectonucleotidase expression profile and activity in human cervical cancer cell lines.</article-title>
<source/><italic>Biochem. Cell Biol.</italic>
<volume>92</volume>
<fpage>95</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1139/bcb-2013-0051</pub-id><pub-id pub-id-type="pmid">24697693</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belhassen</surname><given-names>B.</given-names></name><name><surname>Michowitz</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Unmasking right atrial fibrillation: a new indication of adenosine triphosphate test?</article-title>
<source/><italic>Heart Rhythm</italic>
<volume>13</volume>
<fpage>364</fpage>–<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2015.10.020</pub-id><pub-id pub-id-type="pmid">26476150</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Ari</surname><given-names>Z.</given-names></name><name><surname>Pappo</surname><given-names>O.</given-names></name><name><surname>Yitzhaki</surname><given-names>S.</given-names></name><name><surname>Cheporko</surname><given-names>Y.</given-names></name><name><surname>Shainberg</surname><given-names>A.</given-names></name><name><surname>Zinman</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Uridine-5′-triphosphate protects against hepatic- ischemic/reperfusion injury in mice.</article-title>
<source/><italic>Transplantation</italic>
<volume>87</volume>
<fpage>1155</fpage>–<lpage>1162</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0b013e31819e3cdc</pub-id><pub-id pub-id-type="pmid">19384161</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benitez-Rajal</surname><given-names>J.</given-names></name><name><surname>Lorite</surname><given-names>M. J.</given-names></name><name><surname>Burt</surname><given-names>A. D.</given-names></name><name><surname>Day</surname><given-names>C. P.</given-names></name><name><surname>Thompson</surname><given-names>M. G.</given-names></name></person-group> (<year>2006</year>). <article-title>Phospholipase D and extracellular signal-regulated kinase in hepatic stellate cells: effects of platelet-derived growth factor and extracellular nucleotides.</article-title>
<source/><italic>Am. J Physiol. Gastrointest. Liver Physiol.</italic>
<volume>291</volume>
<fpage>G977</fpage>–<lpage>G986</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.00041.2006</pub-id><pub-id pub-id-type="pmid">17030901</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergamin</surname><given-names>L. S.</given-names></name><name><surname>Braganhol</surname><given-names>E.</given-names></name><name><surname>Figueiró</surname><given-names>F.</given-names></name><name><surname>Casali</surname><given-names>E. A.</given-names></name><name><surname>Zanin</surname><given-names>R. F.</given-names></name><name><surname>Sévigny</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Involvement of purinergic system in the release of cytokines by macrophages exposed to glioma-conditioned medium.</article-title>
<source/><italic>J. Cell Biochem.</italic>
<volume>116</volume>
<fpage>721</fpage>–<lpage>729</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.25018</pub-id><pub-id pub-id-type="pmid">25546398</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Besnard</surname><given-names>A.</given-names></name><name><surname>Gautherot</surname><given-names>J.</given-names></name><name><surname>Julien</surname><given-names>B.</given-names></name><name><surname>Tebbi</surname><given-names>A.</given-names></name><name><surname>Garcin</surname><given-names>I.</given-names></name><name><surname>Doignon</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The P2X4 purinergic receptor impacts liver regeneration after partial hepatectomy in mice through the regulation of biliary homeostasis.</article-title>
<source/><italic>Hepatology</italic>
<volume>64</volume>
<fpage>941</fpage>–<lpage>953</lpage>. <pub-id pub-id-type="doi">10.1002/hep.28675</pub-id><pub-id pub-id-type="pmid">27301647</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beswick</surname><given-names>P. J.</given-names></name><name><surname>Billinton</surname><given-names>A.</given-names></name><name><surname>Chambers</surname><given-names>L. J.</given-names></name><name><surname>Dean</surname><given-names>D. K.</given-names></name><name><surname>Fonfria</surname><given-names>E.</given-names></name><name><surname>Gleave</surname><given-names>R. J.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor.</article-title>
<source/><italic>Bioorg. Med. Chem. Lett.</italic>
<volume>20</volume>
<fpage>4653</fpage>–<lpage>4656</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2010.05.107</pub-id><pub-id pub-id-type="pmid">20579878</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>A.</given-names></name><name><surname>Biber</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>The microglial ATP-gated ion channel P2X7 as a CNS drug target.</article-title>
<source/><italic>Glia</italic>
<volume>64</volume>
<fpage>1772</fpage>–<lpage>1787</lpage>. <pub-id pub-id-type="doi">10.1002/glia.23001</pub-id><pub-id pub-id-type="pmid">27219534</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhave</surname><given-names>S.</given-names></name><name><surname>Gade</surname><given-names>A.</given-names></name><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Hauser</surname><given-names>K. F.</given-names></name><name><surname>Dewey</surname><given-names>W. L.</given-names></name><name><surname>Akbarali</surname><given-names>H. I.</given-names></name></person-group> (<year>2017</year>). <article-title>Connexin-purinergic signaling in enteric glia mediates the prolonged effect of morphine on constipation.</article-title>
<source/><italic>FASEB J.</italic>
<volume>31</volume>
<fpage>2649</fpage>–<lpage>2660</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201601068R</pub-id><pub-id pub-id-type="pmid">28280004</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boldrini</surname><given-names>L.</given-names></name><name><surname>Giordano</surname><given-names>M.</given-names></name><name><surname>Alì</surname><given-names>G.</given-names></name><name><surname>Melfi</surname><given-names>F.</given-names></name><name><surname>Romano</surname><given-names>G.</given-names></name><name><surname>Lucchi</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value.</article-title>
<source/><italic>Oncol. Lett.</italic>
<volume>9</volume>
<fpage>449</fpage>–<lpage>453</lpage>.<pub-id pub-id-type="pmid">25436007</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borea</surname><given-names>P. A.</given-names></name><name><surname>Gessi</surname><given-names>S.</given-names></name><name><surname>Merighi</surname><given-names>S.</given-names></name><name><surname>Varani</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects?</article-title>
<source/><italic>Trends Pharmacol. Sci.</italic>
<volume>37</volume>
<fpage>419</fpage>–<lpage>434</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2016.02.006</pub-id><pub-id pub-id-type="pmid">26944097</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borea</surname><given-names>P. A.</given-names></name><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Vincenzi</surname><given-names>F.</given-names></name><name><surname>Baraldi</surname><given-names>P. G.</given-names></name><name><surname>Tabrizi</surname><given-names>M. A.</given-names></name><name><surname>Merighi</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The A3 adenosine receptor: history and perspectives.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>67</volume>
<fpage>74</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1124/pr.113.008540</pub-id><pub-id pub-id-type="pmid">25387804</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borel</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>R.</given-names></name><name><surname>Visser</surname><given-names>A.</given-names></name><name><surname>Petry</surname><given-names>H.</given-names></name><name><surname>Van Deventer</surname><given-names>S. J.</given-names></name><name><surname>Jansen</surname><given-names>P. L.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs.</article-title>
<source/><italic>Hepatology</italic>
<volume>55</volume>
<fpage>821</fpage>–<lpage>832</lpage>. <pub-id pub-id-type="doi">10.1002/hep.24682</pub-id><pub-id pub-id-type="pmid">21932399</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boros</surname><given-names>D.</given-names></name><name><surname>Thompson</surname><given-names>J.</given-names></name><name><surname>Larson</surname><given-names>D. F.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine regulation of the immune response initiated by ischemia reperfusion injury.</article-title>
<source/><italic>Perfusion</italic>
<volume>31</volume>
<fpage>103</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1177/0267659115586579</pub-id><pub-id pub-id-type="pmid">25987550</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bou Ghanem</surname><given-names>E. N.</given-names></name><name><surname>Clark</surname><given-names>S.</given-names></name><name><surname>Roggensack</surname><given-names>S. E.</given-names></name><name><surname>Mciver</surname><given-names>S. R.</given-names></name><name><surname>Alcaide</surname><given-names>P.</given-names></name><name><surname>Haydon</surname><given-names>P. G.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Extracellular adenosine protects against <italic>Streptococcus pneumoniae</italic> lung infection by regulating pulmonary neutrophil recruitment.</article-title>
<source/><italic>PLOS Pathog.</italic>
<volume>11</volume>:<issue>e1005126</issue>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1005126</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bours</surname><given-names>M. J.</given-names></name><name><surname>Peeters</surname><given-names>R. H.</given-names></name><name><surname>Landewé</surname><given-names>R. B.</given-names></name><name><surname>Beijer</surname><given-names>S.</given-names></name><name><surname>Arts</surname><given-names>I. C.</given-names></name><name><surname>Dagnelie</surname><given-names>P. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Adenosine 5′-triphosphate infusions reduced disease activity and inflammation in a patient with active rheumatoid arthritis.</article-title>
<source/><italic>Rheumatology (Oxford)</italic>
<volume>49</volume>
<fpage>2223</fpage>–<lpage>2225</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/keq177</pub-id><pub-id pub-id-type="pmid">20547656</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowser</surname><given-names>J. L.</given-names></name><name><surname>Blackburn</surname><given-names>M. R.</given-names></name><name><surname>Shipley</surname><given-names>G. L.</given-names></name><name><surname>Molina</surname><given-names>J. G.</given-names></name><name><surname>Dunner</surname><given-names>K.</given-names><suffix>Jr.</suffix></name><name><surname>Broaddus</surname><given-names>R. R.</given-names></name></person-group> (<year>2016</year>). <article-title>Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.</article-title>
<source/><italic>J. Clin. Invest.</italic>
<volume>126</volume>
<fpage>220</fpage>–<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1172/JCI79380</pub-id><pub-id pub-id-type="pmid">26642367</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boy</surname><given-names>C.</given-names></name><name><surname>Meyer</surname><given-names>P. T.</given-names></name><name><surname>Kircheis</surname><given-names>G.</given-names></name><name><surname>Holschbach</surname><given-names>M. H.</given-names></name><name><surname>Herzog</surname><given-names>H.</given-names></name><name><surname>Elmenhorst</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Cerebral A1 adenosine receptors (A1AR) in liver cirrhosis.</article-title>
<source/><italic>Eur. J. Nucl. Med. Mol. Imaging</italic>
<volume>35</volume>
<fpage>589</fpage>–<lpage>597</lpage>. <pub-id pub-id-type="doi">10.1007/s00259-007-0586-z</pub-id><pub-id pub-id-type="pmid">18000666</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braganhol</surname><given-names>E.</given-names></name><name><surname>Kukulski</surname><given-names>F.</given-names></name><name><surname>Lévesque</surname><given-names>S. A.</given-names></name><name><surname>Fausther</surname><given-names>M.</given-names></name><name><surname>Lavoie</surname><given-names>E. G.</given-names></name><name><surname>Zanotto-Filho</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Nucleotide receptors control IL-8/CXCL8 and MCP-1/CCL2 secretions as well as proliferation in human glioma cells.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1852</volume>
<fpage>120</fpage>–<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2014.10.014</pub-id><pub-id pub-id-type="pmid">25445541</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bravo</surname><given-names>D.</given-names></name><name><surname>Maturana</surname><given-names>C. J.</given-names></name><name><surname>Pelissier</surname><given-names>T.</given-names></name><name><surname>Hernández</surname><given-names>A.</given-names></name><name><surname>Constandil</surname><given-names>L.</given-names></name></person-group> (<year>2015</year>). <article-title>Interactions of pannexin 1 with NMDA and P2X7 receptors in central nervous system pathologies: possible role on chronic pain.</article-title>
<source/><italic>Pharmacol. Res.</italic>
<volume>101</volume>
<fpage>86</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2015.07.016</pub-id><pub-id pub-id-type="pmid">26211949</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brock</surname><given-names>J. A.</given-names></name><name><surname>Van Helden</surname><given-names>D. F.</given-names></name></person-group> (<year>1995</year>). <article-title>Enhanced excitatory junction potentials in mesenteric arteries from spontaneously hypertensive rats.</article-title>
<source/><italic>Pflügers Arch. Eur. J. Physiol.</italic>
<volume>430</volume>
<fpage>901</fpage>–<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1007/BF01837403</pub-id><pub-id pub-id-type="pmid">8594542</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broderick</surname><given-names>P. A.</given-names></name><name><surname>Malave</surname><given-names>L. B.</given-names></name></person-group> (<year>2014</year>). <article-title>Cocaine shifts the estrus cycle out of phase and caffeine restores it.</article-title>
<source/><italic>J. Caffeine Res.</italic>
<volume>4</volume>
<fpage>109</fpage>–<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1089/jcr.2014.0015</pub-id><pub-id pub-id-type="pmid">25538863</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouns</surname><given-names>I.</given-names></name><name><surname>Van Genechten</surname><given-names>J.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Timmermans</surname><given-names>J.-P.</given-names></name><name><surname>Adriaensen</surname><given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>Ontogenesis of P2X3 receptor-expressing nerve fibres in the rat lung, with special reference to neuroepithelial bodies.</article-title>
<source/><italic>Biomed. Res.</italic>
<volume>14</volume>
<fpage>80</fpage>–<lpage>86</lpage>.</mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukhari</surname><given-names>M.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Jones</surname><given-names>N.</given-names></name><name><surname>Towne</surname><given-names>Z.</given-names></name><name><surname>Woodworth</surname><given-names>C. D.</given-names></name><name><surname>Samways</surname><given-names>D. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors.</article-title>
<source/><italic>FEBS Lett.</italic>
<volume>589</volume>
<fpage>1498</fpage>–<lpage>1504</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2015.04.044</pub-id><pub-id pub-id-type="pmid">25937122</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulluck</surname><given-names>H.</given-names></name><name><surname>Sirker</surname><given-names>A.</given-names></name><name><surname>Loke</surname><given-names>Y. K.</given-names></name><name><surname>Garcia-Dorado</surname><given-names>D.</given-names></name><name><surname>Hausenloy</surname><given-names>D. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials.</article-title>
<source/><italic>Int. J. Cardiol.</italic>
<volume>202</volume>
<fpage>228</fpage>–<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2015.09.005</pub-id><pub-id pub-id-type="pmid">26402450</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>1972</year>). <article-title>Purinergic nerves.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>24</volume>
<fpage>509</fpage>–<lpage>581</lpage>.<pub-id pub-id-type="pmid">4404211</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>1981</year>). <article-title>Pathophysiology of migraine: a new hypothesis.</article-title>
<source/><italic>Lancet</italic>
<volume>317</volume>
<fpage>1397</fpage>–<lpage>1399</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(81)92572-1</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>1999</year>). <article-title>Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction.</article-title>
<source/><italic>J. Anat.</italic>
<volume>194</volume>
<fpage>335</fpage>–<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1046/j.1469-7580.1999.19430335.x</pub-id><pub-id pub-id-type="pmid">10386771</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2002</year>). <article-title>Purinergic signalling and vascular cell proliferation and death.</article-title>
<source/><italic>Arterioscler. Thromb. Vasc. Biol.</italic>
<volume>22</volume>
<fpage>364</fpage>–<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1161/hq0302.105360</pub-id><pub-id pub-id-type="pmid">11884276</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Pathophysiology and therapeutic potential of purinergic signaling.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>58</volume>
<fpage>58</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1124/pr.58.1.5</pub-id><pub-id pub-id-type="pmid">16507883</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2007</year>). <article-title>Purine and pyrimidine receptors.</article-title>
<source/><italic>Cell. Mol. Life Sci.</italic>
<volume>64</volume>
<fpage>1471</fpage>–<lpage>1483</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-007-6497-0</pub-id><pub-id pub-id-type="pmid">17375261</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2008a</year>). <article-title>Dual control of vascular tone and remodelling by ATP released from nerves and endothelial cells.</article-title>
<source/><italic>Pharmacol. Rep.</italic>
<volume>60</volume>
<fpage>12</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">18276981</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2008b</year>). <article-title>Purinergic signalling and disorders of the central nervous system.</article-title>
<source/><italic>Nat. Rev. Drug Discov.</italic>
<volume>7</volume>
<fpage>575</fpage>–<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2605</pub-id><pub-id pub-id-type="pmid">18591979</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2009</year>). <article-title>Purinergic mechanosensory transduction and visceral pain.</article-title>
<source/><italic>Mol. Pain</italic>
<volume>5</volume>:<issue>69</issue>
<pub-id pub-id-type="doi">10.1186/1744-8069-5-69</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2014a</year>). <article-title>The erasmus lecture 2012, Academia Europaea. The concept of cotransmission: focus on ATP as a cotransmitter and its significance in health and disease.</article-title>
<source/><italic>Eur. Rev.</italic>
<volume>22</volume>
<fpage>1</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1017/S1062798713000586</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2014b</year>). <article-title>Purinergic signalling in endocrine organs.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>10</volume>
<fpage>189</fpage>–<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9396-x</pub-id><pub-id pub-id-type="pmid">24265070</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2014c</year>). <article-title>Purinergic signalling in the reproductive system in health and disease.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>10</volume>
<fpage>157</fpage>–<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9399-7</pub-id><pub-id pub-id-type="pmid">24271059</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2014d</year>). <article-title>Purinergic signalling in the urinary tract in health and disease.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>10</volume>
<fpage>103</fpage>–<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9395-y</pub-id><pub-id pub-id-type="pmid">24265069</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2015a</year>). <article-title>Blood cells: an historical account of the roles of purinergic signalling.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>411</fpage>–<lpage>434</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9462-7</pub-id><pub-id pub-id-type="pmid">26260710</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2015b</year>). <article-title>Physiopathological roles of P2X receptors in the central nervous system.</article-title>
<source/><italic>Curr. Med. Chem.</italic>
<volume>22</volume>
<fpage>819</fpage>–<lpage>844</lpage>.<pub-id pub-id-type="pmid">25005189</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2015c</year>). <article-title>Purinergic signalling in neuroregeneration.</article-title>
<source/><italic>Neural Regen. Res.</italic>
<volume>10</volume>
<issue>1919</issue>
<pub-id pub-id-type="doi">10.4103/1673-5374.165300</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2016a</year>). <article-title>An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>4</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.05.031</pub-id><pub-id pub-id-type="pmid">26056033</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2016b</year>). <article-title>P2X ion channel receptors and inflammation.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>59</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9493-0</pub-id><pub-id pub-id-type="pmid">26739702</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2016c</year>). <article-title>Purinergic receptors and pain - an update.</article-title>
<source/><italic>Front. Med. Chem.</italic>
<volume>9</volume>:<fpage>3</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.2174/9781681082493116090003</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2016d</year>). <article-title>“Purinergic signalling in the gut,” in</article-title>
<source/><italic>The Enteric Nervous System. 30 Years Later</italic>
<volume>Vol. 891</volume>
<role>eds</role>
<person-group person-group-type="editor"><name><surname>Brierley</surname><given-names>S.</given-names></name><name><surname>Costa</surname><given-names>M.</given-names></name></person-group> (<publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>91</fpage>–<lpage>112</lpage>.</mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2016e</year>). <article-title>Purinergic signalling: pathophysiology and therapeutic potential.</article-title>
<source/><italic>J. Drug Res. Dev.</italic>
<volume>2</volume>
<pub-id pub-id-type="doi">10.16966/2470-1009.122</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2016f</year>). <article-title>Short- and long-term (trophic) purinergic signalling.</article-title>
<source/><italic>Philos. Trans. R. Soc. B Biol. Sci.</italic>
<volume>371</volume>:<issue>20150422</issue>
<pub-id pub-id-type="doi">10.1098/rstb.2015.0422</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Purinergic signalling in the cardiovascular system.</article-title>
<source/><italic>Circ. Res.</italic>
<volume>120</volume>
<fpage>207</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309726</pub-id><pub-id pub-id-type="pmid">28057794</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Arnett</surname><given-names>T. R.</given-names></name><name><surname>Orriss</surname><given-names>I. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Purinergic signalling in the musculoskeletal system.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>9</volume>
<fpage>541</fpage>–<lpage>572</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9381-4</pub-id><pub-id pub-id-type="pmid">23943493</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Brouns</surname><given-names>I.</given-names></name><name><surname>Adriaensen</surname><given-names>D.</given-names></name><name><surname>Timmermans</surname><given-names>J. P.</given-names></name></person-group> (<year>2012a</year>). <article-title>Purinergic signalling in the airways.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>64</volume>
<fpage>834</fpage>–<lpage>868</lpage>. <pub-id pub-id-type="doi">10.1124/pr.111.005389</pub-id><pub-id pub-id-type="pmid">22885703</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Di Virgilio</surname><given-names>F.</given-names></name></person-group> (<year>2013</year>). <article-title>Purinergic signalling in cancer.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>9</volume>
<fpage>491</fpage>–<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9372-5</pub-id><pub-id pub-id-type="pmid">23797685</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Evans</surname><given-names>L.</given-names></name><name><surname>Bailey</surname><given-names>M.</given-names></name></person-group> (<year>2014a</year>). <article-title>Purinergic signalling in the kidney in health and disease.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>10</volume>
<fpage>71</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9400-5</pub-id><pub-id pub-id-type="pmid">24265071</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Kennedy</surname><given-names>C.</given-names></name></person-group> (<year>2011</year>). <article-title>“P2X receptors in health and disease,” in</article-title>
<source/><italic>Purine and Pyrimidine Receptor Pharmacology</italic>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Jacobson</surname><given-names>K. A.</given-names></name><name><surname>Linden</surname><given-names>J.</given-names></name></person-group> (<publisher-loc>Burlington</publisher-loc>: <publisher-name>Academic Press</publisher-name>), <fpage>333</fpage>–<lpage>372</lpage>.</mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Knight</surname><given-names>G. E.</given-names></name></person-group> (<year>2004</year>). <article-title>Cellular distribution and functions of P2 receptor subtypes in different systems.</article-title>
<source/><italic>Int. Rev. Cytol.</italic>
<volume>240</volume>
<fpage>31</fpage>–<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/S0074-7696(04)40002-3</pub-id><pub-id pub-id-type="pmid">15548415</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Knight</surname><given-names>G. E.</given-names></name><name><surname>Greig</surname><given-names>A. V. H.</given-names></name></person-group> (<year>2012b</year>). <article-title>Purinergic signalling in healthy and diseased skin.</article-title>
<source/><italic>J. Invest. Dermatol.</italic>
<volume>132</volume>
<fpage>526</fpage>–<lpage>546</lpage>. <pub-id pub-id-type="doi">10.1038/jid.2011.344</pub-id><pub-id pub-id-type="pmid">22158558</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Krügel</surname><given-names>U.</given-names></name><name><surname>Abbracchio</surname><given-names>M. P.</given-names></name><name><surname>Illes</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>Purinergic signalling: from normal behaviour to pathological brain function.</article-title>
<source/><italic>Prog. Neurobiol.</italic>
<volume>95</volume>
<fpage>229</fpage>–<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2011.08.006</pub-id><pub-id pub-id-type="pmid">21907261</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Loesch</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Sympathetic innervation of the kidney in health and disease: emphasis on the role of purinergic cotransmission.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>204</volume>
<fpage>4</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2016.05.007</pub-id><pub-id pub-id-type="pmid">27270214</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Novak</surname><given-names>I.</given-names></name></person-group> (<year>2013</year>). <article-title>Purinergic signalling and diabetes.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>9</volume>
<fpage>307</fpage>–<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9359-2</pub-id><pub-id pub-id-type="pmid">23546842</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Pelleg</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Cardiac purinergic signalling in health and disease.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>1</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-014-9436-1</pub-id><pub-id pub-id-type="pmid">25527177</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Ralevic</surname><given-names>V.</given-names></name></person-group> (<year>2014</year>). <article-title>Purinergic signaling and blood vessels in health and disease.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>66</volume>
<fpage>102</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1124/pr.113.008029</pub-id><pub-id pub-id-type="pmid">24335194</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Sawynok</surname><given-names>J.</given-names></name></person-group> (<year>2010</year>). <article-title>“ATP and adenosine receptors and pain,” in</article-title>
<source/><italic>Pharmacology of Pain</italic>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Beaulieu</surname><given-names>P.</given-names></name><name><surname>Lussier</surname><given-names>D.</given-names></name><name><surname>Porreca</surname><given-names>F.</given-names></name><name><surname>Dickenson</surname><given-names>A. H.</given-names></name></person-group> (<publisher-loc>Seattle</publisher-loc>: <publisher-name>IASP Press</publisher-name>), <fpage>303</fpage>–<lpage>326</lpage>.</mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Vaughn</surname><given-names>B.</given-names></name><name><surname>Robson</surname><given-names>S.</given-names></name></person-group> (<year>2014b</year>). <article-title>Purinergic signalling in the liver in health and disease.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>10</volume>
<fpage>51</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9398-8</pub-id><pub-id pub-id-type="pmid">24271096</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Verkhratsky</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <source/><italic>Purinergic Signalling and the Nervous System.</italic>
<publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>.</mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvén</surname><given-names>J.</given-names></name><name><surname>Akbarshahi</surname><given-names>H.</given-names></name><name><surname>Menzel</surname><given-names>M.</given-names></name><name><surname>Ayata</surname><given-names>C. K.</given-names></name><name><surname>Idzko</surname><given-names>M.</given-names></name><name><surname>Bjermer</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Rhinoviral stimuli, epithelial factors and ATP signalling contribute to bronchial smooth muscle production of IL-33.</article-title>
<source/><italic>J. Transl. Med.</italic>
<volume>13</volume>
<issue>281</issue>
<pub-id pub-id-type="doi">10.1186/s12967-015-0645-3</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvert</surname><given-names>R. C.</given-names></name><name><surname>Banks</surname><given-names>F. C.</given-names></name><name><surname>Thompson</surname><given-names>C. S.</given-names></name><name><surname>Mikhailidis</surname><given-names>D. P.</given-names></name><name><surname>Morgan</surname><given-names>R. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Chronic ethanol consumption impairs adrenoceptor- and purinoceptor-mediated relaxations in isolated rat detrusor smooth muscle.</article-title>
<source/><italic>BJU. Int</italic>
<volume>89</volume>
<fpage>793</fpage>–<lpage>794</lpage>. <pub-id pub-id-type="doi">10.1046/j.1464-410X.2002.t01-4-02801.x</pub-id><pub-id pub-id-type="pmid">11966655</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvert</surname><given-names>R. C.</given-names></name><name><surname>Khan</surname><given-names>M. A.</given-names></name><name><surname>Thompson</surname><given-names>C. S.</given-names></name><name><surname>Mikhailidis</surname><given-names>D. P.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2008a</year>). <article-title>A functional study of purinergic signalling in the normal and pathological rabbit corpus cavernosum.</article-title>
<source/><italic>BJU Int.</italic>
<volume>101</volume>
<fpage>1043</fpage>–<lpage>1047</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2007.07385.x</pub-id><pub-id pub-id-type="pmid">18190636</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvert</surname><given-names>R. C.</given-names></name><name><surname>Thompson</surname><given-names>C. S.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2008b</year>). <article-title>ATP release from the human ureter on distension and P2X3 receptor expression on suburothelial sensory nerves.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>4</volume>
<fpage>377</fpage>–<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-008-9123-1</pub-id><pub-id pub-id-type="pmid">18819020</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>K. O.</given-names></name><name><surname>Kung</surname><given-names>D. W.</given-names></name><name><surname>Kalgutkar</surname><given-names>A. S.</given-names></name><name><surname>Kurumbail</surname><given-names>R. G.</given-names></name><name><surname>Miller</surname><given-names>R.</given-names></name><name><surname>Salatto</surname><given-names>C. T.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic acid (PF-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy.</article-title>
<source/><italic>J. Med. Chem.</italic>
<volume>59</volume>
<fpage>8068</fpage>–<lpage>8081</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00866</pub-id><pub-id pub-id-type="pmid">27490827</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canda</surname><given-names>A. E.</given-names></name><name><surname>Cross</surname><given-names>R. L.</given-names></name><name><surname>Chapple</surname><given-names>C. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Pharmacology of the lower urinary tract and management of overactive bladder.</article-title>
<source/><italic>J. Turk. Ger. Gynecol. Assoc.</italic>
<volume>7</volume>
<fpage>146</fpage>–<lpage>158</lpage>.</mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canda</surname><given-names>A. E.</given-names></name><name><surname>Turna</surname><given-names>B.</given-names></name><name><surname>Cinar</surname><given-names>G. M.</given-names></name><name><surname>Nazli</surname><given-names>O.</given-names></name></person-group> (<year>2007</year>). <article-title>Physiology and pharmacology of the human ureter: basis for current and future treatments.</article-title>
<source/><italic>Urol. Int.</italic>
<volume>78</volume>
<fpage>289</fpage>–<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1159/000100830</pub-id><pub-id pub-id-type="pmid">17495484</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantin</surname><given-names>L. D.</given-names></name><name><surname>Bayrakdarian</surname><given-names>M.</given-names></name><name><surname>Buon</surname><given-names>C.</given-names></name><name><surname>Grazzini</surname><given-names>E.</given-names></name><name><surname>Hu</surname><given-names>Y. J.</given-names></name><name><surname>Labrecque</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Discovery of P2X3 selective antagonists for the treatment of chronic pain.</article-title>
<source/><italic>Bioorg. Med. Chem. Lett.</italic>
<volume>22</volume>
<fpage>2565</fpage>–<lpage>2571</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2012.01.124</pub-id><pub-id pub-id-type="pmid">22370269</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Pu</surname><given-names>J.</given-names></name><name><surname>Scott</surname><given-names>R. H.</given-names></name><name><surname>Ching</surname><given-names>J.</given-names></name><name><surname>Mccaig</surname><given-names>C. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Physiological electrical signals promote chain migration of neuroblasts by up-regulating P2Y1 purinergic receptors and enhancing cell adhesion.</article-title>
<source/><italic>Stem Cell Rev.</italic>
<volume>11</volume>
<fpage>75</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1007/s12015-014-9524-1</pub-id><pub-id pub-id-type="pmid">25096637</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L. P.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>H. H.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Astrocyte-derived ATP modulates depressive-like behaviors.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>19</volume>
<fpage>773</fpage>–<lpage>777</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3162</pub-id><pub-id pub-id-type="pmid">23644515</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carneiro</surname><given-names>M. V.</given-names></name><name><surname>Americo</surname><given-names>T. A.</given-names></name><name><surname>Guimarães</surname><given-names>M. Z.</given-names></name><name><surname>Linden</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>The prion protein selectively binds to and modulates the content of purinergic receptor P2X4R.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>472</volume>
<fpage>293</fpage>–<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.02.122</pub-id><pub-id pub-id-type="pmid">26946358</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casadó-Anguera</surname><given-names>V.</given-names></name><name><surname>Bonaventura</surname><given-names>J.</given-names></name><name><surname>Moreno</surname><given-names>E.</given-names></name><name><surname>Navarro</surname><given-names>G.</given-names></name><name><surname>Cortés</surname><given-names>A.</given-names></name><name><surname>Ferré</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Evidence for the heterotetrameric structure of the adenosine A2A-dopamine D2 receptor complex.</article-title>
<source/><italic>Biochem. Soc. Trans.</italic>
<volume>44</volume>
<fpage>595</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1042/BST20150276</pub-id><pub-id pub-id-type="pmid">27068975</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caseley</surname><given-names>E. A.</given-names></name><name><surname>Muench</surname><given-names>S. P.</given-names></name><name><surname>Roger</surname><given-names>S.</given-names></name><name><surname>Mao</surname><given-names>H. J.</given-names></name><name><surname>Baldwin</surname><given-names>S. A.</given-names></name><name><surname>Jiang</surname><given-names>L. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Non-synonymous single nucleotide polymorphisms in the P2X receptor genes: association with diseases, impact on receptor functions and potential use as diagnosis biomarkers.</article-title>
<source/><italic>Int. J. Mol. Sci.</italic>
<volume>15</volume>
<fpage>13344</fpage>–<lpage>13371</lpage>. <pub-id pub-id-type="doi">10.3390/ijms150813344</pub-id><pub-id pub-id-type="pmid">25079442</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castilhos</surname><given-names>L. G.</given-names></name><name><surname>Rezer</surname><given-names>J. F.</given-names></name><name><surname>Ruchel</surname><given-names>J. B.</given-names></name><name><surname>Thorstenberg</surname><given-names>M. L.</given-names></name><name><surname>Jaques</surname><given-names>J. A.</given-names></name><name><surname>Schlemmer</surname><given-names>J. B.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Effect of <italic>Uncaria tomentosa</italic> extract on purinergic enzyme activities in lymphocytes of rats submitted to experimental adjuvant arthritis model.</article-title>
<source/><italic>BMC Complement. Altern. Med.</italic>
<volume>15</volume>:<issue>189</issue>
<pub-id pub-id-type="doi">10.1186/s12906-015-0694-4</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catanzaro</surname><given-names>J. M.</given-names></name><name><surname>Hueston</surname><given-names>C. M.</given-names></name><name><surname>Deak</surname><given-names>M. M.</given-names></name><name><surname>Deak</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>The impact of the P2X7 receptor antagonist A-804598 on neuroimmune and behavioral consequences of stress.</article-title>
<source/><italic>Behav. Pharmacol.</italic>
<volume>25</volume>
<fpage>582</fpage>–<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1097/FBP.0000000000000072</pub-id><pub-id pub-id-type="pmid">25083574</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cekic</surname><given-names>C.</given-names></name><name><surname>Linden</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic regulation of the immune system.</article-title>
<source/><italic>Nat. Rev. Immunol.</italic>
<volume>16</volume>
<fpage>177</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2016.4</pub-id><pub-id pub-id-type="pmid">26922909</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cekic</surname><given-names>C.</given-names></name><name><surname>Sag</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Theodorescu</surname><given-names>D.</given-names></name><name><surname>Strieter</surname><given-names>R. M.</given-names></name><name><surname>Linden</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Adenosine A2B receptor blockade slows growth of bladder and breast tumor.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>188</volume>
<fpage>198</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1101845</pub-id><pub-id pub-id-type="pmid">22116822</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Certal</surname><given-names>M.</given-names></name><name><surname>Vinhas</surname><given-names>A.</given-names></name><name><surname>Pinheiro</surname><given-names>A. R.</given-names></name><name><surname>Ferreirinha</surname><given-names>F.</given-names></name><name><surname>Costa</surname><given-names>M. A.</given-names></name><name><surname>Correia-De-Sá</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Novel anti-fibrotic effect of the UTP-sensitive P2Y11 receptor in rat cardiac myofibroblasts.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>192</volume>
<issue>72</issue>
<pub-id pub-id-type="doi">10.1016/j.ceca.2015.08.004</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>H. J.</given-names></name><name><surname>Jung</surname><given-names>M. S.</given-names></name><name><surname>Ahn</surname><given-names>D. W.</given-names></name><name><surname>Choi</surname><given-names>J. K.</given-names></name><name><surname>Ock</surname><given-names>M. S.</given-names></name><name><surname>Kim</surname><given-names>K. S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Silencing of MUC8 by siRNA increases P2Y2-induced airway inflammation.</article-title>
<source/><italic>Am. J. Physiol. Lung. Cell Mol. Physiol.</italic>
<volume>308</volume>
<fpage>L495</fpage>–<lpage>L502</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00332.2014</pub-id><pub-id pub-id-type="pmid">25575516</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>E. S.</given-names></name><name><surname>Cronstein</surname><given-names>B. N.</given-names></name></person-group> (<year>2010</year>). <article-title>Adenosine in fibrosis.</article-title>
<source/><italic>Mod. Rheumatol.</italic>
<volume>20</volume>
<fpage>114</fpage>–<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1007/s10165-009-0251-4</pub-id><pub-id pub-id-type="pmid">19949965</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>E. S.</given-names></name><name><surname>Montesinos</surname><given-names>M. C.</given-names></name><name><surname>Fernandez</surname><given-names>P.</given-names></name><name><surname>Desai</surname><given-names>A.</given-names></name><name><surname>Delano</surname><given-names>D. L.</given-names></name><name><surname>Yee</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>148</volume>
<fpage>1144</fpage>–<lpage>1155</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0706812</pub-id><pub-id pub-id-type="pmid">16783407</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chancellor</surname><given-names>M. B.</given-names></name><name><surname>Fowler</surname><given-names>C. J.</given-names></name><name><surname>Apostolidis</surname><given-names>A.</given-names></name><name><surname>De Groat</surname><given-names>W. C.</given-names></name><name><surname>Smith</surname><given-names>C. P.</given-names></name><name><surname>Somogyi</surname><given-names>G. T.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Drug insight: biological effects of botulinum toxin A in the lower urinary tract.</article-title>
<source/><italic>Nat. Clin. Pract. Urol.</italic>
<volume>5</volume>
<fpage>319</fpage>–<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1038/ncpuro1124</pub-id><pub-id pub-id-type="pmid">18461049</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrashekaran</surname><given-names>V.</given-names></name><name><surname>Das</surname><given-names>S.</given-names></name><name><surname>Seth</surname><given-names>R. K.</given-names></name><name><surname>Dattaroy</surname><given-names>D.</given-names></name><name><surname>Alhasson</surname><given-names>F.</given-names></name><name><surname>Michelotti</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1862</volume>
<fpage>32</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2015.10.009</pub-id><pub-id pub-id-type="pmid">26474534</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>M. Y.</given-names></name><name><surname>Lu</surname><given-names>J. K.</given-names></name><name><surname>Tian</surname><given-names>Y. C.</given-names></name><name><surname>Chen</surname><given-names>Y. C.</given-names></name><name><surname>Hung</surname><given-names>C. C.</given-names></name><name><surname>Huang</surname><given-names>Y. H.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Inhibition of the P2X7 receptor reduces cystogenesis in PKD.</article-title>
<source/><italic>J. Am. Soc. Nephrol.</italic>
<volume>22</volume>
<fpage>1696</fpage>–<lpage>1706</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2010070728</pub-id><pub-id pub-id-type="pmid">21636640</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhury</surname><given-names>A.</given-names></name><name><surname>Dendi</surname><given-names>V. S.</given-names></name><name><surname>Mirza</surname><given-names>W.</given-names></name></person-group> (<year>2016</year>). <article-title>Colligative property of ATP: implications for enteric purinergic neuromuscular neurotransmission.</article-title>
<source/><italic>Front. Physiol.</italic>
<volume>7</volume>:<issue>500</issue>
<pub-id pub-id-type="doi">10.3389/fphys.2016.00500</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaves</surname><given-names>M. M.</given-names></name><name><surname>Marques-Da-Silva</surname><given-names>C.</given-names></name><name><surname>Monteiro</surname><given-names>A. P.</given-names></name><name><surname>Canetti</surname><given-names>C.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Leukotriene B4 modulates P2X7 receptor-mediated <italic>Leishmania amazonensis</italic> elimination in murine macrophages.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>192</volume>
<fpage>4765</fpage>–<lpage>4773</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1301058</pub-id><pub-id pub-id-type="pmid">24729618</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain.</article-title>
<source/><italic>Acta Biochim. Biophys. Sin. (Shanghai)</italic>
<volume>44</volume>
<fpage>367</fpage>–<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1093/abbs/gms007</pub-id><pub-id pub-id-type="pmid">22349022</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J. F.</given-names></name><name><surname>Eltzschig</surname><given-names>H. K.</given-names></name><name><surname>Fredholm</surname><given-names>B. B.</given-names></name></person-group> (<year>2013</year>). <article-title>Adenosine receptors as drug targets - what are the challenges?</article-title>
<source/><italic>Nat. Rev. Drug Discov.</italic>
<volume>12</volume>
<fpage>265</fpage>–<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3955</pub-id><pub-id pub-id-type="pmid">23535933</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Molliver</surname><given-names>D. C.</given-names></name><name><surname>Gebhart</surname><given-names>G. F.</given-names></name></person-group> (<year>2010</year>). <article-title>The P2Y2 receptor sensitizes mouse bladder sensory neurons and facilitates purinergic currents.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>30</volume>
<fpage>2365</fpage>–<lpage>2372</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5462-09.2010</pub-id><pub-id pub-id-type="pmid">20147562</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group> (<year>2014</year>). <article-title>LPS-induced dental pulp inflammation increases expression of ionotropic purinergic receptors in rat trigeminal ganglion.</article-title>
<source/><italic>Neuroreport</italic>
<volume>25</volume>
<fpage>991</fpage>–<lpage>997</lpage>. <pub-id pub-id-type="doi">10.1097/WNR.0000000000000193</pub-id><pub-id pub-id-type="pmid">25055139</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>R. D.</given-names></name><name><surname>Ren</surname><given-names>J. J.</given-names></name><name><surname>Zhang</surname><given-names>Y. Y.</given-names></name><name><surname>Ye</surname><given-names>X. M.</given-names></name></person-group> (<year>2014</year>). <article-title>P2X4 receptors expressed on microglial cells in post-ischemic inflammation of brain ischemic injury.</article-title>
<source/><italic>Neurochem. Int.</italic>
<volume>67</volume>
<fpage>9</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2014.01.011</pub-id><pub-id pub-id-type="pmid">24486458</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Mansfield</surname><given-names>K. J.</given-names></name><name><surname>Allen</surname><given-names>W.</given-names></name><name><surname>Millard</surname><given-names>R. J.</given-names></name><name><surname>Burcher</surname><given-names>E.</given-names></name><name><surname>Moore</surname><given-names>K. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Correlation between cystometric volumes, ATP release, and pH in women with overactive bladder versus controls.</article-title>
<source/><italic>Neurourol. Urodyn.</italic>
<volume>32</volume>
<fpage>969</fpage>–<lpage>973</lpage>. <pub-id pub-id-type="doi">10.1002/nau.22344</pub-id><pub-id pub-id-type="pmid">23129360</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesworth</surname><given-names>R.</given-names></name><name><surname>Brown</surname><given-names>R. M.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Ledent</surname><given-names>C.</given-names></name><name><surname>Lawrence</surname><given-names>A. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine 2A receptors modulate reward behaviours for methamphetamine.</article-title>
<source/><italic>Addict. Biol.</italic>
<volume>21</volume>
<fpage>407</fpage>–<lpage>421</lpage>. <pub-id pub-id-type="doi">10.1111/adb.12225</pub-id><pub-id pub-id-type="pmid">25612195</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chetty</surname><given-names>A.</given-names></name><name><surname>Sharda</surname><given-names>A.</given-names></name><name><surname>Warburton</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Xue</surname><given-names>C.</given-names></name><name><surname>Castellot</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Effect of a purinergic P2Y6 receptor agonist on airway remodeling and responsiveness in a mouse model of asthma.</article-title>
<source/><italic>Am. J. Respir. Crit. Care Med.</italic>
<volume>193</volume>
<issue>A2173</issue>.</mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>D. J.</given-names></name><name><surname>Roychowdhury</surname><given-names>S.</given-names></name><name><surname>Bush</surname><given-names>K.</given-names></name><name><surname>Mcmullen</surname><given-names>M. R.</given-names></name><name><surname>Pisano</surname><given-names>S.</given-names></name><name><surname>Niese</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Adenosine 2A receptor antagonist prevented and reversed liver fibrosis in a mouse model of ethanol-exacerbated liver fibrosis.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>8</volume>:<issue>e69114</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0069114</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>G. S.</given-names></name><name><surname>Darmody</surname><given-names>P. T.</given-names></name><name><surname>Walsh</surname><given-names>J. P.</given-names></name><name><surname>Moon</surname><given-names>M. L.</given-names></name><name><surname>Kwakwa</surname><given-names>K. A.</given-names></name><name><surname>Bray</surname><given-names>J. K.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Adenosine through the A2A adenosine receptor increases IL-1β in the brain contributing to anxiety.</article-title>
<source/><italic>Brain Behav. Immun.</italic>
<volume>41</volume>
<fpage>218</fpage>–<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2014.05.018</pub-id><pub-id pub-id-type="pmid">24907587</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>K. C.</given-names></name><name><surname>Tai</surname><given-names>C. J.</given-names></name><name><surname>Tzeng</surname><given-names>C. R.</given-names></name><name><surname>Auersperg</surname><given-names>N.</given-names></name><name><surname>Leung</surname><given-names>P. C.</given-names></name></person-group> (<year>2003</year>). <article-title>Adenosine triphosphate activates mitogen-activated protein kinase in pre-neoplastic and neoplastic ovarian surface epithelial cells.</article-title>
<source/><italic>Biol. Reprod.</italic>
<volume>68</volume>
<fpage>309</fpage>–<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1095/biolreprod.102.006551</pub-id><pub-id pub-id-type="pmid">12493727</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choukèr</surname><given-names>A.</given-names></name><name><surname>Thiel</surname><given-names>M.</given-names></name><name><surname>Lukashev</surname><given-names>D.</given-names></name><name><surname>Ward</surname><given-names>J. M.</given-names></name><name><surname>Kaufmann</surname><given-names>I.</given-names></name><name><surname>Apasov</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway.</article-title>
<source/><italic>Mol. Med.</italic>
<volume>14</volume>
<fpage>116</fpage>–<lpage>123</lpage>. <pub-id pub-id-type="doi">10.2119/2007-00075.Chouker</pub-id><pub-id pub-id-type="pmid">18163162</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>Y. C.</given-names></name><name><surname>Chancellor</surname><given-names>M. B.</given-names></name></person-group> (<year>2006</year>). <article-title>The application of botulinum toxin in the prostate.</article-title>
<source/><italic>J. Urol.</italic>
<volume>176</volume>
<fpage>2375</fpage>–<lpage>2382</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2006.07.127</pub-id><pub-id pub-id-type="pmid">17085104</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuo</surname><given-names>C. H.</given-names></name><name><surname>Devine</surname><given-names>S. M.</given-names></name><name><surname>Scammells</surname><given-names>P. J.</given-names></name><name><surname>Krum</surname><given-names>H.</given-names></name><name><surname>Christopoulos</surname><given-names>A.</given-names></name><name><surname>May</surname><given-names>L. T.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model.</article-title>
<source/><italic>Clin. Exp. Pharmacol. Physiol.</italic>
<volume>43</volume>
<fpage>976</fpage>–<lpage>982</lpage>. <pub-id pub-id-type="doi">10.1111/1440-1681.12616</pub-id><pub-id pub-id-type="pmid">27377874</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicala</surname><given-names>C.</given-names></name><name><surname>Ialenti</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Adenosine signaling in airways: toward a promising antiasthmatic approach.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>714</volume>
<fpage>522</fpage>–<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2013.06.033</pub-id><pub-id pub-id-type="pmid">23850943</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cieslak</surname><given-names>M.</given-names></name><name><surname>Czarnecka</surname><given-names>J.</given-names></name><name><surname>Roszek</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>The roles of purinergic signaling in psychiatric disorders.</article-title>
<source/><italic>Acta Biochim. Pol.</italic>
<volume>63</volume>
<fpage>1</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.18388/abp.2015_1004</pub-id><pub-id pub-id-type="pmid">26495439</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cieslak</surname><given-names>M.</given-names></name><name><surname>Czarnecka</surname><given-names>J.</given-names></name><name><surname>Roszek</surname><given-names>K.</given-names></name><name><surname>Komoszynski</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>The role of purinergic signaling in the etiology of migraine and novel antimigraine treatment.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>307</fpage>–<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9453-8</pub-id><pub-id pub-id-type="pmid">25957584</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cieslak</surname><given-names>M.</given-names></name><name><surname>Roszek</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Purinergic signaling in the pancreas and the therapeutic potential of ecto-nucleotidases in diabetes.</article-title>
<source/><italic>Acta Biochim. Pol.</italic>
<volume>61</volume>
<fpage>655</fpage>–<lpage>662</lpage>.<pub-id pub-id-type="pmid">25522227</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cieslak</surname><given-names>M.</given-names></name><name><surname>Wojtczak</surname><given-names>A.</given-names></name><name><surname>Komoszynski</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Role of the purinergic signaling in epilepsy.</article-title>
<source/><italic>Pharmacol. Rep.</italic>
<volume>69</volume>
<fpage>130</fpage>–<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharep.2016.09.018</pub-id><pub-id pub-id-type="pmid">27915186</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ciruela</surname><given-names>F.</given-names></name><name><surname>Fernández-Dueñas</surname><given-names>V.</given-names></name><name><surname>Contreras</surname><given-names>F.</given-names></name><name><surname>Arnau</surname><given-names>J. M.</given-names></name><name><surname>Menchón</surname><given-names>J. M.</given-names></name><name><surname>Vallano</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>“Adenosine in the neurobiology of schizophrenia: potential adenosine receptor-based pharmacotherapy,” in</article-title>
<source/><italic>Psychiatry and Neuroscience Update: Bridging the Divide</italic>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Gargiulo</surname><given-names>P. Á</given-names></name><name><surname>Arroyo</surname><given-names>H. L. M.</given-names></name></person-group> (<publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>), <fpage>375</fpage>–<lpage>388</lpage>.</mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cisneros-Mejorado</surname><given-names>A.</given-names></name><name><surname>Gottlieb</surname><given-names>M.</given-names></name><name><surname>Cavaliere</surname><given-names>F.</given-names></name><name><surname>Magnus</surname><given-names>T.</given-names></name><name><surname>Koch-Nolte</surname><given-names>F.</given-names></name><name><surname>Scemes</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2015a</year>). <article-title>Blockade of P2X7 receptors or pannexin-1 channels similarly attenuates postischemic damage.</article-title>
<source/><italic>J. Cereb. Blood Flow Metab.</italic>
<volume>35</volume>
<fpage>843</fpage>–<lpage>850</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2014.262</pub-id><pub-id pub-id-type="pmid">25605289</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cisneros-Mejorado</surname><given-names>A.</given-names></name><name><surname>Perez-Samartin</surname><given-names>A.</given-names></name><name><surname>Gottlieb</surname><given-names>M.</given-names></name><name><surname>Matute</surname><given-names>C.</given-names></name></person-group> (<year>2015b</year>). <article-title>ATP signaling in brain: release, excitotoxicity and potential therapeutic targets.</article-title>
<source/><italic>Cell. Mol. Neurobiol.</italic>
<volume>35</volume>
<fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s10571-014-0092-3</pub-id><pub-id pub-id-type="pmid">25096398</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clouet</surname><given-names>S.</given-names></name><name><surname>Di Pietrantonio</surname><given-names>L.</given-names></name><name><surname>Daskalopoulos</surname><given-names>E. P.</given-names></name><name><surname>Esfahani</surname><given-names>H.</given-names></name><name><surname>Horckmans</surname><given-names>M.</given-names></name><name><surname>Vanorlé</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Loss of mouse P2Y6 nucleotide receptor is associated with physiological macrocardia and amplified pathological cardiac hypertrophy.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>291</volume>
<fpage>15841</fpage>–<lpage>15852</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M115.684118</pub-id><pub-id pub-id-type="pmid">27231349</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cockayne</surname><given-names>D. A.</given-names></name><name><surname>Hamilton</surname><given-names>S. G.</given-names></name><name><surname>Zhu</surname><given-names>Q.-M.</given-names></name><name><surname>Dunn</surname><given-names>P. M.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Novakovic</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice.</article-title>
<source/><italic>Nature</italic>
<volume>407</volume>
<fpage>1011</fpage>–<lpage>1015</lpage>. <pub-id pub-id-type="doi">10.1038/35039519</pub-id><pub-id pub-id-type="pmid">11069181</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>S. B.</given-names></name><name><surname>Gill</surname><given-names>S. S.</given-names></name><name><surname>Baer</surname><given-names>G. S.</given-names></name><name><surname>Leo</surname><given-names>B. M.</given-names></name><name><surname>Scheld</surname><given-names>W. M.</given-names></name><name><surname>Diduch</surname><given-names>D. R.</given-names></name></person-group> (<year>2004</year>). <article-title>Reducing joint destruction due to septic arthrosis using an adenosine 2A receptor agonist.</article-title>
<source/><italic>J. Orthop. Res.</italic>
<volume>22</volume>
<fpage>427</fpage>–<lpage>435</lpage>. <pub-id pub-id-type="doi">10.1016/j.orthres.2003.08.011</pub-id><pub-id pub-id-type="pmid">15013106</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corciulo</surname><given-names>C.</given-names></name><name><surname>Lendhey</surname><given-names>M.</given-names></name><name><surname>Wilder</surname><given-names>T.</given-names></name><name><surname>Schoen</surname><given-names>H.</given-names></name><name><surname>Cornelissen</surname><given-names>A. S.</given-names></name><name><surname>Chang</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Endogenous adenosine maintains cartilage homeostasis and exogenous adenosine inhibits osteoarthritis progression.</article-title>
<source/><italic>Nat. Commun.</italic>
<volume>8</volume>:<issue>15019</issue>
<pub-id pub-id-type="doi">10.1038/ncomms15019</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrêa</surname><given-names>G.</given-names></name><name><surname>Almeida</surname><given-names>L. C.</given-names></name><name><surname>Moreira-Souza</surname><given-names>A. C.</given-names></name><name><surname>Savio</surname><given-names>L. E.</given-names></name><name><surname>Takiya</surname><given-names>C. M.</given-names></name><name><surname>Marques-Da-Silva</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Inflammatory early events associated to the role of P2X7 receptor in acute murine toxoplasmosis.</article-title>
<source/><italic>Immunobiology</italic>
<volume>222</volume>
<fpage>676</fpage>–<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1016/j.imbio.2016.12.007</pub-id><pub-id pub-id-type="pmid">28069296</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrêa</surname><given-names>G.</given-names></name><name><surname>Lindenberg</surname><given-names>C. D. A.</given-names></name><name><surname>Fernandes-Santos</surname><given-names>C.</given-names></name><name><surname>Gandini</surname><given-names>M.</given-names></name><name><surname>Petitinga</surname><given-names>P. F.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The purinergic receptor P2X7 role in control of Dengue virus-2 infection and cytokine/chemokine production in infected human monocytes.</article-title>
<source/><italic>Immunobiology</italic>
<volume>221</volume>
<fpage>794</fpage>–<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1016/j.imbio.2016.02.003</pub-id><pub-id pub-id-type="pmid">26969484</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corso</surname><given-names>L.</given-names></name><name><surname>Cavallero</surname><given-names>A.</given-names></name><name><surname>Baroni</surname><given-names>D.</given-names></name><name><surname>Garbati</surname><given-names>P.</given-names></name><name><surname>Prestipino</surname><given-names>G.</given-names></name><name><surname>Bisti</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Saffron reduces ATP-induced retinal cytotoxicity by targeting P2X7 receptors.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>161</fpage>–<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9490-3</pub-id><pub-id pub-id-type="pmid">26739703</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costello</surname><given-names>J. C.</given-names></name><name><surname>Rosenthal</surname><given-names>A. K.</given-names></name><name><surname>Kurup</surname><given-names>I. V.</given-names></name><name><surname>Masuda</surname><given-names>I.</given-names></name><name><surname>Medhora</surname><given-names>M.</given-names></name><name><surname>Ryan</surname><given-names>L. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Parallel regulation of extracellular ATP and inorganic pyrophosphate: roles of growth factors, transduction modulators, and ANK.</article-title>
<source/><italic>Connect. Tissue Res.</italic>
<volume>52</volume>
<fpage>139</fpage>–<lpage>146</lpage>. <pub-id pub-id-type="doi">10.3109/03008207.2010.491928</pub-id><pub-id pub-id-type="pmid">20604715</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Côté</surname><given-names>N.</given-names></name><name><surname>El Husseini</surname><given-names>D.</given-names></name><name><surname>Pepin</surname><given-names>A.</given-names></name><name><surname>Guauque-Olarte</surname><given-names>S.</given-names></name><name><surname>Ducharme</surname><given-names>V.</given-names></name><name><surname>Bouchard-Cannon</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>ATP acts as a survival signal and prevents the mineralization of aortic valve.</article-title>
<source/><italic>J. Mol. Cell Cardiol.</italic>
<volume>52</volume>
<fpage>1191</fpage>–<lpage>1202</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2012.02.003</pub-id><pub-id pub-id-type="pmid">22366713</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlan</surname><given-names>K. S.</given-names></name><name><surname>Mitchem</surname><given-names>M. R.</given-names></name><name><surname>Hogg</surname><given-names>M. C.</given-names></name><name><surname>Prehn</surname><given-names>J. H.</given-names></name></person-group> (<year>2015</year>). <article-title>“Preconditioning” with latrepirdine, an adenosine 5′-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>36</volume>
<fpage>1140</fpage>–<lpage>1150</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.09.022</pub-id><pub-id pub-id-type="pmid">25443289</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristalli</surname><given-names>G.</given-names></name><name><surname>Vittori</surname><given-names>S.</given-names></name><name><surname>Thompson</surname><given-names>R. D.</given-names></name><name><surname>Padgett</surname><given-names>W. L.</given-names></name><name><surname>Shi</surname><given-names>D.</given-names></name><name><surname>Daly</surname><given-names>J. W.</given-names></name><etal></etal></person-group> (<year>1994</year>). <article-title>Inhibition of platelet aggregation by adenosine receptor agonists.</article-title>
<source/><italic>Naunyn Schmiedebergs Arch. Pharmacol.</italic>
<volume>349</volume>
<fpage>644</fpage>–<lpage>650</lpage>.<pub-id pub-id-type="pmid">7969516</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crossland</surname><given-names>R. F.</given-names></name><name><surname>Durgan</surname><given-names>D. J.</given-names></name><name><surname>Lloyd</surname><given-names>E. E.</given-names></name><name><surname>Phillips</surname><given-names>S. C.</given-names></name><name><surname>Reddy</surname><given-names>A. K.</given-names></name><name><surname>Marrelli</surname><given-names>S. P.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>A new rodent model for obstructive sleep apnea: effects on ATP-mediated dilations in cerebral arteries.</article-title>
<source/><italic>Am. J. Physiol. Regul. Integr. Comp. Physiol.</italic>
<volume>305</volume>
<fpage>R334</fpage>–<lpage>R342</lpage>. <pub-id pub-id-type="doi">10.1152/ajpregu.00244.2013</pub-id><pub-id pub-id-type="pmid">23761641</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>F.</given-names></name></person-group> (<year>2013</year>). <article-title>Targets for botulinum toxin in the lower urinary tract.</article-title>
<source/><italic>Neurourol. Urodyn.</italic>
<volume>33</volume>
<fpage>31</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1002/nau.22445</pub-id><pub-id pub-id-type="pmid">23775898</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csóka</surname><given-names>B.</given-names></name><name><surname>Németh</surname><given-names>Z. H.</given-names></name><name><surname>Törö</surname><given-names>G.</given-names></name><name><surname>Idzko</surname><given-names>M.</given-names></name><name><surname>Zech</surname><given-names>A.</given-names></name><name><surname>Koscsó</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing.</article-title>
<source/><italic>FASEB J.</italic>
<volume>29</volume>
<fpage>3626</fpage>–<lpage>3637</lpage>. <pub-id pub-id-type="doi">10.1096/fj.15-272450</pub-id><pub-id pub-id-type="pmid">26060214</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>M. P.</given-names></name><name><surname>Pazini</surname><given-names>F. L.</given-names></name><name><surname>Rosa</surname><given-names>J. M.</given-names></name><name><surname>Ramos-Hryb</surname><given-names>A. B.</given-names></name><name><surname>Oliveira</surname><given-names>Á</given-names></name><name><surname>Kaster</surname><given-names>M. P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A1 and A2A receptor activation.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>215</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9446-7</pub-id><pub-id pub-id-type="pmid">25702084</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Hippocampal adenosine A2A receptor up-regulation isnecessary and sufficient to trigger memory dysfunction inAlzheimer’s disease.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>134</volume>
<issue>322</issue>.</mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>R. A.</given-names></name></person-group> (<year>2016</year>). <article-title>How does adenosine control neuronal dysfunction and neurodegeneration?</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>139</volume>
<fpage>1019</fpage>–<lpage>1055</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13724</pub-id><pub-id pub-id-type="pmid">27365148</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Rocha Lapa</surname><given-names>F.</given-names></name><name><surname>Da Silva</surname><given-names>M. D.</given-names></name><name><surname>De Almeida Cabrini</surname><given-names>D.</given-names></name><name><surname>Santos</surname><given-names>A. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Anti-inflammatory effects of purine nucleosides, adenosine and inosine, in a mouse model of pleurisy: evidence for the role of adenosine A2 receptors.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>8</volume>
<fpage>693</fpage>–<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-012-9299-2</pub-id><pub-id pub-id-type="pmid">22456813</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>da Rocha Lapa</surname><given-names>F.</given-names></name><name><surname>Júnior</surname><given-names>S. J. M.</given-names></name><name><surname>Cerutti</surname><given-names>M. L.</given-names></name><name><surname>Santos</surname><given-names>A. R. S.</given-names></name></person-group> (<year>2014</year>). <article-title>“Pharmacology of adenosine receptors and their signaling role in immunity and inflammation,” in</article-title>
<source/><italic>Pharmacology and Therapeutics</italic>, <role>ed.</role>
<person-group person-group-type="editor"><name><surname>Gowder</surname><given-names>S. J. T.</given-names></name></person-group> (<publisher-loc>Rijeka</publisher-loc>: <publisher-name>InTech</publisher-name>), <fpage>85</fpage>–<lpage>130</lpage>.</mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>M. V.</given-names></name><name><surname>Marosti</surname><given-names>A. R.</given-names></name><name><surname>Mendes</surname><given-names>C. E.</given-names></name><name><surname>Palombit</surname><given-names>K.</given-names></name><name><surname>Castelucci</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Differential effects of experimental ulcerative colitis on P2X7 receptor expression in enteric neurons.</article-title>
<source/><italic>Histochem. Cell Biol.</italic>
<volume>143</volume>
<fpage>171</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1007/s00418-014-1270-6</pub-id><pub-id pub-id-type="pmid">25201348</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>M. V.</given-names></name><name><surname>Marosti</surname><given-names>A. R.</given-names></name><name><surname>Mendes</surname><given-names>C. E.</given-names></name><name><surname>Palombit</surname><given-names>K.</given-names></name><name><surname>Castelucci</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Submucosal neurons and enteric glial cells expressing the P2X7 receptor in rat experimental colitis.</article-title>
<source/><italic>Acta Histochem.</italic>
<volume>119</volume>
<fpage>481</fpage>–<lpage>494</lpage>. <pub-id pub-id-type="doi">10.1016/j.acthis.2017.05.001</pub-id><pub-id pub-id-type="pmid">28501138</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>S. S.</given-names></name><name><surname>Zhou</surname><given-names>Y. G.</given-names></name></person-group> (<year>2011</year>). <article-title>Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury.</article-title>
<source/><italic>Rev. Neurosci.</italic>
<volume>22</volume>
<fpage>231</fpage>–<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1515/RNS.2011.020</pub-id><pub-id pub-id-type="pmid">21476942</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Phatarpekar</surname><given-names>P.</given-names></name><name><surname>Mi</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Blackburn</surname><given-names>M. R.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Adenosine signaling, priapism and novel therapies.</article-title>
<source/><italic>J. Sex. Med.</italic>
<volume>6(Suppl. 3)</volume>, <fpage>292</fpage>–<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1111/j.1743-6109.2008.01187.x</pub-id><pub-id pub-id-type="pmid">19267852</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Alimonte</surname><given-names>I.</given-names></name><name><surname>Nargi</surname><given-names>E.</given-names></name><name><surname>Zuccarini</surname><given-names>M.</given-names></name><name><surname>Lanuti</surname><given-names>P.</given-names></name><name><surname>Di Iorio</surname><given-names>P.</given-names></name><name><surname>Giuliani</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>331</fpage>–<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9454-7</pub-id><pub-id pub-id-type="pmid">25976165</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daneshgari</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Imrey</surname><given-names>P. B.</given-names></name></person-group> (<year>2006</year>). <article-title>Time dependent changes in diabetic cystopathy in rats include compensated and decompensated bladder function.</article-title>
<source/><italic>J. Urol.</italic>
<volume>176</volume>
<fpage>380</fpage>–<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-5347(06)00582-9</pub-id><pub-id pub-id-type="pmid">16753447</pub-id></mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniele</surname><given-names>S.</given-names></name><name><surname>Zappelli</surname><given-names>E.</given-names></name><name><surname>Natali</surname><given-names>L.</given-names></name><name><surname>Martini</surname><given-names>C.</given-names></name><name><surname>Trincavelli</surname><given-names>M. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.</article-title>
<source/><italic>Cell. Death Dis.</italic>
<volume>5</volume>
<issue>e1539</issue>
<pub-id pub-id-type="doi">10.1038/cddis.2014.487</pub-id></mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danquah</surname><given-names>W.</given-names></name><name><surname>Meyer-Schwesinger</surname><given-names>C.</given-names></name><name><surname>Rissiek</surname><given-names>B.</given-names></name><name><surname>Pinto</surname><given-names>C.</given-names></name><name><surname>Serracant-Prat</surname><given-names>A.</given-names></name><name><surname>Amadi</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation.</article-title>
<source/><italic>Sci. Transl. Med.</italic>
<volume>8</volume>
<issue>366ra162</issue>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aaf8463</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darville</surname><given-names>T.</given-names></name><name><surname>Welter-Stahl</surname><given-names>L.</given-names></name><name><surname>Cruz</surname><given-names>C.</given-names></name><name><surname>Sater</surname><given-names>A. A.</given-names></name><name><surname>Andrews</surname><given-names>C. W.</given-names><suffix>Jr.</suffix></name><name><surname>Ojcius</surname><given-names>D. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Effect of the purinergic receptor P2X7 on Chlamydia infection in cervical epithelial cells and vaginally infected mice.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>179</volume>
<fpage>3707</fpage>–<lpage>3714</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.179.6.3707</pub-id><pub-id pub-id-type="pmid">17785807</pub-id></mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Karmouty-Quintana</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>N. Y.</given-names></name><name><surname>Weng</surname><given-names>T.</given-names></name><name><surname>Molina</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Extracellular adenosine is detrimental in lung recovery following hyperoxic lung injury in a murine model of bronchopulmonary dysplasia.</article-title>
<source/><italic>Am. J. Respir. Crit. Care Med.</italic>
<volume>193</volume>
<issue>A3850</issue>.</mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Azevedo</surname><given-names>M. I.</given-names></name><name><surname>Ferreiro</surname><given-names>L.</given-names></name><name><surname>Da Silva</surname><given-names>A. S.</given-names></name><name><surname>Tonin</surname><given-names>A. A.</given-names></name><name><surname>Monteiro</surname><given-names>D. U.</given-names></name><name><surname>Casali</surname><given-names>E. A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Participation of purines in the modulation of inflammatory response in rats experimentally infected by <italic>Cryptococcus neoformans</italic>.</article-title>
<source/><italic>Microb. Pathog.</italic>
<volume>99</volume>
<fpage>36</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2016.07.015</pub-id><pub-id pub-id-type="pmid">27469575</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Diego-Garcia</surname><given-names>L.</given-names></name><name><surname>Ramírez-Escudero</surname><given-names>M.</given-names></name><name><surname>Sebastián-Serrano</surname><given-names>A.</given-names></name><name><surname>Diaz-Hernández</surname><given-names>J. I.</given-names></name><name><surname>Pintor</surname><given-names>J.</given-names></name><name><surname>Lucas</surname><given-names>J. J.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Regulation of proteasome activity by P2Y2 receptor underlies the neuroprotective effects of extracellular nucleotides.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1863</volume>
<fpage>43</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2016.10.012</pub-id><pub-id pub-id-type="pmid">27768902</pub-id></mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lera Ruiz</surname><given-names>M.</given-names></name><name><surname>Lim</surname><given-names>Y. H.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Adenosine A2A receptor as a drug discovery target.</article-title>
<source/><italic>J. Med. Chem.</italic>
<volume>57</volume>
<fpage>3623</fpage>–<lpage>3650</lpage>. <pub-id pub-id-type="doi">10.1021/jm4011669</pub-id><pub-id pub-id-type="pmid">24164628</pub-id></mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>L.</given-names></name><name><surname>Capranzano</surname><given-names>P.</given-names></name><name><surname>Patti</surname><given-names>G.</given-names></name><name><surname>Parodi</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: review of the literature and practical considerations.</article-title>
<source/><italic>Am. Heart J.</italic>
<volume>176</volume>
<fpage>44</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.ahj.2016.03.006</pub-id><pub-id pub-id-type="pmid">27264219</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Mattei</surname><given-names>M.</given-names></name><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Masieri</surname><given-names>F. F.</given-names></name><name><surname>Pellati</surname><given-names>A.</given-names></name><name><surname>Ongaro</surname><given-names>A.</given-names></name><name><surname>Fini</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts.</article-title>
<source/><italic>Osteoarthritis Cartilage</italic>
<volume>17</volume>
<fpage>252</fpage>–<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2008.06.002</pub-id><pub-id pub-id-type="pmid">18640059</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deiteren</surname><given-names>A.</given-names></name><name><surname>Van Der Linden</surname><given-names>L.</given-names></name><name><surname>De Wit</surname><given-names>A.</given-names></name><name><surname>Ceuleers</surname><given-names>H.</given-names></name><name><surname>Buckinx</surname><given-names>R.</given-names></name><name><surname>Timmermans</surname><given-names>J. P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X3 receptors mediate visceral hypersensitivity during acute chemically-induced colitis and in the post-inflammatory phase via different mechanisms of sensitization.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>10</volume>:<issue>e0123810</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0123810</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della Latta</surname><given-names>V.</given-names></name><name><surname>Cabiati</surname><given-names>M.</given-names></name><name><surname>Rocchiccioli</surname><given-names>S.</given-names></name><name><surname>Del Ry</surname><given-names>S.</given-names></name><name><surname>Morales</surname><given-names>M. A.</given-names></name></person-group> (<year>2013</year>). <article-title>The role of the adenosinergic system in lung fibrosis.</article-title>
<source/><italic>Pharmacol. Res.</italic>
<volume>76</volume>
<fpage>182</fpage>–<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2013.08.004</pub-id><pub-id pub-id-type="pmid">23994158</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Densmore</surname><given-names>J. C.</given-names></name><name><surname>Schaid</surname><given-names>T. R.</given-names></name><name><surname>Jeziorczak</surname><given-names>P. M.</given-names></name><name><surname>Medhora</surname><given-names>M.</given-names></name><name><surname>Audi</surname><given-names>S.</given-names></name><name><surname>Nayak</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Lung injury pathways: adenosine receptor 2B signaling limits development of ischemic bronchiolitis obliterans organizing pneumonia.</article-title>
<source/><italic>Exp. Lung Res.</italic>
<volume>43</volume>
<fpage>38</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1080/01902148.2017.1286697</pub-id><pub-id pub-id-type="pmid">28266889</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Oliveira Moreira</surname><given-names>D.</given-names></name><name><surname>Santo Neto</surname><given-names>H.</given-names></name><name><surname>Marques</surname><given-names>M. J.</given-names></name></person-group> (<year>2017</year>). <article-title>P2Y2 purinergic receptors are highly expressed in cardiac and diaphragm muscles of mdx mice, and their expression is decreased by suramin.</article-title>
<source/><italic>Muscle Nerve</italic>
<volume>55</volume>
<fpage>116</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1002/mus.25199</pub-id><pub-id pub-id-type="pmid">27220808</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeOliveira</surname><given-names>C. C.</given-names></name><name><surname>Paiva Caria</surname><given-names>C. R.</given-names></name><name><surname>Ferreira Gotardo</surname><given-names>E. M.</given-names></name><name><surname>Ribeiro</surname><given-names>M. L.</given-names></name><name><surname>Gambero</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Role of A1 and A2A adenosine receptor agonists in adipose tissue inflammation induced by obesity in mice.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>799</volume>
<fpage>154</fpage>–<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2017.02.017</pub-id><pub-id pub-id-type="pmid">28202393</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deplano</surname><given-names>S.</given-names></name><name><surname>Cook</surname><given-names>H. T.</given-names></name><name><surname>Russell</surname><given-names>R.</given-names></name><name><surname>Franchi</surname><given-names>L.</given-names></name><name><surname>Schneiter</surname><given-names>S.</given-names></name><name><surname>Bhangal</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>P2X7 receptor-mediated Nlrp3-inflammasome activation is a genetic determinant of macrophage-dependent crescentic glomerulonephritis.</article-title>
<source/><italic>J. Leukoc. Biol.</italic>
<volume>93</volume>
<fpage>127</fpage>–<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0612284</pub-id><pub-id pub-id-type="pmid">23089744</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diezmos</surname><given-names>E. F.</given-names></name><name><surname>Bertrand</surname><given-names>P. P.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling in gut inflammation: the role of connexins and pannexins.</article-title>
<source/><italic>Front. Neurosci.</italic>
<volume>10</volume>:<issue>311</issue>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00311</pub-id></mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Virgilio</surname><given-names>F.</given-names></name></person-group> (<year>2015</year>). <article-title>P2X receptors and inflammation.</article-title>
<source/><italic>Curr. Med. Chem.</italic>
<volume>22</volume>
<fpage>866</fpage>–<lpage>877</lpage>. <pub-id pub-id-type="doi">10.2174/0929867322666141210155311</pub-id><pub-id pub-id-type="pmid">25524252</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Virgilio</surname><given-names>F.</given-names></name><name><surname>Adinolfi</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Extracellular purines, purinergic receptors and tumor growth.</article-title>
<source/><italic>Oncogene</italic>
<volume>36</volume>
<fpage>293</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2016.206</pub-id><pub-id pub-id-type="pmid">27321181</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Virgilio</surname><given-names>F.</given-names></name><name><surname>Vuerich</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Purinergic signaling in the immune system.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>191</volume>
<fpage>117</fpage>–<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2015.04.011</pub-id><pub-id pub-id-type="pmid">25979766</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djerada</surname><given-names>Z.</given-names></name><name><surname>Feliu</surname><given-names>C.</given-names></name><name><surname>Richard</surname><given-names>V.</given-names></name><name><surname>Millart</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>). <article-title>Current knowledge on the role of P2Y receptors in cardioprotection against ischemia-reperfusion.</article-title>
<source/><italic>Pharmacol. Res.</italic>
<volume>118</volume>
<fpage>5</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2016.08.009</pub-id><pub-id pub-id-type="pmid">27520402</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>do Carmo</surname><given-names>G. M.</given-names></name><name><surname>Doleski</surname><given-names>P. H.</given-names></name><name><surname>De Sá</surname><given-names>M. F.</given-names></name><name><surname>Grando</surname><given-names>T. H.</given-names></name><name><surname>Bottari</surname><given-names>N. B.</given-names></name><name><surname>Leal</surname><given-names>D. B.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Purinergic enzymatic activities in lymphocytes and cardiomyocytes of mice acutely infected by <italic>Trypanosoma cruzi</italic> modulating the inflammatory responses.</article-title>
<source/><italic>Exp. Parasitol.</italic>
<volume>175</volume>
<fpage>44</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.exppara.2017.02.002</pub-id><pub-id pub-id-type="pmid">28167210</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domercq</surname><given-names>M.</given-names></name><name><surname>Perez-Samartin</surname><given-names>A.</given-names></name><name><surname>Aparicio</surname><given-names>D.</given-names></name><name><surname>Alberdi</surname><given-names>E.</given-names></name><name><surname>Pampliega</surname><given-names>O.</given-names></name><name><surname>Matute</surname><given-names>C.</given-names></name></person-group> (<year>2010</year>). <article-title>P2X7 receptors mediate ischemic damage to oligodendrocytes.</article-title>
<source/><italic>Glia</italic>
<volume>58</volume>
<fpage>730</fpage>–<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1002/glia.20958</pub-id><pub-id pub-id-type="pmid">20029962</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>X. J.</given-names></name><name><surname>Jiang</surname><given-names>T. B.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Ischemia triggered ATP release through Pannexin-1 channel by myocardial cells activates sympathetic fibers.</article-title>
<source/><italic>Microvasc. Res.</italic>
<volume>104</volume>
<fpage>32</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.mvr.2015.11.005</pub-id><pub-id pub-id-type="pmid">26596404</pub-id></mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dragicevic</surname><given-names>E.</given-names></name><name><surname>Schiemann</surname><given-names>J.</given-names></name><name><surname>Liss</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Dopamine midbrain neurons in health and Parkinson’s disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels.</article-title>
<source/><italic>Neuroscience</italic>
<volume>284</volume>
<fpage>798</fpage>–<lpage>814</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.10.037</pub-id><pub-id pub-id-type="pmid">25450964</pub-id></mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dranoff</surname><given-names>J. A.</given-names></name><name><surname>Kruglov</surname><given-names>E. A.</given-names></name><name><surname>Abreu-Lanfranco</surname><given-names>O.</given-names></name><name><surname>Nguyen</surname><given-names>T.</given-names></name><name><surname>Arora</surname><given-names>G.</given-names></name><name><surname>Jain</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2′,4′-disulfonate (PPADS).</article-title>
<source/><italic>In Vivo</italic>
<volume>21</volume>
<fpage>k957</fpage>–<lpage>965</lpage>.</mixed-citation>
</ref>
<ref id="B221">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>C.</given-names></name><name><surname>Guan</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Microglial P2X7 receptor in the hypothalamic paraventricular nuclei contributes to sympathoexcitatory responses in acute myocardial infarction rat.</article-title>
<source/><italic>Neurosci. Lett.</italic>
<volume>587</volume>
<fpage>22</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2014.12.026</pub-id><pub-id pub-id-type="pmid">25524407</pub-id></mixed-citation>
</ref>
<ref id="B222">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Ou</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Cong</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Adenosine A2B receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells.</article-title>
<source/><italic>Exp. Biol. Med.</italic>
<volume>240</volume>
<fpage>1472</fpage>–<lpage>1479</lpage>. <pub-id pub-id-type="doi">10.1177/1535370215584939</pub-id></mixed-citation>
</ref>
<ref id="B223">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dziubina</surname><given-names>A.</given-names></name><name><surname>Szmyd</surname><given-names>K.</given-names></name><name><surname>Zygmunt</surname><given-names>M.</given-names></name><name><surname>Sapa</surname><given-names>J.</given-names></name><name><surname>Dudek</surname><given-names>M.</given-names></name><name><surname>Filipek</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Evaluation of antidepressant-like and anxiolytic-like activity of purinedione-derivatives with affinity for adenosine A2A receptors in mice.</article-title>
<source/><italic>Pharmacol. Rep.</italic>
<volume>68</volume>
<fpage>1285</fpage>–<lpage>1292</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharep.2016.07.008</pub-id><pub-id pub-id-type="pmid">27689756</pub-id></mixed-citation>
</ref>
<ref id="B224">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckle</surname><given-names>T.</given-names></name><name><surname>Koeppen</surname><given-names>M.</given-names></name><name><surname>Eltzschig</surname><given-names>H. K.</given-names></name></person-group> (<year>2009</year>). <article-title>Role of extracellular adenosine in acute lung injury.</article-title>
<source/><italic>Physiology</italic>
<volume>24</volume>
<fpage>298</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1152/physiol.00022.2009</pub-id><pub-id pub-id-type="pmid">19815856</pub-id></mixed-citation>
</ref>
<ref id="B225">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Hashim</surname><given-names>A. Z.</given-names></name><name><surname>Mathew</surname><given-names>S.</given-names></name><name><surname>Spina</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>The A1 adenosine receptor is a novel inhibitory receptor that regulates the cough reflex via a central mechanism of action.</article-title>
<source/><italic>Am. J. Respir. Crit. Care Med.</italic>
<volume>193</volume>
<fpage>A6003</fpage>–<lpage>A6003</lpage>.</mixed-citation>
</ref>
<ref id="B226">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsherbiny</surname><given-names>N. M.</given-names></name><name><surname>Ahmad</surname><given-names>S.</given-names></name><name><surname>Naime</surname><given-names>M.</given-names></name><name><surname>Elsherbini</surname><given-names>A. M.</given-names></name><name><surname>Fulzele</surname><given-names>S.</given-names></name><name><surname>Al-Gayyar</surname><given-names>M. M.</given-names></name><etal></etal></person-group> (<year>2013a</year>). <article-title>ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy.</article-title>
<source/><italic>Life Sci.</italic>
<volume>93</volume>
<fpage>78</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2013.05.024</pub-id><pub-id pub-id-type="pmid">23770229</pub-id></mixed-citation>
</ref>
<ref id="B227">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsherbiny</surname><given-names>N. M.</given-names></name><name><surname>Naime</surname><given-names>M.</given-names></name><name><surname>Ahmad</surname><given-names>S.</given-names></name><name><surname>Elsherbini</surname><given-names>A. M.</given-names></name><name><surname>Mohammad</surname><given-names>S.</given-names></name><name><surname>Fulzele</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2013b</year>). <article-title>Potential roles of adenosine deaminase-2 in diabetic retinopathy.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>436</volume>
<fpage>355</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2013.05.023</pub-id><pub-id pub-id-type="pmid">23685153</pub-id></mixed-citation>
</ref>
<ref id="B228">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling-induced neuroinflammation and status epilepticus.</article-title>
<source/><italic>Expert. Rev. Neurother.</italic>
<volume>16</volume>
<fpage>735</fpage>–<lpage>737</lpage>. <pub-id pub-id-type="doi">10.1586/14737175.2016.1164036</pub-id><pub-id pub-id-type="pmid">26953622</pub-id></mixed-citation>
</ref>
<ref id="B229">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>T.</given-names></name><name><surname>Alves</surname><given-names>M.</given-names></name><name><surname>Sheedy</surname><given-names>C.</given-names></name><name><surname>Henshall</surname><given-names>D. C.</given-names></name></person-group> (<year>2016</year>). <article-title>ATPergic signalling during seizures and epilepsy.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>140</fpage>–<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.11.001</pub-id><pub-id pub-id-type="pmid">26549853</pub-id></mixed-citation>
</ref>
<ref id="B230">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erb</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name><name><surname>Ajit</surname><given-names>D.</given-names></name><name><surname>Weisman</surname><given-names>G. A.</given-names></name></person-group> (<year>2015</year>). <article-title>P2Y receptors in Alzheimer’s disease.</article-title>
<source/><italic>Biol. Cell</italic>
<volume>107</volume>
<fpage>1</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1111/boc.201400043</pub-id><pub-id pub-id-type="pmid">25179475</pub-id></mixed-citation>
</ref>
<ref id="B231">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erlinge</surname><given-names>D.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2008</year>). <article-title>P2 receptors in cardiovascular regulation and disease.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>4</volume>
<fpage>1</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-007-9078-7</pub-id></mixed-citation>
</ref>
<ref id="B232">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname><given-names>C.</given-names></name><name><surname>Casanello</surname><given-names>P.</given-names></name><name><surname>Sobrevia</surname><given-names>L.</given-names></name></person-group> (<year>2008</year>). <article-title>Human equilibrative nucleoside transporters 1 and 2 may be differentially modulated by A2B adenosine receptors in placenta microvascular endothelial cells from pre-eclampsia.</article-title>
<source/><italic>Placenta</italic>
<volume>29</volume>
<fpage>816</fpage>–<lpage>825</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2008.06.014</pub-id><pub-id pub-id-type="pmid">18703227</pub-id></mixed-citation>
</ref>
<ref id="B233">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname><given-names>C.</given-names></name><name><surname>Roberts</surname><given-names>J. M.</given-names></name><name><surname>Myatt</surname><given-names>L.</given-names></name><name><surname>Feoktistov</surname><given-names>I.</given-names></name></person-group> (<year>2014</year>). <article-title>Impaired adenosine-mediated angiogenesis in preeclampsia: potential implications for fetal programming.</article-title>
<source/><italic>Front. Pharmacol.</italic>
<volume>5</volume>:<issue>134</issue>
<pub-id pub-id-type="doi">10.3389/fphar.2014.00134</pub-id></mixed-citation>
</ref>
<ref id="B234">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eser</surname><given-names>A.</given-names></name><name><surname>Colombel</surname><given-names>J. F.</given-names></name><name><surname>Rutgeerts</surname><given-names>P.</given-names></name><name><surname>Vermeire</surname><given-names>S.</given-names></name><name><surname>Vogelsang</surname><given-names>H.</given-names></name><name><surname>Braddock</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active Crohn’s disease: a randomized placebo-controlled, double-blind, phase IIa study.</article-title>
<source/><italic>Inflamm. Bowel Dis.</italic>
<volume>21</volume>
<fpage>2247</fpage>–<lpage>2253</lpage>. <pub-id pub-id-type="doi">10.1097/MIB.0000000000000514</pub-id><pub-id pub-id-type="pmid">26197451</pub-id></mixed-citation>
</ref>
<ref id="B235">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Essawy</surname><given-names>S. S.</given-names></name><name><surname>Tawfik</surname><given-names>M. K.</given-names></name><name><surname>Korayem</surname><given-names>H. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity.</article-title>
<source/><italic>Arch. Med. Sci.</italic>
<volume>13</volume>
<fpage>659</fpage>–<lpage>669</lpage>. <pub-id pub-id-type="doi">10.5114/aoms.2017.67284</pub-id><pub-id pub-id-type="pmid">28507584</pub-id></mixed-citation>
</ref>
<ref id="B236">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esther</surname><given-names>C. R.</given-names><suffix>Jr.</suffix></name><name><surname>Olsen</surname><given-names>B. M.</given-names></name><name><surname>Lin</surname><given-names>F. C.</given-names></name><name><surname>Fine</surname><given-names>J.</given-names></name><name><surname>Boucher</surname><given-names>R. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Exhaled breath condensate adenosine tracks lung function changes in cystic fibrosis.</article-title>
<source/><italic>Am. J. Physiol. Lung. Cell Mol. Physiol.</italic>
<volume>304</volume>
<fpage>L504</fpage>–<lpage>L509</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00344.2012</pub-id><pub-id pub-id-type="pmid">23355385</pub-id></mixed-citation>
</ref>
<ref id="B237">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esther</surname><given-names>C. R.</given-names></name><name><surname>Muhlebach</surname><given-names>M. M.</given-names></name><name><surname>Turkovic</surname><given-names>L.</given-names></name><name><surname>Rosenow</surname><given-names>T.</given-names></name><name><surname>Boucher</surname><given-names>R. C.</given-names></name><name><surname>Stick</surname><given-names>S. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Increased airway adenosine metabolism and oxidative stress in early cystic fibrosis lung disease.</article-title>
<source/><italic>Am. J. Respir. Crit. Care Med.</italic>
<volume>191</volume>
<issue>A1032</issue>.</mixed-citation>
</ref>
<ref id="B238">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eun</surname><given-names>S. Y.</given-names></name><name><surname>Ko</surname><given-names>Y. S.</given-names></name><name><surname>Park</surname><given-names>S. W.</given-names></name><name><surname>Chang</surname><given-names>K. C.</given-names></name><name><surname>Kim</surname><given-names>H. J.</given-names></name></person-group> (<year>2015</year>). <article-title>P2Y2 nucleotide receptor-mediated extracellular signal-regulated kinases and protein kinase C activation induces the invasion of highly metastatic breast cancer cells.</article-title>
<source/><italic>Oncol. Rep.</italic>
<volume>34</volume>
<fpage>195</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.3892/or.2015.3972</pub-id><pub-id pub-id-type="pmid">26063340</pub-id></mixed-citation>
</ref>
<ref id="B239">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyo</surname><given-names>U. B.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Swiatkowski</surname><given-names>P.</given-names></name><name><surname>Mukherjee</surname><given-names>A.</given-names></name><name><surname>Bispo</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>L. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>34</volume>
<fpage>10528</fpage>–<lpage>10540</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0416-14.2014</pub-id><pub-id pub-id-type="pmid">25100587</pub-id></mixed-citation>
</ref>
<ref id="B240">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faas</surname><given-names>M. M.</given-names></name><name><surname>Sáez</surname><given-names>T.</given-names></name><name><surname>De Vos</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Extracellular ATP and adenosine: the Yin and Yang in immune responses?</article-title>
<source/><italic>Mol. Aspects Med.</italic>
<volume>55</volume>
<fpage>9</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2017.01.002</pub-id><pub-id pub-id-type="pmid">28093236</pub-id></mixed-citation>
</ref>
<ref id="B241">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabiyi</surname><given-names>A. C.</given-names></name><name><surname>Brading</surname><given-names>A. F.</given-names></name></person-group> (<year>2006</year>). <article-title>The use of the isolated mouse whole bladder for investigating bladder overactivity.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>319</volume>
<fpage>1386</fpage>–<lpage>1394</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.106.108902</pub-id><pub-id pub-id-type="pmid">16943254</pub-id></mixed-citation>
</ref>
<ref id="B242">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falk</surname><given-names>S.</given-names></name><name><surname>Schwab</surname><given-names>S. D.</given-names></name><name><surname>Frosig-Jorgensen</surname><given-names>M.</given-names></name><name><surname>Clausen</surname><given-names>R. P.</given-names></name><name><surname>Dickenson</surname><given-names>A. H.</given-names></name><name><surname>Heegaard</surname><given-names>A. M.</given-names></name></person-group> (<year>2015</year>). <article-title>P2X7 receptor-mediated analgesia in cancer-induced bone pain.</article-title>
<source/><italic>Neuroscience</italic>
<volume>291</volume>
<fpage>93</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.02.011</pub-id><pub-id pub-id-type="pmid">25686524</pub-id></mixed-citation>
</ref>
<ref id="B243">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Kong</surname><given-names>H.</given-names></name><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>ATP-sensitive potassium channels: uncovering novel targets for treating depression.</article-title>
<source/><italic>Brain Struct. Funct.</italic>
<volume>221</volume>
<fpage>3111</fpage>–<lpage>3122</lpage>. <pub-id pub-id-type="doi">10.1007/s00429-015-1090-z</pub-id><pub-id pub-id-type="pmid">26289962</pub-id></mixed-citation>
</ref>
<ref id="B244">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Xie</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The expression of P2X7 receptors in EPCs and their potential role in the targeting of EPCs to brain gliomas.</article-title>
<source/><italic>Cancer Biol. Ther.</italic>
<volume>16</volume>
<fpage>498</fpage>–<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1080/15384047.2015.1016663</pub-id><pub-id pub-id-type="pmid">25839324</pub-id></mixed-citation>
</ref>
<ref id="B245">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faria</surname><given-names>M.</given-names></name><name><surname>Timóteo</surname><given-names>M. A.</given-names></name><name><surname>Lafuente-De-Carvalho</surname><given-names>M.</given-names></name><name><surname>Correia-De-Sá</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>P2 purinoceptor subtyope changes in patients with vasculogenic erectile dysfunction.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>6</volume>
<issue>S115</issue>.</mixed-citation>
</ref>
<ref id="B246">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasullo</surname><given-names>M.</given-names></name><name><surname>Endres</surname><given-names>L.</given-names></name></person-group> (<year>2015</year>). <article-title>Nucleotide salvage deficiencies, DNA damage and neurodegeneration.</article-title>
<source/><italic>Int. J. Mol. Sci.</italic>
<volume>16</volume>
<fpage>9431</fpage>–<lpage>9449</lpage>. <pub-id pub-id-type="doi">10.3390/ijms16059431</pub-id><pub-id pub-id-type="pmid">25923076</pub-id></mixed-citation>
</ref>
<ref id="B247">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fathalla</surname><given-names>A. M.</given-names></name><name><surname>Soliman</surname><given-names>A. M.</given-names></name><name><surname>Ali</surname><given-names>M. H.</given-names></name><name><surname>Moustafa</surname><given-names>A. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine A2A receptor blockade prevents rotenone-induced motor impairment in a rat model of Parkinsonism.</article-title>
<source/><italic>Front. Behav. Neurosci.</italic>
<volume>10</volume>:<issue>35</issue>
<pub-id pub-id-type="doi">10.3389/fnbeh.2016.00035</pub-id></mixed-citation>
</ref>
<ref id="B248">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fausther</surname><given-names>M.</given-names></name><name><surname>Sheung</surname><given-names>N.</given-names></name><name><surname>Saiman</surname><given-names>Y.</given-names></name><name><surname>Bansal</surname><given-names>M. B.</given-names></name><name><surname>Dranoff</surname><given-names>J. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Activated hepatic stellate cells upregulate transcription of ecto-5′-nucleotidase/CD73 via specific SP1 and SMAD promoter elements.</article-title>
<source/><italic>Am. J. Physiol. Gastrointest. Liver Physiol.</italic>
<volume>303</volume>
<fpage>G904</fpage>–<lpage>G914</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.00015.2012</pub-id><pub-id pub-id-type="pmid">22899823</pub-id></mixed-citation>
</ref>
<ref id="B249">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehm</surname><given-names>T.</given-names></name><name><surname>Zwirner</surname><given-names>M.</given-names></name><name><surname>Wallwiener</surname><given-names>D.</given-names></name><name><surname>Seeger</surname><given-names>H.</given-names></name><name><surname>Neubauer</surname><given-names>H.</given-names></name></person-group> (<year>2012</year>). <article-title>Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.</article-title>
<source/><italic>BMC Cancer</italic>
<volume>12</volume>:<issue>308</issue>
<pub-id pub-id-type="doi">10.1186/1471-2407-12-308</pub-id></mixed-citation>
</ref>
<ref id="B250">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Csizmadia</surname><given-names>E.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Bian</surname><given-names>S.</given-names></name><name><surname>Murakami</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.</article-title>
<source/><italic>Neoplasia</italic>
<volume>13</volume>
<fpage>206</fpage>–<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1593/neo.101332</pub-id><pub-id pub-id-type="pmid">21390184</pub-id></mixed-citation>
</ref>
<ref id="B251">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y. H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Gorodeski</surname><given-names>G. I.</given-names></name></person-group> (<year>2006</year>). <article-title>A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>281</volume>
<fpage>17228</fpage>–<lpage>17237</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M602999200</pub-id><pub-id pub-id-type="pmid">16624800</pub-id></mixed-citation>
</ref>
<ref id="B252">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern</surname><given-names>R. F.</given-names></name><name><surname>Matute</surname><given-names>C.</given-names></name><name><surname>Stys</surname><given-names>P. K.</given-names></name></person-group> (<year>2014</year>). <article-title>White matter injury: ischemic and nonischemic.</article-title>
<source/><italic>Glia</italic>
<volume>62</volume>
<fpage>1780</fpage>–<lpage>1789</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22722</pub-id><pub-id pub-id-type="pmid">25043122</pub-id></mixed-citation>
</ref>
<ref id="B253">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernando</surname><given-names>S. L.</given-names></name><name><surname>Saunders</surname><given-names>B. M.</given-names></name><name><surname>Sluyter</surname><given-names>R.</given-names></name><name><surname>Skarratt</surname><given-names>K. K.</given-names></name><name><surname>Goldberg</surname><given-names>H.</given-names></name><name><surname>Marks</surname><given-names>G. B.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis.</article-title>
<source/><italic>Am. J. Respir. Crit. Care Med.</italic>
<volume>175</volume>
<fpage>360</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200607-970OC</pub-id><pub-id pub-id-type="pmid">17095747</pub-id></mixed-citation>
</ref>
<ref id="B254">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrante</surname><given-names>A.</given-names></name><name><surname>Martire</surname><given-names>A.</given-names></name><name><surname>Pepponi</surname><given-names>R.</given-names></name><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Vincenzi</surname><given-names>F.</given-names></name><name><surname>Ferraro</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington’s disease.</article-title>
<source/><italic>Neurobiol. Dis.</italic>
<volume>71</volume>
<fpage>k193</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2014.08.013</pub-id></mixed-citation>
</ref>
<ref id="B255">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>D.</given-names></name><name><surname>Bianchi</surname><given-names>N.</given-names></name><name><surname>Eltzschig</surname><given-names>H. K.</given-names></name><name><surname>Gambari</surname><given-names>R.</given-names></name></person-group> (<year>2016a</year>). <article-title>MicroRNAs modulate the purinergic signaling network.</article-title>
<source/><italic>Trends Mol. Med.</italic>
<volume>22</volume>
<fpage>905</fpage>–<lpage>918</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2016.08.006</pub-id><pub-id pub-id-type="pmid">27623176</pub-id></mixed-citation>
</ref>
<ref id="B256">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>D.</given-names></name><name><surname>Mcnamee</surname><given-names>E. N.</given-names></name><name><surname>Idzko</surname><given-names>M.</given-names></name><name><surname>Gambari</surname><given-names>R.</given-names></name><name><surname>Eltzschig</surname><given-names>H. K.</given-names></name></person-group> (<year>2016b</year>). <article-title>Purinergic signaling during immune cell trafficking.</article-title>
<source/><italic>Trends Immunol.</italic>
<volume>37</volume>
<fpage>399</fpage>–<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2016.04.004</pub-id><pub-id pub-id-type="pmid">27142306</pub-id></mixed-citation>
</ref>
<ref id="B257">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>D.</given-names></name><name><surname>Vitiello</surname><given-names>L.</given-names></name><name><surname>Idzko</surname><given-names>M.</given-names></name><name><surname>La Sala</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Purinergic signaling in atherosclerosis.</article-title>
<source/><italic>Trends Mol. Med.</italic>
<volume>21</volume>
<fpage>184</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2014.12.008</pub-id><pub-id pub-id-type="pmid">25637413</pub-id></mixed-citation>
</ref>
<ref id="B258">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferré</surname><given-names>S.</given-names></name><name><surname>Bonaventura</surname><given-names>J.</given-names></name><name><surname>Tomasi</surname><given-names>D.</given-names></name><name><surname>Navarro</surname><given-names>G.</given-names></name><name><surname>Moreno</surname><given-names>E.</given-names></name><name><surname>Cortés</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>154</fpage>–<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.05.028</pub-id><pub-id pub-id-type="pmid">26051403</pub-id></mixed-citation>
</ref>
<ref id="B259">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrée</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>233</volume>
<fpage>1963</fpage>–<lpage>1979</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-016-4212-2</pub-id><pub-id pub-id-type="pmid">26786412</pub-id></mixed-citation>
</ref>
<ref id="B260">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Festugato</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Adenosine: an endogenous mediator in the pathogenesis of psoriasis.</article-title>
<source/><italic>An. Bras. Dermatol.</italic>
<volume>90</volume>
<fpage>862</fpage>–<lpage>867</lpage>. <pub-id pub-id-type="doi">10.1590/abd1806-4841.20153689</pub-id><pub-id pub-id-type="pmid">26734868</pub-id></mixed-citation>
</ref>
<ref id="B261">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiebich</surname><given-names>B. L.</given-names></name><name><surname>Akter</surname><given-names>S.</given-names></name><name><surname>Akundi</surname><given-names>R. S.</given-names></name></person-group> (<year>2014</year>). <article-title>The two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brain.</article-title>
<source/><italic>Front. Cell Neurosci.</italic>
<volume>8</volume>:<issue>260</issue>
<pub-id pub-id-type="doi">10.3389/fncel.2014.00260</pub-id></mixed-citation>
</ref>
<ref id="B262">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figliuolo</surname><given-names>V. R.</given-names></name><name><surname>Chaves</surname><given-names>S. P.</given-names></name><name><surname>Savio</surname><given-names>L. E. B.</given-names></name><name><surname>Thorstenberg</surname><given-names>M. L. P.</given-names></name><name><surname>Machado Salles</surname><given-names>E.</given-names></name><name><surname>Takiya</surname><given-names>C. M.</given-names></name><etal></etal></person-group> (<year>2017a</year>). <article-title>The role of the P2X7 receptor in murine cutaneous leishmaniasis: aspects of inflammation and parasite control.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>13</volume>
<fpage>143</fpage>–<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9544-1</pub-id><pub-id pub-id-type="pmid">27866341</pub-id></mixed-citation>
</ref>
<ref id="B263">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figliuolo</surname><given-names>V. R.</given-names></name><name><surname>Savio</surname><given-names>L. E. B.</given-names></name><name><surname>Safya</surname><given-names>H.</given-names></name><name><surname>Nanini</surname><given-names>H.</given-names></name><name><surname>Bernardazzi</surname><given-names>C.</given-names></name><name><surname>Abalo</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2017b</year>). <article-title>P2X7 receptor promotes intestinal inflammation in chemically induced colitis and triggers death of mucosal regulatory T cells.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1863</volume>
<fpage>1183</fpage>–<lpage>1194</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2017.03.004</pub-id><pub-id pub-id-type="pmid">28286160</pub-id></mixed-citation>
</ref>
<ref id="B264">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>A. B.</given-names></name><name><surname>Souza-Testasicca</surname><given-names>M. C.</given-names></name><name><surname>Afonso</surname><given-names>L. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling and infection by <italic>Leishmania</italic>: a new approach to evasion of the immune response.</article-title>
<source/><italic>Biomed. J.</italic>
<volume>39</volume>
<fpage>244</fpage>–<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1016/j.bj.2016.08.004</pub-id><pub-id pub-id-type="pmid">27793266</pub-id></mixed-citation>
</ref>
<ref id="B265">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>T.</given-names></name><name><surname>Rotermund</surname><given-names>N.</given-names></name><name><surname>Lohr</surname><given-names>C.</given-names></name><name><surname>Hirnet</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>P2Y1 receptor activation by photolysis of caged ATP enhances neuronal network activity in the developing olfactory bulb.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>8</volume>
<fpage>191</fpage>–<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-011-9286-z</pub-id><pub-id pub-id-type="pmid">22187118</pub-id></mixed-citation>
</ref>
<ref id="B266">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fish</surname><given-names>R. S.</given-names></name><name><surname>Klootwijk</surname><given-names>E.</given-names></name><name><surname>Tam</surname><given-names>F. W. K.</given-names></name><name><surname>Kleta</surname><given-names>R.</given-names></name><name><surname>Wheeler</surname><given-names>D. C.</given-names></name><name><surname>Unwin</surname><given-names>R. J.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>ATP and arterial calcification.</article-title>
<source/><italic>Eur. J. Clin. Invest.</italic>
<volume>43</volume>
<fpage>405</fpage>–<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1111/eci.12055</pub-id><pub-id pub-id-type="pmid">23398250</pub-id></mixed-citation>
</ref>
<ref id="B267">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishman</surname><given-names>P.</given-names></name><name><surname>Ochaion</surname><given-names>A.</given-names></name><name><surname>Cohen</surname><given-names>S.</given-names></name><name><surname>Patoka</surname><given-names>R.</given-names></name><name><surname>Barer</surname><given-names>F.</given-names></name><name><surname>Bar-Yehuda</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.</article-title>
<source/><italic>Expert Opin. Investig. Drugs</italic>
<volume>16</volume>
<fpage>1601</fpage>–<lpage>1613</lpage>. <pub-id pub-id-type="doi">10.1517/13543784.16.10.1601</pub-id></mixed-citation>
</ref>
<ref id="B268">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>B.</given-names></name><name><surname>Martinez-Aguila</surname><given-names>A.</given-names></name><name><surname>De Lara</surname><given-names>M. J. P.</given-names></name><name><surname>Pintor</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>13</volume>
<fpage>171</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9547-y</pub-id><pub-id pub-id-type="pmid">27848070</pub-id></mixed-citation>
</ref>
<ref id="B269">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>A. P.</given-names></name><name><surname>Cockayne</surname><given-names>D. A.</given-names></name></person-group> (<year>2011</year>). <article-title>ATP and P2X purinoceptors in urinary tract disorders.</article-title>
<source/><italic>Handb. Exp. Pharmacol.</italic>
<volume>202</volume>
<fpage>485</fpage>–<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-16499-6_22</pub-id></mixed-citation>
</ref>
<ref id="B270">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>A. P.</given-names></name><name><surname>Undem</surname><given-names>B. J.</given-names></name></person-group> (<year>2013</year>). <article-title>The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders.</article-title>
<source/><italic>Front. Cell Neurosci.</italic>
<volume>7</volume>:<issue>267</issue>
<pub-id pub-id-type="doi">10.3389/fncel.2013.00267</pub-id></mixed-citation>
</ref>
<ref id="B271">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>A. P.</given-names></name><name><surname>Undem</surname><given-names>B. J.</given-names></name><name><surname>Birder</surname><given-names>L. A.</given-names></name><name><surname>Grundy</surname><given-names>D.</given-names></name><name><surname>Pijacka</surname><given-names>W.</given-names></name><name><surname>Paton</surname><given-names>J. F.</given-names></name></person-group> (<year>2015</year>). <article-title>P2X3 receptors and sensitization of autonomic reflexes.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>191</volume>
<fpage>16</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2015.04.005</pub-id><pub-id pub-id-type="pmid">25956567</pub-id></mixed-citation>
</ref>
<ref id="B272">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Förster</surname><given-names>D.</given-names></name><name><surname>Reiser</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Supportive or detrimental roles of P2Y receptors in brain pathology?—The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>441</fpage>–<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9471-6</pub-id><pub-id pub-id-type="pmid">26407872</pub-id></mixed-citation>
</ref>
<ref id="B273">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fotino</surname><given-names>C.</given-names></name><name><surname>Vergani</surname><given-names>A.</given-names></name><name><surname>Fiorina</surname><given-names>P.</given-names></name><name><surname>Pileggi</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>P2X receptors and diabetes.</article-title>
<source/><italic>Curr. Med. Chem.</italic>
<volume>22</volume>
<fpage>891</fpage>–<lpage>901</lpage>. <pub-id pub-id-type="doi">10.2174/0929867321666141012173520</pub-id><pub-id pub-id-type="pmid">25312216</pub-id></mixed-citation>
</ref>
<ref id="B274">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fragakis</surname><given-names>N.</given-names></name><name><surname>Antoniadis</surname><given-names>A. P.</given-names></name><name><surname>Saviano</surname><given-names>M.</given-names></name><name><surname>Vassilikos</surname><given-names>V.</given-names></name><name><surname>Pappone</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>The use of adenosine and adenosine triphosphate testing in the diagnosis, risk stratification and management of patients with syncope: current evidence and future perspectives.</article-title>
<source/><italic>Int. J. Cardiol.</italic>
<volume>183</volume>
<fpage>267</fpage>–<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2015.01.089</pub-id><pub-id pub-id-type="pmid">25725201</pub-id></mixed-citation>
</ref>
<ref id="B275">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>M.</given-names></name><name><surname>Bautista-Perez</surname><given-names>R.</given-names></name><name><surname>Cano-Martinez</surname><given-names>A.</given-names></name><name><surname>Pacheco</surname><given-names>U.</given-names></name><name><surname>Santamaria</surname><given-names>J.</given-names></name><name><surname>Del Valle-Mondragon</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Physiopathological implications of P2X1 and P2X7 receptors in regulation of glomerular hemodynamics in angiotensin II-induced hypertension.</article-title>
<source/><italic>Am. J. Physiol. Renal Physiol.</italic>
<volume>313</volume>
<fpage>F9</fpage>–<lpage>F19</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00663.2016</pub-id><pub-id pub-id-type="pmid">28404593</pub-id></mixed-citation>
</ref>
<ref id="B276">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franklin</surname><given-names>K. M.</given-names></name><name><surname>Asatryan</surname><given-names>L.</given-names></name><name><surname>Jakowec</surname><given-names>M. W.</given-names></name><name><surname>Trudell</surname><given-names>J. R.</given-names></name><name><surname>Bell</surname><given-names>R. L.</given-names></name><name><surname>Davies</surname><given-names>D. L.</given-names></name></person-group> (<year>2014</year>). <article-title>P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders.</article-title>
<source/><italic>Front. Neurosci.</italic>
<volume>8</volume>:<issue>176</issue>
<pub-id pub-id-type="doi">10.3389/fnins.2014.00176</pub-id></mixed-citation>
</ref>
<ref id="B277">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fransson</surname><given-names>A.</given-names></name><name><surname>Järlebark</surname><given-names>L. E.</given-names></name><name><surname>Ulfendahl</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>In vivo infusion of UTP and uridine to the deafened guinea pig inner ear: effects on response thresholds and neural survival.</article-title>
<source/><italic>J. Neurosci. Res.</italic>
<volume>87</volume>
<fpage>1712</fpage>–<lpage>1717</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.21969</pub-id><pub-id pub-id-type="pmid">19115418</pub-id></mixed-citation>
</ref>
<ref id="B278">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frenguelli</surname><given-names>B. G.</given-names></name><name><surname>Wall</surname><given-names>M. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Combined electrophysiological and biosensor approaches to study purinergic regulation of epileptiform activity in cortical tissue.</article-title>
<source/><italic>J. Neurosci. Methods</italic>
<volume>260</volume>
<fpage>202</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2015.09.011</pub-id><pub-id pub-id-type="pmid">26381061</pub-id></mixed-citation>
</ref>
<ref id="B279">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friebe</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>T.</given-names></name><name><surname>Schmidt</surname><given-names>T.</given-names></name><name><surname>Borg</surname><given-names>N.</given-names></name><name><surname>Steckel</surname><given-names>B.</given-names></name><name><surname>Ding</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Purinergic signaling on leukocytes infiltrating the LPS-injured lung.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>9</volume>:<issue>e95382</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0095382</pub-id></mixed-citation>
</ref>
<ref id="B280">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frontini</surname><given-names>A. V.</given-names></name><name><surname>Cd</surname><given-names>D. L. V. E.</given-names></name><name><surname>Nicolorich</surname><given-names>M. V.</given-names></name><name><surname>Naves</surname><given-names>A.</given-names></name><name><surname>Schwarzbaum</surname><given-names>P.</given-names></name><name><surname>Venera</surname><given-names>G. D.</given-names></name></person-group> (<year>2011</year>). <article-title>In vivo effects of adenosine 5′-triphosphate on rat preneoplastic liver.</article-title>
<source/><italic>Medicina</italic>
<volume>71</volume>
<fpage>139</fpage>–<lpage>145</lpage>.<pub-id pub-id-type="pmid">21550930</pub-id></mixed-citation>
</ref>
<ref id="B281">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>S.</given-names></name><name><surname>Davies</surname><given-names>K. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Opiorphin-dependent upregulation of CD73 (a key enzyme in the adenosine signaling pathway) in corporal smooth muscle cells exposed to hypoxic conditions and in corporal tissue in pre-priapic sickle cell mice.</article-title>
<source/><italic>Int. J. Impot. Res.</italic>
<volume>27</volume>
<fpage>140</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1038/ijir.2015.5</pub-id><pub-id pub-id-type="pmid">25833166</pub-id></mixed-citation>
</ref>
<ref id="B282">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>W.</given-names></name><name><surname>Mccormick</surname><given-names>T.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Activation of P2X7-mediated apoptosis Inhibits DMBA/TPA-induced formation of skin papillomas and cancer in mice.</article-title>
<source/><italic>BMC Cancer</italic>
<volume>9</volume>:<issue>114</issue>
<pub-id pub-id-type="doi">10.1186/1471-2407-9-114</pub-id></mixed-citation>
</ref>
<ref id="B283">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>S. J.</given-names></name><name><surname>Stokes</surname><given-names>L.</given-names></name><name><surname>Skarratt</surname><given-names>K. K.</given-names></name><name><surname>Gu</surname><given-names>B. J.</given-names></name><name><surname>Wiley</surname><given-names>J. S.</given-names></name></person-group> (<year>2009</year>). <article-title>Genetics of the P2X7 receptor and human disease.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>5</volume>
<fpage>257</fpage>–<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-009-9136-4</pub-id><pub-id pub-id-type="pmid">19319666</pub-id></mixed-citation>
</ref>
<ref id="B284">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fumagalli</surname><given-names>M.</given-names></name><name><surname>Lecca</surname><given-names>D.</given-names></name><name><surname>Abbracchio</surname><given-names>M. P.</given-names></name></person-group> (<year>2016</year>). <article-title>CNS remyelination as a novel reparative approach to neurodegenerative diseases: the roles of purinergic signaling and the P2Y-like receptor GPR17.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>82</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.10.005</pub-id><pub-id pub-id-type="pmid">26453964</pub-id></mixed-citation>
</ref>
<ref id="B285">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Füredi</surname><given-names>R.</given-names></name><name><surname>Bölcskei</surname><given-names>K.</given-names></name><name><surname>Szolcsányi</surname><given-names>J.</given-names></name><name><surname>Pethö</surname><given-names>G.</given-names></name></person-group> (<year>2010</year>). <article-title>Comparison of the peripheral mediator background of heat injury- and plantar incision-induced drop of the noxious heat threshold in the rat.</article-title>
<source/><italic>Life Sci.</italic>
<volume>86</volume>
<fpage>244</fpage>–<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2009.12.010</pub-id><pub-id pub-id-type="pmid">20036261</pub-id></mixed-citation>
</ref>
<ref id="B286">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furlan-Freguia</surname><given-names>C.</given-names></name><name><surname>Marchese</surname><given-names>P.</given-names></name><name><surname>Gruber</surname><given-names>A.</given-names></name><name><surname>Ruggeri</surname><given-names>Z. M.</given-names></name><name><surname>Ruf</surname><given-names>W.</given-names></name></person-group> (<year>2011</year>). <article-title>P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice.</article-title>
<source/><italic>J. Clin. Invest.</italic>
<volume>121</volume>
<fpage>2932</fpage>–<lpage>2944</lpage>. <pub-id pub-id-type="doi">10.1172/JCI46129</pub-id><pub-id pub-id-type="pmid">21670495</pub-id></mixed-citation>
</ref>
<ref id="B287">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furlong</surname><given-names>T. M.</given-names></name><name><surname>Supit</surname><given-names>A. S.</given-names></name><name><surname>Corbit</surname><given-names>L. H.</given-names></name><name><surname>Killcross</surname><given-names>S.</given-names></name><name><surname>Balleine</surname><given-names>B. W.</given-names></name></person-group> (<year>2015</year>). <article-title>Pulling habits out of rats: adenosine 2A receptor antagonism in dorsomedial striatum rescues meth-amphetamine-induced deficits in goal-directed action.</article-title>
<source/><italic>Addict. Biol.</italic>
<volume>22</volume>
<fpage>172</fpage>–<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1111/adb.12316</pub-id><pub-id pub-id-type="pmid">26515740</pub-id></mixed-citation>
</ref>
<ref id="B288">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>M.</given-names></name><name><surname>Moussaud</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>P.</given-names></name><name><surname>Mclean</surname><given-names>P. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>36</volume>
<fpage>1209</fpage>–<lpage>1220</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.10.037</pub-id><pub-id pub-id-type="pmid">25480524</pub-id></mixed-citation>
</ref>
<ref id="B289">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandelman</surname><given-names>M.</given-names></name><name><surname>Levy</surname><given-names>M.</given-names></name><name><surname>Cassina</surname><given-names>P.</given-names></name><name><surname>Barbeito</surname><given-names>L.</given-names></name><name><surname>Beckman</surname><given-names>J. S.</given-names></name></person-group> (<year>2013</year>). <article-title>P2X7 receptor-induced death of motor neurons by a peroxynitrite/FAS-dependent pathway.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>126</volume>
<fpage>382</fpage>–<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.12286</pub-id><pub-id pub-id-type="pmid">23646980</pub-id></mixed-citation>
</ref>
<ref id="B290">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Qui</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>Z.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Xiang</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Blocking P2X receptors can inhibit the injury-induced proliferation of olfactory epithelium progenitor cells in adult mouse.</article-title>
<source/><italic>Int. J. Pediatr. Otorhinolaryngol.</italic>
<volume>74</volume>
<fpage>747</fpage>–<lpage>751</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijporl.2010.03.030</pub-id><pub-id pub-id-type="pmid">20394994</pub-id></mixed-citation>
</ref>
<ref id="B291">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Wan</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Effect of tetramethylpyrazine on DRG neuron P2X3 receptor involved in transmitting pain after burn.</article-title>
<source/><italic>Burns</italic>
<volume>36</volume>
<fpage>127</fpage>–<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.burns.2009.04.032</pub-id><pub-id pub-id-type="pmid">19726132</pub-id></mixed-citation>
</ref>
<ref id="B292">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gariboldi</surname><given-names>V.</given-names></name><name><surname>Vairo</surname><given-names>D.</given-names></name><name><surname>Guieu</surname><given-names>R.</given-names></name><name><surname>Marlingue</surname><given-names>M.</given-names></name><name><surname>Ravis</surname><given-names>E.</given-names></name><name><surname>Lagier</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Expressions of adenosine A2A receptors in coronary arteries and peripheral blood mononuclear cells are correlated in coronary artery disease patients.</article-title>
<source/><italic>Int. J. Cardiol.</italic>
<volume>230</volume>
<fpage>427</fpage>–<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2016.12.089</pub-id><pub-id pub-id-type="pmid">28041708</pub-id></mixed-citation>
</ref>
<ref id="B293">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazzerro</surname><given-names>E.</given-names></name><name><surname>Baldassari</surname><given-names>S.</given-names></name><name><surname>Assereto</surname><given-names>S.</given-names></name><name><surname>Fruscione</surname><given-names>F.</given-names></name><name><surname>Pistorio</surname><given-names>A.</given-names></name><name><surname>Panicucci</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Enhancement of muscle T regulatory cells and improvement of muscular dystrophic process in mdx mice by blockade of extracellular ATP/P2X axis.</article-title>
<source/><italic>Am. J. Pathol.</italic>
<volume>185</volume>
<fpage>3349</fpage>–<lpage>3360</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2015.08.010</pub-id><pub-id pub-id-type="pmid">26465071</pub-id></mixed-citation>
</ref>
<ref id="B294">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehring</surname><given-names>M. P.</given-names></name><name><surname>Kipper</surname><given-names>F.</given-names></name><name><surname>Nicoletti</surname><given-names>N. F.</given-names></name><name><surname>Sperotto</surname><given-names>N. D.</given-names></name><name><surname>Zanin</surname><given-names>R.</given-names></name><name><surname>Tamajusuku</surname><given-names>A. S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X7 receptor as predictor gene for glioma radiosensitivity and median survival.</article-title>
<source/><italic>Int. J. Biochem. Cell Biol.</italic>
<volume>68</volume>
<fpage>92</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2015.09.001</pub-id><pub-id pub-id-type="pmid">26358881</pub-id></mixed-citation>
</ref>
<ref id="B295">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gendaszewska-Darmach</surname><given-names>E.</given-names></name><name><surname>Kucharska</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Nucleotide receptors as targets in the pharmacological enhancement of dermal wound healing.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>7</volume>
<fpage>193</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-011-9233-z</pub-id><pub-id pub-id-type="pmid">21519856</pub-id></mixed-citation>
</ref>
<ref id="B296">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gendaszewska-Darmach</surname><given-names>E.</given-names></name><name><surname>Szustak</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Thymidine 5′-O-monophosphorothioate induces HeLa cell migration by activation of the P2Y6 receptor.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>199</fpage>–<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9492-1</pub-id><pub-id pub-id-type="pmid">26746211</pub-id></mixed-citation>
</ref>
<ref id="B297">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentile</surname><given-names>D.</given-names></name><name><surname>Natale</surname><given-names>M.</given-names></name><name><surname>Lazzerini</surname><given-names>P. E.</given-names></name><name><surname>Capecchi</surname><given-names>P. L.</given-names></name><name><surname>Laghi-Pasini</surname><given-names>F.</given-names></name></person-group> (<year>2015</year>). <article-title>The role of P2X7 receptors in tissue fibrosis: a brief review.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>435</fpage>–<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9466-3</pub-id><pub-id pub-id-type="pmid">26318434</pub-id></mixed-citation>
</ref>
<ref id="B298">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geraghty</surname><given-names>N. J.</given-names></name><name><surname>Watson</surname><given-names>D.</given-names></name><name><surname>Adhikary</surname><given-names>S. R.</given-names></name><name><surname>Sluyter</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>P2X7 receptor in skin biology and diseases.</article-title>
<source/><italic>World J. Dermatol.</italic>
<volume>5</volume>
<fpage>72</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.5314/wjd.v5.i2.72</pub-id></mixed-citation>
</ref>
<ref id="B299">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanbari</surname><given-names>H.</given-names></name><name><surname>Jani</surname><given-names>R.</given-names></name><name><surname>Hussain-Amin</surname><given-names>A.</given-names></name><name><surname>Al-Assad</surname><given-names>W.</given-names></name><name><surname>Huether</surname><given-names>E.</given-names></name><name><surname>Ansari</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Role of adenosine after antral pulmonary vein isolation of paroxysmal atrial fibrillation: a randomized controlled trial.</article-title>
<source/><italic>Heart Rhythm</italic>
<volume>13</volume>
<fpage>407</fpage>–<lpage>415</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2015.10.016</pub-id><pub-id pub-id-type="pmid">26455342</pub-id></mixed-citation>
</ref>
<ref id="B300">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannuzzo</surname><given-names>A.</given-names></name><name><surname>Saccomano</surname><given-names>M.</given-names></name><name><surname>Napp</surname><given-names>J.</given-names></name><name><surname>Ellegaard</surname><given-names>M.</given-names></name><name><surname>Alves</surname><given-names>F.</given-names></name><name><surname>Novak</surname><given-names>I.</given-names></name></person-group> (<year>2016</year>). <article-title>Targeting of the P2X7 receptor in pancreatic cancer and stellate cells.</article-title>
<source/><italic>Int. J. Cancer</italic>
<volume>139</volume>
<fpage>2540</fpage>–<lpage>2552</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.30380</pub-id><pub-id pub-id-type="pmid">27513892</pub-id></mixed-citation>
</ref>
<ref id="B301">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gicquel</surname><given-names>T.</given-names></name><name><surname>Le Dare</surname><given-names>B.</given-names></name><name><surname>Boichot</surname><given-names>E.</given-names></name><name><surname>Lagente</surname><given-names>V.</given-names></name></person-group> (<year>2017</year>). <article-title>Purinergic receptors: new targets for the treatment of gout and fibrosis.</article-title>
<source/><italic>Fundam. Clin. Pharmacol.</italic>
<volume>31</volume>
<fpage>136</fpage>–<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1111/fcp.12256</pub-id><pub-id pub-id-type="pmid">27885718</pub-id></mixed-citation>
</ref>
<ref id="B302">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gidlöf</surname><given-names>O.</given-names></name><name><surname>Sathanoori</surname><given-names>R.</given-names></name><name><surname>Magistri</surname><given-names>M.</given-names></name><name><surname>Faghihi</surname><given-names>M. A.</given-names></name><name><surname>Wahlestedt</surname><given-names>C.</given-names></name><name><surname>Olde</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Extracellular uridine triphosphate and adenosine triphosphate attenuate endothelial inflammation through miR-22-mediated ICAM-1 inhibition.</article-title>
<source/><italic>J. Vasc. Res.</italic>
<volume>52</volume>
<fpage>71</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1159/000431367</pub-id><pub-id pub-id-type="pmid">26088024</pub-id></mixed-citation>
</ref>
<ref id="B303">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>A.</given-names></name><name><surname>Wortham</surname><given-names>K.</given-names></name><name><surname>Costa</surname><given-names>D.</given-names></name><name><surname>Davis</surname><given-names>W.</given-names></name><name><surname>Ticho</surname><given-names>B.</given-names></name><name><surname>Whalley</surname><given-names>E.</given-names></name></person-group> (<year>2009</year>). <article-title>Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats.</article-title>
<source/><italic>Am. J. Nephrol.</italic>
<volume>30</volume>
<fpage>521</fpage>–<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1159/000248762</pub-id><pub-id pub-id-type="pmid">19828940</pub-id></mixed-citation>
</ref>
<ref id="B304">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giniatullin</surname><given-names>R.</given-names></name><name><surname>Nistri</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Desensitization properties of P2X3 receptors shaping pain signaling.</article-title>
<source/><italic>Front. Cell Neurosci.</italic>
<volume>7</volume>:<issue>245</issue>
<pub-id pub-id-type="doi">10.3389/fncel.2013.00245</pub-id></mixed-citation>
</ref>
<ref id="B305">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgi</surname><given-names>V. S.</given-names></name><name><surname>Witkin</surname><given-names>S. S.</given-names></name><name><surname>Bannwart-Castro</surname><given-names>C. F.</given-names></name><name><surname>Sartori</surname><given-names>M. S.</given-names></name><name><surname>Romao-Veiga</surname><given-names>M.</given-names></name><name><surname>Borges</surname><given-names>V. T.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Elevated circulatingadenosine deaminase activity in women with preeclampsia: association with pro-inflammatory cytokine production and uric acid levels.</article-title>
<source/><italic>Pregnancy Hypertens.</italic>
<volume>6</volume>
<fpage>400</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1016/j.preghy.2016.09.004</pub-id><pub-id pub-id-type="pmid">27939490</pub-id></mixed-citation>
</ref>
<ref id="B306">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliani</surname><given-names>A. L.</given-names></name><name><surname>Colognesi</surname><given-names>D.</given-names></name><name><surname>Ricco</surname><given-names>T.</given-names></name><name><surname>Roncato</surname><given-names>C.</given-names></name><name><surname>Capece</surname><given-names>M.</given-names></name><name><surname>Amoroso</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>9</volume>:<issue>e107224</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0107224</pub-id></mixed-citation>
</ref>
<ref id="B307">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliani</surname><given-names>A. L.</given-names></name><name><surname>Sarti</surname><given-names>A. C.</given-names></name><name><surname>Falzoni</surname><given-names>S.</given-names></name><name><surname>Di Virgilio</surname><given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title>The P2X7 receptor-interleukin-1 liaison.</article-title>
<source/><italic>Front. Pharmacol.</italic>
<volume>8</volume>:<issue>123</issue>
<pub-id pub-id-type="doi">10.3389/fphar.2017.00123</pub-id></mixed-citation>
</ref>
<ref id="B308">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliani</surname><given-names>P.</given-names></name><name><surname>Zuccarini</surname><given-names>M.</given-names></name><name><surname>Buccella</surname><given-names>S.</given-names></name><name><surname>Pena-Altamira</surname><given-names>L. E.</given-names></name><name><surname>Polazzi</surname><given-names>E.</given-names></name><name><surname>Virgili</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Evidence for purine nucleoside phosphorylase (PNP) release from rat C6 glioma cells.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>141</volume>
<fpage>208</fpage>–<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.14004</pub-id><pub-id pub-id-type="pmid">28251649</pub-id></mixed-citation>
</ref>
<ref id="B309">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>R.</given-names></name><name><surname>Bardini</surname><given-names>M.</given-names></name><name><surname>Robson</surname><given-names>T.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2001</year>). <article-title>Expression of nucleotide P2X receptor subtypes during spermatogenesis in the adult rat testis.</article-title>
<source/><italic>Cells Tissues Org.</italic>
<volume>169</volume>
<fpage>377</fpage>–<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1159/000047905</pub-id></mixed-citation>
</ref>
<ref id="B310">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gloria-Bottini</surname><given-names>F.</given-names></name><name><surname>Saccucci</surname><given-names>P.</given-names></name><name><surname>Ammendola</surname><given-names>M.</given-names></name><name><surname>Neri</surname><given-names>A.</given-names></name><name><surname>Magrini</surname><given-names>A.</given-names></name><name><surname>Bottini</surname><given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Genetic variability within Adenosine Deaminase gene and uterine leiomyomas.</article-title>
<source/><italic>Eur. J. Obstet. Gynecol. Reprod. Biol.</italic>
<volume>199</volume>
<fpage>108</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejogrb.2016.02.002</pub-id><pub-id pub-id-type="pmid">26918693</pub-id></mixed-citation>
</ref>
<ref id="B311">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnad</surname><given-names>T.</given-names></name><name><surname>Scheibler</surname><given-names>S.</given-names></name><name><surname>Von Kügelgen</surname><given-names>I.</given-names></name><name><surname>Scheele</surname><given-names>C.</given-names></name><name><surname>Kilic</surname><given-names>A.</given-names></name><name><surname>Glode</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors.</article-title>
<source/><italic>Nature</italic>
<volume>516</volume>
<fpage>395</fpage>–<lpage>399</lpage>. <pub-id pub-id-type="doi">10.1038/nature13816</pub-id><pub-id pub-id-type="pmid">25317558</pub-id></mixed-citation>
</ref>
<ref id="B312">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>G.</given-names></name><name><surname>Sung</surname><given-names>J.-S.</given-names></name><name><surname>Jee</surname><given-names>S.-C.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Jang</surname><given-names>W.-H.</given-names></name><name><surname>Kang</surname><given-names>K.-Y.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>In vitro anti-obesity effects of sesamol mediated by adenosine monophosphate-activated protein kinase and mitogen-activated protein kinase signaling in 3T3-L1 cells.</article-title>
<source/><italic>Food Sci. Biotechnol.</italic>
<volume>26</volume>
<fpage>195</fpage>–<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1007/s10068-017-0026-1</pub-id></mixed-citation>
</ref>
<ref id="B313">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gölöncsér</surname><given-names>F.</given-names></name><name><surname>Sperlágh</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>). <article-title>Effect of genetic deletion and pharmacological antagonism of P2X7 receptors in a mouse animal model of migraine.</article-title>
<source/><italic>J. Headache Pain</italic>
<volume>15</volume>:<issue>24</issue>
<pub-id pub-id-type="doi">10.1186/1129-2377-15-24</pub-id></mixed-citation>
</ref>
<ref id="B314">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Villafuertes</surname><given-names>R.</given-names></name><name><surname>Garcia-Huerta</surname><given-names>P.</given-names></name><name><surname>Diaz-Hernandez</surname><given-names>J. I.</given-names></name><name><surname>Miras-Portugal</surname><given-names>M. T.</given-names></name></person-group> (<year>2015</year>). <article-title>PI3K/Akt signaling pathway triggers P2X7 receptor expression as a pro-survival factor of neuroblastoma cells under limiting growth conditions.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>5</volume>:<issue>18417</issue>
<pub-id pub-id-type="doi">10.1038/srep18417</pub-id></mixed-citation>
</ref>
<ref id="B315">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonçalves</surname><given-names>F. M.</given-names></name><name><surname>Neis</surname><given-names>V. B.</given-names></name><name><surname>Rieger</surname><given-names>D. K.</given-names></name><name><surname>Lopes</surname><given-names>M. W.</given-names></name><name><surname>Heinrich</surname><given-names>I. A.</given-names></name><name><surname>Costa</surname><given-names>A. P.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Signaling pathways underlying the antidepressant-like effect of inosine in mice.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>13</volume>
<fpage>203</fpage>–<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9551-2</pub-id><pub-id pub-id-type="pmid">27966087</pub-id></mixed-citation>
</ref>
<ref id="B316">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goonetilleke</surname><given-names>L.</given-names></name><name><surname>Ralevic</surname><given-names>V.</given-names></name><name><surname>Dunn</surname><given-names>W. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Influence of pressure on adenosine triphosphate function as a sympathetic neurotransmitter in small mesenteric arteries from the spontaneously hypertensive rat.</article-title>
<source/><italic>J. Hypertens.</italic>
<volume>31</volume>
<fpage>312</fpage>–<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1097/HJH.0b013e32835bd74d</pub-id><pub-id pub-id-type="pmid">23263239</pub-id></mixed-citation>
</ref>
<ref id="B317">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorodeski</surname><given-names>G. I.</given-names></name></person-group> (<year>2009</year>). <article-title>P2X7-mediated chemoprevention of epithelial cancers.</article-title>
<source/><italic>Expert. Opin. Ther. Targets</italic>
<volume>13</volume>
<fpage>1313</fpage>–<lpage>1332</lpage>. <pub-id pub-id-type="doi">10.1517/14728220903277249</pub-id><pub-id pub-id-type="pmid">19845494</pub-id></mixed-citation>
</ref>
<ref id="B318">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorodeski</surname><given-names>G. I.</given-names></name></person-group> (<year>2015</year>). <article-title>Purinergic signalling in the reproductive system.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>191</volume>
<fpage>82</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2015.04.008</pub-id><pub-id pub-id-type="pmid">25981553</pub-id></mixed-citation>
</ref>
<ref id="B319">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graubardt</surname><given-names>N.</given-names></name><name><surname>Fahrner</surname><given-names>R.</given-names></name><name><surname>Trochsler</surname><given-names>M.</given-names></name><name><surname>Keogh</surname><given-names>A.</given-names></name><name><surname>Breu</surname><given-names>K.</given-names></name><name><surname>Furer</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Promotion of liver regeneration by natural killer cells in a murine model is dependent on extracellular adenosine triphosphate phosphohydrolysis.</article-title>
<source/><italic>Hepatology</italic>
<volume>57</volume>
<fpage>1969</fpage>–<lpage>1979</lpage>. <pub-id pub-id-type="doi">10.1002/hep.26008</pub-id><pub-id pub-id-type="pmid">22898900</pub-id></mixed-citation>
</ref>
<ref id="B320">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname><given-names>S. J.</given-names></name><name><surname>Sabbah</surname><given-names>H. N.</given-names></name><name><surname>Butler</surname><given-names>J.</given-names></name><name><surname>Voors</surname><given-names>A. A.</given-names></name><name><surname>Abrecht-Küpper</surname><given-names>B. E.</given-names></name><name><surname>Düngen</surname><given-names>H. D.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.</article-title>
<source/><italic>Heart Fail. Rev.</italic>
<volume>21</volume>
<fpage>95</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1007/s10741-015-9522-7</pub-id><pub-id pub-id-type="pmid">26701329</pub-id></mixed-citation>
</ref>
<ref id="B321">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greer</surname><given-names>S.</given-names></name><name><surname>Page</surname><given-names>C. W.</given-names></name><name><surname>Joshi</surname><given-names>T.</given-names></name><name><surname>Yan</surname><given-names>D.</given-names></name><name><surname>Newton</surname><given-names>R.</given-names></name><name><surname>Giembycz</surname><given-names>M. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Concurrent agonism of adenosine A2B and glucocorticoid receptors in human airway epithelial cells cooperatively induces genes with anti-inflammatory potential: a novel approach to treat chronic obstructive pulmonary disease.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>346</volume>
<fpage>473</fpage>–<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.113.206284</pub-id><pub-id pub-id-type="pmid">23820127</pub-id></mixed-citation>
</ref>
<ref id="B322">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grenz</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>J.-H.</given-names></name><name><surname>Bauerle</surname><given-names>J. D.</given-names></name><name><surname>Tak</surname><given-names>E.</given-names></name><name><surname>Eltzschig</surname><given-names>H. K.</given-names></name><name><surname>Clambey</surname><given-names>E. T.</given-names></name></person-group> (<year>2012</year>). <article-title>Adora2b adenosine receptor signaling protects during acute kidney injury via inhibition of neutrophil-dependent TNF-α release.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>189</volume>
<fpage>4566</fpage>–<lpage>4573</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1201651</pub-id><pub-id pub-id-type="pmid">23028059</pub-id></mixed-citation>
</ref>
<ref id="B323">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greve</surname><given-names>A. S.</given-names></name><name><surname>Skals</surname><given-names>M.</given-names></name><name><surname>Fagerberg</surname><given-names>S. K.</given-names></name><name><surname>Tonnus</surname><given-names>W.</given-names></name><name><surname>Ellermann-Eriksen</surname><given-names>S.</given-names></name><name><surname>Evans</surname><given-names>R. J.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>P2X1, P2X4, and P2X7 receptor knock out mice expose differential outcome of sepsis induced by α-haemolysin producing <italic>Escherichia coli</italic>.</article-title>
<source/><italic>Front. Cell Infect. Microbiol.</italic>
<volume>7</volume>:<issue>113</issue>
<pub-id pub-id-type="doi">10.3389/fcimb.2017.00113</pub-id></mixed-citation>
</ref>
<ref id="B324">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>B. J.</given-names></name><name><surname>Field</surname><given-names>J.</given-names></name><name><surname>Dutertre</surname><given-names>S.</given-names></name><name><surname>Ou</surname><given-names>A.</given-names></name><name><surname>Kilpatrick</surname><given-names>T. J.</given-names></name><name><surname>Lechner-Scott</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>24</volume>
<fpage>5644</fpage>–<lpage>5654</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddv278</pub-id><pub-id pub-id-type="pmid">26188005</pub-id></mixed-citation>
</ref>
<ref id="B325">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gualix</surname><given-names>J.</given-names></name><name><surname>León-Otegui</surname><given-names>M.</given-names></name><name><surname>Recuero</surname><given-names>M.</given-names></name><name><surname>Bullido</surname><given-names>M. J.</given-names></name><name><surname>Valdivieso</surname><given-names>F.</given-names></name><name><surname>Miras-Portugal</surname><given-names>M. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Functional characterization of P2Y1 and P2X4 receptors in human neuroblastoma SK-N-MC cells.</article-title>
<source/><italic>An. Real Acad. Farm.</italic>
<volume>81</volume>
<fpage>247</fpage>–<lpage>257</lpage>.</mixed-citation>
</ref>
<ref id="B326">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubert</surname><given-names>C.</given-names></name><name><surname>Fries</surname><given-names>G. R.</given-names></name><name><surname>Wollenhaupt De Aguiar</surname><given-names>B.</given-names></name><name><surname>Ribeiro</surname><given-names>A. R.</given-names></name><name><surname>Busnello</surname><given-names>J. V.</given-names></name><name><surname>Ribeiro</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>The P2X7 purinergic receptor as a molecular target in bipolar disorder.</article-title>
<source/><italic>Neuropsychiatry Neuropsychol.</italic>
<volume>8</volume>
<fpage>1</fpage>–<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="B327">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubert</surname><given-names>C.</given-names></name><name><surname>Jacintho Moritz</surname><given-names>C. E.</given-names></name><name><surname>Vasconcelos-Moreno</surname><given-names>M. P.</given-names></name><name><surname>Quadros Dos Santos</surname><given-names>B. T.</given-names></name><name><surname>Sartori</surname><given-names>J.</given-names></name><name><surname>Fijtman</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Peripheral adenosine levels in euthymic patients with bipolar disorder.</article-title>
<source/><italic>Psychiatry Res.</italic>
<volume>246</volume>
<fpage>421</fpage>–<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2016.10.007</pub-id><pub-id pub-id-type="pmid">27788463</pub-id></mixed-citation>
</ref>
<ref id="B328">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guixà-González</surname><given-names>R.</given-names></name><name><surname>Javanainen</surname><given-names>M.</given-names></name><name><surname>Gómez-Soler</surname><given-names>M.</given-names></name><name><surname>Cordobilla</surname><given-names>B.</given-names></name><name><surname>Domingo</surname><given-names>J. C.</given-names></name><name><surname>Sanz</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Membrane omega-3 fatty acids modulate the oligomerisation kinetics of adenosine A2A and dopamine D2 receptors.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>6</volume>:<issue>19839</issue>
<pub-id pub-id-type="doi">10.1038/srep19839</pub-id></mixed-citation>
</ref>
<ref id="B329">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Fu</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Fan</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Contributions of purinergic P2X3 receptors within the midbrain periaqueductal gray to diabetes-induced neuropathic pain.</article-title>
<source/><italic>J. Physiol. Sci.</italic>
<volume>65</volume>
<fpage>99</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1007/s12576-014-0344-5</pub-id><pub-id pub-id-type="pmid">25367719</pub-id></mixed-citation>
</ref>
<ref id="B330">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>). <article-title>Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington×s disease.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>732</volume>
<fpage>111</fpage>–<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2014.03.032</pub-id><pub-id pub-id-type="pmid">24690258</pub-id></mixed-citation>
</ref>
<ref id="B331">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gür</surname><given-names>S.</given-names></name><name><surname>Kadowitz</surname><given-names>P. J.</given-names></name><name><surname>Abdel-Mageed</surname><given-names>A. S.</given-names></name><name><surname>Kendirci</surname><given-names>M.</given-names></name><name><surname>Sikka</surname><given-names>S. C.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Management of erectile function by penile purinergic P2 receptors in the diabetic rat.</article-title>
<source/><italic>J. Urol.</italic>
<volume>181</volume>
<fpage>2375</fpage>–<lpage>2382</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2009.01.002</pub-id><pub-id pub-id-type="pmid">19303093</pub-id></mixed-citation>
</ref>
<ref id="B332">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gur</surname><given-names>S.</given-names></name><name><surname>Kadowitz</surname><given-names>P. J.</given-names></name><name><surname>Hellstrom</surname><given-names>W. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Purinergic (P2) receptor control of lower genitourinary tract function and new avenues for drug action: an overview.</article-title>
<source/><italic>Curr. Pharm. Des.</italic>
<volume>13</volume>
<fpage>3236</fpage>–<lpage>3244</lpage>. <pub-id pub-id-type="doi">10.2174/138161207782341277</pub-id><pub-id pub-id-type="pmid">18045173</pub-id></mixed-citation>
</ref>
<ref id="B333">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>S. J.</given-names></name><name><surname>Gerevich</surname><given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>P2Y receptors in synaptic transmission and plasticity: therapeutic potential in cognitive dysfunction.</article-title>
<source/><italic>Neural Plast.</italic>
<volume>2016</volume>:<issue>1207393</issue>
<pub-id pub-id-type="doi">10.1155/2016/1207393</pub-id></mixed-citation>
</ref>
<ref id="B334">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman-Aranguez</surname><given-names>A.</given-names></name><name><surname>Gasull</surname><given-names>X.</given-names></name><name><surname>Diebold</surname><given-names>Y.</given-names></name><name><surname>Pintor</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>Purinergic receptors in ocular inflammation.</article-title>
<source/><italic>Mediators Inflamm.</italic>
<volume>2014</volume>:<issue>320906</issue>
<pub-id pub-id-type="doi">10.1155/2014/320906</pub-id></mixed-citation>
</ref>
<ref id="B335">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzmán-Aránguez</surname><given-names>A.</given-names></name><name><surname>Irazu</surname><given-names>M.</given-names></name><name><surname>Yayon</surname><given-names>A.</given-names></name><name><surname>Pintor</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>P2Y receptors activated by diadenosine polyphosphates reestablish Ca<sup>2+</sup> transients in achondroplasic chondrocytes.</article-title>
<source/><italic>Bone</italic>
<volume>42</volume>
<fpage>516</fpage>–<lpage>523</lpage>. <pub-id pub-id-type="doi">10.1016/j.bone.2007.10.023</pub-id><pub-id pub-id-type="pmid">18093889</pub-id></mixed-citation>
</ref>
<ref id="B336">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haanes</surname><given-names>K. A.</given-names></name><name><surname>Edvinsson</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Expression and characterization of purinergic receptors in rat middle meningeal artery-potential role in migraine.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>9</volume>:<issue>e108782</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0108782</pub-id></mixed-citation>
</ref>
<ref id="B337">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafner</surname><given-names>S.</given-names></name><name><surname>Wagner</surname><given-names>K.</given-names></name><name><surname>Weber</surname><given-names>S.</given-names></name><name><surname>Gröger</surname><given-names>M.</given-names></name><name><surname>Wepler</surname><given-names>M.</given-names></name><name><surname>Mccook</surname><given-names>O.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Role of the purinergic receptor P2XR4 after blunt chest trauma in cigarette smoke-exposed mice.</article-title>
<source/><italic>Shock</italic>
<volume>47</volume>
<fpage>193</fpage>–<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1097/SHK.0000000000000726</pub-id><pub-id pub-id-type="pmid">27559703</pub-id></mixed-citation>
</ref>
<ref id="B338">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamidpour</surname><given-names>R.</given-names></name><name><surname>Hamidpour</surname><given-names>S.</given-names></name><name><surname>Hamidpour</surname><given-names>M.</given-names></name><name><surname>Zarabi</surname><given-names>M.</given-names></name><name><surname>Sohraby</surname><given-names>M.</given-names></name><name><surname>Shalari</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Antipurinergic therapy with suramin as a treatment for autism spectrum disorder.</article-title>
<source/><italic>J. Biomed. Sci.</italic>
<volume>5</volume>
<issue>14</issue>
<pub-id pub-id-type="doi">10.4172/2254-609X.100028</pub-id></mixed-citation>
</ref>
<ref id="B339">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>R. R.</given-names></name><name><surname>Nasser</surname><given-names>A.</given-names></name><name><surname>Falk</surname><given-names>S.</given-names></name><name><surname>Baldvinsson</surname><given-names>S. B.</given-names></name><name><surname>Ohlsson</surname><given-names>P. H.</given-names></name><name><surname>Bahl</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>688</volume>
<fpage>27</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2012.05.008</pub-id><pub-id pub-id-type="pmid">22634164</pub-id></mixed-citation>
</ref>
<ref id="B340">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>R. R.</given-names></name><name><surname>Nielsen</surname><given-names>C. K.</given-names></name><name><surname>Nasser</surname><given-names>A.</given-names></name><name><surname>Thomsen</surname><given-names>S. I.</given-names></name><name><surname>Eghorn</surname><given-names>L. F.</given-names></name><name><surname>Pham</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>P2X7 receptor-deficient mice are susceptible to bone cancer pain.</article-title>
<source/><italic>Pain</italic>
<volume>152</volume>
<fpage>1766</fpage>–<lpage>1776</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2011.03.024</pub-id><pub-id pub-id-type="pmid">21565445</pub-id></mixed-citation>
</ref>
<ref id="B341">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>E.</given-names></name><name><surname>Werner</surname><given-names>T.</given-names></name><name><surname>Björklund</surname><given-names>U.</given-names></name><name><surname>Skiöldebrand</surname><given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Therapeutic innovation: inflammatory-reactive astrocytes as targets of inflammation.</article-title>
<source/><italic>IBRO Rep.</italic>
<volume>1</volume>
<fpage>1</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ibror.2016.06.001</pub-id></mixed-citation>
</ref>
<ref id="B342">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>J. F.</given-names></name><name><surname>Chow</surname><given-names>A. W.</given-names></name><name><surname>Cheung</surname><given-names>W. T.</given-names></name><name><surname>Ko</surname><given-names>W. H.</given-names></name></person-group> (<year>2014</year>). <article-title>P2Y6 receptor-mediated proinflammatory signaling in human bronchial epithelia.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>9</volume>:<issue>e106235</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0106235</pub-id></mixed-citation>
</ref>
<ref id="B343">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>L.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Synthesis and antiviral evaluation of novel N-6 substituted adenosine analogues.</article-title>
<source/><italic>Tetrahedron Lett.</italic>
<volume>58</volume>
<fpage>190</fpage>–<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.tetlet.2016.11.059</pub-id></mixed-citation>
</ref>
<ref id="B344">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmse</surname><given-names>R.</given-names></name><name><surname>Van Der Walt</surname><given-names>M. M.</given-names></name><name><surname>Petzer</surname><given-names>J. P.</given-names></name><name><surname>Terre’blanche</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A1 and A2A receptor antagonists.</article-title>
<source/><italic>Bioorg. Med. Chem. Lett.</italic>
<volume>26</volume>
<fpage>5951</fpage>–<lpage>5955</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2016.10.086</pub-id><pub-id pub-id-type="pmid">27836398</pub-id></mixed-citation>
</ref>
<ref id="B345">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasebe</surname><given-names>H.</given-names></name><name><surname>Yoshida</surname><given-names>K.</given-names></name><name><surname>Iida</surname><given-names>M.</given-names></name><name><surname>Hatano</surname><given-names>N.</given-names></name><name><surname>Muramatsu</surname><given-names>T.</given-names></name><name><surname>Aonuma</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>Right-to-left frequency gradient during atrial fibrillation initiated by right atrial ectopies and its augmentation by adenosine triphosphate: implications of right atrial fibrillation.</article-title>
<source/><italic>Heart Rhythm</italic>
<volume>13</volume>
<fpage>354</fpage>–<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2015.09.030</pub-id><pub-id pub-id-type="pmid">26432585</pub-id></mixed-citation>
</ref>
<ref id="B346">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>F.</given-names></name><name><surname>Ohshima</surname><given-names>Y.</given-names></name><name><surname>Seki</surname><given-names>S.</given-names></name><name><surname>Tsukimoto</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>M.</given-names></name><name><surname>Takenouchi</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>695</volume>
<fpage>20</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2012.09.001</pub-id><pub-id pub-id-type="pmid">22981895</pub-id></mixed-citation>
</ref>
<ref id="B347">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayoz</surname><given-names>S.</given-names></name><name><surname>Jia</surname><given-names>C.</given-names></name><name><surname>Hegg</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>Mechanisms of constitutive and ATP-evoked ATP release in neonatal mouse olfactory epithelium.</article-title>
<source/><italic>BMC Neurosci.</italic>
<volume>13</volume>:<issue>53</issue>
<pub-id pub-id-type="doi">10.1186/1471-2202-13-53</pub-id></mixed-citation>
</ref>
<ref id="B348">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Mazumder</surname><given-names>A.</given-names></name><name><surname>Wilder</surname><given-names>T.</given-names></name><name><surname>Cronstein</surname><given-names>B. N.</given-names></name></person-group> (<year>2012</year>). <article-title>Adenosine regulates bone metabolism via A<sub>1</sub>, A<sub>2A</sub> and A<sub>2B</sub> receptors in bone marrow cells from normal humans and patients with multiple myeloma.</article-title>
<source/><italic>FASEB J.</italic>
<volume>27</volume>
<fpage>3446</fpage>–<lpage>3454</lpage>. <pub-id pub-id-type="doi">10.1096/fj.13-231233</pub-id></mixed-citation>
</ref>
<ref id="B349">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Headrick</surname><given-names>J. P.</given-names></name><name><surname>Ashton</surname><given-names>K. J.</given-names></name><name><surname>Rose’meyer</surname><given-names>R. B.</given-names></name><name><surname>Peart</surname><given-names>J. N.</given-names></name></person-group> (<year>2013</year>). <article-title>Cardiovascular adenosine receptors: expression, actions and interactions.</article-title>
<source/><italic>Pharmacol. Ther.</italic>
<volume>140</volume>
<fpage>92</fpage>–<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.06.002</pub-id><pub-id pub-id-type="pmid">23764371</pub-id></mixed-citation>
</ref>
<ref id="B350">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>G.</given-names></name><name><surname>Buchanan</surname><given-names>P.</given-names></name><name><surname>Perriere</surname><given-names>M.</given-names></name><name><surname>Al-Alawi</surname><given-names>M.</given-names></name><name><surname>Costello</surname><given-names>R. W.</given-names></name><name><surname>Verriere</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis.</article-title>
<source/><italic>Am. J. Respir. Cell Mol. Biol.</italic>
<volume>51</volume>
<fpage>178</fpage>–<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2012-0424OC</pub-id><pub-id pub-id-type="pmid">24588705</pub-id></mixed-citation>
</ref>
<ref id="B351">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>M. F.</given-names></name><name><surname>Low</surname><given-names>L. M.</given-names></name><name><surname>Rose’meyer</surname><given-names>R. B.</given-names></name></person-group> (<year>2016</year>). <article-title>Pharmacology of the adenosine A3 receptor in the vasculature and essential hypertension.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>11</volume>:<issue>e0150021</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0150021</pub-id></mixed-citation>
</ref>
<ref id="B352">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>T.</given-names></name><name><surname>Aplin</surname><given-names>F. P.</given-names></name><name><surname>Jobling</surname><given-names>A. I.</given-names></name><name><surname>Phipps</surname><given-names>J. A.</given-names></name><name><surname>De Iongh</surname><given-names>R. U.</given-names></name><name><surname>Greferath</surname><given-names>U.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Localization and possible function of P2X receptors in normal and diseased retinae.</article-title>
<source/><italic>J Ocul. Pharmacol. Ther.</italic>
<volume>32</volume>
<fpage>509</fpage>–<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1089/jop.2015.0158</pub-id><pub-id pub-id-type="pmid">27266716</pub-id></mixed-citation>
</ref>
<ref id="B353">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoegl</surname><given-names>S.</given-names></name><name><surname>Brodsky</surname><given-names>K. S.</given-names></name><name><surname>Blackburn</surname><given-names>M. R.</given-names></name><name><surname>Karmouty-Quintana</surname><given-names>H.</given-names></name><name><surname>Zwissler</surname><given-names>B.</given-names></name><name><surname>Eltzschig</surname><given-names>H. K.</given-names></name></person-group> (<year>2015</year>). <article-title>Alveolar epithelial A2B adenosine receptors in pulmonary protection during acute lung injury.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>195</volume>
<fpage>1815</fpage>–<lpage>1824</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1401957</pub-id><pub-id pub-id-type="pmid">26188061</pub-id></mixed-citation>
</ref>
<ref id="B354">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofer</surname><given-names>M.</given-names></name><name><surname>Pospisil</surname><given-names>M.</given-names></name><name><surname>Dusek</surname><given-names>L.</given-names></name><name><surname>Hoferova</surname><given-names>Z.</given-names></name><name><surname>Weiterova</surname><given-names>L.</given-names></name><name><surname>Komurkova</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>Erythropoiesis- and thrombopoiesis-characterizing parameters in adenosine A3 receptor knock-out mice.</article-title>
<source/><italic>Physiol. Res.</italic>
<volume>62</volume>
<fpage>305</fpage>–<lpage>311</lpage>.<pub-id pub-id-type="pmid">23489188</pub-id></mixed-citation>
</ref>
<ref id="B355">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofman</surname><given-names>P.</given-names></name><name><surname>Cherfils-Vicini</surname><given-names>J.</given-names></name><name><surname>Bazin</surname><given-names>M.</given-names></name><name><surname>Ilie</surname><given-names>M.</given-names></name><name><surname>Juhel</surname><given-names>T.</given-names></name><name><surname>Hébuterne</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer.</article-title>
<source/><italic>Cancer Res.</italic>
<volume>75</volume>
<fpage>835</fpage>–<lpage>845</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1778</pub-id><pub-id pub-id-type="pmid">25564520</pub-id></mixed-citation>
</ref>
<ref id="B356">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname><given-names>S. C.</given-names></name><name><surname>Valomon</surname><given-names>A.</given-names></name><name><surname>Landolt</surname><given-names>H. P.</given-names></name></person-group> (<year>2016</year>). <article-title>Sleep pharmacogenetics: personalized sleep-wake therapy.</article-title>
<source/><italic>Annu. Rev. Pharmacol. Toxicol.</italic>
<volume>56</volume>
<fpage>577</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010715-103801</pub-id><pub-id pub-id-type="pmid">26527070</pub-id></mixed-citation>
</ref>
<ref id="B357">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>J. S.</given-names></name><name><surname>Hadley</surname><given-names>S. H.</given-names></name><name><surname>Morris</surname><given-names>K. F.</given-names></name><name><surname>Breslin</surname><given-names>J. W.</given-names></name><name><surname>Dean</surname><given-names>J. B.</given-names></name><name><surname>Taylor-Clark</surname><given-names>T. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Characterization of cardiovascular reflexes evoked by airway stimulation with allylisothiocyanate, capsaicin, and ATP in Sprague-Dawley rats.</article-title>
<source/><italic>J. Appl. Physiol.</italic>
<volume>120</volume>
<fpage>580</fpage>–<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1152/japplphysiol.00944.2015</pub-id><pub-id pub-id-type="pmid">26718787</pub-id></mixed-citation>
</ref>
<ref id="B358">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoque</surname><given-names>R.</given-names></name><name><surname>Sohail</surname><given-names>M. A.</given-names></name><name><surname>Salhanick</surname><given-names>S.</given-names></name><name><surname>Malik</surname><given-names>A. F.</given-names></name><name><surname>Ghani</surname><given-names>A.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice.</article-title>
<source/><italic>Am. J. Physiol. Gastrointest. Liver Physiol.</italic>
<volume>302</volume>
<fpage>G1171</fpage>–<lpage>G1179</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.00352.2011</pub-id><pub-id pub-id-type="pmid">22383490</pub-id></mixed-citation>
</ref>
<ref id="B359">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horckmans</surname><given-names>M.</given-names></name><name><surname>Esfahani</surname><given-names>H.</given-names></name><name><surname>Beauloye</surname><given-names>C.</given-names></name><name><surname>Clouet</surname><given-names>S.</given-names></name><name><surname>Di Pietrantonio</surname><given-names>L.</given-names></name><name><surname>Robaye</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Loss of mouse P2Y4 nucleotide receptor protects against myocardial infarction through endothelin-1 downregulation.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>194</volume>
<fpage>1874</fpage>–<lpage>1881</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1401364</pub-id><pub-id pub-id-type="pmid">25595790</pub-id></mixed-citation>
</ref>
<ref id="B360">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houchi</surname><given-names>H.</given-names></name><name><surname>Persyn</surname><given-names>W.</given-names></name><name><surname>Legastelois</surname><given-names>R.</given-names></name><name><surname>Naassila</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>The adenosine A2A receptor agonist CGS 21680 decreases ethanol self-administration in both non-dependent and dependent animals.</article-title>
<source/><italic>Addict. Biol.</italic>
<volume>18</volume>
<fpage>812</fpage>–<lpage>825</lpage>. <pub-id pub-id-type="doi">10.1111/adb.12032</pub-id><pub-id pub-id-type="pmid">23301633</pub-id></mixed-citation>
</ref>
<ref id="B361">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Housley</surname><given-names>G. D.</given-names></name><name><surname>Bringmann</surname><given-names>A.</given-names></name><name><surname>Reichenbach</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Purinergic signaling in special senses.</article-title>
<source/><italic>Trends Neurosci.</italic>
<volume>32</volume>
<fpage>128</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2009.01.001</pub-id><pub-id pub-id-type="pmid">19232752</pub-id></mixed-citation>
</ref>
<ref id="B362">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howarth</surname><given-names>A. R.</given-names></name><name><surname>Conway</surname><given-names>B. R.</given-names></name><name><surname>Bailey</surname><given-names>M. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Vascular and inflammatory actions of P2X receptors in renal injury.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>191</volume>
<fpage>135</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2015.05.001</pub-id><pub-id pub-id-type="pmid">25998687</pub-id></mixed-citation>
</ref>
<ref id="B363">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>F.</given-names></name><name><surname>Hui</surname><given-names>Z.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Hypotonic stress promotes ATP release, reactive oxygen species production and cell proliferation via TRPV4 activation in rheumatoid arthritis rat synovial fibroblasts.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>486</volume>
<fpage>108</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2017.03.008</pub-id><pub-id pub-id-type="pmid">28274876</pub-id></mixed-citation>
</ref>
<ref id="B364">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>Blocking of the P2X7 receptor inhibits the activation of the MMP-13 and NF-κB pathways in the cartilage tissue of rats with osteoarthritis.</article-title>
<source/><italic>Int. J. Mol. Med.</italic>
<volume>38</volume>
<fpage>1922</fpage>–<lpage>1932</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2016.2770</pub-id><pub-id pub-id-type="pmid">27748894</pub-id></mixed-citation>
</ref>
<ref id="B365">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Cui</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>P.</given-names></name><name><surname>Wei</surname><given-names>C.</given-names></name><name><surname>Hao</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Protein profiling of bladder urothelial cell carcinoma.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>11</volume>:<issue>e0161922</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0161922</pub-id></mixed-citation>
</ref>
<ref id="B366">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>S. J.</given-names></name><name><surname>Calippe</surname><given-names>B.</given-names></name><name><surname>Lavalette</surname><given-names>S.</given-names></name><name><surname>Roubeix</surname><given-names>C.</given-names></name><name><surname>Montassar</surname><given-names>F.</given-names></name><name><surname>Housset</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Upregulation of P2RX7 in Cx3cr1-deficient mononuclear phagocytes leads to increased interleukin-1β secretion and photoreceptor neurodegeneration.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>35</volume>
<fpage>6987</fpage>–<lpage>6996</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3955-14.2015</pub-id><pub-id pub-id-type="pmid">25948251</pub-id></mixed-citation>
</ref>
<ref id="B367">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Liou</surname><given-names>A. K.</given-names></name><name><surname>Leak</surname><given-names>R. K.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>An</surname><given-names>C.</given-names></name><name><surname>Suenaga</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles.</article-title>
<source/><italic>Prog. Neurobiol.</italic>
<volume>11</volume>
<fpage>60</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2014.06.002</pub-id></mixed-citation>
</ref>
<ref id="B368">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>X.</given-names></name><name><surname>Naselsky</surname><given-names>W. C.</given-names></name><name><surname>Bennett</surname><given-names>W. D.</given-names></name><name><surname>Ledent</surname><given-names>C.</given-names></name><name><surname>Senior</surname><given-names>B. A.</given-names></name><name><surname>Tilley</surname><given-names>S. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Adenosine increases nasal mucociliary clearance rate in mice through A2A and A2B adenosine receptors.</article-title>
<source/><italic>Laryngoscope</italic>
<volume>123</volume>
<fpage>306</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1002/lary.23586</pub-id><pub-id pub-id-type="pmid">22965898</pub-id></mixed-citation>
</ref>
<ref id="B369">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Ouyang</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>H. T.</given-names></name></person-group> (<year>2016</year>). <article-title>Coupling switch of P2Y-IP3 receptors mediates differential Ca<sup>2+</sup> signaling in human embryonic stem cells and derived cardiovascular progenitor cells.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>465</fpage>–<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9512-9</pub-id><pub-id pub-id-type="pmid">27098757</pub-id></mixed-citation>
</ref>
<ref id="B370">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T. C.</given-names></name><name><surname>Chang</surname><given-names>H. Y.</given-names></name><name><surname>Hsu</surname><given-names>C. H.</given-names></name><name><surname>Kuo</surname><given-names>W. H.</given-names></name><name><surname>Chang</surname><given-names>K. J.</given-names></name><name><surname>Juan</surname><given-names>H. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B.</article-title>
<source/><italic>J. Proteome Res.</italic>
<volume>7</volume>
<fpage>1433</fpage>–<lpage>1444</lpage>. <pub-id pub-id-type="doi">10.1021/pr700742h</pub-id><pub-id pub-id-type="pmid">18275135</pub-id></mixed-citation>
</ref>
<ref id="B371">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z. L.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Bai</surname><given-names>X. Y.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>J. K.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Protective effects of the novel adenosine derivative WS0701 in a mouse model of posttraumatic stress disorder.</article-title>
<source/><italic>Acta Pharmacol. Sin.</italic>
<volume>35</volume>
<fpage>24</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2013.143</pub-id><pub-id pub-id-type="pmid">24335837</pub-id></mixed-citation>
</ref>
<ref id="B372">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>S. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Purinoceptor signaling in malaria-infected erythrocytes.</article-title>
<source/><italic>Microbes Infect.</italic>
<volume>14</volume>
<fpage>779</fpage>–<lpage>786</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2012.04.009</pub-id><pub-id pub-id-type="pmid">22580091</pub-id></mixed-citation>
</ref>
<ref id="B373">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huete</surname><given-names>F.</given-names></name><name><surname>Guzmán-Aránguez</surname><given-names>A.</given-names></name><name><surname>Ortin</surname><given-names>J.</given-names></name><name><surname>Hoyle</surname><given-names>C. H.</given-names></name><name><surname>Pintor</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Effects of diadenosine tetraphosphate on FGF9-induced chloride flux changes in achondroplastic chondrocytes.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>7</volume>
<fpage>243</fpage>–<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-011-9234-y</pub-id><pub-id pub-id-type="pmid">21559786</pub-id></mixed-citation>
</ref>
<ref id="B374">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hullugundi</surname><given-names>S. K.</given-names></name><name><surname>Ansuini</surname><given-names>A.</given-names></name><name><surname>Ferrari</surname><given-names>M. D.</given-names></name><name><surname>Van Den Maagdenberg</surname><given-names>A. M.</given-names></name><name><surname>Nistri</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>A hyperexcitability phenotype in mouse trigeminal sensory neurons expressing the R192Q Cacna1a missense mutation of familial hemiplegic migraine type-1.</article-title>
<source/><italic>Neuroscience</italic>
<volume>266</volume>
<fpage>244</fpage>–<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.02.020</pub-id><pub-id pub-id-type="pmid">24583041</pub-id></mixed-citation>
</ref>
<ref id="B375">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hupertan</surname><given-names>V.</given-names></name><name><surname>Neuzillet</surname><given-names>Y.</given-names></name><name><surname>Stücker</surname><given-names>O.</given-names></name><name><surname>Pons</surname><given-names>C.</given-names></name><name><surname>Leammel</surname><given-names>E.</given-names></name><name><surname>Lebret</surname><given-names>T.</given-names></name></person-group> (<year>2012</year>). <article-title>Effects of nucleotides adenosine monophosphate and adenosine triphosphate in combination with L-arginine on male rabbit corpus cavernosum tissue.</article-title>
<source/><italic>Int. J. Androl.</italic>
<volume>35</volume>
<fpage>860</fpage>–<lpage>866</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2605.2012.01290.x</pub-id><pub-id pub-id-type="pmid">22709341</pub-id></mixed-citation>
</ref>
<ref id="B376">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hur</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>N. K.</given-names></name><name><surname>Kim</surname><given-names>H. G.</given-names></name><name><surname>Min</surname><given-names>B. S.</given-names></name><name><surname>Lee</surname><given-names>K. Y.</given-names></name><name><surname>Shin</surname><given-names>S. J.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis.</article-title>
<source/><italic>Br. J. Cancer</italic>
<volume>106</volume>
<fpage>53</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2011.469</pub-id><pub-id pub-id-type="pmid">22068817</pub-id></mixed-citation>
</ref>
<ref id="B377">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurtado-Alvarado</surname><given-names>G.</given-names></name><name><surname>Domínguez-Salazar</surname><given-names>E.</given-names></name><name><surname>Velázquez-Moctezuma</surname><given-names>J.</given-names></name><name><surname>Gómez-González</surname><given-names>B.</given-names></name></person-group> (<year>2016</year>). <article-title>A2A adenosine receptor antagonism reverts the blood-brain barrier dysfunction induced by sleep restriction.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>11</volume>:<issue>e0167236</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0167236</pub-id></mixed-citation>
</ref>
<ref id="B378">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husted</surname><given-names>L. B.</given-names></name><name><surname>Harsløf</surname><given-names>T.</given-names></name><name><surname>Stenkjær</surname><given-names>L.</given-names></name><name><surname>Carstens</surname><given-names>M.</given-names></name><name><surname>Jørgensen</surname><given-names>N. R.</given-names></name><name><surname>Langdahl</surname><given-names>B. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Functional polymorphisms in the P2X7 receptor gene are associated with osteoporosis.</article-title>
<source/><italic>Osteoporos. Int.</italic>
<volume>24</volume>
<fpage>949</fpage>–<lpage>959</lpage>. <pub-id pub-id-type="doi">10.1007/s00198-012-2035-5</pub-id><pub-id pub-id-type="pmid">22707062</pub-id></mixed-citation>
</ref>
<ref id="B379">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Iba</surname><given-names>K.</given-names></name><name><surname>Yamashita</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>“Osteoclast-mediated pain in osteoporosis,” in</article-title>
<source/><italic>Osteoporosis in Orthopedics: Assessment and Therapeutic Options</italic>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Shimada</surname><given-names>Y.</given-names></name><name><surname>Miyakoshi</surname><given-names>N.</given-names></name></person-group> (<publisher-loc>Tokyo</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>23</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1007/978-4-431-55778-4_2</pub-id></mixed-citation>
</ref>
<ref id="B380">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>A. S.</given-names></name><name><surname>El-Shishtawy</surname><given-names>M. M.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Caldwell</surname><given-names>R. B.</given-names></name><name><surname>Liou</surname><given-names>G. I.</given-names></name></person-group> (<year>2011</year>). <article-title>A2A adenosine receptor (A2AAR) as a therapeutic target in diabetic retinopathy.</article-title>
<source/><italic>Am. J. Pathol.</italic>
<volume>178</volume>
<fpage>2136</fpage>–<lpage>2145</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.01.018</pub-id><pub-id pub-id-type="pmid">21514428</pub-id></mixed-citation>
</ref>
<ref id="B381">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>N.</given-names></name><name><surname>Murata</surname><given-names>S.</given-names></name><name><surname>Maruyama</surname><given-names>T.</given-names></name><name><surname>Tamura</surname><given-names>T.</given-names></name><name><surname>Nozaki</surname><given-names>R.</given-names></name><name><surname>Kawasaki</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Platelet-derived adenosine 5′-triphosphate suppresses activation of human hepatic stellate cell: in vitro study.</article-title>
<source/><italic>Hepatol. Res.</italic>
<volume>42</volume>
<fpage>91</fpage>–<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1111/j.1872-034X.2011.00893.x</pub-id><pub-id pub-id-type="pmid">21988364</pub-id></mixed-citation>
</ref>
<ref id="B382">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>Y.</given-names></name><name><surname>Zabbarova</surname><given-names>I. V.</given-names></name><name><surname>Birder</surname><given-names>L. A.</given-names></name><name><surname>De Groat</surname><given-names>W. C.</given-names></name><name><surname>Mccarthy</surname><given-names>C. J.</given-names></name><name><surname>Hanna-Mitchell</surname><given-names>A. T.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder.</article-title>
<source/><italic>Eur. Urol.</italic>
<volume>62</volume>
<fpage>1157</fpage>–<lpage>1164</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2012.03.031</pub-id><pub-id pub-id-type="pmid">22480459</pub-id></mixed-citation>
</ref>
<ref id="B383">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilatovskaya</surname><given-names>D. V.</given-names></name><name><surname>Palygin</surname><given-names>O.</given-names></name><name><surname>Staruschenko</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Functional and therapeutic importance of purinergic signaling in polycystic kidney disease.</article-title>
<source/><italic>Am. J. Physiol. Renal Physiol.</italic>
<volume>311</volume>
<fpage>F1135</fpage>–<lpage>F1139</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00406.2016</pub-id><pub-id pub-id-type="pmid">27654892</pub-id></mixed-citation>
</ref>
<ref id="B384">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illes</surname><given-names>P.</given-names></name><name><surname>Rubini</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Regulation of neural stem/progenitor cell functions by P2X and P2Y receptors.</article-title>
<source/><italic>Neural Regen. Res.</italic>
<volume>12</volume>
<fpage>395</fpage>–<lpage>396</lpage>. <pub-id pub-id-type="doi">10.4103/1673-5374.202937</pub-id><pub-id pub-id-type="pmid">28469648</pub-id></mixed-citation>
</ref>
<ref id="B385">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illes</surname><given-names>P.</given-names></name><name><surname>Verkhratsky</surname><given-names>A.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Sperlagh</surname><given-names>B.</given-names></name></person-group> (<year>2016</year>). <article-title>Purines in neurodegeneration and neuroregeneration.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>1</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.01.020</pub-id><pub-id pub-id-type="pmid">26775822</pub-id></mixed-citation>
</ref>
<ref id="B386">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imarisio</surname><given-names>C.</given-names></name><name><surname>Alchera</surname><given-names>E.</given-names></name><name><surname>Sutti</surname><given-names>S.</given-names></name><name><surname>Valente</surname><given-names>G.</given-names></name><name><surname>Boccafoschi</surname><given-names>F.</given-names></name><name><surname>Albano</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Adenosine A<sub>2A</sub> receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats.</article-title>
<source/><italic>Clin. Sci.</italic>
<volume>123</volume>
<fpage>323</fpage>–<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1042/CS20110504</pub-id><pub-id pub-id-type="pmid">22439844</pub-id></mixed-citation>
</ref>
<ref id="B387">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingwersen</surname><given-names>J.</given-names></name><name><surname>Wingerath</surname><given-names>B.</given-names></name><name><surname>Graf</surname><given-names>J.</given-names></name><name><surname>Lepka</surname><given-names>K.</given-names></name><name><surname>Hofrichter</surname><given-names>M.</given-names></name><name><surname>Schröter</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.</article-title>
<source/><italic>J. Neuroinflammation</italic>
<volume>13</volume>
<issue>48</issue>
<pub-id pub-id-type="doi">10.1186/s12974-016-0512-z</pub-id></mixed-citation>
</ref>
<ref id="B388">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Yoshimura</surname><given-names>K.</given-names></name><name><surname>Kurabe</surname><given-names>N.</given-names></name><name><surname>Kahyo</surname><given-names>T.</given-names></name><name><surname>Kawase</surname><given-names>A.</given-names></name><name><surname>Tanahashi</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.</article-title>
<source/><italic>Oncotarget</italic>
<volume>8</volume>
<fpage>8738</fpage>–<lpage>8751</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.14434</pub-id><pub-id pub-id-type="pmid">28060732</pub-id></mixed-citation>
</ref>
<ref id="B389">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iriyama</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>K.</given-names></name><name><surname>Parchim</surname><given-names>N. F.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Song</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia.</article-title>
<source/><italic>Circulation</italic>
<volume>131</volume>
<fpage>730</fpage>–<lpage>741</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.013740</pub-id><pub-id pub-id-type="pmid">25538227</pub-id></mixed-citation>
</ref>
<ref id="B390">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>T.</given-names></name><name><surname>Miyagi</surname><given-names>M.</given-names></name><name><surname>Ohtori</surname><given-names>S.</given-names></name><name><surname>Aoki</surname><given-names>Y.</given-names></name><name><surname>Ozawa</surname><given-names>T.</given-names></name><name><surname>Doya</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Characteristics of sensory DRG neurons innervating the lumbar facet joints in rats.</article-title>
<source/><italic>Eur. Spine J.</italic>
<volume>14</volume>
<fpage>559</fpage>–<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1007/s00586-004-0834-x</pub-id><pub-id pub-id-type="pmid">15690212</pub-id></mixed-citation>
</ref>
<ref id="B391">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimaru</surname><given-names>M.</given-names></name><name><surname>Tsukimoto</surname><given-names>M.</given-names></name><name><surname>Harada</surname><given-names>H.</given-names></name><name><surname>Kojima</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Involvement of P2Y11 receptor in IFN-γ-induced IL-6 production in human keratinocytes.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>703</volume>
<fpage>67</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2013.02.020</pub-id><pub-id pub-id-type="pmid">23461851</pub-id></mixed-citation>
</ref>
<ref id="B392">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iskandarov</surname><given-names>E.</given-names></name><name><surname>Kadaba Srinivasan</surname><given-names>P.</given-names></name><name><surname>Xin</surname><given-names>W.</given-names></name><name><surname>Bleilevens</surname><given-names>C.</given-names></name><name><surname>Afify</surname><given-names>M.</given-names></name><name><surname>Hamza</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Protective effects of adenosine receptor agonist in a cirrhotic liver resection model.</article-title>
<source/><italic>Hepat. Mon.</italic>
<volume>16</volume>:<issue>e36821</issue>
<pub-id pub-id-type="doi">10.5812/hepatmon.36821</pub-id></mixed-citation>
</ref>
<ref id="B393">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata</surname><given-names>M.</given-names></name><name><surname>Ota</surname><given-names>K. T.</given-names></name><name><surname>Li</surname><given-names>X. Y.</given-names></name><name><surname>Sakaue</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Dutheil</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>80</volume>
<fpage>12</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.11.026</pub-id><pub-id pub-id-type="pmid">26831917</pub-id></mixed-citation>
</ref>
<ref id="B394">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>F.</given-names></name><name><surname>Novo</surname><given-names>C. P.</given-names></name><name><surname>Bachert</surname><given-names>C.</given-names></name><name><surname>Crombruggen</surname><given-names>K.</given-names></name></person-group> (<year>2013</year>). <article-title>Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>9</volume>
<fpage>285</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9357-4</pub-id><pub-id pub-id-type="pmid">23404828</pub-id></mixed-citation>
</ref>
<ref id="B395">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>B.</given-names></name><name><surname>Dussor</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Neurovascular contributions to migraine: moving beyond vasodilation.</article-title>
<source/><italic>Neuroscience</italic>
<volume>338</volume>
<fpage>130</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.06.012</pub-id><pub-id pub-id-type="pmid">27312704</pub-id></mixed-citation>
</ref>
<ref id="B396">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>K. A.</given-names></name><name><surname>Muller</surname><given-names>C. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Medicinal chemistry of adenosine, P2Y and P2X receptors.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>31</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.12.001</pub-id><pub-id pub-id-type="pmid">26686393</pub-id></mixed-citation>
</ref>
<ref id="B397">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jajoo</surname><given-names>S.</given-names></name><name><surname>Mukherjea</surname><given-names>D.</given-names></name><name><surname>Watabe</surname><given-names>K.</given-names></name><name><surname>Ramkumar</surname><given-names>V.</given-names></name></person-group> (<year>2009</year>). <article-title>Adenosine A3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity.</article-title>
<source/><italic>Neoplasia</italic>
<volume>11</volume>
<fpage>1132</fpage>–<lpage>1145</lpage>. <pub-id pub-id-type="doi">10.1593/neo.09744</pub-id><pub-id pub-id-type="pmid">19881949</pub-id></mixed-citation>
</ref>
<ref id="B398">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalkanen</surname><given-names>J.</given-names></name><name><surname>Yegutkin</surname><given-names>G. G.</given-names></name><name><surname>Hollmén</surname><given-names>M.</given-names></name><name><surname>Aalto</surname><given-names>K.</given-names></name><name><surname>Kiviniemi</surname><given-names>T.</given-names></name><name><surname>Salomaa</surname><given-names>V.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis.</article-title>
<source/><italic>Circ. Res.</italic>
<volume>116</volume>
<fpage>1206</fpage>–<lpage>1215</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.305715</pub-id><pub-id pub-id-type="pmid">25645301</pub-id></mixed-citation>
</ref>
<ref id="B399">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jameel</surname><given-names>M. N.</given-names></name><name><surname>Xiong</surname><given-names>Q.</given-names></name><name><surname>Mansoor</surname><given-names>A.</given-names></name><name><surname>Bache</surname><given-names>R. J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>ATP sensitive K<sup>+</sup> channels are critical for maintaining myocardial perfusion and high energy phosphates in the failing heart.</article-title>
<source/><italic>J. Mol. Cell. Cardiol.</italic>
<volume>92</volume>
<fpage>116</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2016.02.005</pub-id><pub-id pub-id-type="pmid">26854629</pub-id></mixed-citation>
</ref>
<ref id="B400">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janes</surname><given-names>K.</given-names></name><name><surname>Symons-Liguori</surname><given-names>A. M.</given-names></name><name><surname>Jacobson</surname><given-names>K. A.</given-names></name><name><surname>Salvemini</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>173</volume>
<fpage>1253</fpage>–<lpage>1267</lpage>. <pub-id pub-id-type="doi">10.1111/bph.13446</pub-id><pub-id pub-id-type="pmid">26804983</pub-id></mixed-citation>
</ref>
<ref id="B401">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jared Bunch</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>One drug, two outcomes after atrial fibrillation ablation: the situational irony of adenosine.</article-title>
<source/><italic>Eur. Heart J.</italic>
<volume>36</volume>
<fpage>3288</fpage>–<lpage>3290</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehv473</pub-id><pub-id pub-id-type="pmid">26377401</pub-id></mixed-citation>
</ref>
<ref id="B402">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jastrzebska</surname><given-names>J.</given-names></name><name><surname>Nowak</surname><given-names>E.</given-names></name><name><surname>Smaga</surname><given-names>I.</given-names></name><name><surname>Bystrowska</surname><given-names>B.</given-names></name><name><surname>Frankowska</surname><given-names>M.</given-names></name><name><surname>Bader</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Adenosine A2A receptor modulation of nicotine-induced locomotor sensitization. A pharmacological and transgenic approach.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>81</volume>
<fpage>318</fpage>–<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.03.002</pub-id><pub-id pub-id-type="pmid">24632528</pub-id></mixed-citation>
</ref>
<ref id="B403">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jelassi</surname><given-names>B.</given-names></name><name><surname>Anchelin</surname><given-names>M.</given-names></name><name><surname>Chamouton</surname><given-names>J.</given-names></name><name><surname>Cayuela</surname><given-names>M. L.</given-names></name><name><surname>Clarysse</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors.</article-title>
<source/><italic>Carcinogenesis</italic>
<volume>34</volume>
<fpage>1487</fpage>–<lpage>1496</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgt099</pub-id><pub-id pub-id-type="pmid">23524196</pub-id></mixed-citation>
</ref>
<ref id="B404">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenner</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>An overview of adenosine A2A receptor antagonists in Parkinson’s disease.</article-title>
<source/><italic>Int. Rev. Neurobiol.</italic>
<volume>119</volume>
<fpage>71</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-801022-8.00003-9</pub-id><pub-id pub-id-type="pmid">25175961</pub-id></mixed-citation>
</ref>
<ref id="B405">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Shin</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>IL-1ra secreted by ATP-induced P2Y2 negatively regulates MUC5AC overproduction via PLCβ3 during airway inflammation.</article-title>
<source/><italic>Mediators Inflamm.</italic>
<volume>2016</volume>:<issue>7984853</issue>
<pub-id pub-id-type="doi">10.1155/2016/7984853</pub-id></mixed-citation>
</ref>
<ref id="B406">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>X.</given-names></name><name><surname>Naito</surname><given-names>Y.</given-names></name><name><surname>Hirokawa</surname><given-names>G.</given-names></name><name><surname>Weng</surname><given-names>H.</given-names></name><name><surname>Hiura</surname><given-names>Y.</given-names></name><name><surname>Takahashi</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>P2X7 receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats.</article-title>
<source/><italic>Hypertens. Res.</italic>
<volume>35</volume>
<fpage>173</fpage>–<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1038/hr.2011.153</pub-id><pub-id pub-id-type="pmid">21918525</pub-id></mixed-citation>
</ref>
<ref id="B407">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>C.</given-names></name><name><surname>Sangsiri</surname><given-names>S.</given-names></name><name><surname>Belock</surname><given-names>B.</given-names></name><name><surname>Iqbal</surname><given-names>T. R.</given-names></name><name><surname>Pestka</surname><given-names>J. J.</given-names></name><name><surname>Hegg</surname><given-names>C. C.</given-names></name></person-group> (<year>2011</year>). <article-title>ATP mediates neuroprotective and neuroproliferative effects in mouse olfactory epithelium following exposure to satratoxin G in vitro and in vivo.</article-title>
<source/><italic>Toxicol. Sci.</italic>
<volume>124</volume>
<fpage>169</fpage>–<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfr213</pub-id><pub-id pub-id-type="pmid">21865290</pub-id></mixed-citation>
</ref>
<ref id="B408">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>X.</given-names></name><name><surname>Naito</surname><given-names>H.</given-names></name><name><surname>Yetti</surname><given-names>H.</given-names></name><name><surname>Tamada</surname><given-names>H.</given-names></name><name><surname>Kitamori</surname><given-names>K.</given-names></name><name><surname>Hayashi</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>The modulation of hepatic adenosine triphosphate and inflammation by eicosapentaenoic acid during severe fibrotic progression in the SHRSP5/Dmcr rat model.</article-title>
<source/><italic>Life Sci.</italic>
<volume>90</volume>
<fpage>934</fpage>–<lpage>943</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2012.04.029</pub-id><pub-id pub-id-type="pmid">22569299</pub-id></mixed-citation>
</ref>
<ref id="B409">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jian</surname><given-names>R.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Zhong</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name></person-group> (<year>2012</year>). <article-title>CD73 protects kidney from ischemia-reperfusion injury through reduction of free radicals.</article-title>
<source/><italic>APMIS</italic>
<volume>120</volume>
<fpage>130</fpage>–<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0463.2011.02827.x</pub-id><pub-id pub-id-type="pmid">22229268</pub-id></mixed-citation>
</ref>
<ref id="B410">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>J. H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yao</surname><given-names>Y. L.</given-names></name><name><surname>Wu</surname><given-names>Y. L.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation.</article-title>
<source/><italic>Pharmacol. Res.</italic>
<volume>117</volume>
<fpage>82</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2016.11.040</pub-id><pub-id pub-id-type="pmid">27940204</pub-id></mixed-citation>
</ref>
<ref id="B411">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiménez</surname><given-names>M.</given-names></name><name><surname>Clavé</surname><given-names>P.</given-names></name><name><surname>Accarino</surname><given-names>A.</given-names></name><name><surname>Gallego</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Purinergic neuromuscular transmission in the gastrointestinal tract; functional basis for future clinical and pharmacological studies.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>171</volume>
<fpage>4360</fpage>–<lpage>4375</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12802</pub-id><pub-id pub-id-type="pmid">24910216</pub-id></mixed-citation>
</ref>
<ref id="B412">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiménez</surname><given-names>M.</given-names></name><name><surname>De Diego</surname><given-names>M.</given-names></name><name><surname>Martínez-Cutillas</surname><given-names>M.</given-names></name><name><surname>Mañé Reed</surname><given-names>N.</given-names></name><name><surname>Gallego</surname><given-names>D.</given-names></name><name><surname>Ojanguren</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Purinergic and nitrergic inhibitory neuromuscular transmission in ganglionic, transitional and aganglionic segments from Hirschsprung’s disease patients.</article-title>
<source/><italic>Neurogastroenterol. Motil.</italic>
<volume>27</volume>
<issue>71</issue>.</mixed-citation>
</ref>
<ref id="B413">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Mateos</surname><given-names>E. M.</given-names></name><name><surname>Arribas-Blazquez</surname><given-names>M.</given-names></name><name><surname>Sanz-Rodriguez</surname><given-names>A.</given-names></name><name><surname>Concannon</surname><given-names>C.</given-names></name><name><surname>Olivos-Ore</surname><given-names>L. A.</given-names></name><name><surname>Reschke</surname><given-names>C. R.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>5</volume>:<issue>17486</issue>
<pub-id pub-id-type="doi">10.1038/srep17486</pub-id></mixed-citation>
</ref>
<ref id="B414">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Analysis on mechanism of ATP-sensitive K<sup>+</sup> channel opener natakalim improving congestive heart failure after myocardial infarction.</article-title>
<source/><italic>Exp. Ther. Med.</italic>
<volume>12</volume>
<fpage>3993</fpage>–<lpage>3997</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2016.3853</pub-id><pub-id pub-id-type="pmid">28101177</pub-id></mixed-citation>
</ref>
<ref id="B415">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Seo</surname><given-names>J.</given-names></name><name><surname>Eun</surname><given-names>S. Y.</given-names></name><name><surname>Joo</surname><given-names>Y. N.</given-names></name><name><surname>Park</surname><given-names>S. W.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>P2Y2R activation by nucleotides promotes skin wound-healing process.</article-title>
<source/><italic>Exp. Dermatol.</italic>
<volume>23</volume>
<fpage>480</fpage>–<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1111/exd.12440</pub-id><pub-id pub-id-type="pmid">24816122</pub-id></mixed-citation>
</ref>
<ref id="B416">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Ren</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine kinase facilitated astrogliosis-induced cortical neuronal death in traumatic brain injury.</article-title>
<source/><italic>J. Mol. Histol.</italic>
<volume>47</volume>
<fpage>259</fpage>–<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1007/s10735-016-9670-7</pub-id><pub-id pub-id-type="pmid">26983602</pub-id></mixed-citation>
</ref>
<ref id="B417">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jörg</surname><given-names>M.</given-names></name><name><surname>Scammells</surname><given-names>P. J.</given-names></name><name><surname>Capuano</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>). <article-title>The dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson’s disease.</article-title>
<source/><italic>Curr. Med. Chem.</italic>
<volume>21</volume>
<fpage>3188</fpage>–<lpage>3210</lpage>. <pub-id pub-id-type="doi">10.2174/1389200215666140217110716</pub-id><pub-id pub-id-type="pmid">24533801</pub-id></mixed-citation>
</ref>
<ref id="B418">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jørgensen</surname><given-names>N. R.</given-names></name><name><surname>Boeynaems</surname><given-names>J. M.</given-names></name><name><surname>Di Virgilio</surname><given-names>F.</given-names></name></person-group> (<year>2011</year>). <article-title>European meeting “P2 receptors: new targets for the treatment of osteoporosis”.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>7</volume>
<fpage>275</fpage>–<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-011-9223-1</pub-id><pub-id pub-id-type="pmid">21484088</pub-id></mixed-citation>
</ref>
<ref id="B419">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jørgensen</surname><given-names>N. R.</given-names></name><name><surname>Grove</surname><given-names>E. L.</given-names></name><name><surname>Schwarz</surname><given-names>P.</given-names></name><name><surname>Vestergaard</surname><given-names>P.</given-names></name></person-group> (<year>2012</year>). <article-title>Clopidogrel and the risk of osteoporotic fractures: a nationwide cohort study.</article-title>
<source/><italic>J. Intern. Med.</italic>
<volume>272</volume>
<fpage>385</fpage>–<lpage>393</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2796.2012.02535.x</pub-id><pub-id pub-id-type="pmid">22372976</pub-id></mixed-citation>
</ref>
<ref id="B420">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jørgensen</surname><given-names>N. R.</given-names></name><name><surname>Syberg</surname><given-names>S.</given-names></name><name><surname>Ellegaard</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>The role of P2X receptors in bone biology.</article-title>
<source/><italic>Curr. Med. Chem.</italic>
<volume>22</volume>
<fpage>902</fpage>–<lpage>914</lpage>. <pub-id pub-id-type="doi">10.2174/0929867321666141215094749</pub-id><pub-id pub-id-type="pmid">25515517</pub-id></mixed-citation>
</ref>
<ref id="B421">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>E. K.</given-names></name><name><surname>Green</surname><given-names>P. G.</given-names></name><name><surname>Ferrari</surname><given-names>L. F.</given-names></name><name><surname>Levine</surname><given-names>J. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Homocysteine-induced attenuation of vascular endothelium-dependent hyperalgesia in the rat.</article-title>
<source/><italic>Neuroscience</italic>
<volume>284</volume>
<fpage>678</fpage>–<lpage>684</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.10.056</pub-id><pub-id pub-id-type="pmid">25451284</pub-id></mixed-citation>
</ref>
<ref id="B422">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junger</surname><given-names>W. G.</given-names></name></person-group> (<year>2011</year>). <article-title>Immune cell regulation by autocrine purinergic signalling.</article-title>
<source/><italic>Nat. Rev. Immunol.</italic>
<volume>11</volume>
<fpage>201</fpage>–<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1038/nri2938</pub-id><pub-id pub-id-type="pmid">21331080</pub-id></mixed-citation>
</ref>
<ref id="B423">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaan</surname><given-names>T. K.</given-names></name><name><surname>Yip</surname><given-names>P. K.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Davies</surname><given-names>M.</given-names></name><name><surname>Marchand</surname><given-names>F.</given-names></name><name><surname>Cockayne</surname><given-names>D. A.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats.</article-title>
<source/><italic>Brain</italic>
<volume>133</volume>
<fpage>2549</fpage>–<lpage>2564</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awq194</pub-id><pub-id pub-id-type="pmid">20802203</pub-id></mixed-citation>
</ref>
<ref id="B424">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Penk</surname><given-names>A.</given-names></name><name><surname>Franke</surname><given-names>H.</given-names></name><name><surname>Krügel</surname><given-names>U.</given-names></name><name><surname>Norenberg</surname><given-names>W.</given-names></name><name><surname>Huster</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Lack of functional P2X7 receptor aggravates brain edema development after middle cerebral artery occlusion.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>453</fpage>–<lpage>463</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9511-x</pub-id><pub-id pub-id-type="pmid">27048203</pub-id></mixed-citation>
</ref>
<ref id="B425">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>Y. H.</given-names></name><name><surname>Lin</surname><given-names>M. S.</given-names></name><name><surname>Chen</surname><given-names>C. M.</given-names></name><name><surname>Wu</surname><given-names>Y. R.</given-names></name><name><surname>Chen</surname><given-names>H. M.</given-names></name><name><surname>Lai</surname><given-names>H. L.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Targeting ENT1 and adenosine tone for the treatment of Huntington’s disease.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>26</volume>
<fpage>467</fpage>–<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddw402</pub-id><pub-id pub-id-type="pmid">28069792</pub-id></mixed-citation>
</ref>
<ref id="B426">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapila</surname><given-names>N.</given-names></name><name><surname>Higa</surname><given-names>J. T.</given-names></name><name><surname>Longhi</surname><given-names>M. S.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Autoimmune hepatitis: clinical review with insights into the purinergic mechanism of disease.</article-title>
<source/><italic>J. Clin. Transl. Hepatol.</italic>
<volume>1</volume>
<fpage>79</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.14218/JCTH.2013.00015</pub-id><pub-id pub-id-type="pmid">26356124</pub-id></mixed-citation>
</ref>
<ref id="B427">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karmakar</surname><given-names>M.</given-names></name><name><surname>Katsnelson</surname><given-names>M. A.</given-names></name><name><surname>Dubyak</surname><given-names>G. R.</given-names></name><name><surname>Pearlman</surname><given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP.</article-title>
<source/><italic>Nat. Commun.</italic>
<volume>7</volume>:<issue>10555</issue>
<pub-id pub-id-type="doi">10.1038/ncomms10555</pub-id></mixed-citation>
</ref>
<ref id="B428">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaster</surname><given-names>M. P.</given-names></name><name><surname>Machado</surname><given-names>N. J.</given-names></name><name><surname>Silva</surname><given-names>H. B.</given-names></name><name><surname>Nunes</surname><given-names>A.</given-names></name><name><surname>Ardais</surname><given-names>A. P.</given-names></name><name><surname>Santana</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A</italic>
<volume>112</volume>
<fpage>7833</fpage>–<lpage>7838</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1423088112</pub-id><pub-id pub-id-type="pmid">26056314</pub-id></mixed-citation>
</ref>
<ref id="B429">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>N. K.</given-names></name><name><surname>Ryals</surname><given-names>J. M.</given-names></name><name><surname>Wright</surname><given-names>D. E.</given-names></name></person-group> (<year>2015</year>). <article-title>Central or peripheral delivery of an adenosine A1 receptor agonist improves mechanical allodynia in a mouse model of painful diabetic neuropathy.</article-title>
<source/><italic>Neuroscience</italic>
<volume>285</volume>
<fpage>312</fpage>–<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.10.065</pub-id><pub-id pub-id-type="pmid">25451280</pub-id></mixed-citation>
</ref>
<ref id="B430">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavanagh</surname><given-names>K. A.</given-names></name><name><surname>Schreiner</surname><given-names>D. C.</given-names></name><name><surname>Levis</surname><given-names>S. C.</given-names></name><name><surname>O’neill</surname><given-names>C. E.</given-names></name><name><surname>Bachtell</surname><given-names>R. K.</given-names></name></person-group> (<year>2015</year>). <article-title>Role of adenosine receptor subtypes in methamphetamine reward and reinforcement.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>89</volume>
<fpage>265</fpage>–<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.09.030</pub-id><pub-id pub-id-type="pmid">25301277</pub-id></mixed-citation>
</ref>
<ref id="B431">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>Y.</given-names></name><name><surname>Kaidoh</surname><given-names>M.</given-names></name><name><surname>Ohhashi</surname><given-names>T.</given-names></name></person-group> (<year>2008</year>). <article-title>MDA-MB-231 produces ATP-mediated ICAM-1-dependent facilitation of the attachment of carcinoma cells to human lymphatic endothelial cells.</article-title>
<source/><italic>Am. J. Physiol. Cell Physiol.</italic>
<volume>295</volume>
<fpage>C1123</fpage>–<lpage>C1132.</lpage>
<pub-id pub-id-type="doi">10.1152/ajpcell.00247.2008</pub-id><pub-id pub-id-type="pmid">18768924</pub-id></mixed-citation>
</ref>
<ref id="B432">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>H.</given-names></name><name><surname>Aswad</surname><given-names>F.</given-names></name><name><surname>Minagawa</surname><given-names>M.</given-names></name><name><surname>Govindarajan</surname><given-names>S.</given-names></name><name><surname>Dennert</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>P2X7 receptors regulate NKT cells in autoimmune hepatitis.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>176</volume>
<fpage>2152</fpage>–<lpage>2160</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.176.4.2152</pub-id><pub-id pub-id-type="pmid">16455971</pub-id></mixed-citation>
</ref>
<ref id="B433">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Cui</surname><given-names>S.</given-names></name><name><surname>Ding</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>A2 adenosine receptor-mediated cardioprotection against reperfusion injury in rat hearts is associated with autophagy downregulation.</article-title>
<source/><italic>J. Cardiovasc. Pharmacol.</italic>
<volume>66</volume>
<fpage>25</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1097/FJC.0000000000000239</pub-id><pub-id pub-id-type="pmid">25706370</pub-id></mixed-citation>
</ref>
<ref id="B434">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keay</surname><given-names>S. K.</given-names></name><name><surname>Birder</surname><given-names>L. A.</given-names></name><name><surname>Chai</surname><given-names>T. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Evidence for bladder urothelial pathophysiology in functional bladder disorders.</article-title>
<source/><italic>Biomed Res. Int.</italic>
<volume>2014</volume>:<issue>865463</issue>
<pub-id pub-id-type="doi">10.1155/2014/865463</pub-id></mixed-citation>
</ref>
<ref id="B435">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehasse</surname><given-names>A.</given-names></name><name><surname>Rich</surname><given-names>C. B.</given-names></name><name><surname>Lee</surname><given-names>A.</given-names></name><name><surname>Mccomb</surname><given-names>M. E.</given-names></name><name><surname>Costello</surname><given-names>C. E.</given-names></name><name><surname>Trinkaus-Randall</surname><given-names>V.</given-names></name></person-group> (<year>2013</year>). <article-title>Epithelial wounds induce differential phosphorylation changes in response to purinergic and EGF receptor activation.</article-title>
<source/><italic>Am. J. Pathol.</italic>
<volume>183</volume>
<fpage>1841</fpage>–<lpage>1852</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2013.08.015</pub-id><pub-id pub-id-type="pmid">24095926</pub-id></mixed-citation>
</ref>
<ref id="B436">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keystone</surname><given-names>E. C.</given-names></name><name><surname>Wang</surname><given-names>M. M.</given-names></name><name><surname>Layton</surname><given-names>M.</given-names></name><name><surname>Hollis</surname><given-names>S.</given-names></name><name><surname>Mcinnes</surname><given-names>I. B.</given-names></name></person-group> (<year>2012</year>). <article-title>Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine.</article-title>
<source/><italic>Ann. Rheum. Dis.</italic>
<volume>71</volume>
<fpage>1630</fpage>–<lpage>1635</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2011-143578</pub-id><pub-id pub-id-type="pmid">22966146</pub-id></mixed-citation>
</ref>
<ref id="B437">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalid</surname><given-names>M.</given-names></name><name><surname>Brisson</surname><given-names>L.</given-names></name><name><surname>Tariq</surname><given-names>M.</given-names></name><name><surname>Hao</surname><given-names>Y.</given-names></name><name><surname>Guibon</surname><given-names>R.</given-names></name><name><surname>Fromont</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells.</article-title>
<source/><italic>Oncotarget</italic>
<volume>8</volume>
<fpage>37278</fpage>–<lpage>37290</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.16191</pub-id><pub-id pub-id-type="pmid">28418839</pub-id></mixed-citation>
</ref>
<ref id="B438">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoja</surname><given-names>S.</given-names></name><name><surname>Shah</surname><given-names>V.</given-names></name><name><surname>Garcia</surname><given-names>D.</given-names></name><name><surname>Asatryan</surname><given-names>L.</given-names></name><name><surname>Jakowec</surname><given-names>M. W.</given-names></name><name><surname>Davies</surname><given-names>D. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>139</volume>
<fpage>134</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13734</pub-id><pub-id pub-id-type="pmid">27402173</pub-id></mixed-citation>
</ref>
<ref id="B439">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilinc</surname><given-names>E.</given-names></name><name><surname>Koroleva</surname><given-names>K.</given-names></name><name><surname>Guerrero Toro</surname><given-names>C.</given-names></name><name><surname>Töre</surname><given-names>F.</given-names></name><name><surname>Giniatullin</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>The role of adenosine triphosphate and its receptors in migraine pathophysiology.</article-title>
<source/><italic>Acta Physiol.</italic>
<volume>215</volume>
<issue>44</issue>.</mixed-citation>
</ref>
<ref id="B440">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killeen</surname><given-names>M. E.</given-names></name><name><surname>Ferris</surname><given-names>L.</given-names></name><name><surname>Kupetsky</surname><given-names>E. A.</given-names></name><name><surname>Falo</surname><given-names>L.</given-names><suffix>Jr.</suffix></name><name><surname>Mathers</surname><given-names>A. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>190</volume>
<fpage>4324</fpage>–<lpage>4336</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1202045</pub-id><pub-id pub-id-type="pmid">23479230</pub-id></mixed-citation>
</ref>
<ref id="B441">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Walsh</surname><given-names>M. C.</given-names></name><name><surname>Takegahara</surname><given-names>N.</given-names></name><name><surname>Middleton</surname><given-names>S. A.</given-names></name><name><surname>Shin</surname><given-names>H. I.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>The purinergic receptor P2X5 regulates inflammasome activity and hyper-multinucleation of murine osteoclasts.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>7</volume>
<issue>196</issue>
<pub-id pub-id-type="doi">10.1038/s41598-017-00139-2</pub-id></mixed-citation>
</ref>
<ref id="B442">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M. J.</given-names></name><name><surname>Turner</surname><given-names>C. M.</given-names></name><name><surname>Hewitt</surname><given-names>R.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name><name><surname>Bhangal</surname><given-names>G.</given-names></name><name><surname>Pusey</surname><given-names>C. D.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Exaggerated renal fibrosis in P2X4 receptor-deficient mice following unilateral ureteric obstruction.</article-title>
<source/><italic>Nephrol. Dial. Transplant.</italic>
<volume>29</volume>
<fpage>1350</fpage>–<lpage>1361</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/gfu019</pub-id><pub-id pub-id-type="pmid">24574541</pub-id></mixed-citation>
</ref>
<ref id="B443">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimbler</surname><given-names>D. E.</given-names></name><name><surname>Shields</surname><given-names>J.</given-names></name><name><surname>Yanasak</surname><given-names>N.</given-names></name><name><surname>Vender</surname><given-names>J. R.</given-names></name><name><surname>Dhandapani</surname><given-names>K. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Activation of P2X7 promotes cerebral edema and neurological injury after traumatic brain injury in mice.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>7</volume>:<issue>e41229</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0041229</pub-id></mixed-citation>
</ref>
<ref id="B444">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinnamon</surname><given-names>S. C.</given-names></name><name><surname>Finger</surname><given-names>T. E.</given-names></name></person-group> (<year>2013</year>). <article-title>A taste for ATP: neurotransmission in taste buds.</article-title>
<source/><italic>Front. Cell Neurosci.</italic>
<volume>7</volume>:<issue>264</issue>
<pub-id pub-id-type="doi">10.3389/fncel.2013.00264</pub-id></mixed-citation>
</ref>
<ref id="B445">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kira</surname><given-names>S.</given-names></name><name><surname>Yoshiyama</surname><given-names>M.</given-names></name><name><surname>Tsuchiya</surname><given-names>S.</given-names></name><name><surname>Shigetomi</surname><given-names>E.</given-names></name><name><surname>Miyamoto</surname><given-names>T.</given-names></name><name><surname>Nakagomi</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>P2Y6-deficiency increases micturition frequency and attenuates sustained contractility of the urinary bladder in mice.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>7</volume>
<issue>771</issue>
<pub-id pub-id-type="doi">10.1038/s41598-017-00824-2</pub-id></mixed-citation>
</ref>
<ref id="B446">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishore</surname><given-names>B. K.</given-names></name><name><surname>Carlson</surname><given-names>N. G.</given-names></name><name><surname>Ecelbarger</surname><given-names>C. M.</given-names></name><name><surname>Kohan</surname><given-names>D. E.</given-names></name><name><surname>Müller</surname><given-names>C. E.</given-names></name><name><surname>Nelson</surname><given-names>R. D.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus.</article-title>
<source/><italic>Acta Physiol.</italic>
<volume>214</volume>
<fpage>176</fpage>–<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1111/apha.12507</pub-id></mixed-citation>
</ref>
<ref id="B447">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitta</surname><given-names>T.</given-names></name><name><surname>Chancellor</surname><given-names>M. B.</given-names></name><name><surname>De Groat</surname><given-names>W. C.</given-names></name><name><surname>Kuno</surname><given-names>S.</given-names></name><name><surname>Nonomura</surname><given-names>K.</given-names></name><name><surname>Yoshimura</surname><given-names>N.</given-names></name></person-group> (<year>2012</year>). <article-title>Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat model of Parkinson disease.</article-title>
<source/><italic>J. Urol.</italic>
<volume>187</volume>
<fpage>1890</fpage>–<lpage>1897</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2011.12.062</pub-id><pub-id pub-id-type="pmid">22425056</pub-id></mixed-citation>
</ref>
<ref id="B448">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kizilirmak</surname><given-names>F.</given-names></name><name><surname>Gunes</surname><given-names>H. M.</given-names></name><name><surname>Demir</surname><given-names>G. G.</given-names></name><name><surname>Gokdeniz</surname><given-names>T.</given-names></name><name><surname>Guler</surname><given-names>E.</given-names></name><name><surname>Cakal</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Impact of intracoronary adenosine on myonecrosis in patients with unstable angina pectoris undergoing percutaneous coronary intervention.</article-title>
<source/><italic>Cardiovasc. Drugs Ther.</italic>
<volume>29</volume>
<fpage>519</fpage>–<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1007/s10557-015-6631-4</pub-id><pub-id pub-id-type="pmid">26631392</pub-id></mixed-citation>
</ref>
<ref id="B449">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>G. E.</given-names></name><name><surname>Bodin</surname><given-names>P.</given-names></name><name><surname>De Groat</surname><given-names>W. C.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2002</year>). <article-title>ATP is released from guinea pig ureter epithelium on distension.</article-title>
<source/><italic>Am. J. Physiol. Renal Physiol.</italic>
<volume>282</volume>
<fpage>F281</fpage>–<lpage>F288</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00293.2000</pub-id><pub-id pub-id-type="pmid">11788442</pub-id></mixed-citation>
</ref>
<ref id="B450">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kofoed</surname><given-names>K.</given-names></name><name><surname>Skov</surname><given-names>L.</given-names></name><name><surname>Zachariae</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>New drugs and treatment targets in psoriasis.</article-title>
<source/><italic>Acta Derm. Venereol.</italic>
<volume>95</volume>
<fpage>133</fpage>–<lpage>139</lpage>. <pub-id pub-id-type="doi">10.2340/00015555-1931</pub-id><pub-id pub-id-type="pmid">25111317</pub-id></mixed-citation>
</ref>
<ref id="B451">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Köhler</surname><given-names>D.</given-names></name><name><surname>Streienberger</surname><given-names>A.</given-names></name><name><surname>Morote-García</surname><given-names>J. C.</given-names></name><name><surname>Granja</surname><given-names>T. F.</given-names></name><name><surname>Schneider</surname><given-names>M.</given-names></name><name><surname>Straub</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Inhibition of adenosine kinase attenuates acute lung injury.</article-title>
<source/><italic>Crit. Care Med.</italic>
<volume>44</volume>
<fpage>e181</fpage>–<lpage>e189</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000001370</pub-id><pub-id pub-id-type="pmid">26491864</pub-id></mixed-citation>
</ref>
<ref id="B452">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komai</surname><given-names>A. M.</given-names></name><name><surname>Brännmark</surname><given-names>C.</given-names></name><name><surname>Musovic</surname><given-names>S.</given-names></name><name><surname>Olofsson</surname><given-names>C. S.</given-names></name></person-group> (<year>2014</year>). <article-title>PKA-independent cAMP stimulation of white adipocyte exocytosis and adipokine secretion: modulations by Ca<sup>2+</sup> and ATP.</article-title>
<source/><italic>J. Physiol.</italic>
<volume>592</volume>
<fpage>5169</fpage>–<lpage>5186</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2014.280388</pub-id><pub-id pub-id-type="pmid">25194045</pub-id></mixed-citation>
</ref>
<ref id="B453">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornum</surname><given-names>B. R.</given-names></name><name><surname>Kawashima</surname><given-names>M.</given-names></name><name><surname>Faraco</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Rico</surname><given-names>T. J.</given-names></name><name><surname>Hesselson</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Common variants in P2RY11 are associated with narcolepsy.</article-title>
<source/><italic>Nat. Genet.</italic>
<volume>43</volume>
<fpage>66</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1038/ng.734</pub-id><pub-id pub-id-type="pmid">21170044</pub-id></mixed-citation>
</ref>
<ref id="B454">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowaluk</surname><given-names>E. A.</given-names></name><name><surname>Jarvis</surname><given-names>M. F.</given-names></name></person-group> (<year>2000</year>). <article-title>Therapeutic potential of adenosine kinase inhibitors.</article-title>
<source/><italic>Expert Opin. Investig. Drugs</italic>
<volume>9</volume>
<fpage>551</fpage>–<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1517/13543784.9.3.551</pub-id></mixed-citation>
</ref>
<ref id="B455">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krasowska</surname><given-names>E.</given-names></name><name><surname>Róg</surname><given-names>J.</given-names></name><name><surname>Sinadinos</surname><given-names>A.</given-names></name><name><surname>Young</surname><given-names>C. N.</given-names></name><name><surname>Górecki</surname><given-names>D. C.</given-names></name><name><surname>Zablocki</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Purinergic receptors in skeletal muscles in health and in muscular dystrophy.</article-title>
<source/><italic>Postepy Biochem.</italic>
<volume>60</volume>
<fpage>483</fpage>–<lpage>489</lpage>.<pub-id pub-id-type="pmid">25807827</pub-id></mixed-citation>
</ref>
<ref id="B456">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kretschmar</surname><given-names>C.</given-names></name><name><surname>Oyarzún</surname><given-names>C.</given-names></name><name><surname>Villablanca</surname><given-names>C.</given-names></name><name><surname>Jaramillo</surname><given-names>C.</given-names></name><name><surname>Alarcón</surname><given-names>S.</given-names></name><name><surname>Perez</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Reduced adenosine uptake and its contribution to signaling that mediates profibrotic activation in renal tubular epithelial cells: implication in diabetic nephropathy.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>11</volume>:<issue>e0147430</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0147430</pub-id></mixed-citation>
</ref>
<ref id="B457">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krizaj</surname><given-names>D.</given-names></name><name><surname>Ryskamp</surname><given-names>D. A.</given-names></name><name><surname>Tian</surname><given-names>N.</given-names></name><name><surname>Tezel</surname><given-names>G.</given-names></name><name><surname>Mitchell</surname><given-names>C. H.</given-names></name><name><surname>Slepak</surname><given-names>V. Z.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>From mechanosensitivity to inflammatory responses: new players in the pathology of glaucoma.</article-title>
<source/><italic>Curr. Eye Res.</italic>
<volume>39</volume>
<fpage>105</fpage>–<lpage>119</lpage>. <pub-id pub-id-type="doi">10.3109/02713683.2013.836541</pub-id><pub-id pub-id-type="pmid">24144321</pub-id></mixed-citation>
</ref>
<ref id="B458">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krügel</surname><given-names>U.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic receptors in psychiatric disorders.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>212</fpage>–<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.10.032</pub-id><pub-id pub-id-type="pmid">26518371</pub-id></mixed-citation>
</ref>
<ref id="B459">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krügel</surname><given-names>U.</given-names></name><name><surname>Köles</surname><given-names>L.</given-names></name><name><surname>Illes</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Integration of neuronal and glial signalling by pyramidal cells of the rat prefrontal cortex; control of cognitive functions and addictive behaviour by purinergic mechanisms.</article-title>
<source/><italic>Neuropsychopharmacol. Hung.</italic>
<volume>15</volume>
<fpage>206</fpage>–<lpage>213</lpage>.<pub-id pub-id-type="pmid">24380961</pub-id></mixed-citation>
</ref>
<ref id="B460">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruglov</surname><given-names>E. A.</given-names></name><name><surname>Correa</surname><given-names>P. R.</given-names></name><name><surname>Arora</surname><given-names>G.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Nathanson</surname><given-names>M. H.</given-names></name><name><surname>Dranoff</surname><given-names>J. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Molecular basis for calcium signaling in hepatic stellate cells.</article-title>
<source/><italic>Am. J. Physiol. Gastrointest. Liver Physiol.</italic>
<volume>292</volume>
<fpage>G975</fpage>–<lpage>G982</lpage>.<pub-id pub-id-type="pmid">17204544</pub-id></mixed-citation>
</ref>
<ref id="B461">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuan</surname><given-names>Y. H.</given-names></name><name><surname>Shih</surname><given-names>H. C.</given-names></name><name><surname>Tang</surname><given-names>S. C.</given-names></name><name><surname>Jeng</surname><given-names>J. S.</given-names></name><name><surname>Shyu</surname><given-names>B. C.</given-names></name></person-group> (<year>2015</year>). <article-title>Targeting P2X7 receptor for the treatment of central post-stroke pain in a rodent model.</article-title>
<source/><italic>Neurobiol. Dis.</italic>
<volume>78</volume>
<fpage>134</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2015.02.028</pub-id><pub-id pub-id-type="pmid">25836422</pub-id></mixed-citation>
</ref>
<ref id="B462">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuan</surname><given-names>Y. H.</given-names></name><name><surname>Shyu</surname><given-names>B. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Nociceptive transmission and modulation via P2X receptors in central pain syndrome.</article-title>
<source/><italic>Mol. Brain</italic>
<volume>9</volume>
<issue>58</issue>
<pub-id pub-id-type="doi">10.1186/s13041-016-0240-4</pub-id></mixed-citation>
</ref>
<ref id="B463">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudira</surname><given-names>R.</given-names></name><name><surname>Malinka</surname><given-names>T.</given-names></name><name><surname>Kohler</surname><given-names>A.</given-names></name><name><surname>Dosch</surname><given-names>M.</given-names></name><name><surname>De Aguero</surname><given-names>M. G.</given-names></name><name><surname>Melin</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>P2X1-regulated IL-22 secretion by innate lymphoid cells is required for efficient liver regeneration.</article-title>
<source/><italic>Hepatology</italic>
<volume>63</volume>
<fpage>2004</fpage>–<lpage>2017</lpage>. <pub-id pub-id-type="doi">10.1002/hep.28492</pub-id><pub-id pub-id-type="pmid">26853442</pub-id></mixed-citation>
</ref>
<ref id="B464">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumahashi</surname><given-names>N.</given-names></name><name><surname>Naitou</surname><given-names>K.</given-names></name><name><surname>Nishi</surname><given-names>H.</given-names></name><name><surname>Oae</surname><given-names>K.</given-names></name><name><surname>Watanabe</surname><given-names>Y.</given-names></name><name><surname>Kuwata</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Correlation of changes in pain intensity with synovial fluid adenosine triphosphate levels after treatment of patients with osteoarthritis of the knee with high-molecular-weight hyaluronic acid.</article-title>
<source/><italic>Knee</italic>
<volume>18</volume>
<fpage>160</fpage>–<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1016/j.knee.2010.04.013</pub-id><pub-id pub-id-type="pmid">20627733</pub-id></mixed-citation>
</ref>
<ref id="B465">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Chapple</surname><given-names>C. R.</given-names></name><name><surname>Rosario</surname><given-names>D.</given-names></name><name><surname>Tophill</surname><given-names>P. R.</given-names></name><name><surname>Chess-Williams</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>In vitro release of adenosine triphosphate from the urothelium of human bladders with detrusor overactivity, both neurogenic and idiopathic.</article-title>
<source/><italic>Eur. Urol.</italic>
<volume>57</volume>
<fpage>1087</fpage>–<lpage>1092</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2009.11.042</pub-id><pub-id pub-id-type="pmid">20022422</pub-id></mixed-citation>
</ref>
<ref id="B466">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kurashima</surname><given-names>Y.</given-names></name><name><surname>Kiyono</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>“Physiological and pathological inflammation at the mucosal frontline,” in</article-title>
<source/><italic>Chronic Inflammation: Mechanisms and Regulation</italic>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Miyasaka</surname><given-names>M.</given-names></name><name><surname>Takatsu</surname><given-names>K.</given-names></name></person-group> (<publisher-loc>Tokyo</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>567</fpage>–<lpage>590</lpage>.</mixed-citation>
</ref>
<ref id="B467">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurashima</surname><given-names>Y.</given-names></name><name><surname>Kiyono</surname><given-names>H.</given-names></name><name><surname>Kunisawa</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Pathophysiological role of extracellular purinergic mediators in the control of intestinal inflammation.</article-title>
<source/><italic>Mediators Inflamm.</italic>
<volume>2015</volume>:<issue>427125</issue>
<pub-id pub-id-type="doi">10.1155/2015/427125</pub-id></mixed-citation>
</ref>
<ref id="B468">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurlak</surname><given-names>L. O.</given-names></name><name><surname>Williams</surname><given-names>P. J.</given-names></name><name><surname>Bulmer</surname><given-names>J. N.</given-names></name><name><surname>Broughton Pipkin</surname><given-names>F.</given-names></name><name><surname>Mistry</surname><given-names>H. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Placental expression of adenosine A2A receptor and hypoxia inducible factor-1 alpha in early pregnancy, term and pre-eclamptic pregnancies: interactions with placental renin-angiotensin system.</article-title>
<source/><italic>Placenta</italic>
<volume>36</volume>
<fpage>611</fpage>–<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2015.02.011</pub-id><pub-id pub-id-type="pmid">25745823</pub-id></mixed-citation>
</ref>
<ref id="B469">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kvist</surname><given-names>T. M.</given-names></name><name><surname>Schwarz</surname><given-names>P.</given-names></name><name><surname>Jørgensen</surname><given-names>N. R.</given-names></name></person-group> (<year>2014</year>). <article-title>The P2X7 receptor: a key player in immune-mediated bone loss?</article-title>
<source/><italic>Sci. World J.</italic>
<volume>2014</volume>:<issue>954530</issue>
<pub-id pub-id-type="doi">10.1155/2014/954530</pub-id></mixed-citation>
</ref>
<ref id="B470">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>S. G.</given-names></name><name><surname>Roh</surname><given-names>D. H.</given-names></name><name><surname>Yoon</surname><given-names>S. Y.</given-names></name><name><surname>Moon</surname><given-names>J. Y.</given-names></name><name><surname>Choi</surname><given-names>S. R.</given-names></name><name><surname>Choi</surname><given-names>H. S.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Blockade of peripheral P2Y1 receptors prevents the induction of thermal hyperalgesia via modulation of TRPV1 expression in carrageenan-induced inflammatory pain rats: involvement of p38 MAPK phosphorylation in DRGs.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>79</volume>
<fpage>368</fpage>–<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.12.005</pub-id><pub-id pub-id-type="pmid">24333674</pub-id></mixed-citation>
</ref>
<ref id="B471">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyle</surname><given-names>B. D.</given-names></name></person-group> (<year>2014</year>). <article-title>Ion channels of the mammalian urethra.</article-title>
<source/><italic>Channels</italic>
<volume>8</volume>
<fpage>393</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.4161/19336950.2014.954224</pub-id><pub-id pub-id-type="pmid">25483582</pub-id></mixed-citation>
</ref>
<ref id="B472">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labazi</surname><given-names>H.</given-names></name><name><surname>Teng</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Mustafa</surname><given-names>S. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Enhanced A2A adenosine receptor-mediated increase in coronary flow in type I diabetic mice.</article-title>
<source/><italic>J. Mol. Cell. Cardiol.</italic>
<volume>90</volume>
<fpage>30</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.11.033</pub-id><pub-id pub-id-type="pmid">26654777</pub-id></mixed-citation>
</ref>
<ref id="B473">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahmann</surname><given-names>C.</given-names></name><name><surname>Clark</surname><given-names>R. H.</given-names></name><name><surname>Iberl</surname><given-names>M.</given-names></name><name><surname>Ashcroft</surname><given-names>F. M.</given-names></name></person-group> (<year>2014</year>). <article-title>A mutation causing increased KATP channel activity leads to reduced anxiety in mice.</article-title>
<source/><italic>Physiol. Behav.</italic>
<volume>129</volume>
<fpage>79</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2014.02.031</pub-id><pub-id pub-id-type="pmid">24582665</pub-id></mixed-citation>
</ref>
<ref id="B474">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lajdova</surname><given-names>I.</given-names></name><name><surname>Oksa</surname><given-names>A.</given-names></name><name><surname>Chorvat</surname><given-names>J. D.</given-names></name><name><surname>Topor</surname><given-names>P.</given-names></name><name><surname>Spustova</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>). <article-title>Purinergic P2X7 receptors participate in disturbed intracellular calcium homeostasis in peripheral blood mononuclear cells of patients with chronic kidney disease.</article-title>
<source/><italic>Kidney Blood Press. Res.</italic>
<volume>35</volume>
<fpage>48</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1159/000330349</pub-id><pub-id pub-id-type="pmid">21860249</pub-id></mixed-citation>
</ref>
<ref id="B475">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laketa</surname><given-names>D.</given-names></name><name><surname>Savic</surname><given-names>J.</given-names></name><name><surname>Bjelobaba</surname><given-names>I.</given-names></name><name><surname>Lavrnja</surname><given-names>I.</given-names></name><name><surname>Vasic</surname><given-names>V.</given-names></name><name><surname>Stojiljkovic</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Brain injury alters ectonucleotidase activities and adenine nucleotide levels in rat serum.</article-title>
<source/><italic>J. Med. Biochem.</italic>
<volume>34</volume>
<fpage>215</fpage>–<lpage>222</lpage>. <pub-id pub-id-type="doi">10.2478/jomb-2014-0025</pub-id><pub-id pub-id-type="pmid">28356834</pub-id></mixed-citation>
</ref>
<ref id="B476">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>O. C.</given-names></name><name><surname>Samarawickrama</surname><given-names>C.</given-names></name><name><surname>Skalicky</surname><given-names>S. E.</given-names></name></person-group> (<year>2014</year>). <article-title>P2Y2 receptor agonists for the treatment of dry eye disease: a review.</article-title>
<source/><italic>Clin. Ophthalmol.</italic>
<volume>8</volume>
<fpage>327</fpage>–<lpage>334</lpage>. <pub-id pub-id-type="doi">10.2147/OPTH.S39699</pub-id><pub-id pub-id-type="pmid">24511227</pub-id></mixed-citation>
</ref>
<ref id="B477">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavrnja</surname><given-names>I.</given-names></name><name><surname>Laketa</surname><given-names>D.</given-names></name><name><surname>Savic</surname><given-names>D.</given-names></name><name><surname>Bozic</surname><given-names>I.</given-names></name><name><surname>Bjelobaba</surname><given-names>I.</given-names></name><name><surname>Pekovic</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Expression of a second ecto-5′-nucleotidase variant besides the usual protein in symptomatic phase of experimental autoimmune encephalomyelitis.</article-title>
<source/><italic>J. Mol. Neurosci.</italic>
<volume>55</volume>
<fpage>898</fpage>–<lpage>911</lpage>. <pub-id pub-id-type="doi">10.1007/s12031-014-0445-x</pub-id><pub-id pub-id-type="pmid">25326791</pub-id></mixed-citation>
</ref>
<ref id="B478">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layland</surname><given-names>J.</given-names></name><name><surname>Carrick</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Oldroyd</surname><given-names>K.</given-names></name><name><surname>Berry</surname><given-names>C.</given-names></name></person-group> (<year>2014</year>). <article-title>Adenosine: physiology, pharmacology, and clinical applications.</article-title>
<source/><italic>JACC Cardiovasc. Interv.</italic>
<volume>7</volume>
<fpage>581</fpage>–<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2014.02.009</pub-id><pub-id pub-id-type="pmid">24835328</pub-id></mixed-citation>
</ref>
<ref id="B479">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledderose</surname><given-names>C.</given-names></name><name><surname>Bao</surname><given-names>Y.</given-names></name><name><surname>Kondo</surname><given-names>Y.</given-names></name><name><surname>Fakhari</surname><given-names>M.</given-names></name><name><surname>Slubowski</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Purinergic signaling and the immune response in sepsis: a review.</article-title>
<source/><italic>Clin. Ther.</italic>
<volume>38</volume>
<fpage>1054</fpage>–<lpage>1065</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinthera.2016.04.002</pub-id><pub-id pub-id-type="pmid">27156007</pub-id></mixed-citation>
</ref>
<ref id="B480">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B. H.</given-names></name><name><surname>Hwang</surname><given-names>D. M.</given-names></name><name><surname>Palaniyar</surname><given-names>N.</given-names></name><name><surname>Grinstein</surname><given-names>S.</given-names></name><name><surname>Philpott</surname><given-names>D. J.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Activation of P2X7 receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>7</volume>:<issue>e35812</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0035812</pub-id></mixed-citation>
</ref>
<ref id="B481">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C. F.</given-names></name><name><surname>Chern</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Adenosine receptors and Huntington’s disease.</article-title>
<source/><italic>Int. Rev. Neurobiol.</italic>
<volume>119</volume>
<fpage>195</fpage>–<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-801022-8.00010-6</pub-id><pub-id pub-id-type="pmid">25175968</pub-id></mixed-citation>
</ref>
<ref id="B482">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C. Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Adenosine protects Sprague Dawley rats from high-fat diet and repeated acute restraint stress-induced intestinal inflammation and altered expression of nutrient transporters.</article-title>
<source/><italic>J. Anim. Physiol. Anim. Nutr.</italic>
<volume>99</volume>
<fpage>317</fpage>–<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1111/jpn.12247</pub-id></mixed-citation>
</ref>
<ref id="B483">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Myers</surname><given-names>J. S.</given-names></name><name><surname>Katz</surname><given-names>L. J.</given-names></name></person-group> (<year>2016</year>). <article-title>The role of adenosine receptor agonists in ocular disorders.</article-title>
<source/><italic>Drugs Future</italic>
<volume>41</volume>
<fpage>547</fpage>–<lpage>552</lpage>. <pub-id pub-id-type="doi">10.1358/dof.2016.041.09.2533858</pub-id></mixed-citation>
</ref>
<ref id="B484">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaire</surname><given-names>A.</given-names></name><name><surname>Vanorlé</surname><given-names>M.</given-names></name><name><surname>Horckmans</surname><given-names>M.</given-names></name><name><surname>Di Pietrantonio</surname><given-names>L.</given-names></name><name><surname>Clouet</surname><given-names>S.</given-names></name><name><surname>Robaye</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Mouse P2Y4 nucleotide receptor is a negative regulator of cardiac adipose-derived stem cell differentiation and cardiac fat formation.</article-title>
<source/><italic>Stem Cells Dev.</italic>
<volume>26</volume>
<fpage>363</fpage>–<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1089/scd.2016.0166</pub-id><pub-id pub-id-type="pmid">27855539</pub-id></mixed-citation>
</ref>
<ref id="B485">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerman</surname><given-names>B. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Ventricular tachycardia: mechanistic insights derived from adenosine.</article-title>
<source/><italic>Circ. Arrhythm. Electrophysiol.</italic>
<volume>8</volume>
<fpage>483</fpage>–<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCEP.115.001693</pub-id><pub-id pub-id-type="pmid">25900991</pub-id></mixed-citation>
</ref>
<ref id="B486">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lertsuwan</surname><given-names>K.</given-names></name><name><surname>Peters</surname><given-names>W.</given-names></name><name><surname>Johnson</surname><given-names>L.</given-names></name><name><surname>Lertsuwan</surname><given-names>J.</given-names></name><name><surname>Marwa</surname><given-names>I.</given-names></name><name><surname>Sikes</surname><given-names>R. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Purinergic receptor expression and cellular responses to purinergic agonists in human prostate cancer cells.</article-title>
<source/><italic>Anticancer Res.</italic>
<volume>37</volume>
<fpage>529</fpage>–<lpage>537</lpage>. <pub-id pub-id-type="doi">10.21873/anticanres.11345</pub-id><pub-id pub-id-type="pmid">28179298</pub-id></mixed-citation>
</ref>
<ref id="B487">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leyva-Grado</surname><given-names>V. H.</given-names></name><name><surname>Ermler</surname><given-names>M. E.</given-names></name><name><surname>Schotsaert</surname><given-names>M.</given-names></name><name><surname>Gonzalez</surname><given-names>M. G.</given-names></name><name><surname>Gillespie</surname><given-names>V.</given-names></name><name><surname>Lim</surname><given-names>J. K.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Contribution of the purinergic receptor P2X7 to development of lung immunopathology during influenza virus infection.</article-title>
<source/><italic>mBio</italic>
<volume>8</volume>:<issue>e00229</issue>–<issue>17</issue>
<pub-id pub-id-type="doi">10.1128/mBio.00229-17</pub-id></mixed-citation>
</ref>
<ref id="B488">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C. L.</given-names></name><name><surname>Yang</surname><given-names>X. L.</given-names></name><name><surname>Wang</surname><given-names>J. J.</given-names></name><name><surname>Du</surname><given-names>G. H.</given-names></name><name><surname>Yang</surname><given-names>W. M.</given-names></name><name><surname>Zhang</surname><given-names>H. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Effects of intracavernous injection of P2X3 and NK1 receptor antagonists on erectile dysfunction induced by spinal cord transection in rats.</article-title>
<source/><italic>Andrologia</italic>
<volume>47</volume>
<fpage>25</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1111/and.12217</pub-id><pub-id pub-id-type="pmid">24387161</pub-id></mixed-citation>
</ref>
<ref id="B489">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>O.</given-names></name><name><surname>Ye</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Inhalation of high concentrations of hydrogen ameliorates liver ischemia/reperfusion injury through A2A receptor mediated PI3K-Akt pathway.</article-title>
<source/><italic>Biochem. Pharmacol.</italic>
<volume>130</volume>
<fpage>83</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2017.02.003</pub-id><pub-id pub-id-type="pmid">28188779</pub-id></mixed-citation>
</ref>
<ref id="B490">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H. J.</given-names></name><name><surname>Wang</surname><given-names>L. Y.</given-names></name><name><surname>Qu</surname><given-names>H. N.</given-names></name><name><surname>Yu</surname><given-names>L. H.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name><name><surname>Ni</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells.</article-title>
<source/><italic>Mol. Cell. Endocrinol.</italic>
<volume>338</volume>
<fpage>28</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2011.02.014</pub-id><pub-id pub-id-type="pmid">21356271</pub-id></mixed-citation>
</ref>
<ref id="B491">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Ye</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>S. P.</given-names></name><name><surname>Bajwa</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>S. J.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Dendritic cells tolerized with adenosine A2AR agonist attenuate acute kidney injury.</article-title>
<source/><italic>J. Clin. Invest.</italic>
<volume>122</volume>
<fpage>3931</fpage>–<lpage>3942</lpage>. <pub-id pub-id-type="doi">10.1172/JCI63170</pub-id><pub-id pub-id-type="pmid">23093781</pub-id></mixed-citation>
</ref>
<ref id="B492">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Geiger</surname><given-names>N. H.</given-names></name><name><surname>Soliman</surname><given-names>M. L.</given-names></name><name><surname>Hui</surname><given-names>L.</given-names></name><name><surname>Geiger</surname><given-names>J. D.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group> (<year>2015</year>). <article-title>Caffeine, through adenosine A3 receptor-mediated actions, suppresses amyloid-β protein precursor internalization and amyloid-β generation.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>47</volume>
<fpage>73</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-142223</pub-id><pub-id pub-id-type="pmid">26402756</pub-id></mixed-citation>
</ref>
<ref id="B493">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Chang</surname><given-names>X.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Ectopic expression of the ATP synthase beta subunit on the membrane of PC-3M cells supports its potential role in prostate cancer metastasis.</article-title>
<source/><italic>Int. J. Oncol.</italic>
<volume>50</volume>
<fpage>1312</fpage>–<lpage>1320</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2017.3878</pub-id><pub-id pub-id-type="pmid">28259978</pub-id></mixed-citation>
</ref>
<ref id="B494">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Silva</surname><given-names>H. B.</given-names></name><name><surname>Real</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y. M.</given-names></name><name><surname>Rial</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington’s disease models.</article-title>
<source/><italic>Neurobiol. Dis.</italic>
<volume>79</volume>
<fpage>70</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2015.03.030</pub-id><pub-id pub-id-type="pmid">25892655</pub-id></mixed-citation>
</ref>
<ref id="B495">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Catera</surname><given-names>D.</given-names></name><name><surname>Rote</surname><given-names>N. S.</given-names></name><name><surname>Potashkin</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells.</article-title>
<source/><italic>Gynecol. Oncol.</italic>
<volume>106</volume>
<fpage>233</fpage>–<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2007.03.032</pub-id><pub-id pub-id-type="pmid">17482244</pub-id></mixed-citation>
</ref>
<ref id="B496">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Fu</surname><given-names>W.</given-names></name><name><surname>Bdul-Karim</surname><given-names>F. W.</given-names></name><name><surname>Maclennan</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>P2X7 receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>5</volume>
<fpage>351</fpage>–<lpage>368</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-009-9161-3</pub-id><pub-id pub-id-type="pmid">19399640</pub-id></mixed-citation>
</ref>
<ref id="B497">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Pu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Optogenetic activation of adenosine A2A receptor signaling in the dorsomedial striatopallidal neurons suppresses goal-directed behavior.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>41</volume>
<fpage>1003</fpage>–<lpage>1013</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2015.227</pub-id><pub-id pub-id-type="pmid">26216520</pub-id></mixed-citation>
</ref>
<ref id="B498">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xue</surname><given-names>L.</given-names></name><name><surname>Miao</surname><given-names>Q.</given-names></name><name><surname>Mao</surname><given-names>F.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Expression and electrophysiological characteristics of P2X3 receptors in interstitial cells of Cajal in rats with partial bladder outlet obstruction.</article-title>
<source/><italic>BJU Int.</italic>
<volume>111</volume>
<fpage>843</fpage>–<lpage>851</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11408.x</pub-id><pub-id pub-id-type="pmid">22882254</pub-id></mixed-citation>
</ref>
<ref id="B499">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lietsche</surname><given-names>J.</given-names></name><name><surname>Imran</surname><given-names>I.</given-names></name><name><surname>Klein</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Extracellular levels of ATP and acetylcholine during lithium-pilocarpine induced status epilepticus in rats.</article-title>
<source/><italic>Neurosci. Lett.</italic>
<volume>611</volume>
<fpage>69</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2015.11.028</pub-id><pub-id pub-id-type="pmid">26610905</pub-id></mixed-citation>
</ref>
<ref id="B500">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liñán-Rico</surname><given-names>A.</given-names></name><name><surname>Wunderlich</surname><given-names>J. E.</given-names></name><name><surname>Enneking</surname><given-names>J. T.</given-names></name><name><surname>Tso</surname><given-names>D. R.</given-names></name><name><surname>Grants</surname><given-names>I.</given-names></name><name><surname>Williams</surname><given-names>K. C.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Neuropharmacology of purinergic receptors in human submucous plexus: involvement of P2X1, P2X2, P2X3 channels, P2Y and A3 metabotropic receptors in neurotransmission.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>95</volume>
<fpage>83</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.02.014</pub-id><pub-id pub-id-type="pmid">25724083</pub-id></mixed-citation>
</ref>
<ref id="B501">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>D.</given-names></name><name><surname>Shan</surname><given-names>D.</given-names></name><name><surname>Ayers-Ringler</surname><given-names>J.</given-names></name><name><surname>Oliveros</surname><given-names>A.</given-names></name><name><surname>Benitez</surname><given-names>J.</given-names></name><name><surname>Prieto</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Purinergic signaling and energy homeostasis in psychiatric disorders.</article-title>
<source/><italic>Curr. Mol. Med.</italic>
<volume>15</volume>
<fpage>275</fpage>–<lpage>295</lpage>. <pub-id pub-id-type="doi">10.2174/1566524015666150330163724</pub-id><pub-id pub-id-type="pmid">25950756</pub-id></mixed-citation>
</ref>
<ref id="B502">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lioi</surname><given-names>A. B.</given-names></name><name><surname>Ferrari</surname><given-names>B. M.</given-names></name><name><surname>Dubyak</surname><given-names>G. R.</given-names></name><name><surname>Weinberg</surname><given-names>A.</given-names></name><name><surname>Sieg</surname><given-names>S. F.</given-names></name></person-group> (<year>2015</year>). <article-title>Human β defensin-3 increases CD86 expression on monocytes by activating the ATP-gated channel P2X7.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>195</volume>
<fpage>4438</fpage>–<lpage>4445</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1401319</pub-id><pub-id pub-id-type="pmid">26416278</pub-id></mixed-citation>
</ref>
<ref id="B503">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Tantry</surname><given-names>U. S.</given-names></name><name><surname>Gurbel</surname><given-names>P. A.</given-names></name></person-group> (<year>2015</year>). <article-title>P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.</article-title>
<source/><italic>Expert Opin. Pharmacother.</italic>
<volume>16</volume>
<fpage>k1149</fpage>–<lpage>1165</lpage>. <pub-id pub-id-type="doi">10.1517/14656566.2015.1035256</pub-id></mixed-citation>
</ref>
<ref id="B504">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Daneshgari</surname><given-names>F.</given-names></name></person-group> (<year>2008</year>). <article-title>Temporal expression of muscarinic and purinergic receptors in diabetic rat bladder.</article-title>
<source/><italic>Neurourol. Urodyn.</italic>
<volume>27</volume>
<fpage>594</fpage>–<lpage>595</lpage>.</mixed-citation>
</ref>
<ref id="B505">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Kuo</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Increased suburothelial nerve fiber and purinergic P2X3 receptor expressions in patients with idiopathic detrusor overactivity and their relationship with botulinum toxin A therapeutic outcome.</article-title>
<source/><italic>Neurourol. Urodyn.</italic>
<volume>32</volume>
<fpage>733</fpage>–<lpage>735</lpage>.</mixed-citation>
</ref>
<ref id="B506">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Beneficial and detrimental role of adenosine signaling in diseases and therapy.</article-title>
<source/><italic>J. Appl. Physiol.</italic>
<volume>119</volume>
<fpage>1173</fpage>–<lpage>1182</lpage>. <pub-id pub-id-type="doi">10.1152/japplphysiol.00350.2015</pub-id><pub-id pub-id-type="pmid">26316513</pub-id></mixed-citation>
</ref>
<ref id="B507">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Prell</surname><given-names>T.</given-names></name><name><surname>Stubendorff</surname><given-names>B.</given-names></name><name><surname>Keiner</surname><given-names>S.</given-names></name><name><surname>Ringer</surname><given-names>T.</given-names></name><name><surname>Gunkel</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Down-regulation of purinergic P2X7 receptor expression and intracellular calcium dysregulation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis.</article-title>
<source/><italic>Neurosci. Lett.</italic>
<volume>630</volume>
<fpage>77</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2016.07.039</pub-id><pub-id pub-id-type="pmid">27453058</pub-id></mixed-citation>
</ref>
<ref id="B508">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Vergani</surname><given-names>A.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Ben</surname><given-names>N. M.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Iken</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Inhibition of the purinergic pathway prolongs mouse lung allograft survival.</article-title>
<source/><italic>Am. J. Respir. Cell Mol. Biol.</italic>
<volume>51</volume>
<fpage>300</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2013-0362OC</pub-id><pub-id pub-id-type="pmid">24661183</pub-id></mixed-citation>
</ref>
<ref id="B509">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Fang</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>J. J.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Upregulation of P2X3 receptors by neuronal calcium sensor protein VILIP-1 in dorsal root ganglions contributes to the bone cancer pain in rats.</article-title>
<source/><italic>Pain</italic>
<volume>154</volume>
<fpage>1551</fpage>–<lpage>1568</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2013.04.022</pub-id><pub-id pub-id-type="pmid">23707265</pub-id></mixed-citation>
</ref>
<ref id="B510">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P. S.</given-names></name><name><surname>Chen</surname><given-names>C. Y.</given-names></name></person-group> (<year>2010</year>). <article-title>Butyl benzyl phthalate suppresses the ATP-induced cell proliferation in human osteosarcoma HOS cells.</article-title>
<source/><italic>Toxicol. Appl. Pharmacol.</italic>
<volume>244</volume>
<fpage>308</fpage>–<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2010.01.007</pub-id><pub-id pub-id-type="pmid">20114058</pub-id></mixed-citation>
</ref>
<ref id="B511">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>The ADP antagonist MRS2179 regulates the phenotype of smooth muscle cells to limit intimal hyperplasia.</article-title>
<source/><italic>Cardiovasc. Drugs Ther.</italic>
<volume>29</volume>
<fpage>23</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1007/s10557-014-6561-6</pub-id><pub-id pub-id-type="pmid">25528944</pub-id></mixed-citation>
</ref>
<ref id="B512">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Turlova</surname><given-names>E.</given-names></name><name><surname>Dong</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Cerebrovascular safety of sulfonylureas: the role of KATP channels in neuroprotection and the risk of stroke in patients with type 2 diabetes.</article-title>
<source/><italic>Diabetes Metab. Res. Rev.</italic>
<volume>65</volume>
<fpage>2795</fpage>–<lpage>2809</lpage>. <pub-id pub-id-type="doi">10.2337/db15-1737</pub-id></mixed-citation>
</ref>
<ref id="B513">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>Q.</given-names></name><name><surname>Zhu</surname><given-names>Q.</given-names></name><name><surname>Zou</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X7 receptor of rat dorsal root ganglia is involved in the effect of moxibustion on visceral hyperalgesia.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>161</fpage>–<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-014-9439-y</pub-id><pub-id pub-id-type="pmid">25527178</pub-id></mixed-citation>
</ref>
<ref id="B514">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Wen</surname><given-names>S.</given-names></name><name><surname>Xie</surname><given-names>Q.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>LncRNA NONRATT021972 siRNA regulates neuropathic pain behaviors in type 2 diabetic rats through the P2X<sub>7</sub> receptor in dorsal root ganglia.</article-title>
<source/><italic>Mol. Brain</italic>
<volume>9</volume>
<issue>44</issue>
<pub-id pub-id-type="doi">10.1186/s13041-016-0226-2</pub-id></mixed-citation>
</ref>
<ref id="B515">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Ao</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Peng</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>miR-9 mediates CALHM1-activated ATP-P2X7R signal in painful diabetic neuropathy rats.</article-title>
<source/><italic>Mol. Neurobiol.</italic>
<volume>54</volume>
<fpage>922</fpage>–<lpage>929</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-9700-1</pub-id><pub-id pub-id-type="pmid">26781424</pub-id></mixed-citation>
</ref>
<ref id="B516">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Fujita</surname><given-names>T.</given-names></name><name><surname>Malmstrom</surname><given-names>H. S.</given-names></name><name><surname>Nedergaard</surname><given-names>M.</given-names></name><name><surname>Ren</surname><given-names>Y. F.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>External dentin stimulation induces ATP release in human teeth.</article-title>
<source/><italic>J. Dent. Res.</italic>
<volume>94</volume>
<fpage>1259</fpage>–<lpage>1266</lpage>. <pub-id pub-id-type="doi">10.1177/0022034515592858</pub-id><pub-id pub-id-type="pmid">26130258</pub-id></mixed-citation>
</ref>
<ref id="B517">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>An</surname><given-names>H.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.</article-title>
<source/><italic>Cancer Sci.</italic>
<volume>106</volume>
<fpage>1224</fpage>–<lpage>1231</lpage>. <pub-id pub-id-type="doi">10.1111/cas.12736</pub-id><pub-id pub-id-type="pmid">26179886</pub-id></mixed-citation>
</ref>
<ref id="B518">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liverani</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Lung injury during LPS-induced inflammation occurs independently of the receptor P2Y1.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>13</volume>
<fpage>119</fpage>–<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9543-2</pub-id><pub-id pub-id-type="pmid">27815804</pub-id></mixed-citation>
</ref>
<ref id="B519">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liverani</surname><given-names>E.</given-names></name><name><surname>Rico</surname><given-names>M. C.</given-names></name><name><surname>Tsygankov</surname><given-names>A. Y.</given-names></name><name><surname>Kilpatrick</surname><given-names>L. E.</given-names></name><name><surname>Kunapuli</surname><given-names>S. P.</given-names></name></person-group> (<year>2016</year>). <article-title>P2Y12 receptor modulates sepsis-induced inflammation.</article-title>
<source/><italic>Arterioscler. Thromb. Vasc. Biol.</italic>
<volume>36</volume>
<fpage>961</fpage>–<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.116.307401</pub-id><pub-id pub-id-type="pmid">27055904</pub-id></mixed-citation>
</ref>
<ref id="B520">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loma</surname><given-names>P.</given-names></name><name><surname>Guzman-Aranguez</surname><given-names>A.</given-names></name><name><surname>Perez De Lara</surname><given-names>M. J.</given-names></name><name><surname>Pintor</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency.</article-title>
<source/><italic>Exp. Eye Res.</italic>
<volume>134</volume>
<fpage>141</fpage>–<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/j.exer.2015.02.014</pub-id><pub-id pub-id-type="pmid">25701803</pub-id></mixed-citation>
</ref>
<ref id="B521">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>An anti-Parkinson’s disease drug via targeting adenosine A2A receptor enhances amyloid-β generation and γ-secretase activity.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>11</volume>:<issue>e0166415</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0166415</pub-id></mixed-citation>
</ref>
<ref id="B522">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Sévigny</surname><given-names>J.</given-names></name><name><surname>Gabelt</surname><given-names>B. T.</given-names></name><name><surname>Kaufman</surname><given-names>P. L.</given-names></name><name><surname>Johnson</surname><given-names>E. C.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Rat, mouse, and primate models of chronic glaucoma show sustained elevation of extracellular ATP and altered purinergic signaling in the posterior eye.</article-title>
<source/><italic>Invest. Ophthalmol. Vis. Sci.</italic>
<volume>56</volume>
<fpage>3075</fpage>–<lpage>3083</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.14-15891</pub-id><pub-id pub-id-type="pmid">26024091</pub-id></mixed-citation>
</ref>
<ref id="B523">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>F.</given-names></name><name><surname>Le</surname><given-names>N. B.</given-names></name><name><surname>Mills</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>N. Y.</given-names></name><name><surname>Karmouty-Quintana</surname><given-names>H.</given-names></name><name><surname>Molina</surname><given-names>J. G.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Extracellular adenosine levels are associated with the progression and exacerbation of pulmonary fibrosis.</article-title>
<source/><italic>FASEB J.</italic>
<volume>30</volume>
<fpage>874</fpage>–<lpage>883</lpage>. <pub-id pub-id-type="doi">10.1096/fj.15-274845</pub-id><pub-id pub-id-type="pmid">26527068</pub-id></mixed-citation>
</ref>
<ref id="B524">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>P2Y1, P2Y2, and TRPV1 receptors are increased in diarrhea-predominant irritable bowel syndrome and P2Y2 correlates with abdominal pain.</article-title>
<source/><italic>Dig. Dis. Sci.</italic>
<volume>61</volume>
<fpage>k2878</fpage>–<lpage>2886</lpage>. <pub-id pub-id-type="doi">10.1007/s10620-016-4211-5</pub-id></mixed-citation>
</ref>
<ref id="B525">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>Estrogen receptor beta (ERβ) activation plays a therapeutic role in murine models of inflammatory bowel disease (IBD) via inhibiting P2X3 and P2X7 receptors.</article-title>
<source/><italic>FASEB J.</italic>
<volume>30</volume>
<fpage>1023</fpage>–<lpage>1023</lpage>.<pub-id pub-id-type="pmid">26625903</pub-id></mixed-citation>
</ref>
<ref id="B526">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>D. F.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name><name><surname>Nakazawa</surname><given-names>T.</given-names></name><name><surname>Niu</surname><given-names>D. F.</given-names></name><name><surname>Mochizuki</surname><given-names>K.</given-names></name><name><surname>Kawasaki</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells.</article-title>
<source/><italic>Hum. Pathol.</italic>
<volume>41</volume>
<fpage>1550</fpage>–<lpage>1557</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2010.04.008</pub-id><pub-id pub-id-type="pmid">20619442</pub-id></mixed-citation>
</ref>
<ref id="B527">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>M.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Effects of brilliant blue G on serum tumor necrosis factor-α levels and depression-like behavior in mice after lipopolysaccharide administration.</article-title>
<source/><italic>Clin. Psychopharmacol. Neurosci.</italic>
<volume>12</volume>
<fpage>31</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.9758/cpn.2014.12.1.31</pub-id><pub-id pub-id-type="pmid">24851118</pub-id></mixed-citation>
</ref>
<ref id="B528">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Ren</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Chemotherapy-induced uridine diphosphate release promotes breast cancer metastasis through P2Y6 activation.</article-title>
<source/><italic>Oncotarget</italic>
<volume>7</volume>
<fpage>29036</fpage>–<lpage>29050</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.8664</pub-id><pub-id pub-id-type="pmid">27074554</pub-id></mixed-citation>
</ref>
<ref id="B529">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name></person-group> (<year>2015</year>). <article-title>Blockade and reversal of spinal morphine tolerance by P2X3 receptor antagonist.</article-title>
<source/><italic>Behav. Pharmacol.</italic>
<volume>26</volume>
<fpage>k260</fpage>–<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1097/FBP.0000000000000105</pub-id></mixed-citation>
</ref>
<ref id="B530">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mac Mullan</surname><given-names>P. A.</given-names></name><name><surname>Peace</surname><given-names>A. J.</given-names></name><name><surname>Madigan</surname><given-names>A. M.</given-names></name><name><surname>Tedesco</surname><given-names>A. F.</given-names></name><name><surname>Kenny</surname><given-names>D.</given-names></name><name><surname>Mccarthy</surname><given-names>G. M.</given-names></name></person-group> (<year>2010</year>). <article-title>Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target.</article-title>
<source/><italic>Rheumatology</italic>
<volume>49</volume>
<fpage>240</fpage>–<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/kep377</pub-id><pub-id pub-id-type="pmid">19965976</pub-id></mixed-citation>
</ref>
<ref id="B531">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macle</surname><given-names>L.</given-names></name><name><surname>Khairy</surname><given-names>P.</given-names></name><name><surname>Weerasooriya</surname><given-names>R.</given-names></name><name><surname>Novak</surname><given-names>P.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name><name><surname>Willems</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial.</article-title>
<source/><italic>Lancet</italic>
<volume>386</volume>
<fpage>672</fpage>–<lpage>679</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60026-5</pub-id><pub-id pub-id-type="pmid">26211828</pub-id></mixed-citation>
</ref>
<ref id="B532">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magni</surname><given-names>G.</given-names></name><name><surname>Merli</surname><given-names>D.</given-names></name><name><surname>Verderio</surname><given-names>C.</given-names></name><name><surname>Abbracchio</surname><given-names>M. P.</given-names></name><name><surname>Ceruti</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>P2Y2 receptor antagonists as anti-allodynic agents in acute and sub-chronic trigeminal sensitization: role of satellite glial cells.</article-title>
<source/><italic>Glia</italic>
<volume>63</volume>
<fpage>1256</fpage>–<lpage>1269</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22819</pub-id><pub-id pub-id-type="pmid">25779655</pub-id></mixed-citation>
</ref>
<ref id="B533">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahi</surname><given-names>N.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Jaggi</surname><given-names>A. S.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Dhawan</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Possible role of pannexin 1/P2x7 purinoceptor in neuroprotective mechanism of ischemic postconditioning in mice.</article-title>
<source/><italic>J. Surg. Res.</italic>
<volume>196</volume>
<fpage>190</fpage>–<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2015.02.050</pub-id><pub-id pub-id-type="pmid">25796110</pub-id></mixed-citation>
</ref>
<ref id="B534">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maminishkis</surname><given-names>A.</given-names></name><name><surname>Jalickee</surname><given-names>S.</given-names></name><name><surname>Blaug</surname><given-names>S. A.</given-names></name><name><surname>Rymer</surname><given-names>J.</given-names></name><name><surname>Yerxa</surname><given-names>B. R.</given-names></name><name><surname>Peterson</surname><given-names>W. M.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>The P2Y2 receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat.</article-title>
<source/><italic>Invest. Ophthalmol. Vis. Sci.</italic>
<volume>43</volume>
<fpage>3555</fpage>–<lpage>3566</lpage>.<pub-id pub-id-type="pmid">12407168</pub-id></mixed-citation>
</ref>
<ref id="B535">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzoor</surname><given-names>S.</given-names></name><name><surname>Akhtar</surname><given-names>U.</given-names></name><name><surname>Naseem</surname><given-names>S.</given-names></name><name><surname>Khalid</surname><given-names>M.</given-names></name><name><surname>Mazhar</surname><given-names>M.</given-names></name><name><surname>Parvaiz</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Ionotropic purinergic receptors P2X4 and P2X7: proviral or antiviral? An insight into P2X receptor signaling and hepatitis C virus infection.</article-title>
<source/><italic>Viral Immunol.</italic>
<volume>29</volume>
<fpage>401</fpage>–<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1089/vim.2016.0008</pub-id><pub-id pub-id-type="pmid">27526181</pub-id></mixed-citation>
</ref>
<ref id="B536">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchenkova</surname><given-names>A.</given-names></name><name><surname>Van Den Maagdenberg</surname><given-names>A. M.</given-names></name><name><surname>Nistri</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Loss of inhibition by brain natriuretic peptide over P2X3 receptors contributes to enhanced spike firing of trigeminal ganglion neurons in a mouse model of familial hemiplegic migraine type-1.</article-title>
<source/><italic>Neuroscience</italic>
<volume>331</volume>
<fpage>197</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.06.034</pub-id><pub-id pub-id-type="pmid">27346147</pub-id></mixed-citation>
</ref>
<ref id="B537">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>C. G.</given-names></name><name><surname>Zamith-Miranda</surname><given-names>D.</given-names></name><name><surname>Da Silva</surname><given-names>M. G.</given-names></name><name><surname>Ribeiro</surname><given-names>K. C.</given-names></name><name><surname>Brandão</surname><given-names>I. T.</given-names></name><name><surname>Silva</surname><given-names>C. L.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2x7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M2 receptors: autoantibody levels, heart functionality and cytokine expression.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>5</volume>:<issue>16940</issue>
<pub-id pub-id-type="doi">10.1038/srep16940</pub-id></mixed-citation>
</ref>
<ref id="B538">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>N. A.</given-names></name><name><surname>Ayala</surname><given-names>A. M.</given-names></name><name><surname>Martinez</surname><given-names>M.</given-names></name><name><surname>Martinez-Rivera</surname><given-names>F. J.</given-names></name><name><surname>Miranda</surname><given-names>J. D.</given-names></name><name><surname>Silva</surname><given-names>W. I.</given-names></name></person-group> (<year>2016</year>). <article-title>Caveolin-1 regulates the P2Y2 receptor signaling in human 1321N1 astrocytoma cells.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>291</volume>
<fpage>12208</fpage>–<lpage>12222</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.730226</pub-id><pub-id pub-id-type="pmid">27129210</pub-id></mixed-citation>
</ref>
<ref id="B539">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>J. P.</given-names></name><name><surname>Silva</surname><given-names>R. B.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name><name><surname>Takiya</surname><given-names>C. M.</given-names></name><name><surname>Battastini</surname><given-names>A. M.</given-names></name><name><surname>Morrone</surname><given-names>F. B.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>The role of P2X7 purinergic receptors in inflammatory and nociceptive changes accompanying cyclophosphamide-induced haemorrhagic cystitis in mice.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>165</volume>
<fpage>183</fpage>–<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01535.x</pub-id><pub-id pub-id-type="pmid">21675966</pub-id></mixed-citation>
</ref>
<ref id="B540">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masahiro</surname><given-names>K.</given-names></name><name><surname>Nakamachi</surname><given-names>Y.</given-names></name><name><surname>Kosaka</surname><given-names>H.</given-names></name><name><surname>Nakazawa</surname><given-names>T.</given-names></name><name><surname>Tsuji</surname><given-names>G.</given-names></name><name><surname>Kumagai</surname><given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>Modification of cytokine milieu in rheumatoid arthritis by signalling through A2A adenosine receptors.</article-title>
<source/><italic>FASEB J.</italic>
<volume>17</volume>
<issue>C69</issue>.</mixed-citation>
</ref>
<ref id="B541">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masino</surname><given-names>S. A.</given-names></name><name><surname>Kawamura</surname><given-names>M.</given-names><suffix>Jr.</suffix></name><name><surname>Cote</surname><given-names>J. L.</given-names></name><name><surname>Williams</surname><given-names>R. B.</given-names></name><name><surname>Ruskin</surname><given-names>D. N.</given-names></name></person-group> (<year>2013</year>). <article-title>Adenosine and autism: a spectrum of opportunities.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>68</volume>
<fpage>116</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.08.013</pub-id><pub-id pub-id-type="pmid">22940000</pub-id></mixed-citation>
</ref>
<ref id="B542">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuch</surname><given-names>A.</given-names></name><name><surname>Shieh</surname><given-names>C. H.</given-names></name><name><surname>Van Rooijen</surname><given-names>N.</given-names></name><name><surname>Van Calker</surname><given-names>D.</given-names></name><name><surname>Biber</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>Mechanism of microglia neuroprotection: involvement of P2X7, TNFα, and valproic acid.</article-title>
<source/><italic>Glia</italic>
<volume>64</volume>
<fpage>76</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22904</pub-id><pub-id pub-id-type="pmid">26295445</pub-id></mixed-citation>
</ref>
<ref id="B543">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matos</surname><given-names>M.</given-names></name><name><surname>Shen</surname><given-names>H. Y.</given-names></name><name><surname>Augusto</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>C. J.</given-names></name><name><surname>Wang</surname><given-names>Y. T.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>78</volume>
<fpage>763</fpage>–<lpage>774</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.02.026</pub-id><pub-id pub-id-type="pmid">25869810</pub-id></mixed-citation>
</ref>
<ref id="B544">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>T.</given-names></name><name><surname>Goulopoulou</surname><given-names>S.</given-names></name><name><surname>Taguchi</surname><given-names>K.</given-names></name><name><surname>Tostes</surname><given-names>R. C.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>172</volume>
<fpage>3980</fpage>–<lpage>4001</lpage>. <pub-id pub-id-type="doi">10.1111/bph.13205</pub-id><pub-id pub-id-type="pmid">26031319</pub-id></mixed-citation>
</ref>
<ref id="B545">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumura</surname><given-names>Y.</given-names></name><name><surname>Yamashita</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>A.</given-names></name><name><surname>Nakata</surname><given-names>E.</given-names></name><name><surname>Kohno</surname><given-names>K.</given-names></name><name><surname>Masuda</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>6</volume>:<issue>32461</issue>
<pub-id pub-id-type="doi">10.1038/srep32461</pub-id></mixed-citation>
</ref>
<ref id="B546">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matta</surname><given-names>C.</given-names></name><name><surname>Fodor</surname><given-names>J.</given-names></name><name><surname>Miosge</surname><given-names>N.</given-names></name><name><surname>Takács</surname><given-names>R.</given-names></name><name><surname>Juhász</surname><given-names>T.</given-names></name><name><surname>Rybaltovszki</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Purinergic signalling is required for calcium oscillations in migratory chondrogenic progenitor cells.</article-title>
<source/><italic>Pflugers Arch.</italic>
<volume>467</volume>
<fpage>429</fpage>–<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1007/s00424-014-1529-8</pub-id><pub-id pub-id-type="pmid">24841338</pub-id></mixed-citation>
</ref>
<ref id="B547">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maynard</surname><given-names>J. P.</given-names></name><name><surname>Lee</surname><given-names>J. S.</given-names></name><name><surname>Sohn</surname><given-names>B. H.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Lopez-Terrada</surname><given-names>D.</given-names></name><name><surname>Finegold</surname><given-names>M. J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients.</article-title>
<source/><italic>Oncotarget</italic>
<volume>6</volume>
<fpage>41162</fpage>–<lpage>41179</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.6240</pub-id><pub-id pub-id-type="pmid">26517690</pub-id></mixed-citation>
</ref>
<ref id="B548">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzon</surname><given-names>E.</given-names></name><name><surname>Esposito</surname><given-names>E.</given-names></name><name><surname>Impellizzeri</surname><given-names>D.</given-names></name><name><surname>Di Paola</surname><given-names>R.</given-names></name><name><surname>Melani</surname><given-names>A.</given-names></name><name><surname>Bramanti</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis.</article-title>
<source/><italic>J. Rheumatol.</italic>
<volume>38</volume>
<fpage>2119</fpage>–<lpage>2129</lpage>. <pub-id pub-id-type="doi">10.3899/jrheum.110111</pub-id><pub-id pub-id-type="pmid">21765105</pub-id></mixed-citation>
</ref>
<ref id="B549">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGovern</surname><given-names>A. E.</given-names></name><name><surname>Mazzone</surname><given-names>S. B.</given-names></name></person-group> (<year>2014</year>). <article-title>Neural regulation of inflammation in the airways and lungs.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>182</volume>
<fpage>95</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2013.12.008</pub-id><pub-id pub-id-type="pmid">24411267</pub-id></mixed-citation>
</ref>
<ref id="B550">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLarnon</surname><given-names>J. G.</given-names></name></person-group> (<year>2017</year>). <article-title>Roles of purinergic P2X7 receptor in glioma and microglia in brain tumors.</article-title>
<source/><italic>Cancer Lett.</italic>
<volume>402</volume>
<fpage>93</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2017.05.004</pub-id><pub-id pub-id-type="pmid">28536012</pub-id></mixed-citation>
</ref>
<ref id="B551">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPhee</surname><given-names>M. D.</given-names></name><name><surname>Whiting</surname><given-names>S. J.</given-names></name></person-group> (<year>1989</year>). <article-title>The effect of adenosine and adenosine analogues on methylxanthine-induced hypercalciuria in the rat.</article-title>
<source/><italic>Can. J. Physiol. Pharmacol.</italic>
<volume>67</volume>
<fpage>1278</fpage>–<lpage>1282</lpage>. <pub-id pub-id-type="doi">10.1139/y89-203</pub-id><pub-id pub-id-type="pmid">2611724</pub-id></mixed-citation>
</ref>
<ref id="B552">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mediavilla-Varela</surname><given-names>M.</given-names></name><name><surname>Luddy</surname><given-names>K.</given-names></name><name><surname>Noyes</surname><given-names>D.</given-names></name><name><surname>Khalil</surname><given-names>F. K.</given-names></name><name><surname>Neuger</surname><given-names>A. M.</given-names></name><name><surname>Soliman</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth.</article-title>
<source/><italic>Cancer Biol. Ther.</italic>
<volume>14</volume>
<fpage>860</fpage>–<lpage>868</lpage>. <pub-id pub-id-type="doi">10.4161/cbt.25643</pub-id><pub-id pub-id-type="pmid">23917542</pub-id></mixed-citation>
</ref>
<ref id="B553">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendieta-Condado</surname><given-names>E.</given-names></name><name><surname>Chagoya de Sanchez</surname><given-names>V.</given-names></name><name><surname>Hernandez-Munoz</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Adenosine can accelerate the cell cycle during rat liver regeneration induced by partial hepatectomy.</article-title>
<source/><italic>J. Hepatol.</italic>
<volume>46</volume>
<fpage>S142</fpage>–<lpage>S143</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.109.156620</pub-id></mixed-citation>
</ref>
<ref id="B554">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menezes</surname><given-names>C. B.</given-names></name><name><surname>Tasca</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>Trichomoniasis immunity and the involvement of the purinergic signaling.</article-title>
<source/><italic>Biomed. J.</italic>
<volume>39</volume>
<fpage>234</fpage>–<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1016/j.bj.2016.06.007</pub-id><pub-id pub-id-type="pmid">27793265</pub-id></mixed-citation>
</ref>
<ref id="B555">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>E.</given-names></name><name><surname>Lin</surname><given-names>W. Y.</given-names></name><name><surname>Lee</surname><given-names>W. C.</given-names></name><name><surname>Chuang</surname><given-names>Y. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Pathophysiology of overactive bladder.</article-title>
<source/><italic>LUTS</italic>
<volume>4</volume>
<fpage>48</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1111/j.1757-5672.2011.00122.x</pub-id><pub-id pub-id-type="pmid">26676700</pub-id></mixed-citation>
</ref>
<ref id="B556">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menzies</surname><given-names>R. I.</given-names></name><name><surname>Tam</surname><given-names>F. W.</given-names></name><name><surname>Unwin</surname><given-names>R. J.</given-names></name><name><surname>Bailey</surname><given-names>M. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Purinergic signaling in kidney disease.</article-title>
<source/><italic>Kidney Int.</italic>
<volume>91</volume>
<fpage>315</fpage>–<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2016.08.029</pub-id><pub-id pub-id-type="pmid">27780585</pub-id></mixed-citation>
</ref>
<ref id="B557">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menzies</surname><given-names>R. I.</given-names></name><name><surname>Unwin</surname><given-names>R. J.</given-names></name><name><surname>Bailey</surname><given-names>M. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Renal P2 receptors and hypertension.</article-title>
<source/><italic>Acta Physiol.</italic>
<volume>213</volume>
<fpage>232</fpage>–<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1111/apha.12412</pub-id></mixed-citation>
</ref>
<ref id="B558">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merighi</surname><given-names>S.</given-names></name><name><surname>Borea</surname><given-names>P. A.</given-names></name><name><surname>Gessi</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Adenosine receptors and diabetes: focus on the A2B adenosine receptor subtype.</article-title>
<source/><italic>Pharmacol. Res.</italic>
<volume>99</volume>
<fpage>229</fpage>–<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2015.06.015</pub-id><pub-id pub-id-type="pmid">26142494</pub-id></mixed-citation>
</ref>
<ref id="B559">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merighi</surname><given-names>S.</given-names></name><name><surname>Borea</surname><given-names>P. A.</given-names></name><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Gessi</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Deregulation of adenosine receptors in psoriatic epidermis: an option for therapeutic treatment.</article-title>
<source/><italic>J. Invest. Dermatol.</italic>
<volume>137</volume>
<fpage>11</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.jid.2016.08.001</pub-id><pub-id pub-id-type="pmid">28010756</pub-id></mixed-citation>
</ref>
<ref id="B560">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merighi</surname><given-names>S.</given-names></name><name><surname>Simioni</surname><given-names>C.</given-names></name><name><surname>Gessi</surname><given-names>S.</given-names></name><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Mirandola</surname><given-names>P.</given-names></name><name><surname>Tabrizi</surname><given-names>M. A.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>A2B and A3 adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.</article-title>
<source/><italic>Neoplasia</italic>
<volume>11</volume>
<fpage>1064</fpage>–<lpage>1073</lpage>. <pub-id pub-id-type="doi">10.1593/neo.09768</pub-id><pub-id pub-id-type="pmid">19794965</pub-id></mixed-citation>
</ref>
<ref id="B561">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzger</surname><given-names>M. W.</given-names></name><name><surname>Walser</surname><given-names>S. M.</given-names></name><name><surname>Aprile-Garcia</surname><given-names>F.</given-names></name><name><surname>Dedic</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name><name><surname>Holsboer</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Genetically dissecting P2rx7 expression within the central nervous system using conditional humanized mice.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>13</volume>
<fpage>153</fpage>–<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9546-z</pub-id><pub-id pub-id-type="pmid">27858314</pub-id></mixed-citation>
</ref>
<ref id="B562">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>C. H.</given-names></name><name><surname>Hotta</surname><given-names>K.</given-names></name><name><surname>Peterson</surname><given-names>W. M.</given-names></name><name><surname>Toth</surname><given-names>C. A.</given-names></name><name><surname>Jaffe</surname><given-names>G. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Effect of INS37217, a P2Y2 receptor agonist, on experimental retinal detachment and electroretinogram in adult rabbits.</article-title>
<source/><italic>Invest. Ophthalmol. Vis. Sci.</italic>
<volume>43</volume>
<fpage>3567</fpage>–<lpage>3574</lpage>.<pub-id pub-id-type="pmid">12407169</pub-id></mixed-citation>
</ref>
<ref id="B563">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalak</surname><given-names>A.</given-names></name><name><surname>Biala</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Alcohol dependence - neurobiology and treatment.</article-title>
<source/><italic>Acta Pol. Pharm.</italic>
<volume>73</volume>
<fpage>3</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">27008795</pub-id></mixed-citation>
</ref>
<ref id="B564">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micioni Di Bonaventura</surname><given-names>M. V.</given-names></name><name><surname>Cifani</surname><given-names>C.</given-names></name><name><surname>Lambertucci</surname><given-names>C.</given-names></name><name><surname>Volpini</surname><given-names>R.</given-names></name><name><surname>Cristalli</surname><given-names>G.</given-names></name><name><surname>Froldi</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Effects of A2A adenosine receptor blockade or stimulation on alcohol intake in alcohol-preferring rats.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>219</volume>
<fpage>945</fpage>–<lpage>957</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-011-2430-1</pub-id><pub-id pub-id-type="pmid">21833502</pub-id></mixed-citation>
</ref>
<ref id="B565">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milicic</surname><given-names>I.</given-names></name><name><surname>Buckner</surname><given-names>S. A.</given-names></name><name><surname>Daza</surname><given-names>A.</given-names></name><name><surname>Coghlan</surname><given-names>M.</given-names></name><name><surname>Fey</surname><given-names>T. A.</given-names></name><name><surname>Brune</surname><given-names>M. E.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Pharmacological characterization of urinary bladder smooth muscle contractility following partial bladder outlet obstruction in pigs.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>532</volume>
<fpage>107</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2005.12.076</pub-id><pub-id pub-id-type="pmid">16487510</pub-id></mixed-citation>
</ref>
<ref id="B566">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minns</surname><given-names>M. S.</given-names></name><name><surname>Teicher</surname><given-names>G.</given-names></name><name><surname>Rich</surname><given-names>C. B.</given-names></name><name><surname>Trinkaus-Randall</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinoreceptor P2X7 regulation of Ca<sup>2+</sup> mobilization and cytoskeletal rearrangement is required for corneal reepithelialization after injury.</article-title>
<source/><italic>Am. J. Pathol.</italic>
<volume>186</volume>
<fpage>285</fpage>–<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2015.10.006</pub-id><pub-id pub-id-type="pmid">26683661</pub-id></mixed-citation>
</ref>
<ref id="B567">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minns</surname><given-names>M. S.</given-names></name><name><surname>Trinkaus-Randall</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling in corneal wound healing: a tale of 2 receptors.</article-title>
<source/><italic>J. Ocul. Pharmacol. Ther.</italic>
<volume>32</volume>
<fpage>498</fpage>–<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1089/jop.2016.0009</pub-id><pub-id pub-id-type="pmid">27643999</pub-id></mixed-citation>
</ref>
<ref id="B568">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>M. F.</given-names></name><name><surname>Hamani</surname><given-names>C.</given-names></name><name><surname>De Almeida</surname><given-names>A. C.</given-names></name><name><surname>Amorim</surname><given-names>B. O.</given-names></name><name><surname>Macedo</surname><given-names>C. E.</given-names></name><name><surname>Fernandes</surname><given-names>M. J.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Role of adenosine in the antiepileptic effects of deep brain stimulation.</article-title>
<source/><italic>Front. Cell. Neurosci.</italic>
<volume>8</volume>:<issue>312</issue>
<pub-id pub-id-type="doi">10.3389/fncel.2014.00312</pub-id></mixed-citation>
</ref>
<ref id="B569">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miras-Portugal</surname><given-names>M. T.</given-names></name><name><surname>Diaz-Hernandez</surname><given-names>J. I.</given-names></name><name><surname>Gomez-Villafuertes</surname><given-names>R.</given-names></name><name><surname>Diaz-Hernandez</surname><given-names>M.</given-names></name><name><surname>Artalejo</surname><given-names>A. R.</given-names></name><name><surname>Gualix</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Role of P2X7 and P2Y2 receptors on α-secretase-dependent APP processing: control of amyloid plaques formation “in vivo” by P2X7 receptor.</article-title>
<source/><italic>Comput. Struct. Biotechnol. J.</italic>
<volume>13</volume>
<fpage>176</fpage>–<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2015.02.005</pub-id><pub-id pub-id-type="pmid">25848496</pub-id></mixed-citation>
</ref>
<ref id="B570">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>A.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>More</surname><given-names>S.</given-names></name><name><surname>Weng</surname><given-names>T.</given-names></name><name><surname>Chintagari</surname><given-names>N. R.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>A critical role for P2X7 receptor-induced VCAM-1 shedding and neutrophil infiltration during acute lung injury.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>197</volume>
<fpage>2828</fpage>–<lpage>2837</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1501041</pub-id><pub-id pub-id-type="pmid">27559050</pub-id></mixed-citation>
</ref>
<ref id="B571">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>R.</given-names></name><name><surname>Chan</surname><given-names>B.</given-names></name><name><surname>Grati</surname><given-names>M.</given-names></name><name><surname>Mittal</surname><given-names>J.</given-names></name><name><surname>Patel</surname><given-names>K.</given-names></name><name><surname>Debs</surname><given-names>L. H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Molecular structure and regulation of P2X receptors with a special emphasis on the role of P2X2 in the auditory system.</article-title>
<source/><italic>J. Cell. Physiol.</italic>
<volume>231</volume>
<fpage>1656</fpage>–<lpage>1670</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.25274</pub-id><pub-id pub-id-type="pmid">26627116</pub-id></mixed-citation>
</ref>
<ref id="B572">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molck</surname><given-names>C.</given-names></name><name><surname>Ryall</surname><given-names>J.</given-names></name><name><surname>Failla</surname><given-names>L. M.</given-names></name><name><surname>Coates</surname><given-names>J. L.</given-names></name><name><surname>Pascussi</surname><given-names>J. M.</given-names></name><name><surname>Heath</surname><given-names>J. K.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The A2b adenosine receptor antagonist PSB-603 promotes oxidative phosphorylation and ROS production in colorectal cancer cells via adenosine receptor-independent mechanism.</article-title>
<source/><italic>Cancer Lett.</italic>
<volume>383</volume>
<fpage>135</fpage>–<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2016.09.018</pub-id><pub-id pub-id-type="pmid">27693637</pub-id></mixed-citation>
</ref>
<ref id="B573">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>C. E.</given-names></name><name><surname>Llach</surname><given-names>A.</given-names></name><name><surname>Herraiz-Martínez</surname><given-names>A.</given-names></name><name><surname>Tarifa</surname><given-names>C.</given-names></name><name><surname>Barriga</surname><given-names>M.</given-names></name><name><surname>Wiegerinck</surname><given-names>R. F.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Prevention of adenosine A2A receptor activation diminishes beat-to-beat alternation in human atrial myocytes.</article-title>
<source/><italic>Basic Res. Cardiol.</italic>
<volume>111</volume>
<issue>5</issue>
<pub-id pub-id-type="doi">10.1007/s00395-015-0525-2</pub-id></mixed-citation>
</ref>
<ref id="B574">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molz</surname><given-names>S.</given-names></name><name><surname>Olescowicz</surname><given-names>G.</given-names></name><name><surname>Kraus</surname><given-names>J. R.</given-names></name><name><surname>Ludka</surname><given-names>F. K.</given-names></name><name><surname>Tasca</surname><given-names>C. I.</given-names></name></person-group> (<year>2015</year>). <article-title>Purine receptors are required for DHA-mediated neuroprotection against oxygen and glucose deprivation in hippocampal slices.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>117</fpage>–<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-014-9438-z</pub-id><pub-id pub-id-type="pmid">25504554</pub-id></mixed-citation>
</ref>
<ref id="B575">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monção-Ribeiro</surname><given-names>L. C.</given-names></name><name><surname>Faffe</surname><given-names>D. S.</given-names></name><name><surname>Santana</surname><given-names>P. T.</given-names></name><name><surname>Vieira</surname><given-names>F. S.</given-names></name><name><surname>Da Graca</surname><given-names>C. L.</given-names></name><name><surname>Marques-Da-Silva</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>P2X7 receptor modulates inflammatory and functional pulmonary changes induced by silica.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>9</volume>:<issue>e110185</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0110185</pub-id></mixed-citation>
</ref>
<ref id="B576">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montesinos</surname><given-names>M. C.</given-names></name><name><surname>Desai-Merchant</surname><given-names>A.</given-names></name><name><surname>Cronstein</surname><given-names>B. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Promotion of wound healing by an agonist of adenosine A2A receptor is dependent on tissue plasminogen activator.</article-title>
<source/><italic>Inflammation</italic>
<volume>38</volume>
<fpage>2036</fpage>–<lpage>2041</lpage>. <pub-id pub-id-type="doi">10.1007/s10753-015-0184-3</pub-id><pub-id pub-id-type="pmid">25991438</pub-id></mixed-citation>
</ref>
<ref id="B577">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morandini</surname><given-names>A. C.</given-names></name><name><surname>Savio</surname><given-names>L. E.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>The role of P2X7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases.</article-title>
<source/><italic>Biomed. J.</italic>
<volume>37</volume>
<fpage>169</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.4103/2319-4170.127803</pub-id><pub-id pub-id-type="pmid">25116711</pub-id></mixed-citation>
</ref>
<ref id="B578">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morello</surname><given-names>S.</given-names></name><name><surname>Sorrentino</surname><given-names>R.</given-names></name><name><surname>Montinaro</surname><given-names>A.</given-names></name><name><surname>Luciano</surname><given-names>A.</given-names></name><name><surname>Maiolino</surname><given-names>P.</given-names></name><name><surname>Ngkelo</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>NK1.1<sup>+</sup> cells and CD8<sup>+</sup> T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model.</article-title>
<source/><italic>Neoplasia</italic>
<volume>13</volume>
<fpage>365</fpage>–<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1593/neo.101628</pub-id><pub-id pub-id-type="pmid">21472141</pub-id></mixed-citation>
</ref>
<ref id="B579">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson’s disease.</article-title>
<source/><italic>Int. Rev. Neurobiol.</italic>
<volume>119</volume>
<fpage>k87</fpage>–<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-801022-8.00004-0</pub-id></mixed-citation>
</ref>
<ref id="B580">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrone</surname><given-names>F. B.</given-names></name><name><surname>Gehring</surname><given-names>M. P.</given-names></name><name><surname>Nicoletti</surname><given-names>N. F.</given-names></name></person-group> (<year>2016</year>). <article-title>Calcium channels and associated receptors in malignant brain tumor therapy.</article-title>
<source/><italic>Mol. Pharmacol.</italic>
<volume>90</volume>
<fpage>403</fpage>–<lpage>409</lpage>. <pub-id pub-id-type="doi">10.1124/mol.116.103770</pub-id><pub-id pub-id-type="pmid">27418672</pub-id></mixed-citation>
</ref>
<ref id="B581">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mrazek</surname><given-names>F.</given-names></name><name><surname>Gallo</surname><given-names>J.</given-names></name><name><surname>Stahelova</surname><given-names>A.</given-names></name><name><surname>Petrek</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Functional variants of the P2RX7 gene, aseptic osteolysis, and revision of the total hip arthroplasty: a preliminary study.</article-title>
<source/><italic>Hum. Immunol.</italic>
<volume>71</volume>
<fpage>201</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2009.10.013</pub-id><pub-id pub-id-type="pmid">19891999</pub-id></mixed-citation>
</ref>
<ref id="B582">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mujoomdar</surname><given-names>M.</given-names></name><name><surname>Bennett</surname><given-names>A.</given-names></name><name><surname>Hoskin</surname><given-names>D.</given-names></name><name><surname>Blay</surname><given-names>J.</given-names></name></person-group> (<year>2004</year>). <article-title>Adenosine stimulation of proliferation of breast carcinoma cell lines: evaluation of the [3H]thymidine assay system and modulatory effects of the cellular microenvironment in vitro.</article-title>
<source/><italic>J. Cell. Physiol.</italic>
<volume>201</volume>
<fpage>429</fpage>–<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.20089</pub-id><pub-id pub-id-type="pmid">15389546</pub-id></mixed-citation>
</ref>
<ref id="B583">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulryan</surname><given-names>K.</given-names></name><name><surname>Gitterman</surname><given-names>D. P.</given-names></name><name><surname>Lewis</surname><given-names>C. J.</given-names></name><name><surname>Vial</surname><given-names>C.</given-names></name><name><surname>Leckie</surname><given-names>B. J.</given-names></name><name><surname>Cobb</surname><given-names>A. L.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors.</article-title>
<source/><italic>Nature</italic>
<volume>403</volume>
<fpage>86</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1038/47495</pub-id><pub-id pub-id-type="pmid">10638758</pub-id></mixed-citation>
</ref>
<ref id="B584">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mumtaz</surname><given-names>F. H.</given-names></name><name><surname>Lau</surname><given-names>D. H.</given-names></name><name><surname>Siddiqui</surname><given-names>E. J.</given-names></name><name><surname>Morgan</surname><given-names>R. J.</given-names></name><name><surname>Thompson</surname><given-names>C. S.</given-names></name><name><surname>Mikhailidis</surname><given-names>D. P.</given-names></name></person-group> (<year>2006</year>). <article-title>Changes in cholinergic and purinergic neurotransmission in the diabetic rabbit bladder.</article-title>
<source/><italic>In Vivo</italic>
<volume>20</volume>
<fpage>1</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">16433020</pub-id></mixed-citation>
</ref>
<ref id="B585">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>A.</given-names></name><name><surname>Romain</surname><given-names>Z.</given-names></name><name><surname>Munch</surname><given-names>E.</given-names></name><name><surname>Gangitano</surname><given-names>D.</given-names></name><name><surname>Boone</surname><given-names>T.</given-names></name><name><surname>Smith</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Changes in purinergic and nitrergic sensory signals in female rats during early diabetes.</article-title>
<source/><italic>Neurourol. Urodyn.</italic>
<volume>28</volume>
<fpage>110</fpage>–<lpage>111</lpage>.</mixed-citation>
</ref>
<ref id="B586">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>A.</given-names></name><name><surname>Somogyi</surname><given-names>G. T.</given-names></name><name><surname>Boone</surname><given-names>T. B.</given-names></name><name><surname>Ford</surname><given-names>A. P.</given-names></name><name><surname>Smith</surname><given-names>C. P.</given-names></name></person-group> (<year>2012</year>). <article-title>Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3 receptors.</article-title>
<source/><italic>BJU Int.</italic>
<volume>110</volume>
<fpage>E409</fpage>–<lpage>E414</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11189.x</pub-id><pub-id pub-id-type="pmid">22540742</pub-id></mixed-citation>
</ref>
<ref id="B587">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>A.</given-names></name><name><surname>Yazdi</surname><given-names>I. K.</given-names></name><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Rivera</surname><given-names>C.</given-names></name><name><surname>Taghipour</surname><given-names>N.</given-names></name><name><surname>Grossman</surname><given-names>R. G.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Localized inhibition of P2X7R at the spinal cord injury site improves neurogenic bladder dysfunction by decreasing urothelial P2X3R expression in rats.</article-title>
<source/><italic>Life Sci.</italic>
<volume>171</volume>
<fpage>60</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2016.12.017</pub-id><pub-id pub-id-type="pmid">28039004</pub-id></mixed-citation>
</ref>
<ref id="B588">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>S.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Masunaga</surname><given-names>K.</given-names></name><name><surname>Maeda</surname><given-names>Y.</given-names></name><name><surname>Ueda</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Change in acetylcholine release from rat bladder with partial outlet obstruction.</article-title>
<source/><italic>BJU Int.</italic>
<volume>101</volume>
<fpage>633</fpage>–<lpage>639</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2007.07325.x</pub-id><pub-id pub-id-type="pmid">18070174</pub-id></mixed-citation>
</ref>
<ref id="B589">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muti</surname><given-names>M.</given-names></name><name><surname>Del Grande</surname><given-names>C.</given-names></name><name><surname>Musetti</surname><given-names>L.</given-names></name><name><surname>Marazziti</surname><given-names>D.</given-names></name><name><surname>Turri</surname><given-names>M.</given-names></name><name><surname>Cirronis</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium.</article-title>
<source/><italic>Psychiatry Res.</italic>
<volume>225</volume>
<fpage>604</fpage>–<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2014.11.038</pub-id><pub-id pub-id-type="pmid">25547850</pub-id></mixed-citation>
</ref>
<ref id="B590">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagahama</surname><given-names>M.</given-names></name><name><surname>Seike</surname><given-names>S.</given-names></name><name><surname>Shirai</surname><given-names>H.</given-names></name><name><surname>Takagishi</surname><given-names>T.</given-names></name><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Takehara</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Role of P2X7 receptor in <italic>Clostridium perfringens</italic> beta-toxin-mediated cellular injury.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1850</volume>
<fpage>2159</fpage>–<lpage>2167</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2015.08.011</pub-id><pub-id pub-id-type="pmid">26299247</pub-id></mixed-citation>
</ref>
<ref id="B591">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>Y.</given-names></name><name><surname>Yoshioka</surname><given-names>M.</given-names></name><name><surname>Abe</surname><given-names>Y.</given-names></name><name><surname>Uchinami</surname><given-names>H.</given-names></name><name><surname>Ohba</surname><given-names>T.</given-names></name><name><surname>Ono</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Enhancement of liver regeneration by adenosine triphosphate-sensitive K+ channel opener (diazoxide) after partial hepatectomy.</article-title>
<source/><italic>Transplantation</italic>
<volume>93</volume>
<fpage>1094</fpage>–<lpage>1100</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0b013e31824ef1d1</pub-id><pub-id pub-id-type="pmid">22466787</pub-id></mixed-citation>
</ref>
<ref id="B592">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamachi</surname><given-names>Y.</given-names></name><name><surname>Koshiba</surname><given-names>M.</given-names></name><name><surname>Nakazawa</surname><given-names>T.</given-names></name><name><surname>Hatachi</surname><given-names>S.</given-names></name><name><surname>Saura</surname><given-names>R.</given-names></name><name><surname>Kurosaka</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts.</article-title>
<source/><italic>Arthritis Rheum.</italic>
<volume>48</volume>
<fpage>668</fpage>–<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1002/art.10956</pub-id><pub-id pub-id-type="pmid">12632419</pub-id></mixed-citation>
</ref>
<ref id="B593">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>H. W.</given-names></name><name><surname>Bruner</surname><given-names>R. C.</given-names></name><name><surname>Choi</surname><given-names>D. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Adenosine signaling in striatal circuits and alcohol use disorders.</article-title>
<source/><italic>Mol. Cells</italic>
<volume>36</volume>
<fpage>195</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1007/s10059-013-0192-9</pub-id><pub-id pub-id-type="pmid">23912595</pub-id></mixed-citation>
</ref>
<ref id="B594">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>F.</given-names></name><name><surname>Pousinha</surname><given-names>P. A.</given-names></name><name><surname>Correia</surname><given-names>A. M.</given-names></name><name><surname>Gomes</surname><given-names>R.</given-names></name><name><surname>Sebastião</surname><given-names>A. M.</given-names></name><name><surname>Ribeiro</surname><given-names>J. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Adenosine A2A receptors activation facilitates neuromuscular transmission in the pre-symptomatic phase of the SOD1(G93A) ALS mice, but not in the symptomatic phase.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>9</volume>:<issue>e104081</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0104081</pub-id></mixed-citation>
</ref>
<ref id="B595">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>F.</given-names></name><name><surname>Sebastião</surname><given-names>A. M.</given-names></name><name><surname>Ribeiro</surname><given-names>J. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>11</volume>
<fpage>471</fpage>–<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9465-4</pub-id><pub-id pub-id-type="pmid">26335190</pub-id></mixed-citation>
</ref>
<ref id="B596">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>G.</given-names></name><name><surname>Borroto-Escuela</surname><given-names>D. O.</given-names></name><name><surname>Fuxe</surname><given-names>K.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling in Parkinson’s disease. Relevance for treatment.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>161</fpage>–<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.07.024</pub-id><pub-id pub-id-type="pmid">26211977</pub-id></mixed-citation>
</ref>
<ref id="B597">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naviaux</surname><given-names>J. C.</given-names></name><name><surname>Schuchbauer</surname><given-names>M. A.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Risbrough</surname><given-names>V. B.</given-names></name><name><surname>Powell</surname><given-names>S. B.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy.</article-title>
<source/><italic>Transl. Psychiatry</italic>
<volume>4</volume>
<issue>e400</issue>
<pub-id pub-id-type="doi">10.1038/tp.2014.33</pub-id></mixed-citation>
</ref>
<ref id="B598">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naviaux</surname><given-names>J. C.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Bright</surname><given-names>A. T.</given-names></name><name><surname>Alaynick</surname><given-names>W. A.</given-names></name><name><surname>Williams</surname><given-names>K. R.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Antipurinergic therapy corrects the autism-like features in the Fragile X (<italic>Fmr1</italic> knockout) mouse model.</article-title>
<source/><italic>Mol. Autism</italic>
<volume>6</volume>:<issue>1</issue>
<pub-id pub-id-type="doi">10.1186/2040-2392-6-1</pub-id></mixed-citation>
</ref>
<ref id="B599">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>S.</given-names></name><name><surname>Kiyono</surname><given-names>H.</given-names></name><name><surname>Kurashima</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Epithelial extracellular ATP: an initiator of immunity to parasitic infections.</article-title>
<source/><italic>Immunol. Cell Biol.</italic>
<volume>95</volume>
<fpage>117</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1038/icb.2016.106</pub-id><pub-id pub-id-type="pmid">27874014</pub-id></mixed-citation>
</ref>
<ref id="B600">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuhuber</surname><given-names>W. L.</given-names></name><name><surname>Tiegs</surname><given-names>G.</given-names></name></person-group> (<year>2004</year>). <article-title>Innervation of immune cells: evidence for neuroimmunomodulation in the liver.</article-title>
<source/><italic>Anat. Rec. A Discov. Mol. Cell. Evol. Biol.</italic>
<volume>280</volume>
<fpage>884</fpage>–<lpage>892</lpage>. <pub-id pub-id-type="doi">10.1002/ar.a.20093</pub-id><pub-id pub-id-type="pmid">15382013</pub-id></mixed-citation>
</ref>
<ref id="B601">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neves</surname><given-names>A. R.</given-names></name><name><surname>Castelo-Branco</surname><given-names>M. T.</given-names></name><name><surname>Figliuolo</surname><given-names>V. R.</given-names></name><name><surname>Bernardazzi</surname><given-names>C.</given-names></name><name><surname>Buongusto</surname><given-names>F.</given-names></name><name><surname>Yoshimoto</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Overexpression of ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn’s disease.</article-title>
<source/><italic>Inflamm. Bowel Dis.</italic>
<volume>20</volume>
<fpage>444</fpage>–<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1097/01.MIB.0000441201.10454.06</pub-id><pub-id pub-id-type="pmid">24412990</pub-id></mixed-citation>
</ref>
<ref id="B602">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>S. K.</given-names></name><name><surname>Higashimori</surname><given-names>H.</given-names></name><name><surname>Tolman</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis.</article-title>
<source/><italic>Exp. Neurol.</italic>
<volume>267</volume>
<fpage>115</fpage>–<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2015.03.004</pub-id><pub-id pub-id-type="pmid">25779930</pub-id></mixed-citation>
</ref>
<ref id="B603">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>R.</given-names></name><name><surname>Zheng</surname><given-names>D.</given-names></name><name><surname>Xiong</surname><given-names>S.</given-names></name><name><surname>Hill</surname><given-names>D. J.</given-names></name><name><surname>Sun</surname><given-names>T.</given-names></name><name><surname>Gardiner</surname><given-names>R. B.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Mitochondrial calpain-1 disrupts ATP synthase and induces superoxide generation in type 1 diabetic hearts: a novel mechanism contributing to diabetic cardiomyopathy.</article-title>
<source/><italic>Diabetes Metab. Res. Rev.</italic>
<volume>65</volume>
<fpage>255</fpage>–<lpage>268</lpage>. <pub-id pub-id-type="doi">10.2337/db15-0963</pub-id></mixed-citation>
</ref>
<ref id="B604">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>C.</given-names></name><name><surname>Wen</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Blackburn</surname><given-names>M.</given-names></name><name><surname>Kellems</surname><given-names>R.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name></person-group> (<year>2012a</year>). <article-title>Impaired adenosine signaling contributes to erectile dysfunction.</article-title>
<source/><italic>J. Sex. Med.</italic>
<volume>9</volume>
<fpage>183</fpage>–<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.111.226803</pub-id><pub-id pub-id-type="pmid">22862809</pub-id></mixed-citation>
</ref>
<ref id="B605">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>J.</given-names></name><name><surname>Blackburn</surname><given-names>M.</given-names></name><name><surname>Kellems</surname><given-names>R.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name></person-group> (<year>2012b</year>). <article-title>Adenosine signaling in priapism and novel therapies.</article-title>
<source/><italic>J. Sex. Med.</italic>
<volume>9</volume>
<issue>223</issue>.</mixed-citation>
</ref>
<ref id="B606">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noronha-Matos</surname><given-names>J. B.</given-names></name><name><surname>Morais</surname><given-names>T.</given-names></name><name><surname>Trigo</surname><given-names>D.</given-names></name><name><surname>Timóteo</surname><given-names>M. A.</given-names></name><name><surname>Magalhães-Cardoso</surname><given-names>M. T.</given-names></name><name><surname>Oliveira</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Tetanic failure due to decreased endogenous adenosine A2A tonus operating neuronal Cav 1 (L-type) influx in Myasthenia gravis.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>117</volume>
<fpage>797</fpage>–<lpage>811</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07216.x</pub-id><pub-id pub-id-type="pmid">21323926</pub-id></mixed-citation>
</ref>
<ref id="B607">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novitskaya</surname><given-names>T.</given-names></name><name><surname>Chepurko</surname><given-names>E.</given-names></name><name><surname>Covarrubias</surname><given-names>R.</given-names></name><name><surname>Novitskiy</surname><given-names>S.</given-names></name><name><surname>Ryzhov</surname><given-names>S. V.</given-names></name><name><surname>Feoktistov</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Extracellular nucleotide regulation and signaling in cardiac fibrosis.</article-title>
<source/><italic>J. Mol. Cell. Cardiol.</italic>
<volume>93</volume>
<fpage>47</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2016.02.010</pub-id><pub-id pub-id-type="pmid">26891859</pub-id></mixed-citation>
</ref>
<ref id="B608">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nylander</surname><given-names>S.</given-names></name><name><surname>Schulz</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>173</volume>
<fpage>1163</fpage>–<lpage>1178</lpage>. <pub-id pub-id-type="doi">10.1111/bph.13429</pub-id><pub-id pub-id-type="pmid">26758983</pub-id></mixed-citation>
</ref>
<ref id="B609">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa-Cortes</surname><given-names>F.</given-names></name><name><surname>Liñán-Rico</surname><given-names>A.</given-names></name><name><surname>Jacobson</surname><given-names>K. A.</given-names></name><name><surname>Christofi</surname><given-names>F. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Potential for developing purinergic drugs for gastrointestinal diseases.</article-title>
<source/><italic>Inflamm. Bowel Dis.</italic>
<volume>20</volume>
<fpage>1259</fpage>–<lpage>1287</lpage>. <pub-id pub-id-type="doi">10.1097/MIB.0000000000000047</pub-id><pub-id pub-id-type="pmid">24859298</pub-id></mixed-citation>
</ref>
<ref id="B610">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohshima</surname><given-names>Y.</given-names></name><name><surname>Tsukimoto</surname><given-names>M.</given-names></name><name><surname>Takenouchi</surname><given-names>T.</given-names></name><name><surname>Harada</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>A.</given-names></name><name><surname>Sato</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>γ-Irradiation induces P2X7 receptor-dependent ATP release from B16 melanoma cells.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1800</volume>
<fpage>40</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2009.10.008</pub-id><pub-id pub-id-type="pmid">19854240</pub-id></mixed-citation>
</ref>
<ref id="B611">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olatunji</surname><given-names>O. J.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Olatunji</surname><given-names>O. O.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Ouyang</surname><given-names>Z.</given-names></name><name><surname>Su</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Neuroprotective effects of adenosine isolated from <italic>Cordyceps cicadae</italic> against oxidative and ER stress damages induced by glutamate in PC12 cells.</article-title>
<source/><italic>Environ. Toxicol. Pharmacol.</italic>
<volume>44</volume>
<fpage>53</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.etap.2016.02.009</pub-id><pub-id pub-id-type="pmid">27114365</pub-id></mixed-citation>
</ref>
<ref id="B612">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>A. G.</given-names></name><name><surname>Marques</surname><given-names>P. E.</given-names></name><name><surname>Amaral</surname><given-names>S. S.</given-names></name><name><surname>Quintão</surname><given-names>J. L.</given-names></name><name><surname>Cogliati</surname><given-names>B.</given-names></name><name><surname>Dagli</surname><given-names>M. L.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Purinergic signalling during sterile liver injury.</article-title>
<source/><italic>Liver Int.</italic>
<volume>33</volume>
<fpage>353</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1111/liv.12109</pub-id><pub-id pub-id-type="pmid">23402607</pub-id></mixed-citation>
</ref>
<ref id="B613">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>L.</given-names></name><name><surname>Correia</surname><given-names>A.</given-names></name><name><surname>Costa</surname><given-names>A. C.</given-names></name><name><surname>Guerra-Gomes</surname><given-names>S.</given-names></name><name><surname>Ferreirinha</surname><given-names>F.</given-names></name><name><surname>Magalhães-Cardoso</surname><given-names>M. T.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Deficits in endogenous adenosine formation by ecto-5′-nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis.</article-title>
<source/><italic>Mediators Inflamm.</italic>
<volume>2015</volume>:<issue>460610</issue>
<pub-id pub-id-type="doi">10.1155/2015/460610</pub-id></mixed-citation>
</ref>
<ref id="B614">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivier</surname><given-names>E.</given-names></name><name><surname>Dutot</surname><given-names>M.</given-names></name><name><surname>Regazzetti</surname><given-names>A.</given-names></name><name><surname>Leguillier</surname><given-names>T.</given-names></name><name><surname>Dargere</surname><given-names>D.</given-names></name><name><surname>Auzeil</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>P2X7-pannexin-1 and amyloid β-induced oxysterol input in human retinal cell: role in age-related macular degeneration?</article-title>
<source/><italic>Biochimie</italic>
<volume>127</volume>
<fpage>70</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.biochi.2016.04.014</pub-id><pub-id pub-id-type="pmid">27109381</pub-id></mixed-citation>
</ref>
<ref id="B615">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ondrakova</surname><given-names>M.</given-names></name><name><surname>Knot</surname><given-names>J.</given-names></name><name><surname>Ulman</surname><given-names>J.</given-names></name><name><surname>Maly</surname><given-names>M.</given-names></name><name><surname>Motovska</surname><given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>Efficacy of P2Y12 receptor antagonists in patients with atrial fibrillation according to the CHA2DS2VASc score.</article-title>
<source/><italic>Int. J. Cardiol.</italic>
<volume>207</volume>
<fpage>84</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2016.01.039</pub-id><pub-id pub-id-type="pmid">26797336</pub-id></mixed-citation>
</ref>
<ref id="B616">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ongaro</surname><given-names>A.</given-names></name><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Masieri</surname><given-names>F. F.</given-names></name><name><surname>Pellati</surname><given-names>A.</given-names></name><name><surname>Massari</surname><given-names>L.</given-names></name><name><surname>Cadossi</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblasts.</article-title>
<source/><italic>J. Cell. Physiol.</italic>
<volume>227</volume>
<fpage>2461</fpage>–<lpage>2469</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.22981</pub-id><pub-id pub-id-type="pmid">21830213</pub-id></mixed-citation>
</ref>
<ref id="B617">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Reilly</surname><given-names>B. A.</given-names></name><name><surname>Kosaka</surname><given-names>A. H.</given-names></name><name><surname>Knight</surname><given-names>G. E.</given-names></name><name><surname>Chang</surname><given-names>T. K.</given-names></name><name><surname>Ford</surname><given-names>A. P. D. W.</given-names></name><name><surname>Rymer</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>P2X receptors and their role in female idiopathic detrusor instability.</article-title>
<source/><italic>J. Urol.</italic>
<volume>167</volume>
<fpage>157</fpage>–<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-5347(05)65403-1</pub-id><pub-id pub-id-type="pmid">11743296</pub-id></mixed-citation>
</ref>
<ref id="B618">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orriss</surname><given-names>I. R.</given-names></name><name><surname>Arnett</surname><given-names>T. R.</given-names></name><name><surname>Russell</surname><given-names>R. G.</given-names></name></person-group> (<year>2016</year>). <article-title>Pyrophosphate: a key inhibitor of mineralisation.</article-title>
<source/><italic>Curr. Opin. Pharmacol.</italic>
<volume>28</volume>
<fpage>57</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2016.03.003</pub-id><pub-id pub-id-type="pmid">27061894</pub-id></mixed-citation>
</ref>
<ref id="B619">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orth</surname><given-names>S. R.</given-names></name><name><surname>Amann</surname><given-names>K.</given-names></name><name><surname>Strojek</surname><given-names>K.</given-names></name><name><surname>Ritz</surname><given-names>E.</given-names></name></person-group> (<year>2001</year>). <article-title>Sympathetic overactivity and arterial hypertension in renal failure.</article-title>
<source/><italic>Nephrol. Dial. Transplant.</italic>
<volume>16(Suppl. 1)</volume>, <fpage>67</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1093/ndt/16.suppl_1.67</pub-id></mixed-citation>
</ref>
<ref id="B620">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>R.</given-names></name><name><surname>Ulrich</surname><given-names>H.</given-names></name><name><surname>Zarate</surname><given-names>C. A.</given-names><suffix>Jr.</suffix></name><name><surname>Machado-Vieira</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.</article-title>
<source/><italic>Prog. Neuropsychopharmacol. Biol. Psychiatry</italic>
<volume>57</volume>
<fpage>117</fpage>–<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2014.10.016</pub-id><pub-id pub-id-type="pmid">25445063</pub-id></mixed-citation>
</ref>
<ref id="B621">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>You</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Olig2-targeted G-protein-coupled receptor Gpr17 regulates oligodendrocyte survival in response to lysolecithin-induced demyelination.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>36</volume>
<fpage>k10560</fpage>–<lpage>10573</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0898-16.2016</pub-id></mixed-citation>
</ref>
<ref id="B622">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oury</surname><given-names>C.</given-names></name><name><surname>Lecut</surname><given-names>C.</given-names></name><name><surname>Hego</surname><given-names>A.</given-names></name><name><surname>Wéra</surname><given-names>O.</given-names></name><name><surname>Delierneux</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>Purinergic control of inflammation and thrombosis: role of P2X1 receptors.</article-title>
<source/><italic>Comput. Struct. Biotechnol. J.</italic>
<volume>13</volume>
<fpage>106</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2014.11.008</pub-id><pub-id pub-id-type="pmid">25709760</pub-id></mixed-citation>
</ref>
<ref id="B623">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyarzun</surname><given-names>C.</given-names></name><name><surname>Garrido</surname><given-names>W.</given-names></name><name><surname>Alarcon</surname><given-names>S.</given-names></name><name><surname>Yanez</surname><given-names>A.</given-names></name><name><surname>Sobrevia</surname><given-names>L.</given-names></name><name><surname>Quezada</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Adenosine contribution to normal renal physiology and chronic kidney disease.</article-title>
<source/><italic>Mol. Aspects Med.</italic>
<volume>55</volume>
<fpage>75</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2017.01.004</pub-id><pub-id pub-id-type="pmid">28109856</pub-id></mixed-citation>
</ref>
<ref id="B624">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>T.</given-names></name><name><surname>Muramatsu</surname><given-names>R.</given-names></name><name><surname>Sasai</surname><given-names>M.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Kubota</surname><given-names>Y.</given-names></name><name><surname>Fujinaka</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The P2X4 receptor is required for neuroprotection via ischemic preconditioning.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>6</volume>:<issue>25893</issue>
<pub-id pub-id-type="doi">10.1038/srep25893</pub-id></mixed-citation>
</ref>
<ref id="B625">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacheco</surname><given-names>P. A.</given-names></name><name><surname>Faria</surname><given-names>R. X.</given-names></name><name><surname>Ferreira</surname><given-names>L. G.</given-names></name><name><surname>Paixão</surname><given-names>I. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Putative roles of purinergic signaling in human immunodeficiency virus-1 infection.</article-title>
<source/><italic>Biol. Direct</italic>
<volume>9</volume>:<issue>21</issue>
<pub-id pub-id-type="doi">10.1186/1745-6150-9-21</pub-id></mixed-citation>
</ref>
<ref id="B626">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandolfi</surname><given-names>J. B.</given-names></name><name><surname>Ferraro</surname><given-names>A. A.</given-names></name><name><surname>Sananez</surname><given-names>I.</given-names></name><name><surname>Gancedo</surname><given-names>M. C.</given-names></name><name><surname>Baz</surname><given-names>P.</given-names></name><name><surname>Billordo</surname><given-names>L. A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>ATP-induced inflammation drives tissue-resident Th17 cells in metabolically unhealthy obesity.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>196</volume>
<fpage>3287</fpage>–<lpage>3296</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1502506</pub-id><pub-id pub-id-type="pmid">26951799</pub-id></mixed-citation>
</ref>
<ref id="B627">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panjehpour</surname><given-names>M.</given-names></name><name><surname>Hemati</surname><given-names>S.</given-names></name><name><surname>Forghani</surname><given-names>M. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Expression of A1 and A3 adenosine receptors in human breast tumors.</article-title>
<source/><italic>Tumori</italic>
<volume>98</volume>
<fpage>137</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1700/1053.11512</pub-id><pub-id pub-id-type="pmid">22495714</pub-id></mixed-citation>
</ref>
<ref id="B628">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parabucki</surname><given-names>A.</given-names></name><name><surname>Savic</surname><given-names>D.</given-names></name><name><surname>Laketa</surname><given-names>D.</given-names></name><name><surname>Pekovic</surname><given-names>S.</given-names></name><name><surname>Stojiljkovic</surname><given-names>M.</given-names></name><name><surname>Nedeljkovic</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Expression of major ectonucleotidases after cortical stab brain injury in rats: a real-time PCR study.</article-title>
<source/><italic>Arch. Biol. Sci. Belgrade</italic>
<volume>66</volume>
<fpage>149</fpage>–<lpage>155</lpage>. <pub-id pub-id-type="doi">10.2298/ABS1401148P</pub-id></mixed-citation>
</ref>
<ref id="B629">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Honoré</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Polycystins and renovascular mechanosensory transduction.</article-title>
<source/><italic>Nat. Rev. Nephrol.</italic>
<volume>6</volume>
<fpage>530</fpage>–<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2010.97</pub-id><pub-id pub-id-type="pmid">20625375</pub-id></mixed-citation>
</ref>
<ref id="B630">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedata</surname><given-names>F.</given-names></name><name><surname>Dettori</surname><given-names>I.</given-names></name><name><surname>Coppi</surname><given-names>E.</given-names></name><name><surname>Melani</surname><given-names>A.</given-names></name><name><surname>Fusco</surname><given-names>I.</given-names></name><name><surname>Corradetti</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Purinergic signalling in brain ischemia.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>105</fpage>–<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.11.007</pub-id><pub-id pub-id-type="pmid">26581499</pub-id></mixed-citation>
</ref>
<ref id="B631">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedata</surname><given-names>F.</given-names></name><name><surname>Pugliese</surname><given-names>A. M.</given-names></name><name><surname>Coppi</surname><given-names>E.</given-names></name><name><surname>Dettori</surname><given-names>I.</given-names></name><name><surname>Maraula</surname><given-names>G.</given-names></name><name><surname>Cellai</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Adenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemia.</article-title>
<source/><italic>Mediators Inflamm.</italic>
<volume>2014</volume>:<issue>805198</issue>
<pub-id pub-id-type="doi">10.1155/2014/805198</pub-id></mixed-citation>
</ref>
<ref id="B632">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>H.</given-names></name><name><surname>Linden</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine influences myeloid cells to inhibit aeroallergen sensitization.</article-title>
<source/><italic>Am. J. Physiol. Lung Cell. Mol. Physiol.</italic>
<volume>310</volume>
<fpage>L985</fpage>–<lpage>L992</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00330.2015</pub-id><pub-id pub-id-type="pmid">27016586</pub-id></mixed-citation>
</ref>
<ref id="B633">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelleg</surname><given-names>A.</given-names></name><name><surname>Schulman</surname><given-names>E. S.</given-names></name><name><surname>Barnes</surname><given-names>P. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Extracellular adenosine 5′-triphosphate in obstructive airway diseases.</article-title>
<source/><italic>Chest</italic>
<volume>150</volume>
<fpage>908</fpage>–<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2016.06.045</pub-id><pub-id pub-id-type="pmid">27568579</pub-id></mixed-citation>
</ref>
<ref id="B634">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>lncRNA NONRATT021972 siRNA decreases diabetic neuropathic pain mediated by the P2X3 receptor in dorsal root ganglia.</article-title>
<source/><italic>Mol. Neurobiol.</italic>
<volume>54</volume>
<fpage>511</fpage>–<lpage>523</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-015-9632-1</pub-id><pub-id pub-id-type="pmid">26742527</pub-id></mixed-citation>
</ref>
<ref id="B635">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>W.</given-names></name><name><surname>Cotrina</surname><given-names>M. L.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Bekar</surname><given-names>L.</given-names></name><name><surname>Blum</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>106</volume>
<fpage>12489</fpage>–<lpage>12493</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0902531106</pub-id><pub-id pub-id-type="pmid">19666625</pub-id></mixed-citation>
</ref>
<ref id="B636">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>V. S.</given-names></name><name><surname>Casarotto</surname><given-names>P. C.</given-names></name><name><surname>Hiroaki-Sato</surname><given-names>V. A.</given-names></name><name><surname>Sartim</surname><given-names>A. G.</given-names></name><name><surname>Guimarães</surname><given-names>F. S.</given-names></name><name><surname>Joca</surname><given-names>S. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: involvement of nitric oxide.</article-title>
<source/><italic>Eur. Neuropsychopharmacol.</italic>
<volume>23</volume>
<fpage>1769</fpage>–<lpage>1778</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2013.01.008</pub-id><pub-id pub-id-type="pmid">23434291</pub-id></mixed-citation>
</ref>
<ref id="B637">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez de Lara</surname><given-names>M. J.</given-names></name><name><surname>Guzmán-Aránguez</surname><given-names>A.</given-names></name><name><surname>De La Villa</surname><given-names>P.</given-names></name><name><surname>Díaz-Hernández</surname><given-names>J. I.</given-names></name><name><surname>Miras-Portugal</surname><given-names>M. T.</given-names></name><name><surname>Pintor</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Increased levels of extracellular ATP in glaucomatous retinas: possible role of the vesicular nucleotide transporter during the development of the pathology.</article-title>
<source/><italic>Mol. Vis.</italic>
<volume>21</volume>
<fpage>1060</fpage>–<lpage>1070</lpage>.<pub-id pub-id-type="pmid">26392744</pub-id></mixed-citation>
</ref>
<ref id="B638">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Aso</surname><given-names>M.</given-names></name><name><surname>Mediero</surname><given-names>A.</given-names></name><name><surname>Low</surname><given-names>Y. C.</given-names></name><name><surname>Levine</surname><given-names>J.</given-names></name><name><surname>Cronstein</surname><given-names>B. N.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine A2A receptor plays an important role in radiation-induced dermal injury.</article-title>
<source/><italic>FASEB J.</italic>
<volume>30</volume>
<fpage>457</fpage>–<lpage>465</lpage>. <pub-id pub-id-type="doi">10.1096/fj.15-280388</pub-id><pub-id pub-id-type="pmid">26415936</pub-id></mixed-citation>
</ref>
<ref id="B639">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez-Sen</surname><given-names>R.</given-names></name><name><surname>Queipo</surname><given-names>M. J.</given-names></name><name><surname>Morente</surname><given-names>V.</given-names></name><name><surname>Ortega</surname><given-names>F.</given-names></name><name><surname>Delicado</surname><given-names>E. G.</given-names></name><name><surname>Miras-Portugal</surname><given-names>M. T.</given-names></name></person-group> (<year>2015</year>). <article-title>Neuroprotection mediated by P2Y13 nucleotide receptors in neurons.</article-title>
<source/><italic>Comput. Struct. Biotechnol. J.</italic>
<volume>13</volume>
<fpage>160</fpage>–<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2015.02.002</pub-id><pub-id pub-id-type="pmid">25750704</pub-id></mixed-citation>
</ref>
<ref id="B640">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persson</surname><given-names>P.</given-names></name><name><surname>Friederich-Persson</surname><given-names>M.</given-names></name><name><surname>Fasching</surname><given-names>A.</given-names></name><name><surname>Hansell</surname><given-names>P.</given-names></name><name><surname>Inagi</surname><given-names>R.</given-names></name><name><surname>Palm</surname><given-names>F.</given-names></name></person-group> (<year>2015</year>). <article-title>Adenosine A2 a receptor stimulation prevents proteinuria in diabetic rats by promoting an anti-inflammatory phenotype without affecting oxidative stress.</article-title>
<source/><italic>Acta Physiol.</italic>
<volume>214</volume>
<fpage>311</fpage>–<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1111/apha.12511</pub-id></mixed-citation>
</ref>
<ref id="B641">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrasek</surname><given-names>J.</given-names></name><name><surname>Iracheta-Vellve</surname><given-names>A.</given-names></name><name><surname>Saha</surname><given-names>B.</given-names></name><name><surname>Satishchandran</surname><given-names>A.</given-names></name><name><surname>Kodys</surname><given-names>K.</given-names></name><name><surname>Fitzgerald</surname><given-names>K. A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease.</article-title>
<source/><italic>J. Leukoc. Biol.</italic>
<volume>98</volume>
<fpage>249</fpage>–<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.3AB1214-590R</pub-id><pub-id pub-id-type="pmid">25934928</pub-id></mixed-citation>
</ref>
<ref id="B642">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettengill</surname><given-names>M. A.</given-names></name><name><surname>Abdul-Sater</surname><given-names>A.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name><name><surname>Ojcius</surname><given-names>D. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Danger signals, inflammasomes, and the intricate intracellular lives of chlamydiae.</article-title>
<source/><italic>Biomed. J.</italic>
<volume>39</volume>
<fpage>306</fpage>–<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1016/j.bj.2016.07.001</pub-id><pub-id pub-id-type="pmid">27884377</pub-id></mixed-citation>
</ref>
<ref id="B643">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>E.</given-names></name><name><surname>Carpenter</surname><given-names>C.</given-names></name><name><surname>Oates</surname><given-names>R. D.</given-names></name></person-group> (<year>2014</year>). <article-title>Ejaculatory dysfunction.</article-title>
<source/><italic>Urol. Clin. North Am.</italic>
<volume>41</volume>
<fpage>115</fpage>–<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1016/j.ucl.2013.08.018</pub-id><pub-id pub-id-type="pmid">24286771</pub-id></mixed-citation>
</ref>
<ref id="B644">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pijacka</surname><given-names>W.</given-names></name><name><surname>Moraes</surname><given-names>D. J. A.</given-names></name><name><surname>Ratcliffe</surname><given-names>L. E. K.</given-names></name><name><surname>Nightingale</surname><given-names>A. K.</given-names></name><name><surname>Hart</surname><given-names>E. C.</given-names></name><name><surname>Da Silva</surname><given-names>M. P.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Purinergic receptors in the carotid body as a new drug target for controlling hypertension.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>22</volume>
<fpage>1151</fpage>–<lpage>1159</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4173</pub-id><pub-id pub-id-type="pmid">27595323</pub-id></mixed-citation>
</ref>
<ref id="B645">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinna</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.</article-title>
<source/><italic>CNS Drugs</italic>
<volume>28</volume>
<fpage>455</fpage>–<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1007/s40263-014-0161-7</pub-id><pub-id pub-id-type="pmid">24687255</pub-id></mixed-citation>
</ref>
<ref id="B646">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pintsuk</surname><given-names>J.</given-names></name><name><surname>Borroto-Escuela</surname><given-names>D. O.</given-names></name><name><surname>Pomierny</surname><given-names>B.</given-names></name><name><surname>Wydra</surname><given-names>K.</given-names></name><name><surname>Zaniewska</surname><given-names>M.</given-names></name><name><surname>Filip</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Cocaine self-administration differentially affects allosteric A2A-D2 receptor-receptor interactions in the striatum. Relevance for cocaine use disorder.</article-title>
<source/><italic>Pharmacol. Biochem. Behav.</italic>
<volume>144</volume>
<fpage>85</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2016.03.004</pub-id><pub-id pub-id-type="pmid">26987369</pub-id></mixed-citation>
</ref>
<ref id="B647">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plemel</surname><given-names>J. R.</given-names></name><name><surname>Keough</surname><given-names>M. B.</given-names></name><name><surname>Duncan</surname><given-names>G. J.</given-names></name><name><surname>Sparling</surname><given-names>J. S.</given-names></name><name><surname>Yong</surname><given-names>V. W.</given-names></name><name><surname>Stys</surname><given-names>P. K.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Remyelination after spinal cord injury: is it a target for repair?</article-title>
<source/><italic>Prog. Neurobiol.</italic>
<volume>117</volume>
<fpage>54</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2014.02.006</pub-id><pub-id pub-id-type="pmid">24582777</pub-id></mixed-citation>
</ref>
<ref id="B648">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pochmann</surname><given-names>D.</given-names></name><name><surname>Rucker</surname><given-names>B.</given-names></name><name><surname>Battastini</surname><given-names>A. M.</given-names></name><name><surname>Sarkis</surname><given-names>J. J.</given-names></name></person-group> (<year>2004</year>). <article-title>Ovariectomy and estradiol replacement therapy alters the adenine nucleotide hydrolysis in rat blood serum.</article-title>
<source/><italic>Thromb. Res.</italic>
<volume>114</volume>
<fpage>275</fpage>–<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1016/j.thromres.2004.06.021</pub-id><pub-id pub-id-type="pmid">15381391</pub-id></mixed-citation>
</ref>
<ref id="B649">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portales-Cervantes</surname><given-names>L.</given-names></name><name><surname>Niño-Moreno</surname><given-names>P.</given-names></name><name><surname>Doníz-Padilla</surname><given-names>L.</given-names></name><name><surname>Baranda-Candido</surname><given-names>L.</given-names></name><name><surname>García-Hernández</surname><given-names>M.</given-names></name><name><surname>Salgado-Bustamante</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Expression and function of the P2X7 purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.</article-title>
<source/><italic>Hum. Immunol.</italic>
<volume>71</volume>
<fpage>818</fpage>–<lpage>825</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2010.05.008</pub-id><pub-id pub-id-type="pmid">20493226</pub-id></mixed-citation>
</ref>
<ref id="B650">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portales-Cervantes</surname><given-names>L.</given-names></name><name><surname>Niño-Moreno</surname><given-names>P.</given-names></name><name><surname>Salgado-Bustamante</surname><given-names>M.</given-names></name><name><surname>García-Hernández</surname><given-names>M. H.</given-names></name><name><surname>Baranda-Candido</surname><given-names>L.</given-names></name><name><surname>Reynaga-Hernández</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>The His155Tyr (489C&gt;T) single nucleotide polymorphism of P2RX7 gene confers an enhanced function of P2X7 receptor in immune cells from patients with rheumatoid arthritis.</article-title>
<source/><italic>Cell. Immunol.</italic>
<volume>276</volume>
<fpage>168</fpage>–<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.cellimm.2012.05.005</pub-id><pub-id pub-id-type="pmid">22703695</pub-id></mixed-citation>
</ref>
<ref id="B651">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritchard</surname><given-names>M.</given-names></name><name><surname>Mandal</surname><given-names>P.</given-names></name><name><surname>Chiang</surname><given-names>D. J.</given-names></name><name><surname>Ndum</surname><given-names>O.</given-names></name><name><surname>Nagy</surname><given-names>L. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Adenosine and adenosine signaling contribute to the anti-inflammatory effect of globular adiponectin in macrophages.</article-title>
<source/><italic>Hepatology</italic>
<volume>54</volume>
<fpage>1099A</fpage>–<lpage>1100A</lpage>.</mixed-citation>
</ref>
<ref id="B652">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puchalowicz</surname><given-names>K.</given-names></name><name><surname>Tarnowski</surname><given-names>M.</given-names></name><name><surname>Baranowska-Bosiacka</surname><given-names>I.</given-names></name><name><surname>Chlubek</surname><given-names>D.</given-names></name><name><surname>Dziedziejko</surname><given-names>V.</given-names></name></person-group> (<year>2014</year>). <article-title>P2X and P2Y receptors-role in the pathophysiology of the nervous system.</article-title>
<source/><italic>Int. J. Mol. Sci.</italic>
<volume>15</volume>
<fpage>23672</fpage>–<lpage>23704</lpage>. <pub-id pub-id-type="doi">10.3390/ijms151223672</pub-id><pub-id pub-id-type="pmid">25530618</pub-id></mixed-citation>
</ref>
<ref id="B653">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>Z. J.</given-names></name><name><surname>Sun</surname><given-names>L. Y.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>Z. G.</given-names></name></person-group> (<year>2017</year>). <article-title>Correlation between survival interval and CD4+ T-cell intracellular ATP levels in liver transplant recipients.</article-title>
<source/><italic>Transplant. Proc.</italic>
<volume>49</volume>
<fpage>316</fpage>–<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1016/j.transproceed.2016.11.044</pub-id><pub-id pub-id-type="pmid">28219591</pub-id></mixed-citation>
</ref>
<ref id="B654">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quezada</surname><given-names>C.</given-names></name><name><surname>Alarcón</surname><given-names>S.</given-names></name><name><surname>Jaramillo</surname><given-names>C.</given-names></name><name><surname>Muñoz</surname><given-names>D.</given-names></name><name><surname>Oyarzún</surname><given-names>C.</given-names></name><name><surname>San Martín</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Targeting adenosine signaling to treatment of diabetic nephropathy.</article-title>
<source/><italic>Curr. Drug Targets</italic>
<volume>14</volume>
<fpage>490</fpage>–<lpage>496</lpage>. <pub-id pub-id-type="doi">10.2174/1389450111314040010</pub-id><pub-id pub-id-type="pmid">23316933</pub-id></mixed-citation>
</ref>
<ref id="B655">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>B.</given-names></name><name><surname>Kaur</surname><given-names>J.</given-names></name><name><surname>Jacobs</surname><given-names>R.</given-names></name><name><surname>Anand</surname><given-names>S. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Adenosine deaminase in saliva as a diagnostic marker of squamous cell carcinoma of tongue.</article-title>
<source/><italic>Clin. Oral Investig.</italic>
<volume>15</volume>
<fpage>347</fpage>–<lpage>349</lpage>. <pub-id pub-id-type="doi">10.1007/s00784-010-0404-z</pub-id></mixed-citation>
</ref>
<ref id="B656">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralevic</surname><given-names>V.</given-names></name></person-group> (<year>2015</year>). <article-title>P2X receptors in the cardiovascular system and their potential as therapeutic targets in disease.</article-title>
<source/><italic>Curr. Med. Chem.</italic>
<volume>22</volume>
<fpage>851</fpage>–<lpage>865</lpage>. <pub-id pub-id-type="doi">10.2174/0929867321666141215094050</pub-id><pub-id pub-id-type="pmid">25515516</pub-id></mixed-citation>
</ref>
<ref id="B657">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralevic</surname><given-names>V.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>1998</year>). <article-title>Receptors for purines and pyrimidines.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>50</volume>
<fpage>413</fpage>–<lpage>492</lpage>.<pub-id pub-id-type="pmid">9755289</pub-id></mixed-citation>
</ref>
<ref id="B658">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rama Rao</surname><given-names>K. V.</given-names></name><name><surname>Kielian</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>Neuron-astrocyte interactions in neurodegenerative diseases: role of neuroinflammation.</article-title>
<source/><italic>Clin. Exp. Neuroimmunol.</italic>
<volume>6</volume>
<fpage>245</fpage>–<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1111/cen3.12237</pub-id><pub-id pub-id-type="pmid">26543505</pub-id></mixed-citation>
</ref>
<ref id="B659">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>D. B.</given-names></name><name><surname>Muller</surname><given-names>G. C.</given-names></name><name><surname>Rocha</surname><given-names>G. B.</given-names></name><name><surname>Dellavia</surname><given-names>G. H.</given-names></name><name><surname>Almeida</surname><given-names>R. F.</given-names></name><name><surname>Pettenuzzo</surname><given-names>L. F.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Intranasal guanosine administration presents a wide therapeutic time window to reduce brain damage induced by permanent ischemia in rats.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>149</fpage>–<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9489-9</pub-id><pub-id pub-id-type="pmid">26695181</pub-id></mixed-citation>
</ref>
<ref id="B660">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>H.</given-names></name><name><surname>Duan</surname><given-names>W.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Hou</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Critical contribution of adenosine A2A receptors in bone marrow-derived cells to white matter lesions induced by chronic cerebral hypoperfusion.</article-title>
<source/><italic>J. Neuropathol. Exp. Neurol.</italic>
<volume>74</volume>
<fpage>305</fpage>–<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1097/NEN.0000000000000174</pub-id><pub-id pub-id-type="pmid">25756592</pub-id></mixed-citation>
</ref>
<ref id="B661">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Jia</surname><given-names>T.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>The effect of sinomenine in diabetic neuropathic pain mediated by the P2X3 receptor in dorsal root ganglia.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>13</volume>
<fpage>227</fpage>–<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9554-z</pub-id><pub-id pub-id-type="pmid">28054206</pub-id></mixed-citation>
</ref>
<ref id="B662">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rassendren</surname><given-names>F.</given-names></name><name><surname>Audinat</surname><given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling in epilepsy.</article-title>
<source/><italic>J. Neurosci. Res.</italic>
<volume>94</volume>
<fpage>781</fpage>–<lpage>793</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.23770</pub-id><pub-id pub-id-type="pmid">27302739</pub-id></mixed-citation>
</ref>
<ref id="B663">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rau</surname><given-names>A. R.</given-names></name><name><surname>Ariwodola</surname><given-names>O. J.</given-names></name><name><surname>Weiner</surname><given-names>J. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Presynaptic adenosine A1 receptors modulate excitatory transmission in the rat basolateral amygdala.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>77</volume>
<fpage>465</fpage>–<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.10.029</pub-id><pub-id pub-id-type="pmid">24212058</pub-id></mixed-citation>
</ref>
<ref id="B664">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayalam</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>J. Y.</given-names></name><name><surname>La-Fera</surname><given-names>M. A.</given-names></name><name><surname>Baile</surname><given-names>C. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Novel molecular targets for prevention of obesity and osteoporosis.</article-title>
<source/><italic>J. Nutr. Biochem.</italic>
<volume>22</volume>
<fpage>k1099</fpage>–<lpage>1104</lpage>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2010.11.009</pub-id></mixed-citation>
</ref>
<ref id="B665">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rech</surname><given-names>J. C.</given-names></name><name><surname>Bhattacharya</surname><given-names>A.</given-names></name><name><surname>Letavic</surname><given-names>M. A.</given-names></name><name><surname>Savall</surname><given-names>B. M.</given-names></name></person-group> (<year>2016</year>). <article-title>The evolution of P2X7 antagonists with a focus on CNS indications.</article-title>
<source/><italic>Bioorg. Med. Chem. Lett.</italic>
<volume>26</volume>
<fpage>3838</fpage>–<lpage>3845</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2016.06.048</pub-id><pub-id pub-id-type="pmid">27426304</pub-id></mixed-citation>
</ref>
<ref id="B666">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichenbach</surname><given-names>A.</given-names></name><name><surname>Bringmann</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling in retinal degeneration and regeneration.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>194</fpage>–<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.05.005</pub-id><pub-id pub-id-type="pmid">25998275</pub-id></mixed-citation>
</ref>
<ref id="B667">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reigada</surname><given-names>D.</given-names></name><name><surname>Navarro-Ruiz</surname><given-names>R. M.</given-names></name><name><surname>Caballero-López</surname><given-names>M. J.</given-names></name><name><surname>Del Águila</surname><given-names>Á</given-names></name><name><surname>Muñoz-Galdeano</surname><given-names>T.</given-names></name><name><surname>Maza</surname><given-names>R. M.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Diadenosine tetraphosphate (Ap4A) inhibits ATP-induced excitotoxicity: a neuroprotective strategy for traumatic spinal cord injury treatment.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>13</volume>
<fpage>75</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9541-4</pub-id><pub-id pub-id-type="pmid">27761681</pub-id></mixed-citation>
</ref>
<ref id="B668">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiss</surname><given-names>A. B.</given-names></name><name><surname>Cronstein</surname><given-names>B. N.</given-names></name></person-group> (<year>2012</year>). <article-title>Regulation of foam cells by adenosine.</article-title>
<source/><italic>Arterioscler. Thromb. Vasc. Biol.</italic>
<volume>32</volume>
<fpage>879</fpage>–<lpage>886</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.111.226878</pub-id><pub-id pub-id-type="pmid">22423040</pub-id></mixed-citation>
</ref>
<ref id="B669">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>C.</given-names></name><name><surname>Qiu</surname><given-names>C. Y.</given-names></name><name><surname>Gan</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>T. T.</given-names></name><name><surname>Qu</surname><given-names>Z. W.</given-names></name><name><surname>Rao</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Prokineticin 2 facilitates mechanical allodynia induced by α,β-methylene ATP in rats.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>767</volume>
<fpage>24</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2015.09.047</pub-id><pub-id pub-id-type="pmid">26435025</pub-id></mixed-citation>
</ref>
<ref id="B670">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Dong</surname><given-names>S.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Adenosine triphosphate postconditioning is associated with better preserved global and regional cardiac function during myocardial ischemia and reperfusion: a speckle tracking imaging-based echocardiologic study.</article-title>
<source/><italic>Cardiovasc. Ther.</italic>
<volume>34</volume>
<fpage>343</fpage>–<lpage>351</lpage>. <pub-id pub-id-type="doi">10.1111/1755-5922.12205</pub-id><pub-id pub-id-type="pmid">27328167</pub-id></mixed-citation>
</ref>
<ref id="B671">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rial</surname><given-names>D.</given-names></name><name><surname>Lara</surname><given-names>D. R.</given-names></name><name><surname>Cunha</surname><given-names>R. A.</given-names></name></person-group> (<year>2014</year>). <article-title>The adenosine neuromodulation system in schizophrenia.</article-title>
<source/><italic>Int. Rev. Neurobiol.</italic>
<volume>119</volume>
<fpage>395</fpage>–<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-801022-8.00016-7</pub-id><pub-id pub-id-type="pmid">25175974</pub-id></mixed-citation>
</ref>
<ref id="B672">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>F. F.</given-names></name><name><surname>Xapelli</surname><given-names>S.</given-names></name><name><surname>Miranda-Lourenco</surname><given-names>C.</given-names></name><name><surname>Tanqueiro</surname><given-names>S. R.</given-names></name><name><surname>Fonseca-Gomes</surname><given-names>J.</given-names></name><name><surname>Diogenes</surname><given-names>M. J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Purine nucleosides in neuroregeneration and neuroprotection.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>226</fpage>–<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.11.006</pub-id><pub-id pub-id-type="pmid">26577017</pub-id></mixed-citation>
</ref>
<ref id="B673">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>J. P.</given-names></name><name><surname>Bowles</surname><given-names>E. A.</given-names></name><name><surname>Gordon</surname><given-names>W. R.</given-names></name><name><surname>Ellsworth</surname><given-names>M. L.</given-names></name><name><surname>Stephenson</surname><given-names>A. H.</given-names></name><name><surname>Sprague</surname><given-names>R. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Mechanisms of C-peptide-mediated rescue of low O2-induced ATP release from erythrocytes of humans with Type 2 diabetes.</article-title>
<source/><italic>Am. J. Physiol. Regul. Integr. Comp. Physiol.</italic>
<volume>308</volume>
<fpage>R411</fpage>–<lpage>R418</lpage>. <pub-id pub-id-type="doi">10.1152/ajpregu.00420.2014</pub-id><pub-id pub-id-type="pmid">25552662</pub-id></mixed-citation>
</ref>
<ref id="B674">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riding</surname><given-names>A.</given-names></name><name><surname>Pullar</surname><given-names>C. E.</given-names></name></person-group> (<year>2016</year>). <article-title>ATP release and P2Y receptor signaling are essential for keratinocyte galvanotaxis.</article-title>
<source/><italic>J. Cell. Physiol.</italic>
<volume>231</volume>
<fpage>181</fpage>–<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.25070</pub-id><pub-id pub-id-type="pmid">26058714</pub-id></mixed-citation>
</ref>
<ref id="B675">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname><given-names>S.</given-names></name><name><surname>Enk</surname><given-names>A.</given-names></name><name><surname>Mahnke</surname><given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>A role for adenosine triphosphate in regulating immune responses during melanoma growth.</article-title>
<source/><italic>J. Invest. Dermatol.</italic>
<volume>131</volume>
<issue>S91</issue>.</mixed-citation>
</ref>
<ref id="B676">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>V.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Rajakumar</surname><given-names>S.</given-names></name><name><surname>Cowan</surname><given-names>P. J.</given-names></name><name><surname>Dwyer</surname><given-names>K. M.</given-names></name></person-group> (<year>2013</year>). <article-title>The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>9</volume>
<fpage>135</fpage>–<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-012-9342-3</pub-id><pub-id pub-id-type="pmid">23188420</pub-id></mixed-citation>
</ref>
<ref id="B677">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>V. H.</given-names></name><name><surname>Webster</surname><given-names>R. P.</given-names></name><name><surname>Brockman</surname><given-names>D. E.</given-names></name><name><surname>Pitzer</surname><given-names>B. A.</given-names></name><name><surname>Myatt</surname><given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Post-translational modifications of the P2X4 purinergic receptor subtype in the human placenta are altered in preeclampsia.</article-title>
<source/><italic>Placenta</italic>
<volume>28</volume>
<fpage>270</fpage>–<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2006.04.008</pub-id><pub-id pub-id-type="pmid">16793133</pub-id></mixed-citation>
</ref>
<ref id="B678">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockenbach</surname><given-names>L.</given-names></name><name><surname>Bavaresco</surname><given-names>L.</given-names></name><name><surname>Fernandes</surname><given-names>F. P.</given-names></name><name><surname>Cappellari</surname><given-names>A. R.</given-names></name><name><surname>Barrios</surname><given-names>C. H.</given-names></name><name><surname>Bueno</surname><given-names>M. F.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Alterations in the extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells.</article-title>
<source/><italic>Urol. Oncol.</italic>
<volume>31</volume>
<fpage>1204</fpage>–<lpage>1211</lpage>. <pub-id pub-id-type="doi">10.1016/j.urolonc.2011.10.009</pub-id><pub-id pub-id-type="pmid">22137869</pub-id></mixed-citation>
</ref>
<ref id="B679">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>A. M.</given-names></name><name><surname>Bergamaschi</surname><given-names>C. T.</given-names></name><name><surname>Fernandes</surname><given-names>M. J.</given-names></name><name><surname>Paredes-Gamero</surname><given-names>E. J.</given-names></name><name><surname>Buri</surname><given-names>M. V.</given-names></name><name><surname>Ferreira</surname><given-names>A. T.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>P2X7 receptor in the kidneys of diabetic rats submitted to aerobic training or to N-acetylcysteine supplementation [corrected].</article-title>
<source/><italic>PLOS ONE</italic>
<volume>9</volume>:<issue>e97452</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0097452</pub-id></mixed-citation>
</ref>
<ref id="B680">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>L.</given-names></name><name><surname>Miranda</surname><given-names>I. M.</given-names></name><name><surname>Andrade</surname><given-names>G. M.</given-names></name><name><surname>Mota</surname><given-names>M.</given-names></name><name><surname>Cortes</surname><given-names>L.</given-names></name><name><surname>Rodrigues</surname><given-names>A. G.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Blunted dynamics of adenosine A2A receptors is associated with increased susceptibility to <italic>Candida albicans</italic> infection in the elderly.</article-title>
<source/><italic>Oncotarget</italic>
<volume>7</volume>
<fpage>62862</fpage>–<lpage>62872</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.11760</pub-id><pub-id pub-id-type="pmid">27590517</pub-id></mixed-citation>
</ref>
<ref id="B681">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>R. J.</given-names></name><name><surname>Tomé</surname><given-names>A. R.</given-names></name><name><surname>Cunha</surname><given-names>R. A.</given-names></name></person-group> (<year>2015</year>). <article-title>ATP as a multi-target danger signal in the brain.</article-title>
<source/><italic>Front. Neurosci.</italic>
<volume>9</volume>:<issue>148</issue>
<pub-id pub-id-type="doi">10.3389/fnins.2015.00148</pub-id></mixed-citation>
</ref>
<ref id="B682">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Alvarez</surname><given-names>N.</given-names></name><name><surname>Jimenez-Mateos</surname><given-names>E. M.</given-names></name><name><surname>Engel</surname><given-names>T.</given-names></name><name><surname>Quinlan</surname><given-names>S.</given-names></name><name><surname>Reschke</surname><given-names>C. R.</given-names></name><name><surname>Conroy</surname><given-names>R. M.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Effects of P2X7 receptor antagonists on hypoxia-induced neonatal seizures in mice.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>116</volume>
<fpage>351</fpage>–<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.01.005</pub-id><pub-id pub-id-type="pmid">28082183</pub-id></mixed-citation>
</ref>
<ref id="B683">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rollini</surname><given-names>F.</given-names></name><name><surname>Franchi</surname><given-names>F.</given-names></name><name><surname>Angiolillo</surname><given-names>D. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Switching P2Y12-receptor inhibitors in patients with coronary artery disease.</article-title>
<source/><italic>Nat. Rev. Cardiol.</italic>
<volume>13</volume>
<fpage>11</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1038/nrcardio.2015.113</pub-id><pub-id pub-id-type="pmid">26283269</pub-id></mixed-citation>
</ref>
<ref id="B684">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rollini</surname><given-names>F.</given-names></name><name><surname>Franchi</surname><given-names>F.</given-names></name><name><surname>Angiolillo</surname><given-names>D. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Drug-drug interactions when switching between intravenous and oral P2Y12 receptor inhibitors: how real is it?</article-title>
<source/><italic>JACC Cardiovasc. Interv.</italic>
<volume>10</volume>
<fpage>130</fpage>–<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2016.11.021</pub-id><pub-id pub-id-type="pmid">28104205</pub-id></mixed-citation>
</ref>
<ref id="B685">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romagnoli</surname><given-names>R.</given-names></name><name><surname>Baraldi</surname><given-names>P. G.</given-names></name><name><surname>Cruz-Lopez</surname><given-names>O.</given-names></name><name><surname>Lopez-Cara</surname><given-names>C.</given-names></name><name><surname>Preti</surname><given-names>D.</given-names></name><name><surname>Borea</surname><given-names>P. A.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>The P2X7 receptor as a therapeutic target.</article-title>
<source/><italic>Expert Opin. Ther. Targets</italic>
<volume>12</volume>
<fpage>647</fpage>–<lpage>661</lpage>. <pub-id pub-id-type="doi">10.1517/14728222.12.5.647</pub-id><pub-id pub-id-type="pmid">18410246</pub-id></mixed-citation>
</ref>
<ref id="B686">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>W.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2004</year>). <article-title>Activation of ureter nociceptors by exogenous and endogenous ATP in guinea pig.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>47</volume>
<fpage>1093</fpage>–<lpage>1101</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.08.003</pub-id><pub-id pub-id-type="pmid">15555643</pub-id></mixed-citation>
</ref>
<ref id="B687">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>C.</given-names></name><name><surname>Santini</surname><given-names>E.</given-names></name><name><surname>Chiarugi</surname><given-names>M.</given-names></name><name><surname>Salvati</surname><given-names>A.</given-names></name><name><surname>Comassi</surname><given-names>M.</given-names></name><name><surname>Vitolo</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>The complex P2X7 receptor/inflammasome in perivascular fat tissue of heavy smokers.</article-title>
<source/><italic>Eur. J. Clin. Invest.</italic>
<volume>44</volume>
<fpage>295</fpage>–<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1111/eci.12232</pub-id><pub-id pub-id-type="pmid">24372548</pub-id></mixed-citation>
</ref>
<ref id="B688">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotte</surname><given-names>A.</given-names></name><name><surname>Garmann</surname><given-names>D.</given-names></name><name><surname>Buss</surname><given-names>I.</given-names></name><name><surname>Jaehde</surname><given-names>U.</given-names></name></person-group> (<year>2010</year>). <article-title>Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian carcinoma cells.</article-title>
<source/><italic>Chemotherapy</italic>
<volume>56</volume>
<fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1159/000287351</pub-id><pub-id pub-id-type="pmid">20185910</pub-id></mixed-citation>
</ref>
<ref id="B689">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy Chowdhury</surname><given-names>U.</given-names></name><name><surname>Bahler</surname><given-names>C. K.</given-names></name><name><surname>Holman</surname><given-names>B. H.</given-names></name><name><surname>Dosa</surname><given-names>P. I.</given-names></name><name><surname>Fautsch</surname><given-names>M. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Ocular hypotensive effects of the ATP-sensitive potassium channel opener cromakalim in human and murine experimental model systems.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>10</volume>:<issue>e0141783</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0141783</pub-id></mixed-citation>
</ref>
<ref id="B690">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy Chowdhury</surname><given-names>U.</given-names></name><name><surname>Viker</surname><given-names>K. B.</given-names></name><name><surname>Stoltz</surname><given-names>K. L.</given-names></name><name><surname>Holman</surname><given-names>B. H.</given-names></name><name><surname>Fautsch</surname><given-names>M. P.</given-names></name><name><surname>Dosa</surname><given-names>P. I.</given-names></name></person-group> (<year>2016</year>). <article-title>Analogs of the ATP-sensitive potassium (KATP) channel opener cromakalim with in vivo ocular hypotensive activity.</article-title>
<source/><italic>J. Med. Chem.</italic>
<volume>59</volume>
<fpage>6221</fpage>–<lpage>6231</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00406</pub-id><pub-id pub-id-type="pmid">27367033</pub-id></mixed-citation>
</ref>
<ref id="B691">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ru</surname><given-names>Q.</given-names></name><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>Y. X.</given-names></name><name><surname>Wu</surname><given-names>R. H.</given-names></name><name><surname>Pi</surname><given-names>M. S.</given-names></name><name><surname>Li</surname><given-names>C. Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Voltage-gated and ATP-sensitive K+ channels are associated with cell proliferation and tumorigenesis of human glioma.</article-title>
<source/><italic>Oncol. Rep.</italic>
<volume>31</volume>
<fpage>842</fpage>–<lpage>848</lpage>. <pub-id pub-id-type="doi">10.3892/or.2013.2875</pub-id><pub-id pub-id-type="pmid">24284968</pub-id></mixed-citation>
</ref>
<ref id="B692">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubaiy</surname><given-names>H. N.</given-names></name></person-group> (<year>2016</year>). <article-title>The therapeutic agents that target ATP-sensitive potassium channels.</article-title>
<source/><italic>Acta Pharm.</italic>
<volume>66</volume>
<fpage>23</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1515/acph-2016-0006</pub-id><pub-id pub-id-type="pmid">27029082</pub-id></mixed-citation>
</ref>
<ref id="B693">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruzsnavszky</surname><given-names>O.</given-names></name><name><surname>Telek</surname><given-names>A.</given-names></name><name><surname>Gönczi</surname><given-names>M.</given-names></name><name><surname>Balogh</surname><given-names>A.</given-names></name><name><surname>Remenyik</surname><given-names>E.</given-names></name><name><surname>Csernoch</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>UV-B induced alteration in purinergic receptors and signaling on HaCaT keratinocytes.</article-title>
<source/><italic>J. Photochem. Photobiol. B</italic>
<volume>105</volume>
<fpage>113</fpage>–<lpage>118</lpage>. <pub-id pub-id-type="doi">10.1016/j.jphotobiol.2011.07.009</pub-id><pub-id pub-id-type="pmid">21862341</pub-id></mixed-citation>
</ref>
<ref id="B694">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryten</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>S. Y.</given-names></name><name><surname>Dunn</surname><given-names>P. M.</given-names></name><name><surname>Goldspink</surname><given-names>G.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2004</year>). <article-title>Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures.</article-title>
<source/><italic>FASEB J.</italic>
<volume>18</volume>
<fpage>k1404</fpage>–<lpage>1406</lpage>. <pub-id pub-id-type="doi">10.1096/fj.03-1175fje</pub-id></mixed-citation>
</ref>
<ref id="B695">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>E.</given-names></name><name><surname>Recupero</surname><given-names>S. M.</given-names></name><name><surname>Bientinesi</surname><given-names>R.</given-names></name><name><surname>Palermo</surname><given-names>G.</given-names></name><name><surname>D’agostino</surname><given-names>D.</given-names></name><name><surname>Currò</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Pioneering drugs for overactive bladder and detrusor overactivity: ongoing research and future directions.</article-title>
<source/><italic>World J. Obstet. Gynecol.</italic>
<volume>4</volume>
<fpage>k24</fpage>–<lpage>39</lpage>.</mixed-citation>
</ref>
<ref id="B696">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachdeva</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Adenosine and its receptors as therapeutic targets: an overview.</article-title>
<source/><italic>Saudi. Pharm. J.</italic>
<volume>21</volume>
<fpage>245</fpage>–<lpage>253</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsps.2012.05.011</pub-id><pub-id pub-id-type="pmid">23960840</pub-id></mixed-citation>
</ref>
<ref id="B697">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadovnick</surname><given-names>A. D.</given-names></name><name><surname>Gu</surname><given-names>B. J.</given-names></name><name><surname>Traboulsee</surname><given-names>A. L.</given-names></name><name><surname>Bernales</surname><given-names>C. Q.</given-names></name><name><surname>Encarnacion</surname><given-names>M.</given-names></name><name><surname>Yee</surname><given-names>I. M.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis.</article-title>
<source/><italic>Hum. Mutat.</italic>
<volume>38</volume>
<fpage>736</fpage>–<lpage>744</lpage>. <pub-id pub-id-type="doi">10.1002/humu.23218</pub-id><pub-id pub-id-type="pmid">28326637</pub-id></mixed-citation>
</ref>
<ref id="B698">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sáez-Orellana</surname><given-names>F.</given-names></name><name><surname>Godoy</surname><given-names>P. A.</given-names></name><name><surname>Bastidas</surname><given-names>C. Y.</given-names></name><name><surname>Silva-Grecchi</surname><given-names>T.</given-names></name><name><surname>Guzmán</surname><given-names>L.</given-names></name><name><surname>Aguayo</surname><given-names>L. G.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>ATP leakage induces P2XR activation and contributes to acute synaptic excitotoxicity induced by soluble oligomers of β-amyloid peptide in hippocampal neurons.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>100</volume>
<fpage>116</fpage>–<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.04.005</pub-id><pub-id pub-id-type="pmid">25896766</pub-id></mixed-citation>
</ref>
<ref id="B699">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K.</given-names></name><name><surname>Endo</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Fujimura</surname><given-names>K.</given-names></name><name><surname>Kurauchi</surname><given-names>Y.</given-names></name><name><surname>Mori</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X7 receptor antagonists protect against N-methyl-D-aspartic acid-induced neuronal injury in the rat retina.</article-title>
<source/><italic>Eur. J Pharmacol.</italic>
<volume>756</volume>
<fpage>52</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2015.03.008</pub-id><pub-id pub-id-type="pmid">25796199</pub-id></mixed-citation>
</ref>
<ref id="B700">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salgado-Puga</surname><given-names>K.</given-names></name><name><surname>Rodriguez-Colorado</surname><given-names>J.</given-names></name><name><surname>Prado-Alcala</surname><given-names>R. A.</given-names></name><name><surname>Pena-Ortega</surname><given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title>Subclinical doses of ATP-sensitive potassium channel modulators prevent alterations in memory and synaptic plasticity induced by amyloid-β.</article-title>
<source/><italic>J. Alzheimers Dis.</italic>
<volume>57</volume>
<fpage>205</fpage>–<lpage>226</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-160543</pub-id><pub-id pub-id-type="pmid">28222502</pub-id></mixed-citation>
</ref>
<ref id="B701">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvetti</surname><given-names>N. R.</given-names></name><name><surname>Panzani</surname><given-names>C. G.</given-names></name><name><surname>Gimeno</surname><given-names>E. J.</given-names></name><name><surname>Neme</surname><given-names>L. G.</given-names></name><name><surname>Alfaro</surname><given-names>N. S.</given-names></name><name><surname>Ortega</surname><given-names>H. H.</given-names></name></person-group> (<year>2009</year>). <article-title>An imbalance between apoptosis and proliferation contributes to follicular persistence in polycystic ovaries in rats.</article-title>
<source/><italic>Reprod. Biol. Endocrinol.</italic>
<volume>7</volume>:<issue>68</issue>
<pub-id pub-id-type="doi">10.1186/1477-7827-7-68</pub-id></mixed-citation>
</ref>
<ref id="B702">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>S. S.</given-names></name><name><surname>Mani</surname><given-names>A.</given-names></name><name><surname>Tachett</surname><given-names>B.</given-names></name><name><surname>Desai</surname><given-names>M.</given-names></name><name><surname>Thevananther</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>P2Y2 purinergic receptor activation is essential for endotoxin-induced acute liver injury in mice.</article-title>
<source/><italic>Hepatology</italic>
<volume>52</volume>:<issue>608A</issue>.</mixed-citation>
</ref>
<ref id="B703">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanderson</surname><given-names>J.</given-names></name><name><surname>Dartt</surname><given-names>D. A.</given-names></name><name><surname>Trinkaus-Randall</surname><given-names>V.</given-names></name><name><surname>Pintor</surname><given-names>J.</given-names></name><name><surname>Civan</surname><given-names>M. M.</given-names></name><name><surname>Delamere</surname><given-names>N. A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Purines in the eye: recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, Muller cells, lens, trabecular meshwork, cornea and lacrimal gland.</article-title>
<source/><italic>Exp. Eye Res.</italic>
<volume>127</volume>
<fpage>270</fpage>–<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1016/j.exer.2014.08.009</pub-id><pub-id pub-id-type="pmid">25151301</pub-id></mixed-citation>
</ref>
<ref id="B704">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santana</surname><given-names>P. T.</given-names></name><name><surname>Benjamim</surname><given-names>C. F.</given-names></name><name><surname>Martinez</surname><given-names>C. G.</given-names></name><name><surname>Kurtenbach</surname><given-names>E.</given-names></name><name><surname>Takiya</surname><given-names>C. M.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>The P2X7 receptor contributes to the development of the exacerbated inflammatory response associated with sepsis.</article-title>
<source/><italic>J. Innate Immun.</italic>
<volume>7</volume>
<fpage>417</fpage>–<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1159/000371388</pub-id><pub-id pub-id-type="pmid">25675986</pub-id></mixed-citation>
</ref>
<ref id="B705">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>A. R.</given-names></name><name><surname>Baptista</surname><given-names>F. I.</given-names></name><name><surname>Santos</surname><given-names>P. F.</given-names></name><name><surname>Cristóvão</surname><given-names>G.</given-names></name><name><surname>Ambrósio</surname><given-names>A. F.</given-names></name><name><surname>Cunha</surname><given-names>R. A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Role of microglia adenosine A2A receptors in retinal and brain neurodegenerative diseases.</article-title>
<source/><italic>Mediators Inflamm.</italic>
<volume>2014</volume>:<issue>465694</issue>
<pub-id pub-id-type="doi">10.1155/2014/465694</pub-id></mixed-citation>
</ref>
<ref id="B706">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarafoff</surname><given-names>N.</given-names></name><name><surname>Byrne</surname><given-names>R. A.</given-names></name><name><surname>Sibbing</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>Clinical use of clopidogrel.</article-title>
<source/><italic>Curr. Pharm. Des.</italic>
<volume>18</volume>
<fpage>5224</fpage>–<lpage>5239</lpage>. <pub-id pub-id-type="doi">10.2174/138161212803251853</pub-id><pub-id pub-id-type="pmid">22724411</pub-id></mixed-citation>
</ref>
<ref id="B707">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sashindranath</surname><given-names>M.</given-names></name><name><surname>Dwyer</surname><given-names>K. M.</given-names></name><name><surname>Dezfouli</surname><given-names>S.</given-names></name><name><surname>Selan</surname><given-names>C.</given-names></name><name><surname>Crikis</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>13</volume>
<fpage>259</fpage>–<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-017-9558-3</pub-id><pub-id pub-id-type="pmid">28343356</pub-id></mixed-citation>
</ref>
<ref id="B708">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>A. V.</given-names></name><name><surname>Mrak</surname><given-names>E.</given-names></name><name><surname>Hernandez</surname><given-names>R. J.</given-names></name><name><surname>Zacchi</surname><given-names>E.</given-names></name><name><surname>Cavani</surname><given-names>F.</given-names></name><name><surname>Casiraghi</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency.</article-title>
<source/><italic>Blood</italic>
<volume>114</volume>
<fpage>3216</fpage>–<lpage>3226</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-03-209221</pub-id><pub-id pub-id-type="pmid">19633200</pub-id></mixed-citation>
</ref>
<ref id="B709">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savio</surname><given-names>L. E.</given-names></name><name><surname>Andrade</surname><given-names>M. G.</given-names></name><name><surname>De Andrade Mello</surname><given-names>P.</given-names></name><name><surname>Santana</surname><given-names>P. T.</given-names></name><name><surname>Moreira-Souza</surname><given-names>A. C.</given-names></name><name><surname>Kolling</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>P2X7 receptor signaling contributes to sepsis-associated brain dysfunction.</article-title>
<source/><italic>Mol. Neurobiol.</italic>
<volume>54</volume>
<fpage>6459</fpage>–<lpage>6470</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-0168-9</pub-id></mixed-citation>
</ref>
<ref id="B710">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savio</surname><given-names>L. E.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling in infection and autoimmune disease.</article-title>
<source/><italic>Biomed. J.</italic>
<volume>39</volume>
<fpage>304</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1016/j.bj.2016.09.002</pub-id><pub-id pub-id-type="pmid">27884376</pub-id></mixed-citation>
</ref>
<ref id="B711">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawynok</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine receptor targets for pain.</article-title>
<source/><italic>Neuroscience</italic>
<volume>338</volume>
<fpage>1</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.10.031</pub-id><pub-id pub-id-type="pmid">26500181</pub-id></mixed-citation>
</ref>
<ref id="B712">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schepp</surname><given-names>C. P.</given-names></name><name><surname>Reutershan</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Bench-to-bedside review: adenosine receptors–promising targets in acute lung injury?</article-title>
<source/><italic>Crit. Care</italic>
<volume>12</volume>:<issue>226</issue>
<pub-id pub-id-type="doi">10.1186/cc6990</pub-id></mixed-citation>
</ref>
<ref id="B713">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>G.</given-names></name><name><surname>Glaser</surname><given-names>T.</given-names></name><name><surname>Lameu</surname><given-names>C.</given-names></name><name><surname>Bdelbaset-Ismail</surname><given-names>A.</given-names></name><name><surname>Sellers</surname><given-names>Z. P.</given-names></name><name><surname>Moniuszko</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Extracellular nucleotides as novel, underappreciated pro-metastatic factors that stimulate purinergic signaling in human lung cancer cells.</article-title>
<source/><italic>Mol. Cancer</italic>
<volume>14</volume>:<issue>201</issue>
<pub-id pub-id-type="doi">10.1186/s12943-015-0469-z</pub-id></mixed-citation>
</ref>
<ref id="B714">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte am Esch</surname><given-names>J.</given-names></name><name><surname>Akyildiz</surname><given-names>A.</given-names></name><name><surname>Tustas</surname><given-names>R. Y.</given-names></name><name><surname>Ganschow</surname><given-names>R.</given-names></name><name><surname>Schmelzle</surname><given-names>M.</given-names></name><name><surname>Krieg</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>ADP-dependent platelet function prior to and in the early course of pediatric liver transplantation and persisting thrombocytopenia are positively correlated with ischemia/reperfusion injury.</article-title>
<source/><italic>Transpl. Int.</italic>
<volume>23</volume>
<fpage>745</fpage>–<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-2277.2010.01054.x</pub-id><pub-id pub-id-type="pmid">20136783</pub-id></mixed-citation>
</ref>
<ref id="B715">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>K. C.</given-names></name><name><surname>Charbord</surname><given-names>J.</given-names></name><name><surname>Mattsson</surname><given-names>C. L.</given-names></name><name><surname>Tao</surname><given-names>L.</given-names></name><name><surname>Tworus</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Critical role for adenosine receptor A2a in β-cell proliferation.</article-title>
<source/><italic>Mol. Metab.</italic>
<volume>5</volume>
<fpage>1138</fpage>–<lpage>1146</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmet.2016.09.006</pub-id><pub-id pub-id-type="pmid">27818940</pub-id></mixed-citation>
</ref>
<ref id="B716">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebastián-Serrano</surname><given-names>A.</given-names></name><name><surname>Engel</surname><given-names>T.</given-names></name><name><surname>De Diego-García</surname><given-names>L.</given-names></name><name><surname>Olivos-Oré</surname><given-names>L. A.</given-names></name><name><surname>Arribas-Blázquez</surname><given-names>M.</given-names></name><name><surname>Martínez-Frailes</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Neurodevelopmental alterations and seizures developed by mouse model of infantile hypophosphatasia are associated with purinergic signalling deregulation.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>25</volume>
<fpage>4143</fpage>–<lpage>4156</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddw248</pub-id><pub-id pub-id-type="pmid">27466191</pub-id></mixed-citation>
</ref>
<ref id="B717">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seref-Ferlengez</surname><given-names>Z.</given-names></name><name><surname>Maung</surname><given-names>S.</given-names></name><name><surname>Schaffler</surname><given-names>M. B.</given-names></name><name><surname>Spray</surname><given-names>D. C.</given-names></name><name><surname>Suadicani</surname><given-names>S. O.</given-names></name><name><surname>Thi</surname><given-names>M. M.</given-names></name></person-group> (<year>2016</year>). <article-title>P2X7R-Panx1 complex impairs bone mechanosignaling under high glucose levels associated with Type-1 diabetes.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>11</volume>:<issue>e0155107</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0155107</pub-id></mixed-citation>
</ref>
<ref id="B718">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabbir</surname><given-names>M.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2009</year>). <article-title>Purinergic receptor-mediated effects of ATP in urogenital malignant diseases.</article-title>
<source/><italic>Int. J. Urol.</italic>
<volume>16</volume>
<fpage>143</fpage>–<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1111/j.1442-2042.2008.02207.x</pub-id><pub-id pub-id-type="pmid">19183233</pub-id></mixed-citation>
</ref>
<ref id="B719">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabbir</surname><given-names>M.</given-names></name><name><surname>Ryten</surname><given-names>M.</given-names></name><name><surname>Thompson</surname><given-names>C. S.</given-names></name><name><surname>Mikhailidis</surname><given-names>D. P.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2008</year>). <article-title>Purinergic receptor-mediated effects of ATP in high-grade bladder cancer.</article-title>
<source/><italic>BJU Int.</italic>
<volume>101</volume>
<fpage>106</fpage>–<lpage>112</lpage>.<pub-id pub-id-type="pmid">17941929</pub-id></mixed-citation>
</ref>
<ref id="B720">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaikh</surname><given-names>G.</given-names></name><name><surname>Cronstein</surname><given-names>B.</given-names></name></person-group> (<year>2016</year>). <article-title>Signaling pathways involving adenosine A2A and A2B receptors in wound healing and fibrosis.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>191</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9498-3</pub-id><pub-id pub-id-type="pmid">26847815</pub-id></mixed-citation>
</ref>
<ref id="B721">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shcherbatko</surname><given-names>A.</given-names></name><name><surname>Foletti</surname><given-names>D.</given-names></name><name><surname>Poulsen</surname><given-names>K.</given-names></name><name><surname>Strop</surname><given-names>P.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>Hasa-Moreno</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Modulation of P2X3 and P2X2/3 receptors by monoclonal antibodies.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>291</volume>
<fpage>12254</fpage>–<lpage>12270</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.722330</pub-id><pub-id pub-id-type="pmid">27129281</pub-id></mixed-citation>
</ref>
<ref id="B722">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibukawa</surname><given-names>Y.</given-names></name><name><surname>Sato</surname><given-names>M.</given-names></name><name><surname>Kimura</surname><given-names>M.</given-names></name><name><surname>Sobhan</surname><given-names>U.</given-names></name><name><surname>Shimada</surname><given-names>M.</given-names></name><name><surname>Nishiyama</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Odontoblasts as sensory receptors: transient receptor potential channels, pannexin-1, and ionotropic ATP receptors mediate intercellular odontoblast-neuron signal transduction.</article-title>
<source/><italic>Pflugers. Arch.</italic>
<volume>467</volume>
<fpage>843</fpage>–<lpage>863</lpage>. <pub-id pub-id-type="doi">10.1007/s00424-014-1551-x</pub-id><pub-id pub-id-type="pmid">24939701</pub-id></mixed-citation>
</ref>
<ref id="B723">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>Y.</given-names></name><name><surname>Calvert</surname><given-names>J. W.</given-names></name></person-group> (<year>2016</year>). <article-title>Recycling KATP channels for cardioprotection.</article-title>
<source/><italic>Am. J. Physiol. Heart Circ. Physiol.</italic>
<volume>310</volume>
<fpage>H1381</fpage>–<lpage>H1382</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00309.2016</pub-id><pub-id pub-id-type="pmid">27199122</pub-id></mixed-citation>
</ref>
<ref id="B724">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shishikura</surname><given-names>Y.</given-names></name><name><surname>Koarai</surname><given-names>A.</given-names></name><name><surname>Sugiura</surname><given-names>H.</given-names></name><name><surname>Aizawa</surname><given-names>H.</given-names></name><name><surname>Hashimoto</surname><given-names>Y.</given-names></name><name><surname>Numakura</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Extracellular ATP involves in dsRNA-induced MUC5AC production via P2Y2R in human airway epithelium.</article-title>
<source/><italic>Am. J. Respir. Crit. Care Med.</italic>
<volume>193</volume>
<issue>A5851</issue>.</mixed-citation>
</ref>
<ref id="B725">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sillero</surname><given-names>M. A.</given-names></name><name><surname>De Diego</surname><given-names>A.</given-names></name><name><surname>Tavares</surname><given-names>J. E.</given-names></name><name><surname>Silva</surname><given-names>J. A.</given-names></name><name><surname>Pérez-Zúñiga</surname><given-names>F. J.</given-names></name><name><surname>Sillero</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Synthesis of ATP derivatives of compounds of the mevalonate pathway (isopentenyl di- and triphosphate; geranyl di- and triphosphate, farnesyl di- and triphosphate, and dimethylallyl diphosphate) catalyzed by T4 RNA ligase, T4 DNA ligase and other ligases Potential relationship with the effect of bisphosphonates on osteoclasts.</article-title>
<source/><italic>Biochem. Pharmacol.</italic>
<volume>78</volume>
<fpage>335</fpage>–<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2009.04.028</pub-id><pub-id pub-id-type="pmid">19414000</pub-id></mixed-citation>
</ref>
<ref id="B726">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>C. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic signaling in schistosomal infection.</article-title>
<source/><italic>Biomed. J.</italic>
<volume>39</volume>
<fpage>316</fpage>–<lpage>325</lpage>. <pub-id pub-id-type="doi">10.1016/j.bj.2016.06.006</pub-id><pub-id pub-id-type="pmid">27884378</pub-id></mixed-citation>
</ref>
<ref id="B727">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva-Ramos</surname><given-names>M.</given-names></name><name><surname>Silva</surname><given-names>I.</given-names></name><name><surname>Oliveira</surname><given-names>J. C.</given-names></name><name><surname>Correia-De-Sa</surname><given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>Increased urinary adenosine triphosphate in patients with bladder outlet obstruction due to benign prostate hyperplasia.</article-title>
<source/><italic>Prostate</italic>
<volume>76</volume>
<fpage>1353</fpage>–<lpage>1363</lpage>. <pub-id pub-id-type="doi">10.1002/pros.23207</pub-id><pub-id pub-id-type="pmid">27418113</pub-id></mixed-citation>
</ref>
<ref id="B728">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva-Ramos</surname><given-names>M.</given-names></name><name><surname>Silva</surname><given-names>I.</given-names></name><name><surname>Oliveira</surname><given-names>O.</given-names></name><name><surname>Ferreira</surname><given-names>S.</given-names></name><name><surname>Reis</surname><given-names>M. J.</given-names></name><name><surname>Oliveira</surname><given-names>J. C.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>8</volume>:<issue>e64696</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0064696</pub-id></mixed-citation>
</ref>
<ref id="B729">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silveira</surname><given-names>G. F.</given-names></name><name><surname>Buffon</surname><given-names>A.</given-names></name><name><surname>Bruno</surname><given-names>A. N.</given-names></name></person-group> (<year>2013</year>). <article-title>New approaches to thyroid hormones and purinergic signaling.</article-title>
<source/><italic>J. Thyroid Res.</italic>
<volume>2013</volume>:<issue>434727</issue>
<pub-id pub-id-type="doi">10.1155/2013/434727</pub-id></mixed-citation>
</ref>
<ref id="B730">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>M. H.</given-names></name><name><surname>Strand</surname><given-names>V.</given-names></name><name><surname>Markovits</surname><given-names>D.</given-names></name><name><surname>Nahir</surname><given-names>M.</given-names></name><name><surname>Reitblat</surname><given-names>T.</given-names></name><name><surname>Molad</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.</article-title>
<source/><italic>J. Rheumatol.</italic>
<volume>35</volume>
<fpage>41</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">18050382</pub-id></mixed-citation>
</ref>
<ref id="B731">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinadinos</surname><given-names>A.</given-names></name><name><surname>Young</surname><given-names>C. N.</given-names></name><name><surname>Al-Khalidi</surname><given-names>R.</given-names></name><name><surname>Teti</surname><given-names>A.</given-names></name><name><surname>Kalinski</surname><given-names>P.</given-names></name><name><surname>Mohamad</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.</article-title>
<source/><italic>PLOS Med.</italic>
<volume>12</volume>:<issue>e1001888</issue>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1001888</pub-id></mixed-citation>
</ref>
<ref id="B732">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Roy</surname><given-names>K. K.</given-names></name><name><surname>Khan</surname><given-names>S. R.</given-names></name><name><surname>Kashyap</surname><given-names>V. K.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Jaiswal</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating <italic>M. tuberculosis</italic>.</article-title>
<source/><italic>Bioorg. Med. Chem.</italic>
<volume>23</volume>
<fpage>742</fpage>–<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2014.12.060</pub-id><pub-id pub-id-type="pmid">25614114</pub-id></mixed-citation>
</ref>
<ref id="B733">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivak</surname><given-names>K. V.</given-names></name><name><surname>Vasin</surname><given-names>A. V.</given-names></name><name><surname>Egorov</surname><given-names>V. V.</given-names></name><name><surname>Tsevtkov</surname><given-names>V. B.</given-names></name><name><surname>Kuzmich</surname><given-names>N. N.</given-names></name><name><surname>Savina</surname><given-names>V. A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Adenosine A2A receptor as a drug target for treatment of sepsis.</article-title>
<source/><italic>Mol. Biol.</italic>
<volume>50</volume>
<fpage>231</fpage>–<lpage>245</lpage>. <pub-id pub-id-type="doi">10.7868/S0026898416020233</pub-id></mixed-citation>
</ref>
<ref id="B734">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjuve Scott</surname><given-names>R.</given-names></name><name><surname>Uvelius</surname><given-names>B.</given-names></name><name><surname>Arner</surname><given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Changes in intracellular calcium concentration and P2X1 receptor expression in hypertrophic rat urinary bladder smooth muscle.</article-title>
<source/><italic>Neurourol. Urodyn.</italic>
<volume>23</volume>
<fpage>361</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1002/nau.20047</pub-id><pub-id pub-id-type="pmid">15227655</pub-id></mixed-citation>
</ref>
<ref id="B735">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>M.</given-names></name><name><surname>Danieletto</surname><given-names>S.</given-names></name><name><surname>Gidley-Baird</surname><given-names>A.</given-names></name><name><surname>Teh</surname><given-names>L. C.</given-names></name><name><surname>Barden</surname><given-names>J. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors.</article-title>
<source/><italic>Histopathology</italic>
<volume>44</volume>
<fpage>206</fpage>–<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1111/j.0309-0167.2004.01798.x</pub-id><pub-id pub-id-type="pmid">14987223</pub-id></mixed-citation>
</ref>
<ref id="B736">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C. P.</given-names></name><name><surname>Vemulakonda</surname><given-names>V. M.</given-names></name><name><surname>Kiss</surname><given-names>S.</given-names></name><name><surname>Boone</surname><given-names>T. B.</given-names></name><name><surname>Somogyi</surname><given-names>G. T.</given-names></name></person-group> (<year>2005</year>). <article-title>Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A.</article-title>
<source/><italic>Neurochem. Int.</italic>
<volume>47</volume>
<fpage>291</fpage>–<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2005.04.021</pub-id><pub-id pub-id-type="pmid">15970360</pub-id></mixed-citation>
</ref>
<ref id="B737">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>S. B.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Novitskaya</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Chepurko</surname><given-names>E.</given-names></name><name><surname>Pu</surname><given-names>X. A.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Impact of cardiac-specific expression of CD39 on myocardial infarct size in mice.</article-title>
<source/><italic>Life Sci.</italic>
<volume>179</volume>
<fpage>54</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2016.10.016</pub-id><pub-id pub-id-type="pmid">27756600</pub-id></mixed-citation>
</ref>
<ref id="B738">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares</surname><given-names>A. F.</given-names></name><name><surname>Diniz</surname><given-names>C.</given-names></name><name><surname>Fresco</surname><given-names>P.</given-names></name></person-group> (<year>2012</year>). <article-title>A3-adenosine receptor effects on malignant melanoma cells.</article-title>
<source/><italic>FEBS J.</italic>
<volume>279</volume>:<issue>547</issue>.</mixed-citation>
</ref>
<ref id="B739">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares-Bezerra</surname><given-names>R. J.</given-names></name><name><surname>Pinho</surname><given-names>R. T.</given-names></name><name><surname>Bisaggio Rda</surname><given-names>C.</given-names></name><name><surname>Benevolo-De-Andrade</surname><given-names>T. C.</given-names></name><name><surname>Alves</surname><given-names>L. A.</given-names></name></person-group> (<year>2015</year>). <article-title>The search for new agonists to P2X7R for clinical use: tuberculosis as a possible target.</article-title>
<source/><italic>Cell Physiol. Biochem.</italic>
<volume>37</volume>
<fpage>409</fpage>–<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1159/000430364</pub-id><pub-id pub-id-type="pmid">26314826</pub-id></mixed-citation>
</ref>
<ref id="B740">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solini</surname><given-names>A.</given-names></name><name><surname>Menini</surname><given-names>S.</given-names></name><name><surname>Rossi</surname><given-names>C.</given-names></name><name><surname>Ricci</surname><given-names>C.</given-names></name><name><surname>Santini</surname><given-names>E.</given-names></name><name><surname>Blasetti Fantauzzi</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation.</article-title>
<source/><italic>J. Pathol.</italic>
<volume>231</volume>
<fpage>342</fpage>–<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1002/path.4237</pub-id><pub-id pub-id-type="pmid">23843215</pub-id></mixed-citation>
</ref>
<ref id="B741">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soma</surname><given-names>T.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Nakagome</surname><given-names>K.</given-names></name><name><surname>Nagata</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Clinical implication of adenosine triphosphate in sputum in asthma.</article-title>
<source/><italic>Am. J. Respir. Crit. Care Med.</italic>
<volume>193</volume>
<issue>A1394</issue>.</mixed-citation>
</ref>
<ref id="B742">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Dai</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Activation of adenosine monophosphate-activated protein kinase suppresses neuroinflammation and ameliorates bone cancer pain: involvement of inhibition on mitogen-activated protein kinase.</article-title>
<source/><italic>Anesthesiology</italic>
<volume>123</volume>
<fpage>1170</fpage>–<lpage>1185</lpage>. <pub-id pub-id-type="doi">10.1097/ALN.0000000000000856</pub-id><pub-id pub-id-type="pmid">26378398</pub-id></mixed-citation>
</ref>
<ref id="B743">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Jacobson</surname><given-names>K. N.</given-names></name><name><surname>Mcdermott</surname><given-names>K. M.</given-names></name><name><surname>Reddy</surname><given-names>S. P.</given-names></name><name><surname>Cress</surname><given-names>A. E.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>ATP promotes cell survival via regulation of cytosolic [Ca2+] and Bcl-2/Bax ratio in lung cancer cells.</article-title>
<source/><italic>Am. J. Physiol. Cell Physiol.</italic>
<volume>310</volume>
<fpage>C99</fpage>–<lpage>C114</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00092.2015</pub-id><pub-id pub-id-type="pmid">26491047</pub-id></mixed-citation>
</ref>
<ref id="B744">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>J. B.</given-names></name><name><surname>Diniz</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>The adenosinergic system as a therapeutic target in the vasculature: new ligands and challenges.</article-title>
<source/><italic>Molecules</italic>
<volume>22</volume>:<issue>E752</issue>
<pub-id pub-id-type="doi">10.3390/molecules22050752</pub-id></mixed-citation>
</ref>
<ref id="B745">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaans</surname><given-names>F.</given-names></name><name><surname>Melgert</surname><given-names>B. N.</given-names></name><name><surname>Borghuis</surname><given-names>T.</given-names></name><name><surname>Klok</surname><given-names>P. A.</given-names></name><name><surname>De Vos</surname><given-names>P.</given-names></name><name><surname>Bakker</surname><given-names>W. W.</given-names></name><etal></etal></person-group> (<year>2014a</year>). <article-title>Extracellular adenosine triphosphate affects systemic and kidney immune cell populations in pregnant rats.</article-title>
<source/><italic>Am. J. Reprod. Immunol.</italic>
<volume>72</volume>
<fpage>k305</fpage>–<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1111/aji.12267</pub-id></mixed-citation>
</ref>
<ref id="B746">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaans</surname><given-names>F.</given-names></name><name><surname>Melgert</surname><given-names>B. N.</given-names></name><name><surname>Chiang</surname><given-names>C.</given-names></name><name><surname>Borghuis</surname><given-names>T.</given-names></name><name><surname>Klok</surname><given-names>P. A.</given-names></name><name><surname>De Vos</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2014b</year>). <article-title>Extracellular ATP decreases trophoblast invasion, spiral artery remodeling and immune cells in the mesometrial triangle in pregnant rats.</article-title>
<source/><italic>Placenta</italic>
<volume>35</volume>
<fpage>587</fpage>–<lpage>595</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2014.05.013</pub-id><pub-id pub-id-type="pmid">24953164</pub-id></mixed-citation>
</ref>
<ref id="B747">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperlagh</surname><given-names>B.</given-names></name><name><surname>Illes</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>P2X7 receptor: an emerging target in central nervous system diseases.</article-title>
<source/><italic>Trends Pharmacol. Sci.</italic>
<volume>35</volume>
<fpage>537</fpage>–<lpage>547</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2014.08.002</pub-id><pub-id pub-id-type="pmid">25223574</pub-id></mixed-citation>
</ref>
<ref id="B748">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squadrito</surname><given-names>F.</given-names></name><name><surname>Bitto</surname><given-names>A.</given-names></name><name><surname>Altavilla</surname><given-names>D.</given-names></name><name><surname>Arcoraci</surname><given-names>V.</given-names></name><name><surname>De Caridi</surname><given-names>G.</given-names></name><name><surname>De Feo</surname><given-names>M. E.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial.</article-title>
<source/><italic>J. Clin. Endocrinol. Metab.</italic>
<volume>99</volume>
<fpage>E746</fpage>–<lpage>E753</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2013-3569</pub-id><pub-id pub-id-type="pmid">24483158</pub-id></mixed-citation>
</ref>
<ref id="B749">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stachon</surname><given-names>P.</given-names></name><name><surname>Heidenreich</surname><given-names>A.</given-names></name><name><surname>Merz</surname><given-names>J.</given-names></name><name><surname>Hoppe</surname><given-names>N.</given-names></name><name><surname>Bode</surname><given-names>C.</given-names></name><name><surname>Idzko</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Deficiency of purinergic receptor P2X7 reduces atherosclerosis in mice.</article-title>
<source/><italic>Circulation</italic>
<volume>134(Suppl._1)</volume>, <issue>A16502</issue>.</mixed-citation>
</ref>
<ref id="B750">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stagg</surname><given-names>J.</given-names></name><name><surname>Beavis</surname><given-names>P. A.</given-names></name><name><surname>Divisekera</surname><given-names>U.</given-names></name><name><surname>Liu</surname><given-names>M. C.</given-names></name><name><surname>Moller</surname><given-names>A.</given-names></name><name><surname>Darcy</surname><given-names>P. K.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>CD73-deficient mice are resistant to carcinogenesis.</article-title>
<source/><italic>Cancer Res.</italic>
<volume>72</volume>
<fpage>2190</fpage>–<lpage>2196</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0420</pub-id><pub-id pub-id-type="pmid">22396496</pub-id></mixed-citation>
</ref>
<ref id="B751">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stagg</surname><given-names>J.</given-names></name><name><surname>Divisekera</surname><given-names>U.</given-names></name><name><surname>Mclaughlin</surname><given-names>N.</given-names></name><name><surname>Sharkey</surname><given-names>J.</given-names></name><name><surname>Pommey</surname><given-names>S.</given-names></name><name><surname>Denoyer</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>107</volume>
<fpage>1547</fpage>–<lpage>1552</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0908801107</pub-id><pub-id pub-id-type="pmid">20080644</pub-id></mixed-citation>
</ref>
<ref id="B752">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamp</surname><given-names>L. K.</given-names></name><name><surname>Hazlett</surname><given-names>J.</given-names></name><name><surname>Roberts</surname><given-names>R. L.</given-names></name><name><surname>Frampton</surname><given-names>C.</given-names></name><name><surname>Highton</surname><given-names>J.</given-names></name><name><surname>Hessian</surname><given-names>P. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action.</article-title>
<source/><italic>Arthritis Res. Ther.</italic>
<volume>14</volume>:<issue>R138</issue>
<pub-id pub-id-type="doi">10.1186/ar3871</pub-id></mixed-citation>
</ref>
<ref id="B753">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steculorum</surname><given-names>S. M.</given-names></name><name><surname>Timper</surname><given-names>K.</given-names></name><name><surname>Engström Ruud</surname><given-names>L.</given-names></name><name><surname>Evers</surname><given-names>N.</given-names></name><name><surname>Paeger</surname><given-names>L.</given-names></name><name><surname>Bremser</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Inhibition of P2Y6 signaling in AgRP neurons reduces food intake and improves systemic insulin sensitivity in obesity.</article-title>
<source/><italic>Cell Rep.</italic>
<volume>18</volume>
<fpage>1587</fpage>–<lpage>1597</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2017.01.047</pub-id><pub-id pub-id-type="pmid">28199831</pub-id></mixed-citation>
</ref>
<ref id="B754">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stemmer</surname><given-names>S.</given-names></name><name><surname>Silverman</surname><given-names>M. H.</given-names></name><name><surname>Kerns</surname><given-names>W. D.</given-names></name><name><surname>Bar-Yehuda</surname><given-names>S.</given-names></name><name><surname>Fishman</surname><given-names>S.</given-names></name><name><surname>Harpaz</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Phase 1/2 trial of CF102, a selective A3 adenosine receptor (A3AR) agonist, in patients with hepatocellular carcinoma (HCC).</article-title>
<source/><italic>Eur. J. Cancer</italic>
<volume>8</volume>:<issue>122</issue>
<pub-id pub-id-type="doi">10.1634/theoncologist.2012-0211</pub-id></mixed-citation>
</ref>
<ref id="B755">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sterle</surname><given-names>I.</given-names></name><name><surname>Zupancic</surname><given-names>D.</given-names></name><name><surname>Romih</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Correlation between urothelial differentiation and sensory proteins P2X3, P2X5, TRPV1, and TRPV4 in normal urothelium and papillary carcinoma of human bladder.</article-title>
<source/><italic>Biomed. Res. Int.</italic>
<volume>2014</volume>:<issue>805236</issue>
<pub-id pub-id-type="doi">10.1155/2014/805236</pub-id></mixed-citation>
</ref>
<ref id="B756">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>Y. O.</given-names></name><name><surname>Bebich</surname><given-names>B.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name><name><surname>Schuppan</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>The selective adenosine 2B receptor antagonist MRS1754 mitigates hepatic collagen deposition during fibrosis progression and induces mild fibrosis regression.</article-title>
<source/><italic>Gastroenterology</italic>
<volume>142</volume>
<fpage>S974</fpage>–<lpage>S975</lpage>. <pub-id pub-id-type="doi">10.1016/S0016-5085(12)63778-0</pub-id></mixed-citation>
</ref>
<ref id="B757">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Straub</surname><given-names>R. H.</given-names></name><name><surname>Rauch</surname><given-names>L.</given-names></name><name><surname>Fassold</surname><given-names>A.</given-names></name><name><surname>Lowin</surname><given-names>T.</given-names></name><name><surname>Pongratz</surname><given-names>G.</given-names></name></person-group> (<year>2008</year>). <article-title>Neuronally released sympathetic neurotransmitters stimulate splenic interferon-γ secretion from T cells in early type II collagen-induced arthritis.</article-title>
<source/><italic>Arthritis Rheum.</italic>
<volume>58</volume>
<fpage>3450</fpage>–<lpage>3460</lpage>. <pub-id pub-id-type="doi">10.1002/art.24030</pub-id><pub-id pub-id-type="pmid">18975332</pub-id></mixed-citation>
</ref>
<ref id="B758">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suadicani</surname><given-names>S. O.</given-names></name><name><surname>Urban-Maldonado</surname><given-names>M.</given-names></name><name><surname>Tar</surname><given-names>M. T.</given-names></name><name><surname>Melman</surname><given-names>A.</given-names></name><name><surname>Spray</surname><given-names>D. C.</given-names></name></person-group> (<year>2009</year>). <article-title>Effects of ageing and streptozotocin-induced diabetes on connexin43 and P2 purinoceptor expression in the rat corpora cavernosa and urinary bladder.</article-title>
<source/><italic>BJU Int.</italic>
<volume>103</volume>
<fpage>1686</fpage>–<lpage>1693</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.08337.x</pub-id><pub-id pub-id-type="pmid">19154470</pub-id></mixed-citation>
</ref>
<ref id="B759">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>M.</given-names></name><name><surname>Kini</surname><given-names>R.</given-names></name><name><surname>Madasu</surname><given-names>M.</given-names></name><name><surname>Ohta</surname><given-names>A.</given-names></name><name><surname>Nowak</surname><given-names>M.</given-names></name><name><surname>Exley</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Extracellular adenosine controls NKT-cell-dependent hepatitis induction.</article-title>
<source/><italic>Eur. J. Immunol.</italic>
<volume>44</volume>
<fpage>1119</fpage>–<lpage>1129</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201343866</pub-id><pub-id pub-id-type="pmid">24448964</pub-id></mixed-citation>
</ref>
<ref id="B760">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Role of P2X7 receptors in the development of diabetic retinopathy.</article-title>
<source/><italic>World J. Diabetes</italic>
<volume>5</volume>
<fpage>141</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.4239/wjd.v5.i2.141</pub-id><pub-id pub-id-type="pmid">24748927</pub-id></mixed-citation>
</ref>
<ref id="B761">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H. S.</given-names></name><name><surname>Xu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Xiao</surname><given-names>A.</given-names></name><name><surname>Turlova</surname><given-names>E.</given-names></name><name><surname>Alibraham</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Neuronal KATP channels mediate hypoxic preconditioning and reduce subsequent neonatal hypoxic-ischemic brain injury.</article-title>
<source/><italic>Exp. Neurol.</italic>
<volume>263</volume>
<fpage>161</fpage>–<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2014.10.003</pub-id><pub-id pub-id-type="pmid">25448006</pub-id></mixed-citation>
</ref>
<ref id="B762">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>A novel cognitive impairment mechanism that astrocytic p-connexin 43 promotes neuronic autophagy via activation of P2X7R and down-regulation of GLT-1 expression in the hippocampus following traumatic brain injury in rats.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>291</volume>
<fpage>315</fpage>–<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2015.05.049</pub-id><pub-id pub-id-type="pmid">26031379</pub-id></mixed-citation>
</ref>
<ref id="B763">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Seth</surname><given-names>P.</given-names></name><name><surname>Bian</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Csizmadia</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice.</article-title>
<source/><italic>Hepatology</italic>
<volume>57</volume>
<fpage>k205</fpage>–<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1002/hep.25989</pub-id></mixed-citation>
</ref>
<ref id="B764">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Imai</surname><given-names>M.</given-names></name><name><surname>Nowak-Machen</surname><given-names>M.</given-names></name><name><surname>Guckelberger</surname><given-names>O.</given-names></name><name><surname>Enjyoji</surname><given-names>K.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemia.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>7</volume>
<fpage>427</fpage>–<lpage>434</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-011-9239-6</pub-id><pub-id pub-id-type="pmid">21656186</pub-id></mixed-citation>
</ref>
<ref id="B765">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunggip</surname><given-names>C.</given-names></name><name><surname>Nishimura</surname><given-names>A.</given-names></name><name><surname>Shimoda</surname><given-names>K.</given-names></name><name><surname>Numaga-Tomita</surname><given-names>T.</given-names></name><name><surname>Tsuda</surname><given-names>M.</given-names></name><name><surname>Nishida</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Purinergic P2Y6 receptors: A new therapeutic target of age-dependent hypertension.</article-title>
<source/><italic>Pharmacol. Res.</italic>
<volume>120</volume>
<fpage>51</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2017.03.013</pub-id><pub-id pub-id-type="pmid">28336370</pub-id></mixed-citation>
</ref>
<ref id="B766">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suriyaphol</surname><given-names>G.</given-names></name><name><surname>Sarikaputi</surname><given-names>M.</given-names></name><name><surname>Suriyaphol</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>). <article-title>Differential responses of cells from human skin keratinocyte and bovine mammary epithelium to attack by pore-forming <italic>Staphylococcus aureus</italic> α-toxin.</article-title>
<source/><italic>Comp. Immunol. Microbiol. Infect. Dis.</italic>
<volume>32</volume>
<fpage>491</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/j.cimid.2008.07.002</pub-id><pub-id pub-id-type="pmid">18757097</pub-id></mixed-citation>
</ref>
<ref id="B767">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swennen</surname><given-names>E. L.</given-names></name><name><surname>Dagnelie</surname><given-names>P. C.</given-names></name><name><surname>Van Den Beucken</surname><given-names>T.</given-names></name><name><surname>Bast</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Radioprotective effects of ATP in human blood ex vivo.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>367</volume>
<fpage>383</fpage>–<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2007.12.125</pub-id><pub-id pub-id-type="pmid">18164682</pub-id></mixed-citation>
</ref>
<ref id="B768">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swiatkowski</surname><given-names>P.</given-names></name><name><surname>Murugan</surname><given-names>M.</given-names></name><name><surname>Eyo</surname><given-names>U. B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Rangaraju</surname><given-names>S.</given-names></name><name><surname>Oh</surname><given-names>S. B.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Activation of microglial P2Y12 receptor is required for outward potassium currents in response to neuronal injury.</article-title>
<source/><italic>Neuroscience</italic>
<volume>318</volume>
<fpage>22</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.01.008</pub-id><pub-id pub-id-type="pmid">26791526</pub-id></mixed-citation>
</ref>
<ref id="B769">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szkudelski</surname><given-names>T.</given-names></name></person-group> (<year>2007</year>). <article-title>Intracellular mediators in regulation of leptin secretion from adipocytes.</article-title>
<source/><italic>Physiol. Res.</italic>
<volume>56</volume>
<fpage>503</fpage>–<lpage>512</lpage>.<pub-id pub-id-type="pmid">17184148</pub-id></mixed-citation>
</ref>
<ref id="B770">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szuster-Ciesielska</surname><given-names>A.</given-names></name><name><surname>Sztanke</surname><given-names>K.</given-names></name><name><surname>Kandefer-Szerszen</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>A novel fused 1,2,4-triazine aryl derivative as antioxidant and nonselective antagonist of adenosine A2A receptors in ethanol-activated liver stellate cells.</article-title>
<source/><italic>Chem. Biol. Interact.</italic>
<volume>195</volume>
<fpage>18</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2011.10.004</pub-id><pub-id pub-id-type="pmid">22063920</pub-id></mixed-citation>
</ref>
<ref id="B771">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>Y. H.</given-names></name><name><surname>Cheng</surname><given-names>P. Y.</given-names></name><name><surname>Tsai</surname><given-names>R. Y.</given-names></name><name><surname>Chen</surname><given-names>Y. F.</given-names></name><name><surname>Wong</surname><given-names>C. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Purinergic P2X receptor regulates N-methyl-D-aspartate receptor expression and synaptic excitatory amino acid concentration in morphine-tolerant rats.</article-title>
<source/><italic>Anesthesiology</italic>
<volume>113</volume>
<fpage>1163</fpage>–<lpage>1175</lpage>. <pub-id pub-id-type="doi">10.1097/ALN.0b013e3181f11aa2</pub-id><pub-id pub-id-type="pmid">20938337</pub-id></mixed-citation>
</ref>
<ref id="B772">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>E.</given-names></name><name><surname>Jun</surname><given-names>D. Y.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Park</surname><given-names>G. C.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Upregulation of P2Y2 nucleotide receptor in human hepatocellular carcinoma cells.</article-title>
<source/><italic>J. Int. Med. Res.</italic>
<volume>44</volume>
<fpage>1234</fpage>–<lpage>1247</lpage>. <pub-id pub-id-type="doi">10.1177/0300060516662135</pub-id><pub-id pub-id-type="pmid">27807254</pub-id></mixed-citation>
</ref>
<ref id="B773">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>E.</given-names></name><name><surname>Ridyard</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Zimmerman</surname><given-names>M.</given-names></name><name><surname>Werner</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>X. X.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy.</article-title>
<source/><italic>J. Am. Soc. Nephrol.</italic>
<volume>25</volume>
<fpage>547</fpage>–<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2012101014</pub-id><pub-id pub-id-type="pmid">24262796</pub-id></mixed-citation>
</ref>
<ref id="B774">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>E.</given-names></name><name><surname>Tsukimoto</surname><given-names>M.</given-names></name><name><surname>Harada</surname><given-names>H.</given-names></name><name><surname>Kojima</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Involvement of P2Y6 receptor in p38 MAPK-mediated COX-2 expression in response to UVB irradiation of human keratinocytes.</article-title>
<source/><italic>Radiat. Res.</italic>
<volume>175</volume>
<fpage>358</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1667/RR2375.1</pub-id><pub-id pub-id-type="pmid">21388279</pub-id></mixed-citation>
</ref>
<ref id="B775">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>E.</given-names></name><name><surname>Tsukimoto</surname><given-names>M.</given-names></name><name><surname>Harada</surname><given-names>H.</given-names></name><name><surname>Kojima</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>10</volume>
<fpage>487</fpage>–<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-014-9411-x</pub-id><pub-id pub-id-type="pmid">24627191</pub-id></mixed-citation>
</ref>
<ref id="B776">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takenouchi</surname><given-names>T.</given-names></name><name><surname>Tsukimoto</surname><given-names>M.</given-names></name><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Kitani</surname><given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>Inflammasome activation by danger signals: extracellular ATP and pH.</article-title>
<source/><italic>Inflammasome</italic>
<volume>1</volume>
<fpage>76</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.2478/infl-2014-0008</pub-id></mixed-citation>
</ref>
<ref id="B777">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S.</given-names></name><name><surname>Kudo</surname><given-names>H.</given-names></name><name><surname>Asari</surname><given-names>T.</given-names></name><name><surname>Ono</surname><given-names>A.</given-names></name><name><surname>Motomura</surname><given-names>S.</given-names></name><name><surname>Toh</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>P2Y1 transient overexpression induced mineralization in spinal ligament cells derived from patients with ossification of the posterior longitudinal ligament of the cervical spine.</article-title>
<source/><italic>Calcif. Tissue Int.</italic>
<volume>88</volume>
<fpage>263</fpage>–<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1007/s00223-010-9456-y</pub-id><pub-id pub-id-type="pmid">21210088</pub-id></mixed-citation>
</ref>
<ref id="B778">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>M. P.</given-names></name><name><surname>Zhou</surname><given-names>H. H.</given-names></name><name><surname>Chen</surname><given-names>X. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Platelet inhibition agents: current and future P2Y12 receptor antagonists.</article-title>
<source/><italic>Curr. Vasc. Pharmacol.</italic>
<volume>13</volume>
<fpage>566</fpage>–<lpage>577</lpage>. <pub-id pub-id-type="doi">10.2174/1570161112666141127162209</pub-id><pub-id pub-id-type="pmid">25440595</pub-id></mixed-citation>
</ref>
<ref id="B779">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>L. M.</given-names></name><name><surname>Zhu</surname><given-names>J. F.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Qian</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Mo</surname><given-names>Q.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Activation of adenosine A2A receptor attenuates inflammatory response in a rat model of small-for-size liver transplantation.</article-title>
<source/><italic>Transplant. Proc.</italic>
<volume>42</volume>
<fpage>1915</fpage>–<lpage>1920</lpage>. <pub-id pub-id-type="doi">10.1016/j.transproceed.2010.02.084</pub-id><pub-id pub-id-type="pmid">20620548</pub-id></mixed-citation>
</ref>
<ref id="B780">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tantry</surname><given-names>S. J.</given-names></name><name><surname>Markad</surname><given-names>S. D.</given-names></name><name><surname>Shinde</surname><given-names>V.</given-names></name><name><surname>Bhat</surname><given-names>J.</given-names></name><name><surname>Balakrishnan</surname><given-names>G.</given-names></name><name><surname>Gupta</surname><given-names>A. K.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Discovery of imidazo[1,2-a]pyridine ethers and squaramides as selective and potent inhibitors of mycobacterial adenosine triphosphate (ATP) synthesis.</article-title>
<source/><italic>J. Med. Chem.</italic>
<volume>60</volume>
<fpage>1379</fpage>–<lpage>1399</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01358</pub-id><pub-id pub-id-type="pmid">28075132</pub-id></mixed-citation>
</ref>
<ref id="B781">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson’s disease: a meta-analysis of randomized controlled trials.</article-title>
<source/><italic>Cell Biochem. Biophys.</italic>
<volume>71</volume>
<fpage>57</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1007/s12013-014-0162-7</pub-id><pub-id pub-id-type="pmid">25096504</pub-id></mixed-citation>
</ref>
<ref id="B782">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taskiran</surname><given-names>E.</given-names></name><name><surname>Erbas</surname><given-names>O.</given-names></name><name><surname>Yigittürk</surname><given-names>G.</given-names></name><name><surname>Meral</surname><given-names>A.</given-names></name><name><surname>Akar</surname><given-names>H.</given-names></name><name><surname>Taskiran</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Exogenously administered adenosine attenuates renal damage in streptozotocin-induced diabetic rats.</article-title>
<source/><italic>Ren. Fail.</italic>
<volume>38</volume>
<fpage>1276</fpage>–<lpage>1282</lpage>. <pub-id pub-id-type="doi">10.1080/0886022X.2016.1207054</pub-id><pub-id pub-id-type="pmid">27418253</pub-id></mixed-citation>
</ref>
<ref id="B783">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>J. M.</given-names></name><name><surname>Han</surname><given-names>Z.</given-names></name></person-group> (<year>2010</year>). <article-title>Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>5</volume>:<issue>e15784</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0015784</pub-id></mixed-citation>
</ref>
<ref id="B784">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>S. R. J.</given-names></name><name><surname>Turner</surname><given-names>C. M.</given-names></name><name><surname>Elliott</surname><given-names>J. I.</given-names></name><name><surname>Hewitt</surname><given-names>R.</given-names></name><name><surname>Pickering</surname><given-names>M.</given-names></name><name><surname>Cook</surname><given-names>H. T.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>P2X7-deficiency ameliorates accelerated nephrotoxic nephritis in mice.</article-title>
<source/><italic>J. Am. Soc. Nephrol.</italic>
<volume>20</volume>
<fpage>1275</fpage>–<lpage>1281</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2008060559</pub-id><pub-id pub-id-type="pmid">19389853</pub-id></mixed-citation>
</ref>
<ref id="B785">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>J. M.</given-names></name><name><surname>Bobinski</surname><given-names>F.</given-names></name><name><surname>Parada</surname><given-names>C. A.</given-names></name><name><surname>Sluka</surname><given-names>K. A.</given-names></name><name><surname>Tambeli</surname><given-names>C. H.</given-names></name></person-group> (<year>2016</year>). <article-title>P2X3 and P2X2/3 receptors play a crucial role in articular hyperalgesia development through inflammatory mechanisms in the knee joint experimental synovitis.</article-title>
<source/><italic>Mol. Neurobiol.</italic>
<pub-id pub-id-type="doi">10.1007/s12035-016-0146-2</pub-id>
<comment>[Epub ahead of print]</comment>.</mixed-citation>
</ref>
<ref id="B786">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teramachi</surname><given-names>J.</given-names></name><name><surname>Kukita</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>Y. J.</given-names></name><name><surname>Ushijima</surname><given-names>Y.</given-names></name><name><surname>Ohkuma</surname><given-names>H.</given-names></name><name><surname>Wada</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis.</article-title>
<source/><italic>Lab. Invest.</italic>
<volume>91</volume>
<fpage>719</fpage>–<lpage>731</lpage>. <pub-id pub-id-type="doi">10.1038/labinvest.2011.9</pub-id><pub-id pub-id-type="pmid">21339747</pub-id></mixed-citation>
</ref>
<ref id="B787">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thevananther</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Hernandez</surname><given-names>A.</given-names></name><name><surname>Awad</surname><given-names>S. S.</given-names></name><name><surname>Karpen</surname><given-names>S. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Impaired hepatocellular proliferation in P2Y2 purinergic receptor knockout mice: mitogenic role of extracellular ATP.</article-title>
<source/><italic>Hepatology</italic>
<volume>44</volume>:<issue>206A</issue>.</mixed-citation>
</ref>
<ref id="B788">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thevananther</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Arjunan</surname><given-names>V.</given-names></name><name><surname>Awad</surname><given-names>S. S.</given-names></name><name><surname>Wyllie</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes.</article-title>
<source/><italic>Hepatology</italic>
<volume>39</volume>
<fpage>393</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1002/hep.20075</pub-id><pub-id pub-id-type="pmid">14767992</pub-id></mixed-citation>
</ref>
<ref id="B789">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>MicroRNA-16 is putatively involved in the NF-κB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>6</volume>:<issue>30824</issue>
<pub-id pub-id-type="doi">10.1038/srep30824</pub-id></mixed-citation>
</ref>
<ref id="B790">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Marshall</surname><given-names>M.</given-names></name><name><surname>French</surname><given-names>B. A.</given-names></name><name><surname>Linden</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name></person-group> (<year>2015</year>). <article-title>The infarct-sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A2A receptors.</article-title>
<source/><italic>Basic Res. Cardiol.</italic>
<volume>110</volume>:<issue>16</issue>
<pub-id pub-id-type="doi">10.1007/s00395-015-0473-x</pub-id></mixed-citation>
</ref>
<ref id="B791">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>C. Y.</given-names></name><name><surname>Zhang</surname><given-names>Y. B.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Expression of ATP binding cassette E1 enhances viability and invasiveness of lung adenocarcinoma cells in vitro.</article-title>
<source/><italic>Mol. Med. Rep.</italic>
<volume>14</volume>
<fpage>1345</fpage>–<lpage>1350</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2016.5388</pub-id><pub-id pub-id-type="pmid">27314749</pub-id></mixed-citation>
</ref>
<ref id="B792">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>A.</given-names></name><name><surname>Vargas</surname><given-names>Y.</given-names></name><name><surname>Uribe</surname><given-names>D.</given-names></name><name><surname>Jaramillo</surname><given-names>C.</given-names></name><name><surname>Gleisner</surname><given-names>A.</given-names></name><name><surname>Salazar-Onfray</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells.</article-title>
<source/><italic>Oncotarget</italic>
<volume>7</volume>
<fpage>67373</fpage>–<lpage>67386</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.12033</pub-id><pub-id pub-id-type="pmid">27634913</pub-id></mixed-citation>
</ref>
<ref id="B793">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>B. T.</given-names></name><name><surname>Jimenez</surname><given-names>D. A.</given-names></name><name><surname>Budsberg</surname><given-names>S. C.</given-names></name></person-group> (<year>2016</year>). <article-title>Elevated synovial fluid concentration of adenosine triphosphate in dogs with osteoarthritis or sodium urate-induced synovitis of the stifle.</article-title>
<source/><italic>Vet. Comp. Orthop. Traumatol.</italic>
<volume>29</volume>
<fpage>344</fpage>–<lpage>346</lpage>. <pub-id pub-id-type="doi">10.3415/VCOT-15-06-0111</pub-id><pub-id pub-id-type="pmid">27432274</pub-id></mixed-citation>
</ref>
<ref id="B794">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Fuentes</surname><given-names>J. L.</given-names></name><name><surname>Rios</surname><given-names>M.</given-names></name><name><surname>Moreno</surname><given-names>R. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Involvement of a P2X7 receptor in the acrosome reaction induced by ATP in rat spermatozoa.</article-title>
<source/><italic>J. Cell. Physiol.</italic>
<volume>230</volume>
<fpage>3068</fpage>–<lpage>3075</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.25044</pub-id><pub-id pub-id-type="pmid">25989529</pub-id></mixed-citation>
</ref>
<ref id="B795">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truong</surname><given-names>L. D.</given-names></name><name><surname>Trostel</surname><given-names>J.</given-names></name><name><surname>Mcmahan</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>J. F.</given-names></name><name><surname>Garcia</surname><given-names>G. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Macrophage A2A adenosine receptors are essential to protect from progressive kidney injury.</article-title>
<source/><italic>Am. J. Pathol.</italic>
<volume>186</volume>
<fpage>2601</fpage>–<lpage>2613</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2016.06.017</pub-id><pub-id pub-id-type="pmid">27520357</pub-id></mixed-citation>
</ref>
<ref id="B796">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Microglia in the spinal cord and neuropathic pain.</article-title>
<source/><italic>J. Diabetes Investig.</italic>
<volume>7</volume>
<fpage>17</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1111/jdi.12379</pub-id></mixed-citation>
</ref>
<ref id="B797">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>P2 receptors, microglial cytokines and chemokines, and neuropathic pain.</article-title>
<source/><italic>J. Neurosci. Res.</italic>
<volume>95</volume>
<fpage>1319</fpage>–<lpage>1329</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.23816</pub-id><pub-id pub-id-type="pmid">27376880</pub-id></mixed-citation>
</ref>
<ref id="B798">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>M.</given-names></name><name><surname>Inoue</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>Neuron-microglia interaction by purinergic signaling in neuropathic pain following neurodegeneration.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>76</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.08.042</pub-id><pub-id pub-id-type="pmid">26327676</pub-id></mixed-citation>
</ref>
<ref id="B799">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>M.</given-names></name><name><surname>Koga</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Zhuo</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuronal and microglial mechanisms for neuropathic pain in the spinal dorsal horn and anterior cingulate cortex.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>141</volume>
<fpage>486</fpage>–<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.14001</pub-id><pub-id pub-id-type="pmid">28251660</pub-id></mixed-citation>
</ref>
<ref id="B800">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>G.</given-names></name><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Lv</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Long noncoding NONRATT021972 siRNA normalized abnormal sympathetic activity mediated by the upregulation of P2X7 receptor in superior cervical ganglia after myocardial ischemia.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>521</fpage>–<lpage>535</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9518-3</pub-id><pub-id pub-id-type="pmid">27215605</pub-id></mixed-citation>
</ref>
<ref id="B801">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turcin</surname><given-names>A.</given-names></name><name><surname>Dolzan</surname><given-names>V.</given-names></name><name><surname>Porcelli</surname><given-names>S.</given-names></name><name><surname>Serretti</surname><given-names>A.</given-names></name><name><surname>Plesnicar</surname><given-names>B. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine hypothesis of antipsychotic drugs revisited: pharmacogenomics variation in nonacute schizophrenia.</article-title>
<source/><italic>OMICS</italic>
<volume>20</volume>
<fpage>283</fpage>–<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1089/omi.2016.0003</pub-id><pub-id pub-id-type="pmid">27195966</pub-id></mixed-citation>
</ref>
<ref id="B802">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>S.</given-names></name><name><surname>Soshiroda</surname><given-names>K.</given-names></name><name><surname>Okita</surname><given-names>E.</given-names></name><name><surname>Kawai-Uchida</surname><given-names>M.</given-names></name><name><surname>Mori</surname><given-names>A.</given-names></name><name><surname>Jenner</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>747</volume>
<fpage>160</fpage>–<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2014.11.038</pub-id><pub-id pub-id-type="pmid">25499739</pub-id></mixed-citation>
</ref>
<ref id="B803">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uluçkan</surname><given-names>Ö.</given-names></name><name><surname>Eagleton</surname><given-names>M. C.</given-names></name><name><surname>Floyd</surname><given-names>D. H.</given-names></name><name><surname>Morgan</surname><given-names>E. A.</given-names></name><name><surname>Hirbe</surname><given-names>A. C.</given-names></name><name><surname>Kramer</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice.</article-title>
<source/><italic>J. Cell. Biochem</italic>
<volume>104</volume>
<fpage>1311</fpage>–<lpage>1323</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.21709</pub-id><pub-id pub-id-type="pmid">18260128</pub-id></mixed-citation>
</ref>
<ref id="B804">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ursu</surname><given-names>D.</given-names></name><name><surname>Ebert</surname><given-names>P.</given-names></name><name><surname>Langron</surname><given-names>E.</given-names></name><name><surname>Ruble</surname><given-names>C.</given-names></name><name><surname>Munsie</surname><given-names>L.</given-names></name><name><surname>Zou</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Gain and loss of function of P2X7 receptors: mechanisms, pharmacology and relevance to diabetic neuropathic pain.</article-title>
<source/><italic>Mol. Pain</italic>
<volume>10</volume>:<issue>37</issue>
<pub-id pub-id-type="doi">10.1186/1744-8069-10-37</pub-id></mixed-citation>
</ref>
<ref id="B805">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valladares</surname><given-names>D.</given-names></name><name><surname>Altamirano</surname><given-names>F.</given-names></name><name><surname>Henríquez-Olguín</surname><given-names>C.</given-names></name><name><surname>Díaz-Vegas</surname><given-names>A.</given-names></name><name><surname>Intriago</surname><given-names>G.</given-names></name><name><surname>Contreras-Ferrat</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>ATP signaling complex is altered in muscular dystrophy and was partly recovered after nifedipine treatment.</article-title>
<source/><italic>FASEB J.</italic>
<volume>28</volume>
<issue>762.3</issue>.</mixed-citation>
</ref>
<ref id="B806">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbeuch</surname><given-names>A.</given-names></name><name><surname>Anderson</surname><given-names>C. B.</given-names></name><name><surname>Parnes</surname><given-names>J.</given-names></name><name><surname>Enjyoji</surname><given-names>K.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name><name><surname>Finger</surname><given-names>T. E.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Role of the ectonucleotidase NTPDase2 in taste bud function.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>110</volume>
<fpage>14789</fpage>–<lpage>14794</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1309468110</pub-id><pub-id pub-id-type="pmid">23959882</pub-id></mixed-citation>
</ref>
<ref id="B807">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbeuch</surname><given-names>A.</given-names></name><name><surname>Larson</surname><given-names>E. D.</given-names></name><name><surname>Anderson</surname><given-names>C. B.</given-names></name><name><surname>Smith</surname><given-names>S. A.</given-names></name><name><surname>Ford</surname><given-names>A. P.</given-names></name><name><surname>Finger</surname><given-names>T. E.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Postsynaptic P2X3-containing receptors in gustatory nerve fibres mediate responses to all taste qualities in mice.</article-title>
<source/><italic>J. Physiol.</italic>
<volume>593</volume>
<fpage>1113</fpage>–<lpage>1125</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2014.281014</pub-id><pub-id pub-id-type="pmid">25524179</pub-id></mixed-citation>
</ref>
<ref id="B808">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderstocken</surname><given-names>G.</given-names></name><name><surname>Van De Paar</surname><given-names>E.</given-names></name><name><surname>Robaye</surname><given-names>B.</given-names></name><name><surname>Di Pietrantonio</surname><given-names>L.</given-names></name><name><surname>Bondue</surname><given-names>B.</given-names></name><name><surname>Boeynaems</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Protective role of P2Y2 receptor against lung infection induced by pneumonia virus of mice.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>7</volume>:<issue>e50385</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0050385</pub-id></mixed-citation>
</ref>
<ref id="B809">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Padovan</surname><given-names>M.</given-names></name><name><surname>Govoni</surname><given-names>M.</given-names></name><name><surname>Vincenzi</surname><given-names>F.</given-names></name><name><surname>Trotta</surname><given-names>F.</given-names></name><name><surname>Borea</surname><given-names>P. A.</given-names></name></person-group> (<year>2010a</year>). <article-title>The role of adenosine receptors in rheumatoid arthritis.</article-title>
<source/><italic>Autoimmun. Rev.</italic>
<volume>10</volume>
<fpage>61</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2010.07.019</pub-id><pub-id pub-id-type="pmid">20691813</pub-id></mixed-citation>
</ref>
<ref id="B810">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Vincenzi</surname><given-names>F.</given-names></name><name><surname>Targa</surname><given-names>M.</given-names></name><name><surname>Paradiso</surname><given-names>B.</given-names></name><name><surname>Parrilli</surname><given-names>A.</given-names></name><name><surname>Fini</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>The stimulation of A3 adenosine receptors reduces bone-residing breast cancer in a rat preclinical model.</article-title>
<source/><italic>Eur. J. Cancer</italic>
<volume>49</volume>
<fpage>482</fpage>–<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2012.06.005</pub-id><pub-id pub-id-type="pmid">22770890</pub-id></mixed-citation>
</ref>
<ref id="B811">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varani</surname><given-names>K.</given-names></name><name><surname>Vincenzi</surname><given-names>F.</given-names></name><name><surname>Tosi</surname><given-names>A.</given-names></name><name><surname>Targa</surname><given-names>M.</given-names></name><name><surname>Masieri</surname><given-names>F. F.</given-names></name><name><surname>Ongaro</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2010b</year>). <article-title>Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>160</volume>
<fpage>101</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00667.x</pub-id><pub-id pub-id-type="pmid">20331607</pub-id></mixed-citation>
</ref>
<ref id="B812">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughn</surname><given-names>B. P.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name><name><surname>Longhi</surname><given-names>M. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Purinergic signaling in liver disease.</article-title>
<source/><italic>Dig. Dis.</italic>
<volume>32</volume>
<fpage>516</fpage>–<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1159/000360498</pub-id><pub-id pub-id-type="pmid">25034284</pub-id></mixed-citation>
</ref>
<ref id="B813">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vazquez-Cuevas</surname><given-names>F. G.</given-names></name><name><surname>Martinez-Ramirez</surname><given-names>A. S.</given-names></name><name><surname>Robles-Martinez</surname><given-names>L.</given-names></name><name><surname>Garay</surname><given-names>E.</given-names></name><name><surname>Garcia-Carranca</surname><given-names>A.</given-names></name><name><surname>Perez-Montiel</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Paracrine stimulation of P2X7 receptor by ATP activates a proliferative pathway in ovarian carcinoma cells.</article-title>
<source/><italic>J. Cell. Biochem.</italic>
<volume>115</volume>
<fpage>1955</fpage>–<lpage>1966</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.24867</pub-id><pub-id pub-id-type="pmid">24913779</pub-id></mixed-citation>
</ref>
<ref id="B814">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergani</surname><given-names>A.</given-names></name><name><surname>Fotino</surname><given-names>C.</given-names></name><name><surname>D’addio</surname><given-names>F.</given-names></name><name><surname>Tezza</surname><given-names>S.</given-names></name><name><surname>Podetta</surname><given-names>M.</given-names></name><name><surname>Gatti</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection.</article-title>
<source/><italic>Diabetes Metab. Res. Rev.</italic>
<volume>62</volume>
<fpage>1665</fpage>–<lpage>1675</lpage>. <pub-id pub-id-type="doi">10.2337/db12-0242</pub-id></mixed-citation>
</ref>
<ref id="B815">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veselá</surname><given-names>R.</given-names></name><name><surname>Aronsson</surname><given-names>P.</given-names></name><name><surname>Andersson</surname><given-names>M.</given-names></name><name><surname>Wsol</surname><given-names>V.</given-names></name><name><surname>Tobin</surname><given-names>G.</given-names></name></person-group> (<year>2012a</year>). <article-title>The potential of non-adrenergic, non-cholinergic targets in the treatment of interstitial cystitis/painful bladder syndrome.</article-title>
<source/><italic>J. Physiol. Pharmacol.</italic>
<volume>63</volume>
<fpage>k209</fpage>–<lpage>216</lpage>.</mixed-citation>
</ref>
<ref id="B816">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veselá</surname><given-names>R.</given-names></name><name><surname>Aronsson</surname><given-names>P.</given-names></name><name><surname>Tobin</surname><given-names>G.</given-names></name></person-group> (<year>2011</year>). <article-title>Functional and morphological examinations of P1A1 purinoceptors in the normal and inflamed urinary bladder of the rat.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>159</volume>
<fpage>26</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2010.07.008</pub-id><pub-id pub-id-type="pmid">20685181</pub-id></mixed-citation>
</ref>
<ref id="B817">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veselá</surname><given-names>R.</given-names></name><name><surname>Asklund</surname><given-names>H.</given-names></name><name><surname>Aronsson</surname><given-names>P.</given-names></name><name><surname>Johnsson</surname><given-names>M.</given-names></name><name><surname>Wsol</surname><given-names>V.</given-names></name><name><surname>Andersson</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2012b</year>). <article-title>Coupled nitric oxide and autonomic receptor functional responses in the normal and inflamed urinary bladder of the rat.</article-title>
<source/><italic>Physiol. Res.</italic>
<volume>61</volume>
<fpage>371</fpage>–<lpage>380</lpage>.<pub-id pub-id-type="pmid">22670695</pub-id></mixed-citation>
</ref>
<ref id="B818">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieira</surname><given-names>F. S.</given-names></name><name><surname>Nanini</surname><given-names>H. F.</given-names></name><name><surname>Takiya</surname><given-names>C. M.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>P2X7 receptor knockout prevents streptozotocin-induced type 1 diabetes in mice.</article-title>
<source/><italic>Mol. Cell. Endocrinol.</italic>
<volume>419</volume>
<fpage>148</fpage>–<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2015.10.008</pub-id><pub-id pub-id-type="pmid">26483196</pub-id></mixed-citation>
</ref>
<ref id="B819">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>I. S.</given-names></name><name><surname>Okusa</surname><given-names>M. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Adenosine 2A receptors in acute kidney injury.</article-title>
<source/><italic>Acta Physiol.</italic>
<volume>214</volume>
<fpage>303</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1111/apha.12508</pub-id></mixed-citation>
</ref>
<ref id="B820">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincenzi</surname><given-names>F.</given-names></name><name><surname>Padovan</surname><given-names>M.</given-names></name><name><surname>Targa</surname><given-names>M.</given-names></name><name><surname>Corciulo</surname><given-names>C.</given-names></name><name><surname>Giacuzzo</surname><given-names>S.</given-names></name><name><surname>Merighi</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>A2A adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats.</article-title>
<source/><italic>PLOS ONE</italic>
<volume>8</volume>:<issue>e54195</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0054195</pub-id></mixed-citation>
</ref>
<ref id="B821">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincenzi</surname><given-names>F.</given-names></name><name><surname>Ravani</surname><given-names>A.</given-names></name><name><surname>Pasquini</surname><given-names>S.</given-names></name><name><surname>Merighi</surname><given-names>S.</given-names></name><name><surname>Gessi</surname><given-names>S.</given-names></name><name><surname>Romagnoli</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>111</volume>
<fpage>283</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.09.015</pub-id><pub-id pub-id-type="pmid">27639989</pub-id></mixed-citation>
</ref>
<ref id="B822">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vindeirinho</surname><given-names>J.</given-names></name><name><surname>Santiago</surname><given-names>A. R.</given-names></name><name><surname>Cavadas</surname><given-names>C.</given-names></name><name><surname>Ambrósio</surname><given-names>A. F.</given-names></name><name><surname>Santos</surname><given-names>P. F.</given-names></name></person-group> (<year>2016</year>). <article-title>The adenosinergic system in diabetic retinopathy.</article-title>
<source/><italic>J. Diabetes Res.</italic>
<volume>2016</volume>:<issue>4270301</issue>
<pub-id pub-id-type="doi">10.1155/2016/4270301</pub-id></mixed-citation>
</ref>
<ref id="B823">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlajkovic</surname><given-names>S. M.</given-names></name><name><surname>Ambepitiya</surname><given-names>K.</given-names></name><name><surname>Barclay</surname><given-names>M.</given-names></name><name><surname>Boison</surname><given-names>D.</given-names></name><name><surname>Housley</surname><given-names>G. D.</given-names></name><name><surname>Thorne</surname><given-names>P. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Adenosine receptors regulate susceptibility to noise-induced neural injury in the mouse cochlea and hearing loss.</article-title>
<source/><italic>Hear. Res.</italic>
<volume>345</volume>
<fpage>43</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.heares.2016.12.015</pub-id><pub-id pub-id-type="pmid">28034618</pub-id></mixed-citation>
</ref>
<ref id="B824">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlaskovska</surname><given-names>M.</given-names></name><name><surname>Kasakov</surname><given-names>L.</given-names></name><name><surname>Rong</surname><given-names>W.</given-names></name><name><surname>Bodin</surname><given-names>P.</given-names></name><name><surname>Bardini</surname><given-names>M.</given-names></name><name><surname>Cockayne</surname><given-names>D. A.</given-names></name><etal></etal></person-group> (<year>2001</year>). <article-title>P2X3 knockout mice reveal a major sensory role for urothelially released ATP.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>21</volume>
<fpage>5670</fpage>–<lpage>5677</lpage>.<pub-id pub-id-type="pmid">11466438</pub-id></mixed-citation>
</ref>
<ref id="B825">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Völkl</surname><given-names>T.</given-names></name><name><surname>Ogilvie</surname><given-names>A.</given-names></name><name><surname>Neuhuber</surname><given-names>W.</given-names></name><name><surname>Ogilvie</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Cell death induced by uridine 5′-triphosphate (UTP) in contrast to adenosine 5′-triphosphate (ATP) in human epidermoid carcinoma cells (A-431).</article-title>
<source/><italic>Cell Physiol. Biochem.</italic>
<volume>22</volume>
<fpage>441</fpage>–<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1159/000185491</pub-id><pub-id pub-id-type="pmid">19088426</pub-id></mixed-citation>
</ref>
<ref id="B826">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volonté</surname><given-names>C.</given-names></name><name><surname>Apolloni</surname><given-names>S.</given-names></name><name><surname>Parisi</surname><given-names>C.</given-names></name><name><surname>Amadio</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic contribution to amyotrophic lateral sclerosis.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>180</fpage>–<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.10.026</pub-id><pub-id pub-id-type="pmid">26514402</pub-id></mixed-citation>
</ref>
<ref id="B827">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Versen-Höynck</surname><given-names>F.</given-names></name><name><surname>Rajakumar</surname><given-names>A.</given-names></name><name><surname>Bainbridge</surname><given-names>S. A.</given-names></name><name><surname>Gallaher</surname><given-names>M. J.</given-names></name><name><surname>Roberts</surname><given-names>J. M.</given-names></name><name><surname>Powers</surname><given-names>R. W.</given-names></name></person-group> (<year>2009</year>). <article-title>Human placental adenosine receptor expression is elevated in preeclampsia and hypoxia increases expression of the A2A receptor.</article-title>
<source/><italic>Placenta</italic>
<volume>30</volume>
<fpage>434</fpage>–<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1016/j.placenta.2009.02.004</pub-id><pub-id pub-id-type="pmid">19303140</pub-id></mixed-citation>
</ref>
<ref id="B828">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vonend</surname><given-names>O.</given-names></name><name><surname>Turner</surname><given-names>C.</given-names></name><name><surname>Chan</surname><given-names>C. M.</given-names></name><name><surname>Loesch</surname><given-names>A.</given-names></name><name><surname>Dell’anna</surname><given-names>G. C.</given-names></name><name><surname>Srai</surname><given-names>S. K.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Glomerular expression of the ATP-sensitive P2X7 receptor in diabetic and hypertensive rat models.</article-title>
<source/><italic>Kidney Int.</italic>
<volume>66</volume>
<fpage>157</fpage>–<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00717.x</pub-id><pub-id pub-id-type="pmid">15200422</pub-id></mixed-citation>
</ref>
<ref id="B829">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voors</surname><given-names>A. A.</given-names></name><name><surname>Dungen</surname><given-names>H. D.</given-names></name><name><surname>Senni</surname><given-names>M.</given-names></name><name><surname>Nodari</surname><given-names>S.</given-names></name><name><surname>Agostoni</surname><given-names>P.</given-names></name><name><surname>Ponikowski</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure.</article-title>
<source/><italic>J. Clin. Pharmacol.</italic>
<volume>57</volume>
<fpage>440</fpage>–<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1002/jcph.828</pub-id><pub-id pub-id-type="pmid">27624622</pub-id></mixed-citation>
</ref>
<ref id="B830">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vorovenci</surname><given-names>R. J.</given-names></name><name><surname>Antonini</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease.</article-title>
<source/><italic>Expert Rev. Neurother.</italic>
<volume>15</volume>
<fpage>1383</fpage>–<lpage>1390</lpage>. <pub-id pub-id-type="doi">10.1586/14737175.2015.1113131</pub-id><pub-id pub-id-type="pmid">26630457</pub-id></mixed-citation>
</ref>
<ref id="B831">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waeber</surname><given-names>C.</given-names></name><name><surname>Moskowitz</surname><given-names>M. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Therapeutic implications of central and peripheral neurologic mechanisms in migraine.</article-title>
<source/><italic>Neurology</italic>
<volume>61</volume>
<fpage>S9</fpage>–<lpage>S20</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.61.8_suppl_4.S9</pub-id><pub-id pub-id-type="pmid">14581653</pub-id></mixed-citation>
</ref>
<ref id="B832">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>C. A.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Mansfield</surname><given-names>K. J.</given-names></name><name><surname>Parkin</surname><given-names>K.</given-names></name><name><surname>Mukerjee</surname><given-names>C.</given-names></name><name><surname>Moore</surname><given-names>K. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Decreased intravesical adenosine triphosphate in patients with refractory detrusor overactivity and bacteriuria.</article-title>
<source/><italic>J. Urol.</italic>
<volume>189</volume>
<fpage>1383</fpage>–<lpage>1387</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2012.10.003</pub-id><pub-id pub-id-type="pmid">23063632</pub-id></mixed-citation>
</ref>
<ref id="B833">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>H. X.</given-names></name><name><surname>Hu</surname><given-names>J. H.</given-names></name><name><surname>Xie</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>S. M.</given-names></name><name><surname>Dong</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Important roles of P2Y receptors in the inflammation and cancer of digestive system.</article-title>
<source/><italic>Oncotarget</italic>
<volume>7</volume>
<fpage>28736</fpage>–<lpage>28747</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.7518</pub-id><pub-id pub-id-type="pmid">26908460</pub-id></mixed-citation>
</ref>
<ref id="B834">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Extracellular ATP mediates inflammatory responses in colitis via P2 x 7 receptor signaling.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>6</volume>:<issue>19108</issue>
<pub-id pub-id-type="doi">10.1038/srep19108</pub-id></mixed-citation>
</ref>
<ref id="B835">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>S. M.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Qiao</surname><given-names>S. G.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>C. F.</given-names></name></person-group> (<year>2015</year>). <article-title>Role of mitochondrial ATP-sensitive potassium channel-mediated PKC-ε in delayed protection against myocardial ischemia/reperfusion injury in isolated hearts of sevoflurane-preconditioned rats.</article-title>
<source/><italic>Braz. J. Med. Biol. Res.</italic>
<volume>48</volume>
<fpage>528</fpage>–<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1590/1414-431X20143876</pub-id><pub-id pub-id-type="pmid">25831209</pub-id></mixed-citation>
</ref>
<ref id="B836">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wan</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Ni</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Critical roles of adenosine A2A receptor in regulating the balance of Treg/Th17cells in allergic asthma.</article-title>
<source/><italic>Clin. Respir. J.</italic>
<pub-id pub-id-type="doi">10.1111/crj.12503</pub-id>
<comment>[Epub ahead of print]</comment>.</mixed-citation>
</ref>
<ref id="B837">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Rumney</surname><given-names>R. M.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Robaye</surname><given-names>B.</given-names></name><name><surname>Boeynaems</surname><given-names>J. M.</given-names></name><name><surname>Skerry</surname><given-names>T. M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>The P2Y13 receptor regulates extracellular ATP metabolism and the osteogenic response to mechanical loading.</article-title>
<source/><italic>J. Bone Miner. Res.</italic>
<volume>28</volume>
<fpage>1446</fpage>–<lpage>1456</lpage>. <pub-id pub-id-type="doi">10.1002/jbmr.1877</pub-id><pub-id pub-id-type="pmid">23362109</pub-id></mixed-citation>
</ref>
<ref id="B838">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Arcuino</surname><given-names>G.</given-names></name><name><surname>Takano</surname><given-names>T.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>W. G.</given-names></name><name><surname>Wan</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>P2X7 receptor inhibition improves recovery after spinal cord injury.</article-title>
<source/><italic>Nat. Med.</italic>
<volume>10</volume>
<fpage>821</fpage>–<lpage>827</lpage>. <pub-id pub-id-type="doi">10.1038/nm1082</pub-id><pub-id pub-id-type="pmid">15258577</pub-id></mixed-citation>
</ref>
<ref id="B839">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X. H.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>X. G.</given-names></name><name><surname>Shang</surname><given-names>H.</given-names></name><name><surname>He</surname><given-names>Z. Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson’s disease.</article-title>
<source/><italic>Mol. Med. Rep.</italic>
<volume>15</volume>
<fpage>768</fpage>–<lpage>776</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2016.6070</pub-id><pub-id pub-id-type="pmid">28035410</pub-id></mixed-citation>
</ref>
<ref id="B840">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Cristofaro</surname><given-names>V.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Ge</surname><given-names>R.</given-names></name><name><surname>Sullivan</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Urothelium-released ATP contributes to bladder dysfunction in type 2 diabetes.</article-title>
<source/><italic>J. Urol.</italic>
<volume>189</volume>
<issue>e116</issue>
<pub-id pub-id-type="doi">10.1016/j.juro.2013.02.1668</pub-id></mixed-citation>
</ref>
<ref id="B841">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>C. J.</given-names></name><name><surname>Augusto</surname><given-names>E.</given-names></name><name><surname>Gomes</surname><given-names>C. A.</given-names></name><name><surname>Singer</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Boison</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Regulation of fear responses by striatal and extrastriatal adenosine A2A receptors in forebrain.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>75</volume>
<fpage>855</fpage>–<lpage>863</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2013.05.003</pub-id><pub-id pub-id-type="pmid">23820821</pub-id></mixed-citation>
</ref>
<ref id="B842">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>Costanzi</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Q. Z.</given-names></name><name><surname>Gao</surname><given-names>Z. G.</given-names></name><name><surname>Jacobson</surname><given-names>K. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells.</article-title>
<source/><italic>Biochem. Pharmacol.</italic>
<volume>82</volume>
<fpage>418</fpage>–<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2011.05.013</pub-id><pub-id pub-id-type="pmid">21632028</pub-id></mixed-citation>
</ref>
<ref id="B843">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Du</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>A2B adenosine receptor agonist improves erectile function in diabetic rats.</article-title>
<source/><italic>Tohoku J. Exp. Med.</italic>
<volume>237</volume>
<fpage>141</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1620/tjem.237.141</pub-id><pub-id pub-id-type="pmid">26447087</pub-id></mixed-citation>
</ref>
<ref id="B844">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Adenosine signaling: good or bad in erectile function?</article-title>
<source/><italic>Arterioscler. Thromb. Vasc. Biol.</italic>
<volume>32</volume>
<fpage>845</fpage>–<lpage>850</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.111.226803</pub-id><pub-id pub-id-type="pmid">22423035</pub-id></mixed-citation>
</ref>
<ref id="B845">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wesselius</surname><given-names>A.</given-names></name><name><surname>Bours</surname><given-names>M. J.</given-names></name><name><surname>Jørgensen</surname><given-names>N. R.</given-names></name><name><surname>Wiley</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>B.</given-names></name><name><surname>Van Helden</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Non-synonymous polymorphisms in the P2RX4 are related to bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>9</volume>
<fpage>123</fpage>–<lpage>130</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-012-9337-0</pub-id><pub-id pub-id-type="pmid">23138503</pub-id></mixed-citation>
</ref>
<ref id="B846">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wessels</surname><given-names>J. A.</given-names></name><name><surname>Kooloos</surname><given-names>W. M.</given-names></name><name><surname>De Jonge</surname><given-names>R.</given-names></name><name><surname>De Vries-Bouwstra</surname><given-names>J. K.</given-names></name><name><surname>Allaart</surname><given-names>C. F.</given-names></name><name><surname>Linssen</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.</article-title>
<source/><italic>Arthritis Rheum.</italic>
<volume>54</volume>
<fpage>2830</fpage>–<lpage>2839</lpage>. <pub-id pub-id-type="doi">10.1002/art.22032</pub-id><pub-id pub-id-type="pmid">16947783</pub-id></mixed-citation>
</ref>
<ref id="B847">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wettstein</surname><given-names>M. S.</given-names></name><name><surname>Buser</surname><given-names>L.</given-names></name><name><surname>Hermanns</surname><given-names>T.</given-names></name><name><surname>Roudnicky</surname><given-names>F.</given-names></name><name><surname>Eberli</surname><given-names>D.</given-names></name><name><surname>Baumeister</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>CD73 predicts favorable prognosis in patients with nonmuscle-invasive urothelial bladder cancer.</article-title>
<source/><italic>Dis. Markers</italic>
<volume>2015</volume>:<issue>785461</issue>
<pub-id pub-id-type="doi">10.1155/2015/785461</pub-id></mixed-citation>
</ref>
<ref id="B848">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>C. W.</given-names></name><name><surname>Choong</surname><given-names>Y. T.</given-names></name><name><surname>Short</surname><given-names>J. L.</given-names></name><name><surname>Exintaris</surname><given-names>B.</given-names></name><name><surname>Malone</surname><given-names>D. T.</given-names></name><name><surname>Allen</surname><given-names>A. M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Male contraception via simultaneous knockout of α1A-adrenoceptors and P2X1-purinoceptors in mice.</article-title>
<source/><italic>Proc. Natl. Acad. Sci U.S.A.</italic>
<volume>110</volume>
<fpage>20825</fpage>–<lpage>20830</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1318624110</pub-id><pub-id pub-id-type="pmid">24297884</pub-id></mixed-citation>
</ref>
<ref id="B849">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>N.</given-names></name><name><surname>Butler</surname><given-names>P. E. M.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2005</year>). <article-title>Human melanomas express functional P2X7 receptors.</article-title>
<source/><italic>Cell Tissue Res.</italic>
<volume>321</volume>
<fpage>411</fpage>–<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-005-1149-x</pub-id><pub-id pub-id-type="pmid">15991050</pub-id></mixed-citation>
</ref>
<ref id="B850">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>N.</given-names></name><name><surname>Knight</surname><given-names>G. E.</given-names></name><name><surname>Butler</surname><given-names>P. E. M.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name></person-group> (<year>2009</year>). <article-title>An in vivo model of melanoma: treatment with ATP.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>5</volume>
<fpage>327</fpage>–<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-009-9156-0</pub-id><pub-id pub-id-type="pmid">19347609</pub-id></mixed-citation>
</ref>
<ref id="B851">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiesler</surname><given-names>B.</given-names></name><name><surname>Zech</surname><given-names>A.</given-names></name><name><surname>Idzko</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>The purinergic receptor P2X4 mediates acute airway inflammation by regulating dendritic cell function.</article-title>
<source/><italic>Am. J. Respir. Crit. Care Med.</italic>
<volume>193</volume>
<issue>A7543</issue>.</mixed-citation>
</ref>
<ref id="B852">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wille</surname><given-names>A.</given-names></name><name><surname>Amort</surname><given-names>T.</given-names></name><name><surname>Singewald</surname><given-names>N.</given-names></name><name><surname>Sartori</surname><given-names>S. B.</given-names></name><name><surname>Lusser</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Dysregulation of select ATP-dependent chromatin remodeling factors in high trait anxiety.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>311</volume>
<fpage>141</fpage>–<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2016.05.036</pub-id><pub-id pub-id-type="pmid">27208790</pub-id></mixed-citation>
</ref>
<ref id="B853">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winerdal</surname><given-names>M.</given-names></name><name><surname>Winerdal</surname><given-names>M. E.</given-names></name><name><surname>Wang</surname><given-names>Y. Q.</given-names></name><name><surname>Fredholm</surname><given-names>B. B.</given-names></name><name><surname>Winqvist</surname><given-names>O.</given-names></name><name><surname>Ådén</surname><given-names>U.</given-names></name></person-group> (<year>2016</year>). <article-title>Adenosine A1 receptors contribute to immune regulation after neonatal hypoxic ischemic brain injury.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>89</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9482-3</pub-id><pub-id pub-id-type="pmid">26608888</pub-id></mixed-citation>
</ref>
<ref id="B854">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirsdörfer</surname><given-names>F.</given-names></name><name><surname>De Leve</surname><given-names>S.</given-names></name><name><surname>Cappuccini</surname><given-names>F.</given-names></name><name><surname>Eldh</surname><given-names>T.</given-names></name><name><surname>Meyer</surname><given-names>A. V.</given-names></name><name><surname>Gau</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Extracellular adenosine production by ecto-5′-nucleotidase (CD73) enhances radiation-induced lung fibrosis.</article-title>
<source/><italic>Cancer Res.</italic>
<volume>76</volume>
<fpage>3045</fpage>–<lpage>3056</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2310</pub-id><pub-id pub-id-type="pmid">26921334</pub-id></mixed-citation>
</ref>
<ref id="B855">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojcik</surname><given-names>M.</given-names></name><name><surname>Zieleniak</surname><given-names>A.</given-names></name><name><surname>Mac-Marcjanek</surname><given-names>K.</given-names></name><name><surname>Wozniak</surname><given-names>L. A.</given-names></name><name><surname>Cypryk</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>The elevated gene expression level of the A2B adenosine receptor is associated with hyperglycemia in women with gestational diabetes mellitus.</article-title>
<source/><italic>Diabetes Metab. Res. Rev.</italic>
<volume>30</volume>
<fpage>42</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1002/dmrr.2446</pub-id><pub-id pub-id-type="pmid">23956030</pub-id></mixed-citation>
</ref>
<ref id="B856">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>L. T.</given-names></name><name><surname>Ajit</surname><given-names>D.</given-names></name><name><surname>Camden</surname><given-names>J. M.</given-names></name><name><surname>Erb</surname><given-names>L.</given-names></name><name><surname>Weisman</surname><given-names>G. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Purinergic receptors as potential therapeutic targets in Alzheimer’s disease.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>104</volume>
<fpage>169</fpage>–<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.10.031</pub-id><pub-id pub-id-type="pmid">26519903</pub-id></mixed-citation>
</ref>
<ref id="B857">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>A.</given-names></name><name><surname>Mahaut-Smith</surname><given-names>M.</given-names></name><name><surname>Symon</surname><given-names>F.</given-names></name><name><surname>Sylvius</surname><given-names>N.</given-names></name><name><surname>Ran</surname><given-names>S.</given-names></name><name><surname>Bafadhel</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Impaired P2X1 receptor-mediated adhesion in eosinophils from asthmatic patients.</article-title>
<source/><italic>J. Immunol.</italic>
<volume>196</volume>
<fpage>4877</fpage>–<lpage>4884</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1501585</pub-id><pub-id pub-id-type="pmid">27183585</pub-id></mixed-citation>
</ref>
<ref id="B858">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>S. R.</given-names></name><name><surname>Zanos</surname><given-names>P.</given-names></name><name><surname>Georgiou</surname><given-names>P.</given-names></name><name><surname>Yoo</surname><given-names>J. H.</given-names></name><name><surname>Ledent</surname><given-names>C.</given-names></name><name><surname>Hourani</surname><given-names>S. M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>A critical role of striatal A2A R-mGlu R interactions in modulating the psychomotor and drug-seeking effects of methamphetamine.</article-title>
<source/><italic>Addict. Biol.</italic>
<volume>21</volume>
<fpage>811</fpage>–<lpage>825</lpage>. <pub-id pub-id-type="doi">10.1111/adb.12259</pub-id><pub-id pub-id-type="pmid">25975203</pub-id></mixed-citation>
</ref>
<ref id="B859">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Lv</surname><given-names>Q.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>LncRNA uc.<italic>48</italic>+ siRNA improved diabetic sympathetic neuropathy in type 2 diabetic rats mediated by P2X7 receptor in SCG.</article-title>
<source/><italic>Auton. Neurosci.</italic>
<volume>197</volume>
<fpage>14</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.autneu.2016.04.001</pub-id><pub-id pub-id-type="pmid">27118262</pub-id></mixed-citation>
</ref>
<ref id="B860">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Nie</surname><given-names>Y.</given-names></name><name><surname>Xiong</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X7 receptor expression in peripheral blood monocytes is correlated with plasma C-reactive protein and cytokine levels in patients with type 2 diabetes mellitus: a preliminary report.</article-title>
<source/><italic>Inflammation</italic>
<volume>38</volume>
<fpage>2076</fpage>–<lpage>2081</lpage>. <pub-id pub-id-type="doi">10.1007/s10753-015-0189-y</pub-id><pub-id pub-id-type="pmid">26021292</pub-id></mixed-citation>
</ref>
<ref id="B861">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J. X.</given-names></name><name><surname>Xu</surname><given-names>M. Y.</given-names></name><name><surname>Miao</surname><given-names>X. R.</given-names></name><name><surname>Lu</surname><given-names>Z. J.</given-names></name><name><surname>Yuan</surname><given-names>X. M.</given-names></name><name><surname>Li</surname><given-names>X. Q.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain.</article-title>
<source/><italic>Eur. J. Pain</italic>
<volume>16</volume>
<fpage>1378</fpage>–<lpage>1388</lpage>. <pub-id pub-id-type="doi">10.1002/j.1532-2149.2012.00149.x</pub-id><pub-id pub-id-type="pmid">22528605</pub-id></mixed-citation>
</ref>
<ref id="B862">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Sahbaie</surname><given-names>P.</given-names></name><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Lobato</surname><given-names>R.</given-names></name><name><surname>Boison</surname><given-names>D.</given-names></name><name><surname>Clark</surname><given-names>J. D.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Opiate-induced changes in brain adenosine levels and narcotic drug responses.</article-title>
<source/><italic>Neuroscience</italic>
<volume>228</volume>
<fpage>235</fpage>–<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.10.031</pub-id><pub-id pub-id-type="pmid">23098802</pub-id></mixed-citation>
</ref>
<ref id="B863">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Tan</surname><given-names>W.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>MicroRNA-206 is involved in the pathogenesis of ulcerative colitis via regulation of adenosine A3 receptor.</article-title>
<source/><italic>Oncotarget</italic>
<volume>8</volume>
<fpage>705</fpage>–<lpage>721</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.13525</pub-id><pub-id pub-id-type="pmid">27893428</pub-id></mixed-citation>
</ref>
<ref id="B864">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Role of ATP-sensitive potassium channels in modulating nociception in rat model of bone cancer pain.</article-title>
<source/><italic>Brain Res.</italic>
<volume>1554</volume>
<fpage>29</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2014.01.032</pub-id><pub-id pub-id-type="pmid">24480471</pub-id></mixed-citation>
</ref>
<ref id="B865">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>He</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway.</article-title>
<source/><italic>Oncol. Rep.</italic>
<volume>34</volume>
<fpage>103</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.3892/or.2015.3979</pub-id><pub-id pub-id-type="pmid">25976617</pub-id></mixed-citation>
</ref>
<ref id="B866">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>H. J.</given-names></name><name><surname>Liu</surname><given-names>Z. C.</given-names></name><name><surname>Wang</surname><given-names>D. S.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y. L.</given-names></name><name><surname>Dou</surname><given-names>K. F.</given-names></name></person-group> (<year>2006</year>). <article-title>Adenosine A2b receptor is highly expressed in human hepatocellular carcinoma.</article-title>
<source/><italic>Hepatol. Res.</italic>
<volume>36</volume>
<fpage>56</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.hepres.2006.06.008</pub-id><pub-id pub-id-type="pmid">16844405</pub-id></mixed-citation>
</ref>
<ref id="B867">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F.</given-names></name><name><surname>Waldrop</surname><given-names>S. L.</given-names></name><name><surname>Khimji</surname><given-names>A. K.</given-names></name><name><surname>Kilic</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Pannexin1 contributes to pathophysiological ATP release in lipoapoptosis induced by saturated free fatty acids in liver cells.</article-title>
<source/><italic>Am. J. Physiol. Cell Physiol.</italic>
<volume>303</volume>
<fpage>C1034</fpage>–<lpage>C1044</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00175.2012</pub-id><pub-id pub-id-type="pmid">22972801</pub-id></mixed-citation>
</ref>
<ref id="B868">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Si</surname><given-names>L. Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Meng</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>The effects of adenosine A2A receptor knockout on renal interstitial fibrosis in a mouse model of unilateral ureteral obstruction.</article-title>
<source/><italic>Acta Histochem.</italic>
<volume>115</volume>
<fpage>315</fpage>–<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1016/j.acthis.2012.09.002</pub-id><pub-id pub-id-type="pmid">23026406</pub-id></mixed-citation>
</ref>
<ref id="B869">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Wen</surname><given-names>G.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>289</volume>
<fpage>19137</fpage>–<lpage>19149</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.540047</pub-id><pub-id pub-id-type="pmid">24847054</pub-id></mixed-citation>
</ref>
<ref id="B870">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Williams</surname><given-names>C. D.</given-names></name><name><surname>Mcgill</surname><given-names>M. R.</given-names></name><name><surname>Lebofsky</surname><given-names>M.</given-names></name><name><surname>Ramachandran</surname><given-names>A.</given-names></name><name><surname>Jaeschke</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Purinergic receptor antagonist A438079 protects against acetaminophen-induced liver injury by inhibiting P450 isoenzymes, not by inflammasome activation.</article-title>
<source/><italic>Toxicol. Sci.</italic>
<volume>131</volume>
<fpage>325</fpage>–<lpage>335</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfs283</pub-id><pub-id pub-id-type="pmid">22986947</pub-id></mixed-citation>
</ref>
<ref id="B871">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Chu</surname><given-names>K. L.</given-names></name><name><surname>Brederson</surname><given-names>J. D.</given-names></name><name><surname>Jarvis</surname><given-names>M. F.</given-names></name><name><surname>Mcgaraughty</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Spontaneous firing and evoked responses of spinal nociceptive neurons are attenuated by blockade of P2X3 and P2X2/3 receptors in inflamed rats.</article-title>
<source/><italic>J. Neurosci. Res.</italic>
<volume>90</volume>
<fpage>1597</fpage>–<lpage>1606</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.23042</pub-id><pub-id pub-id-type="pmid">22422599</pub-id></mixed-citation>
</ref>
<ref id="B872">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>R.</given-names></name><name><surname>Murugan</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Extracellular ATP enhances radiation-induced brain injury through microglial activation and paracrine signaling via P2X7 receptor.</article-title>
<source/><italic>Brain Behav. Immun.</italic>
<volume>50</volume>
<fpage>87</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.06.020</pub-id><pub-id pub-id-type="pmid">26122280</pub-id></mixed-citation>
</ref>
<ref id="B873">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Qin</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Adenosine effectively restores endotoxin-induced inhibition of human neutrophil chemotaxis via A1 receptor-p38 pathway.</article-title>
<source/><italic>Inflamm. Res.</italic>
<volume>66</volume>
<fpage>353</fpage>–<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-016-1021-3</pub-id><pub-id pub-id-type="pmid">28074216</pub-id></mixed-citation>
</ref>
<ref id="B874">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>M.</given-names></name><name><surname>Kanda</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Involvement of adenosine A2A receptors in depression and anxiety.</article-title>
<source/><italic>Int. Rev. Neurobiol.</italic>
<volume>119</volume>
<fpage>373</fpage>–<lpage>393</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-801022-8.00015-5</pub-id><pub-id pub-id-type="pmid">25175973</pub-id></mixed-citation>
</ref>
<ref id="B875">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname><given-names>T.</given-names></name><name><surname>Kadowaki</surname><given-names>T.</given-names></name></person-group> (<year>2013</year>). <article-title>Adiponectin receptor as a key player in healthy longevity and obesity-related diseases.</article-title>
<source/><italic>Cell Metab.</italic>
<volume>17</volume>
<fpage>185</fpage>–<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2013.01.001</pub-id><pub-id pub-id-type="pmid">23352188</pub-id></mixed-citation>
</ref>
<ref id="B876">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Walsh</surname><given-names>T.</given-names></name><name><surname>Xie</surname><given-names>D.</given-names></name><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Sirmaci</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Mutation of the ATP-gated P2X2 receptor leads to progressive hearing loss and increased susceptibility to noise.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>110</volume>
<fpage>2228</fpage>–<lpage>2233</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1222285110</pub-id><pub-id pub-id-type="pmid">23345450</pub-id></mixed-citation>
</ref>
<ref id="B877">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>E.</given-names></name><name><surname>Feng</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name></person-group> (<year>2016</year>). <article-title>Role of A3 adenosine receptor in diabetic neuropathy.</article-title>
<source/><italic>J. Neurosci. Res.</italic>
<volume>94</volume>
<fpage>936</fpage>–<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.23774</pub-id><pub-id pub-id-type="pmid">27319979</pub-id></mixed-citation>
</ref>
<ref id="B878">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>F1F0 ATP synthase-cyclophilin D interaction contributes to diabetes-induced synaptic dysfunction and cognitive decline.</article-title>
<source/><italic>Diabetes Metab. Res. Rev.</italic>
<volume>65</volume>
<fpage>3482</fpage>–<lpage>3494</lpage>.</mixed-citation>
</ref>
<ref id="B879">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Bai</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Tolbert</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>P2X7 receptor inhibition protects against ischemic acute kidney injury in mice.</article-title>
<source/><italic>Am. J. Physiol. Cell Physiol.</italic>
<volume>308</volume>
<fpage>C463</fpage>–<lpage>C472</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00245.2014</pub-id><pub-id pub-id-type="pmid">25588875</pub-id></mixed-citation>
</ref>
<ref id="B880">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Donor pretreatment with adenosine monophosphate-activated protein kinase activator protects cardiac grafts from cold ischaemia/reperfusion injury.</article-title>
<source/><italic>Eur. J Cardiothorac. Surg.</italic>
<volume>49</volume>
<fpage>1354</fpage>–<lpage>1360</lpage>. <pub-id pub-id-type="doi">10.1093/ejcts/ezv413</pub-id><pub-id pub-id-type="pmid">26609046</pub-id></mixed-citation>
</ref>
<ref id="B881">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>H.</given-names></name><name><surname>Tian</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Identification of a new series of potent adenosine A2A receptor antagonists based on 4-amino-5-carbonitrile pyrimidine template for the treatment of Parkinson’s disease.</article-title>
<source/><italic>ACS Chem. Neurosci.</italic>
<volume>7</volume>
<fpage>1575</fpage>–<lpage>1584</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.6b00218</pub-id><pub-id pub-id-type="pmid">27569066</pub-id></mixed-citation>
</ref>
<ref id="B882">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhan</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Endogenous A1 adenosine receptor protects mice from acute ethanol-induced hepatotoxicity.</article-title>
<source/><italic>Toxicology</italic>
<volume>309</volume>
<fpage>100</fpage>–<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2013.05.003</pub-id><pub-id pub-id-type="pmid">23692951</pub-id></mixed-citation>
</ref>
<ref id="B883">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>S. C.</given-names></name><name><surname>Lee</surname><given-names>H. T.</given-names></name></person-group> (<year>2012</year>). <article-title>Adenosine and protection from acute kidney injury.</article-title>
<source/><italic>Curr Opin. Nephrol. Hypertens</italic>
<volume>21</volume>
<fpage>24</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1097/MNH.0b013e32834d2ec9</pub-id><pub-id pub-id-type="pmid">22080856</pub-id></mixed-citation>
</ref>
<ref id="B884">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yegutkin</surname><given-names>G. G.</given-names></name><name><surname>Guerrero-Toro</surname><given-names>C.</given-names></name><name><surname>Kilinc</surname><given-names>E.</given-names></name><name><surname>Koroleva</surname><given-names>K.</given-names></name><name><surname>Ishchenko</surname><given-names>Y.</given-names></name><name><surname>Abushik</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Nucleotide homeostasis and purinergic nociceptive signaling in rat meninges in migraine-like conditions.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>12</volume>
<fpage>561</fpage>–<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-016-9521-8</pub-id><pub-id pub-id-type="pmid">27369815</pub-id></mixed-citation>
</ref>
<ref id="B885">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yegutkin</surname><given-names>G. G.</given-names></name><name><surname>Marttila-Ichihara</surname><given-names>F.</given-names></name><name><surname>Karikoski</surname><given-names>M.</given-names></name><name><surname>Niemela</surname><given-names>J.</given-names></name><name><surname>Laurila</surname><given-names>J. P.</given-names></name><name><surname>Elima</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.</article-title>
<source/><italic>Eur. J. Immunol.</italic>
<volume>41</volume>
<fpage>1231</fpage>–<lpage>1241</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201041292</pub-id><pub-id pub-id-type="pmid">21469131</pub-id></mixed-citation>
</ref>
<ref id="B886">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yelovitch</surname><given-names>S.</given-names></name><name><surname>Barr</surname><given-names>H. M.</given-names></name><name><surname>Camden</surname><given-names>J.</given-names></name><name><surname>Weisman</surname><given-names>G. A.</given-names></name><name><surname>Shai</surname><given-names>E.</given-names></name><name><surname>Varon</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y1 receptor agonist.</article-title>
<source/><italic>J. Med. Chem.</italic>
<volume>55</volume>
<fpage>7623</fpage>–<lpage>7635</lpage>. <pub-id pub-id-type="doi">10.1021/jm3006355</pub-id><pub-id pub-id-type="pmid">22873688</pub-id></mixed-citation>
</ref>
<ref id="B887">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yetgin</surname><given-names>T.</given-names></name><name><surname>Uitterdijk</surname><given-names>A.</given-names></name><name><surname>Te Lintel Hekkert</surname><given-names>M.</given-names></name><name><surname>Merkus</surname><given-names>D.</given-names></name><name><surname>Krabbendam-Peters</surname><given-names>I.</given-names></name><name><surname>Van Beusekom</surname><given-names>H. M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Limitation of infarct size and no-reflow by intracoronary adenosine depends critically on dose and duration.</article-title>
<source/><italic>JACC Cardiovasc. Interv.</italic>
<volume>8</volume>
<fpage>1990</fpage>–<lpage>1999</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2015.08.033</pub-id><pub-id pub-id-type="pmid">26738671</pub-id></mixed-citation>
</ref>
<ref id="B888">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>L.</given-names></name><name><surname>Taylor</surname><given-names>C.</given-names></name><name><surname>Whiting</surname><given-names>C. C.</given-names></name><name><surname>Fathman</surname><given-names>C. G.</given-names></name></person-group> (<year>2013</year>). <article-title>Diminished adenosine A1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes.</article-title>
<source/><italic>Diabetes Metab. Res. Rev.</italic>
<volume>62</volume>
<fpage>4208</fpage>–<lpage>4219</lpage>. <pub-id pub-id-type="doi">10.2337/db13-0614</pub-id></mixed-citation>
</ref>
<ref id="B889">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoneyama</surname><given-names>Y.</given-names></name><name><surname>Sawa</surname><given-names>R.</given-names></name><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>S.</given-names></name><name><surname>Power</surname><given-names>G. G.</given-names></name><name><surname>Araki</surname><given-names>T.</given-names></name></person-group> (<year>1996</year>). <article-title>The relationship between uterine artery Doppler velocimetry and umbilical venous adenosine levels in pregnancies complicated by preeclampsia.</article-title>
<source/><italic>Am. J. Obstet. Gynecol.</italic>
<volume>174</volume>
<fpage>267</fpage>–<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9378(96)70406-4</pub-id><pub-id pub-id-type="pmid">8572019</pub-id></mixed-citation>
</ref>
<ref id="B890">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoneyama</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Sawa</surname><given-names>R.</given-names></name><name><surname>Araki</surname><given-names>T.</given-names></name></person-group> (<year>2004</year>). <article-title>Plasma adenosine concentrations increase in women with hyperemesis gravidarum.</article-title>
<source/><italic>Clin. Chim. Acta</italic>
<volume>342</volume>
<fpage>99</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.cccn.2003.12.004</pub-id><pub-id pub-id-type="pmid">15026270</pub-id></mixed-citation>
</ref>
<ref id="B891">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>K.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name><name><surname>Matsuoka</surname><given-names>I.</given-names></name></person-group> (<year>2015</year>). <article-title>P2X7 receptor antagonist activity of the anti-allergic agent oxatomide.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>767</volume>
<fpage>41</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2015.10.002</pub-id><pub-id pub-id-type="pmid">26463039</pub-id></mixed-citation>
</ref>
<ref id="B892">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>C. N. J.</given-names></name><name><surname>Sinadinos</surname><given-names>A.</given-names></name><name><surname>Gorecki</surname><given-names>D. C.</given-names></name></person-group> (<year>2013</year>). <article-title>P2X receptor signaling in skeletal muscle health and disease.</article-title>
<source/><italic>Wiley Interdiscip. Rev. Membr. Transp. Signal.</italic>
<volume>2</volume>
<fpage>265</fpage>–<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20141551</pub-id></mixed-citation>
</ref>
<ref id="B893">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Ouyang</surname><given-names>Q.</given-names></name><name><surname>He</surname><given-names>C.</given-names></name><name><surname>Burnstock</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Block of P2X7 receptors could partly reverse the delayed neuronal death in area CA1 of the hippocampus after transient global cerebral ischemia.</article-title>
<source/><italic>Purinergic Signal.</italic>
<volume>9</volume>
<fpage>663</fpage>–<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-013-9379-y</pub-id><pub-id pub-id-type="pmid">23877788</pub-id></mixed-citation>
</ref>
<ref id="B894">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Robson</surname><given-names>S. C.</given-names></name><name><surname>Hill</surname><given-names>W. G.</given-names></name></person-group> (<year>2013</year>). <article-title>Extracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y6 activation of the phospholipase C/inositol trisphosphate pathway.</article-title>
<source/><italic>FASEB J.</italic>
<volume>27</volume>
<fpage>1895</fpage>–<lpage>1903</lpage>. <pub-id pub-id-type="doi">10.1096/fj.12-219006</pub-id><pub-id pub-id-type="pmid">23362118</pub-id></mixed-citation>
</ref>
<ref id="B895">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Nucleotide modulates odor response through activation of purinergic receptor in olfactory sensory neuron.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>463</volume>
<fpage>1006</fpage>–<lpage>1011</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2015.06.050</pub-id><pub-id pub-id-type="pmid">26072377</pub-id></mixed-citation>
</ref>
<ref id="B896">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group> (<year>2014</year>). <article-title>Purinergic signaling negatively regulates activity of an olfactory receptor in an odorant-dependent manner.</article-title>
<source/><italic>Neuroscience</italic>
<volume>275</volume>
<fpage>89</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.05.055</pub-id><pub-id pub-id-type="pmid">24928349</pub-id></mixed-citation>
</ref>
<ref id="B897">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y. C.</given-names></name><name><surname>Sohma</surname><given-names>Y.</given-names></name><name><surname>Hwang</surname><given-names>T. C.</given-names></name></person-group> (<year>2016</year>). <article-title>On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.</article-title>
<source/><italic>J. Physiol.</italic>
<volume>594</volume>
<fpage>3227</fpage>–<lpage>3244</lpage>. <pub-id pub-id-type="doi">10.1113/JP271723</pub-id><pub-id pub-id-type="pmid">26846474</pub-id></mixed-citation>
</ref>
<ref id="B898">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuryeva</surname><given-names>K.</given-names></name><name><surname>Saltykova</surname><given-names>I.</given-names></name><name><surname>Ogorodova</surname><given-names>L.</given-names></name><name><surname>Kirillova</surname><given-names>N.</given-names></name><name><surname>Kulikov</surname><given-names>E.</given-names></name><name><surname>Korotkaya</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Expression of adenosine receptors in monocytes from patients with bronchial asthma.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>464</volume>
<fpage>1314</fpage>–<lpage>1320</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2015.07.141</pub-id><pub-id pub-id-type="pmid">26232643</pub-id></mixed-citation>
</ref>
<ref id="B899">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zafrah</surname><given-names>H. A.</given-names></name><name><surname>Alotaibi</surname><given-names>M. F.</given-names></name></person-group> (<year>2017</year>). <article-title>The effect of extracellular ATP on rat uterine contraction from different gestational stages and its possible mechanisms of action.</article-title>
<source/><italic>J. Basic Clin. Physiol. Pharmacol.</italic>
<volume>28</volume>
<fpage>209</fpage>–<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1515/jbcpp-2016-0118</pub-id><pub-id pub-id-type="pmid">28358713</pub-id></mixed-citation>
</ref>
<ref id="B900">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zakeri</surname><given-names>Z.</given-names></name><name><surname>Izadi</surname><given-names>S.</given-names></name><name><surname>Niazi</surname><given-names>A.</given-names></name><name><surname>Bari</surname><given-names>Z.</given-names></name><name><surname>Zendeboodi</surname><given-names>S.</given-names></name><name><surname>Shakiba</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Comparison of adenosine deaminase levels in serum and synovial fluid between patients with rheumatoid arthritis and osteoarthritis.</article-title>
<source/><italic>Int. J. Clin. Exp. Med.</italic>
<volume>5</volume>
<fpage>195</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">22567181</pub-id></mixed-citation>
</ref>
<ref id="B901">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanin</surname><given-names>R. F.</given-names></name><name><surname>Da Silva</surname><given-names>G. L.</given-names></name><name><surname>Erig</surname><given-names>T.</given-names></name><name><surname>Sperotto</surname><given-names>N. D.</given-names></name><name><surname>Leite</surname><given-names>C. E.</given-names></name><name><surname>Coutinho-Silva</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Decrease of serum adenine nucleotide hydrolysis in an irritant contact dermatitis mice model: potential P2X7R involvement.</article-title>
<source/><italic>Mol. Cell. Biochem.</italic>
<volume>404</volume>
<fpage>221</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-015-2381-7</pub-id><pub-id pub-id-type="pmid">25772484</pub-id></mixed-citation>
</ref>
<ref id="B902">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarjou</surname><given-names>A.</given-names></name><name><surname>Agarwal</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>ATP as a death factor: purinergic signaling in renal epithelial-fibroblast cross talk.</article-title>
<source/><italic>Am. J. Physiol. Renal Physiol.</italic>
<volume>300</volume>
<fpage>F60</fpage>–<lpage>F61</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00593.2010</pub-id><pub-id pub-id-type="pmid">20962119</pub-id></mixed-citation>
</ref>
<ref id="B903">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zempo</surname><given-names>H.</given-names></name><name><surname>Sugita</surname><given-names>Y.</given-names></name><name><surname>Ogawa</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>R.</given-names></name><name><surname>Suzuki</surname><given-names>J.</given-names></name><name><surname>Isobe</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>A P2X7 receptor antagonist attenuates experimental autoimmune myocarditis via suppressed myocardial CD4+ T and macrophage infiltration and NADPH oxidase 2/4 expression in mice.</article-title>
<source/><italic>Heart Vessels</italic>
<volume>30</volume>
<fpage>527</fpage>–<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1007/s00380-014-0527-2</pub-id><pub-id pub-id-type="pmid">24879505</pub-id></mixed-citation>
</ref>
<ref id="B904">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Cheng</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>F. S.</given-names></name><name><surname>Ding</surname><given-names>J. H.</given-names></name><name><surname>Feng</surname><given-names>Y. Y.</given-names></name><name><surname>Zhuo</surname><given-names>G. Z.</given-names></name><etal></etal></person-group> (<year>2015a</year>). <article-title>High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma.</article-title>
<source/><italic>Tumour. Biol.</italic>
<volume>36</volume>
<fpage>9411</fpage>–<lpage>9419</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-015-3683-9</pub-id><pub-id pub-id-type="pmid">26113408</pub-id></mixed-citation>
</ref>
<ref id="B905">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Yi</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Ye</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Adenosine triphosphate regresses endometrial explants in a rat model of endometriosis.</article-title>
<source/><italic>Reprod. Sci.</italic>
<volume>23</volume>
<fpage>924</fpage>–<lpage>930</lpage>. <pub-id pub-id-type="doi">10.1177/1933719115625847</pub-id><pub-id pub-id-type="pmid">26887426</pub-id></mixed-citation>
</ref>
<ref id="B906">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>You</surname><given-names>X.</given-names></name><name><surname>Kong</surname><given-names>P.</given-names></name><name><surname>Song</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>P2X7 as a new target for chrysophanol to treat lipopolysaccharide-induced depression in mice.</article-title>
<source/><italic>Neurosci. Lett.</italic>
<volume>613</volume>
<fpage>60</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2015.12.043</pub-id><pub-id pub-id-type="pmid">26724370</pub-id></mixed-citation>
</ref>
<ref id="B907">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Qin</surname><given-names>J.</given-names></name><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Lv</surname><given-names>Z.</given-names></name><name><surname>Tan</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Extracellular ADP facilitates monocyte recruitment in bacterial infection via ERK signaling.</article-title>
<source/><italic>Cell Mol. Immunol.</italic>
<pub-id pub-id-type="doi">10.1038/cmi.2016.56</pub-id>
<comment>[Epub ahead of print]</comment>.</mixed-citation>
</ref>
<ref id="B908">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2015b</year>). <article-title>P2Y purinergic receptor-regulated insulin secretion is mediated by a cAMP/Epac/Kv channel pathway.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>460</volume>
<fpage>850</fpage>–<lpage>856</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2015.03.121</pub-id><pub-id pub-id-type="pmid">25839655</pub-id></mixed-citation>
</ref>
<ref id="B909">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Peti-Peterdi</surname><given-names>J.</given-names></name><name><surname>Müller</surname><given-names>C. E.</given-names></name><name><surname>Carlson</surname><given-names>N. G.</given-names></name><name><surname>Baqi</surname><given-names>Y.</given-names></name><name><surname>Strasburg</surname><given-names>D. L.</given-names></name><etal></etal></person-group> (<year>2015c</year>). <article-title>P2Y12 receptor localizes in the renal collecting duct and its blockade augments arginine vasopressin action and alleviates nephrogenic diabetes insipidus.</article-title>
<source/><italic>J. Am. Soc. Nephrol.</italic>
<volume>26</volume>
<fpage>2978</fpage>–<lpage>2987</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2014010118</pub-id><pub-id pub-id-type="pmid">25855780</pub-id></mixed-citation>
</ref>
<ref id="B910">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>F.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Zhai</surname><given-names>Z.</given-names></name><name><surname>Ganghuang Du</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>P2X7 receptor blockade protects against cisplatin-induced nephrotoxicity in mice by decreasing the activities of inflammasome components, oxidative stress and caspase-3.</article-title>
<source/><italic>Toxicol. Appl. Pharmacol.</italic>
<volume>281</volume>
<fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2014.09.016</pub-id><pub-id pub-id-type="pmid">25308879</pub-id></mixed-citation>
</ref>
<ref id="B911">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Dai</surname><given-names>Z.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>J. H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>P2X7 receptor suppression preserves blood-brain barrier through inhibiting RhoA activation after experimental intracerebral hemorrhage in rats.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>6</volume>:<issue>23286</issue>
<pub-id pub-id-type="doi">10.1038/srep23286</pub-id></mixed-citation>
</ref>
<ref id="B912">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Dai</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>P2X7 blockade attenuates lupus nephritis by inhibiting NLRP3/ASC/caspase-1 activation.</article-title>
<source/><italic>Arthritis Rheum.</italic>
<volume>65</volume>
<fpage>3176</fpage>–<lpage>3185</lpage>. <pub-id pub-id-type="doi">10.1002/art.38174</pub-id><pub-id pub-id-type="pmid">24022661</pub-id></mixed-citation>
</ref>
<ref id="B913">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Liang</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Blockade of extracellular ATP effect by oxidized ATP effectively mitigated induced mouse experimental autoimmune uveitis (EAU).</article-title>
<source/><italic>PLOS ONE</italic>
<volume>11</volume>:<issue>e0155953</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0155953</pub-id></mixed-citation>
</ref>
<ref id="B914">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>B.</given-names></name><name><surname>Lai</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zuo</surname><given-names>Z.</given-names></name></person-group> (<year>2017</year>). <article-title>Critical role of P2X7 receptors in the neuroinflammation and cognitive dysfunction after surgery.</article-title>
<source/><italic>Brain Behav. Immun.</italic>
<volume>61</volume>
<fpage>365</fpage>–<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2017.01.005</pub-id><pub-id pub-id-type="pmid">28089560</pub-id></mixed-citation>
</ref>
<ref id="B915">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Dai</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Genetic polymorphisms of the P2X7 gene associated with susceptibility to and prognosis of pulmonary tuberculosis.</article-title>
<source/><italic>Infect. Genet. Evol.</italic>
<volume>53</volume>
<fpage>24</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.meegid.2017.05.003</pub-id><pub-id pub-id-type="pmid">28495473</pub-id></mixed-citation>
</ref>
<ref id="B916">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Belardinelli</surname><given-names>L.</given-names></name><name><surname>Zeng</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Pro-fibrotic roles of the A2B adenosine receptor in human primary hepatic stellate cells.</article-title>
<source/><italic>J. Hepatol.</italic>
<volume>46</volume>
<fpage>S135</fpage>–<lpage>S135</lpage>. <pub-id pub-id-type="doi">10.1016/S0168-8278(07)61943-6</pub-id></mixed-citation>
</ref>
<ref id="B917">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>W. C.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name></person-group> (<year>2013</year>). <article-title>Adenosine, adenosine receptors and glaucoma: an updated overview.</article-title>
<source/><italic>Biochim. Biophys. Acta</italic>
<volume>1830</volume>
<fpage>2882</fpage>–<lpage>2890</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2013.01.005</pub-id><pub-id pub-id-type="pmid">23328492</pub-id></mixed-citation>
</ref>
<ref id="B918">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yue</surname><given-names>M.</given-names></name><name><surname>Hu</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Platelets promote cartilage repair and chondrocyte proliferation via ADP in a rodent model of osteoarthritis.</article-title>
<source/><italic>Platelets</italic>
<volume>27</volume>
<fpage>212</fpage>–<lpage>222</lpage>. <pub-id pub-id-type="doi">10.3109/09537104.2015.1075493</pub-id><pub-id pub-id-type="pmid">26325015</pub-id></mixed-citation>
</ref>
<ref id="B919">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>L. M.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Yuan</surname><given-names>J. X.</given-names></name><name><surname>Li</surname><given-names>R. H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Upregulated P2X3 receptor expression in patients with intractable temporal lobe epilepsy and in a rat model of epilepsy.</article-title>
<source/><italic>Neurochem. Res.</italic>
<volume>41</volume>
<fpage>1263</fpage>–<lpage>1273</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-015-1820-x</pub-id><pub-id pub-id-type="pmid">26738991</pub-id></mixed-citation>
</ref>
<ref id="B920">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Qin</surname><given-names>H.</given-names></name><name><surname>Lei</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer.</article-title>
<source/><italic>Mol. Cancer</italic>
<volume>16</volume>:<issue>34</issue>
<pub-id pub-id-type="doi">10.1186/s12943-017-0591-1</pub-id></mixed-citation>
</ref>
<ref id="B921">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>H. B.</given-names></name></person-group> (<year>2012</year>). <article-title>ATP activates P2X receptors to mediate gap junctional coupling in the cochlea.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>426</volume>
<fpage>528</fpage>–<lpage>532</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2012.08.119</pub-id><pub-id pub-id-type="pmid">22982314</pub-id></mixed-citation>
</ref>
<ref id="B922">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y. J.</given-names></name><name><surname>Lu</surname><given-names>T. J.</given-names></name></person-group> (<year>2010</year>). <article-title>A multi-scale view of skin thermal pain: from nociception to pain sensation.</article-title>
<source/><italic>Philos. Trans. A Math. Phys. Eng. Sci.</italic>
<volume>368</volume>
<fpage>521</fpage>–<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1098/rsta.2009.0234</pub-id><pub-id pub-id-type="pmid">20047938</pub-id></mixed-citation>
</ref>
<ref id="B923">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zierhut</surname><given-names>M.</given-names></name><name><surname>Dyckhoff</surname><given-names>S.</given-names></name><name><surname>Masouris</surname><given-names>I.</given-names></name><name><surname>Klein</surname><given-names>M.</given-names></name><name><surname>Hammerschmidt</surname><given-names>S.</given-names></name><name><surname>Pfister</surname><given-names>H. W.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Role of purinergic signaling in experimental pneumococcal meningitis.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>7</volume>:<issue>44625</issue>
<pub-id pub-id-type="doi">10.1038/srep44625</pub-id></mixed-citation>
</ref>
<ref id="B924">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziganshin</surname><given-names>A. U.</given-names></name><name><surname>Vafina</surname><given-names>Z. R.</given-names></name><name><surname>Fatkullin</surname><given-names>I. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Contrasting effects of P2 receptor agonists on spontaneous contractility of human fallopian tubes with and without acute inflammation.</article-title>
<source/><italic>Pharmacol. Res.</italic>
<volume>57</volume>
<fpage>56</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2007.11.004</pub-id><pub-id pub-id-type="pmid">18155558</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>